US20230000952A1

US20230000952A1 - Therapeutic agents comprising elastin-like peptides

Info

Publication number: US20230000952A1
Application number: US17/459,556
Authority: US
Inventors: Ashutosh Chilkoti
Original assignee: Duke University
Current assignee: Duke University
Priority date: 2008-06-27
Filing date: 2021-08-27
Publication date: 2023-01-05
Also published as: WO2009158704A2; US9821036B2; EP2307038A2; WO2009158704A3; US20100022455A1; EP3412300A1; US20130085099A1; JP2017088627A; JP2015218177A; US9127047B2; CA2726894A1; US10596230B2; CA2953975A1; CA2953975C; US20190091297A1; HK1215182A1; EP2926825A1; US20200282022A1; US20160030521A1; US20160120952A1

Abstract

The present invention provides therapeutic agents and compositions comprising elastin-like peptides (ELPs) and therapeutic proteins. In some embodiments, the therapeutic protein is a GLP-1 receptor agonist, insulin, or Factor VII/VIIa, including functional analogs. The present invention further provides encoding polynucleotides, as well as methods of making and using the therapeutic agents. The therapeutic agents have improvements in relation to their use as therapeutics, including, inter alia, one or more of half-life, clearance and/or persistance in the body, solubility, and bioavailability.

Description

PRIORITY

This application is a continuation of U.S. application Ser. No. 16/720,970, filed Dec. 19, 2019 which is a continuation of U.S. application Ser. No. 16/000,300, filed Jun. 5, 2018, now U.S. Pat. No. 10,596,230, issued Mar. 24, 2020 which is a continuation of U.S. Ser. No. 15/816,018, filed Nov. 17, 2017, now abandoned, which is a continuation of U.S. application Ser. No. 14/822,512, filed Aug. 10, 2015, now U.S. Pat. No. 9,821,036, issued Nov. 21, 2017 which is a continuation of U.S. application Ser. No. 13/524,812, filed Jun. 15, 2012, now U.S. Pat. No. 9,127,047, issued Sep. 8, 2015 which is a continuation of U.S. application Ser. No. 13/445,979, filed Apr. 13, 2012, now U.S. Pat. No. 9,200,083, issued Dec. 1, 2015 which is a continuation of U.S. application Ser. No. 12/493,912, filed Jun. 29, 2009, now U.S. Pat. No. 8,178,495, issued May 15, 2012, which claims priority to U.S. Provisional Application No. 61/076,221, filed Jun. 27, 2008, the contents of each of which are hereby incorporated by reference in their entireties.

FIELD OF THE INVENTION

This application discloses therapeutic agents comprising elastin-like-peptides, and is related to PCT/US2007/077767 (published as WO 2008/030968 on Mar. 13, 2008) having an International Filing Date of Sep. 6, 2007. This application is also related to PCT/US2006/048572 (published as WO 2007/073486 on Jun. 28, 2007) having an International Filing Date of Dec. 20, 2006. WO 2008/030968 and WO 2007/073486 are each hereby incorporated by reference in their entireties.

DESCRIPTION OF THE TEXT FILE SUBMITTED ELECTRONICALLY

The contents of the text file submitted electronically herewith are incorporated herein by reference in their entirety: A computer readable format copy of the Sequence Listing (filename:PHAS-010_10US_SeqList_ST25.txt, date recorded: Aug. 27, 2021, file size 52.7 kb).

BACKGROUND OF THE INVENTION

Therapeutic proteins or peptides in their native state or when recombinantly produced can be labile molecules exhibiting, inter alia, short periods of serum stability, serum half-life (i.e., circulatory half-life), or limited persistance in the body. Such molecules can also be extremely labile when formulated, such as when formulated in aqueous solutions.
In some instances, polyethylene glycol (PEG) conjugated to a proteinaceous molecule results in a longer-acting, sustained activity of the molecule. PEG attachment, however, can often substantially reduce or even destroy the protein's therapeutic activity. Therapeutic proteins and/or peptides have also been stabilized by fusion to certain proteins that are capable of extending serum half-life. For example, in some instances, therapeutic proteins fused to albumin, transferrin, and antibody fragments exhibit extended serum half-life when compared to the therapeutic protein in the unfused state. See U.S. Pat. No. 7,238,667 (particularly with respect to albumin conjugates), U.S. Pat. No. 7,176,278 (particularly with respect to transferrin conjugates), and U.S. Pat. No. 5,766,883, which are each hereby incorporated by reference in their entireties.
There remains a need in the art for more stable, longer acting, and/or effective proteinaceous molecules.

SUMMARY OF THE INVENTION

The present invention provides therapeutic agents comprising an elastin-like peptide (ELP) component and a therapeutic proteinacious component. The ELP component contains structural peptide units, which may be repeating units, structurally related to, or derived from, sequences of the elastin protein. Such ELP components provide certain therapeutic advantages to the therapeutic agent, such as comparatively better stability, solubility, bioavailability, half-life, persistance, and/or biological action of the therapeutic proteinaceous component. Such properties may be determined, for example, with respect to the therapeutic component's unfused or unconjugated counterpart. In some embodiments, the ELP components may undergo a reversible inverse phase transition, which may impart additional practical and/or therapeutic advantages. The invention further provides polynucleotides encoding the therapeutic agents of the invention, as well as methods of treatment or prophylaxis for certain biological conditions.
In a first aspect, the invention provides a therapeutic agent comprising an elastin-like peptide (ELP) component and a therapeutic proteinacious component, as well as pharmaceutical compositions containing the same for delivery to a subject or patient in need. The therapeutic component may be selected from active portions of the therapeutic proteins listed in Table 1, or functional analogs thereof. In certain embodiments, the therapeutic component is a GLP-1 receptor agonist, such as GLP-1, exendin-4, or a functional analog thereof. Such therapeutic components are generally effective for, among other things, increasing insulin secretion from the pancreas in a glucose-dependent manner. In other embodiments, the therapeutic component is an insulin or functional analog thereof, which is generally effective for promoting glucose uptake from the blood and storage within cells. In still other embodiments, the therapeutic component is a Factor VII/VIIa or functional analog thereof, which is generally effective for promoting coagulation by activation of Factor X or Factor IX.
The ELP and therapeutic components may be covalently coupled by various means, including chemical coupling (e.g., conjugation) and recombinant fusion technology. In addition, the number of ELP or therapeutic components per molecule, and their respective positions within the molecule, may vary as needed. The therapeutic agent may further include one or more spacer or linker moieties, which in addition to providing the desired functional independence of the ELP and therapeutic components, may optionally provide for additional functionalities, such as a protease-sensitive feature to allow for proteolytic release or activation of the therapeutic component. The therapeutic agent may further include one or more targeting components such as, for example, a peptide or protein to target the therapeutic agent to a particular cell type, e.g., a cancer cell, or to a particular organ.
In a second aspect, the invention provides polynucleotides, such polynucleotides comprising a nucleotide sequence encoding a therapeutic agent of the invention. For example, the nucleotide sequence encodes an ELP fusion with a functional portion of at least one therapeutic protein listed in Table 1 (or functional analog thereof). In certain embodiments, the therapeutic component is a GLP-1 receptor agonist (including GLP-1 and exendin-4), insulin, Factor VII/VIIa, or functional analog thereof. Such polynucleotides may further comprise additional control element(s) operably linked to the nucleotide sequence, such as promoter elements and/or other transcription or expression-related signals. The polynucleotide may be inserted into various vectors, which may be useful for production of the therapeutic agent in host cells, including, for example, bacterial and eukaryotic host cells.
In a third aspect, the invention provides a method for treating or preventing a disease, disorder, or condition in a subject, such as in a mammalian patient, including a human patient. The method comprises administering an effective amount of the therapeutic agent of the invention (or pharmaceutical composition containing the same) to a subject or patient in need thereof. For example, the patient may be in need of an agent having a biological activity or preferred indication listed in Table 1. In certain embodiments employing a GLP-1 receptor agonist/ELP compound or employing an insulin/ELP compound, the invention provides a method for treating one or more disorders including type 1 or type 2 diabetes, hyperglycemia, and impaired glucose tolerance. In certain other embodiments employing Factor VII/VIIa/ELP compound, the invention provides a method for treating one or more disorders including hemophilia, post-surgical bleeding, anticoagulation-induced bleeding, thrombocytopenia, factor VII deficiency, factor XI deficiency, and intracranial hemorrhage.
Various other aspects, features and embodiments of the invention will be more fully apparent from the following disclosure and appended claims.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 depicts plasmid pET24d-ELP1-90, encoding an ELP component with a 10 unit VPGXG (SEQ ID NO: 3) repeat motif, where guest position X is V, G, and A in the ratio of 5:3:2. This motif is repeated eight times with a final C-terminal 10-unit repeat where X is V, G, A, and W in the ratio 4:3:2:1. This ELP component is represented generally as [(VPGXG)₁₀]₉.

FIG. 2A depicts plasmid pET24d-Ex-4 ELP1-90 encoding an ELP component with VPGXG (SEQ ID NO: 3) repeat motif (as in FIG. 1 ) cloned in frame with an N-terminal exendin-4 component. FIG. 2B depicts the nucleotide and amino acid sequence of the exendin-4/ELP fusion (SEQ ID NOS: 23 and 24). Primer sequences are indicated (SEQ ID NOS:35-40).

FIG. 3A depicts the nucleotide and amino acid sequence of an exendin-4 construct having an N-terminal Tev (Tobacco Etch Virus cysteine protease) cleavage site (SEQ ID NOS: 25 and 26). Primer sequences are indicated (SEQ ID NOS:38, 41, 42). FIG. 3B also depicts the nucleotide and amino acid sequence of an exendin-4 construct having an N-terminal Tev cleavage site, but with an additional sequence N-terminal to the Tev cleavage site to provide a better target for the protease (SEQ ID NOS: 27 and 28). Primer sequences are indicated (SEQ ID NOS:38, 43,44).

FIG. 4A depicts the nucleotide and amino acid sequence of an exendin-4/ELP fusion as in FIGS. 1-3 , but with a DsbA leader sequence to direct secretion into the periplasmic space (SEQ ID NOS: 29 and 30). Primer sequences are indicated (SEQ ID NOS:38, 45, 46). FIG. 4B depicts plasmid pET24d-DsbA-Ex-4 ELP1-90 encoding the fusion of FIG. 4A.

FIG. 5A depicts pPB0868, which encodes GLP-1(A8G,7-37)ELP1-90.

FIG. 5B depicts the nucleotide and amino acid sequence of the encoded fusion protein (SEQ ID NOS: 53 and 54, respectively).

FIG. 6A depicts pPB1022, which encodes GLP-1(A8G,7-37)ELP1-120.

FIG. 6B depicts the nucleotide and amino acid sequence of the encoded fusion protein (SEQ ID NOS: 55 and 56, respectively).

FIG. 7A depicts pPB0788, which encodes Factor VII-ELP1-90. FIG. 7B depicts the nucleotide and amino acid sequence of the encoded fusion protein (SEQ ID NOS: 57 and 58, respectively).

FIG. 8A depicts the nucleotide and amino acid sequence of an insulin (B, C, and A chains) having the ELP component cloned in frame (SEQ ID NOS: 31 and 32). Primer sequences are indicated (SEQ ID NOS: 47 and 48). FIG. 8B depicts plasmid pET24d Insulin-ELP1-90 expressing the insulin/ELP fusion of FIG. 8A.

FIG. 9 is a Western blot for FVII-ELP1-90 from transient transfection of Freestyle HEK293, detected with mouse anti-human FVII monoclonal antibody. Lanes are: (1) culture media; (2) FVII ELP1-90 after purification by phase transition; and FVII control.

FIG. 10 is an SDS-PAGE showing recombinant production of an Exendin-4/ELP4-60 fusion. Lanes are: (M) Protein markers; (1) Exendin-4 ELP4-60 from total lysate; (2) Exendin-4 ELP4-60 from insoluble lysate; (3) Exendin-4 ELP4-60 from soluble lysate; (4) Exendin-4 ELP4-60 from 1st transition (equal volume); (5) Exendin-4 ELP4-60 from 2nd transition (concentrated); (6) Exendin-4 ELP4-60 from 3rd transition (concentrated).

FIG. 11 shows the activation of Factor X by FactorVIIa-ELP1-90, and by Factor VIIa as a comparison. As shown, FactorVIIa-ELP retains full activity.

FIG. 12 shows that Factor VIIa-ELP1-90 has a long PK when administered by i.v. in rats. FactorVIIa has a T_1/2of about 690 min. as compared to about 45-60 min. for Factor VIIa.

FIG. 13 shows the high in vitro activity of GLP1-ELP and Exendin-4-ELP, when compared to the activity of Exendin peptide.

FIG. 14 shows that GLP1-ELP has a T_1/2, of about 12.9 hours when administered by i.v. to rats, and a T_1/2, of about 8.6 hours when administered subcutaneously (SQ).

FIG. 15 shows that GLP-1 ELP has a long half-life in rabbits of about 20 hours when administered i.v., and about 24 hours when administered sub-cutaneously.

FIG. 16 shows sustained glycemic control in diabetic mice with GLP-1-ELP.

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides therapeutic agents comprising an elastin-like peptide (ELP) (“the ELP component”) and a therapeutic component. The therapeutic component may be selected from Table 1 (e.g., selected from a Therapeutic Protein, or functional portion or functional analog thereof, listed in Table 1). In certain embodiments, the therapeutic component is a GLP-1 receptor agonist, such as GLP-1 or exendin-4, or may be insulin, Factor VII/VIIa, or functional analog thereof. The ELP component contains structural units related to, or derived from, sequences of the elastin protein, which provides certain therapeutic advantages, such as comparatively better persistence, stability, solubility, bioavailability, half-life, and/or biological action of the therapeutic component. Such properties may be determined with respect to, for example, an unfused or unconjugated counterpart of the therapeutic component. The invention further provides polynucleotides encoding the therapeutic agents of the invention, as well as methods of treatment or prophylaxis for certain biological conditions, including the preferred indications listed in Table 1, and including diabetes (e.g., Type I and Type II), hyperglycemia, bleeding, hemophilia, and hemorrhage, among others.
For ease of reference in the ensuing discussion, set out below are definitions of some terms appearing in the discussion.
As used herein, the term “therapeutic agent” or “therapeutic component” refers to an agent or component capable of inducing a biological effect in vivo and/or in vitro. The biological effect may be useful for treating and/or preventing a condition, disorder, or disease in a subject or patient.
As used herein, the term “coupled” means that the specified components are either directly covalently bonded to one another (e.g., via chemical conjugation or recombinant fusion technology), or indirectly covalently joined to one another (e.g., via chemical conjugation or recombinant fusion technology) through an intervening moiety or moieties, such as a bridge, spacer, or linker.
As used herein, “half-life” (which generally refers to in vivo half-life or circulatory half-life) is the period of time that is required for a 50% diminution of bioactivity of the active agent to occur. Such term is to be contrasted with “persistence,” which is the overall temporal duration of the active agent in the body, and “rate of clearance” as being a dynamically changing variable that may or may not be correlative with the numerical values of half-life and persistence.
The term “functional analog” refers to a protein that is an active analog (e.g., either chemical or protein analog), derivative, fragment, truncation isoform or the like of a native protein. For example, the functional analog may be a functional analog of a therapeutic protein listed in Table 1, or may be a functional analog of a GLP-1 receptor agonist (e.g., GLP-1, exendin), insulin, or Factor VII/VIIa. A polypeptide is active when it retains some or all of the biological activity of the corresponding native polypeptide, as determined in vivo or in one or more indicative in vitro assays. Exemplary activity assays for certain therapeutic proteins, which are determinative of activity, are listed Table 1. Further, such biological activities and assays for GLP-1 receptor agonists, insulin, and Factor VII/VIIa, which are determinative of whether a given molecule is a “functional analog,” are described in detail elsewhere herein.
As used herein, the term “native,” as used in reference to an amino acid sequence, indicates that the amino acid sequence is found in a naturally-occurring protein.
As used herein, the term “spacer” refers to any moiety, peptide or other chemical entity, that may be interposed between the ELP component and the therapeutic component. For example, the spacer may be a divalent group that is covalently bonded at one terminus to the ELP component, and covalently bonded at the other terminus to the therapeutic component. The therapeutic agents may therefore be open to the inclusion of additional chemical structure that does not preclude the efficacy of the agent for its intended purpose. The spacer may, for example, be a protease-sensitive spacer moiety that is provided to control the pharmacokinetics of the agent, or the spacer may be a protease-resistant moiety.
The therapeutic component and the ELP component may be coupled with one another in any suitable covalent manner, including chemical coupling and recombinant technology, such that the therapeutic agent is efficacious for its intended purpose, and such that the presence of the ELP component enhances the therapeutic component in some functional, therapeutic or physiological aspect. For example, the ELP-coupled therapeutic component may be enhanced in, e.g., its bioavailability, bio-unavailability, therapeutically effective dose, biological action, formulation compatibility, resistance to proteolysis or other degradative modality, solubility, half-life or other measure of persistence in the body subsequent to administration, rate of clearance from the body subsequent to administration, etc. Such enhancement may be determined, for example, in relation to a corresponding unconjugated or unfused counterpart therapeutic (e.g., determined relative to native GLP-1, exendin, insulin, or Factor VII/VIIa, or a therapeutic protein listed in Table 1).
In some embodiments, the therapeutic agent of the invention circulates or exists in the body in a soluble form, and escapes filtration by the kidney thereby persisting in the body in an active form. In some embodiments, the therapeutic agents of the invention have a molecular weight of less than the generally recognized cut-off for filtration through the kidney, such as less than about 60 kD, or in some embodiments less than about 55, 50, 45, 40, 30, or 20 kDa, and persist in the body by at least 2-fold, 3-fold, 4-fold, 5-fold, 10-fold, 20-fold, or 100-fold longer than an uncoupled (e.g., unfused or unconjugated) therapeutic counterpart.
The number of ELP and/or therapeutic components per molecule, and their respective positions within the molecule, may vary among embodiments of the invention. For example, in embodiments where the agent is a recombinant fusion, at least one ELP component may be placed at one or both of the N-terminus and the C-terminus. Where the ELP component is at both the N-terminus and C-terminus of the fusion, the ELP components will flank the therapeutic component. Alternatively, the therapeutic component may be positioned at either or both of the N-terminus and C-terminus. Where the therapeutic component is at both the N-terminus and C-terminus, the therapeutic component will flank the ELP component. In a further embodiment, different therapeutic components are positioned at the N-terminus and C-terminus of the molecule. As discussed in detail herein, in certain embodiments, such therapeutic component(s) may be released by proteolysis of a spacer moiety separating the ELP and therapeutic components. In certain embodiments, the therapeutic component may be inactive in the fused state, and becoming active upon proteolytic release from the ELP component(s). Alternatively, the therapeutic component remains active in the fused state, making proteolytic processing of the therapeutic agent unnecessary for biological activity.
When prepared as recombinant fusions, the therapeutic agent can be prepared by known recombinant expression techniques. For example, to recombinantly produce the therapeutic agent, a nucleic acid sequence encoding the chimeric gene is operatively linked to a suitable promoter sequence such that the nucleic acid sequence encoding such fusion protein will be transcribed and/or translated into the desired fusion protein in the host cells. Preferred promoters are those useful for expression in E. coli, such as the T7 promoter. Any commonly used expression system may be used, including eukaryotic or prokaryotic systems. Specific examples include yeast (e.g., Saccharomyces spp., Pichia spp.), baculovirus, mammalian, and bacterial systems, such as E. coli, and Caulobacter.
The various aspects and embodiments of the invention are described in greater detail in the following sections.

Elastin-Like Peptide (ELP) Component

The therapeutic agent of the invention may comprise one or more ELP components. The ELP components comprise or consist of structural peptide units or sequences that are related to, or derived from, the elastin protein. Such sequences are useful for improving the properties of therapeutic proteins, such as those listed in Table 1, as well as GLP-1 receptor agonists (e.g., GLP-1 or exendin-4), insulin, and Factor VII/VIIa in one or more of bioavailability, therapeutically effective dose, biological action, formulation compatibility, resistance to proteolysis, solubility, half-life or other measure of persistence in the body subsequent to administration, and/or rate of clearance from the body.
The ELP component is constructed from structural units of from three to about twenty amino acids, or in some embodiments, from four to ten amino acids, such as five or six amino acids. The length of the individual structural units, in a particular ELP component, may vary or may be uniform. In certain embodiments, the ELP component is constructed of a polytetra-, polypenta-, polyhexa-, polyhepta-, polyocta, and polynonapeptide motif of repeating structural units. Exemplary structural units include units defined by SEQ ID NOS: 1-12 (below), which may be employed as repeating structural units, including tandem-repeating units, or may be employed in some combination, to create an ELP effective for improving the properties of the therapeutic component. Thus, the ELP component may comprise or consist essentially of structural unit(s) selected from SEQ ID NOS: 1-12, as defined below.
The ELP component, comprising such structural units, may be of varying sizes. For example, the ELP component may comprise or consist essentially of from about 10 to about 500 structural units, or in certain embodiments about 15 to about 150 structural units, or in certain embodiments from about 20 to about 100 structural units, or from about 50 to about 90 structural units, including one or a combination of units defined by SEQ ID NOS: 1-12. Thus, the ELP component may have a length of from about 50 to about 2000 amino acid residues, or from about 100 to about 600 amino acid residues, or from about 200 to about 500 amino acid residues, or from about 200 to about 400 amino acid residues.
In some embodiments, the ELP component, or in some cases the therapeutic agent, has a size of less than about 65 kDa, or less than about 60 kDa, or less than about 55 kDa, or less than about 50 kDa, or less than about 40 kDa, or less than about 30 or 25 kDa. Three major blood proteins, Human Serum Albumin (HSA), Transferrin (Tf) and IgG, or the Fc portion of IgGs in their glycosylated form, have been exploited to extend the half-lives of proteins and peptides for improved therapeutic use. These molecules are 585, 679 and 480 amino acids in length giving molecular weights of about 66, 77, and ˜75 kDa (including glycosylations), respectively. They are each globular and relatively compact. The half life of these molecules is determined by a number of factors, including charge distribution, rescue of molecules by the neonatal Fc receptor (FcRn) (HSA and Fc) or cycling of Tf through the Tf receptor (TfR), and their size which prevents filtering through the kidney glomerulus. HSA is slightly below the generally regarded cut-off for filtration through the kidney (˜70 kDa) but its charge distribution helps prevent this. It would be anticipated that, in order to achieve half-life extension of the same order as that achieved with HSA, Tf and Fc, a protein of at least this molecular weight range would be required or desirable, i.e. having over 550 amino acids and being over 65 kDa. However, an ELP with a small number of amino acids relative to HSA, Tf and Fc (e.g., in the range of about 300 to 400) and around 30 to 40 kDa may have a half life that matches and/or exceeds that of HSA, Tf, and Fc.
In some embodiments, the ELP component in the untransitioned state may have an extended, relatively unstructured and non-globular form, and thus such molecules may have a large expanded structure in comparison to HSA, Tf and Fc, so as to escape kidney filtration. In such embodiments, the therapeutic agents of the invention have a molecular weight of less than the generally recognized cut-off for filtration through the kidney, such as less than about 60 kD, or in some embodiments less than about 55, 50, 45, 40, 30, or 25 kDa, and persist in the body by at least 2-fold, 3-fold, 4-fold, 5-fold, 10-fold, 20-fold, or 100-fold longer than an uncoupled (e.g., unfused or unconjugated) therapeutic counterpart.
In certain embodiments, the ELP component undergoes a reversible inverse phase transition. That is, the ELP components are structurally disordered and highly soluble in water below a transition temperature (Tt), but exhibit a sharp (2-3° C. range) disorder-to-order phase transition when the temperature is raised above the Tt, leading to desolvation and aggregation of the ELP components. For example, the ELP forms insoluble polymers, when reaching sufficient size, which can be readily removed and isolated from solution by centrifugation. Such phase transition is reversible, and isolated insoluble ELPs can be completely resolubilized in buffer solution when the temperature is returned below the Tt of the ELPs. Thus, the therapeutic agents of the invention can, in some embodiments, be separated from other contaminating proteins to high purity using inverse transition cycling procedures, e.g., utilizing the temperature-dependent solubility of the therapeutic agent, or salt addition to the medium. Successive inverse phase transition cycles can be used to obtain a high degree of purity. In addition to temperature and ionic strength, other environmental variables useful for modulating the inverse transition of the therapeutic agents include pH, the addition of inorganic and organic solutes and solvents, side-chain ionization or chemical modification, and pressure.
In certain embodiments, the ELP component does not undergo a reversible inverse phase transition, or does not undergo such a transition at a biologically relevant Tt, and thus the improvements in the biological and/or physiological properties of the molecule (as described elsewhere herein), may be entirely or substantially independent of any phase transition properties. Nevertheless, such phase transition properties may impart additional practical advantages, for example, in relation to the recovery and purification of such molecules.
In certain embodiments, the ELP component(s) may be formed of structural units, including but not limited to:

- (a) the tetrapeptide Val-Pro-Gly-Gly, or VPGG (SEQ ID NO: 1);
- (b) the tetrapeptide Ile-Pro-Gly-Gly, or IPGG (SEQ ID NO: 2);
- (c) the pentapeptide Val-Pro-Gly-X-Gly (SEQ ID NO: 3), or VPGXG, where X is any natural or non-natural amino acid residue, and where X optionally varies among polymeric or oligomeric repeats;
- (d) the pentapeptide Ala-Val-Gly-Val-Pro, or AVGVP (SEQ ID NO: 4);
- (e) the pentapeptide Ile-Pro-Gly-X-Gly, or IPGXG (SEQ ID NO: 5), where X is any natural or non-natural amino acid residue, and where X optionally varies among polymeric or oligomeric repeats;
- (e) the pentapeptide Ile-Pro-Gly-Val-Gly, or IPGVG (SEQ ID NO: 6);
- (f) the pentapeptide Leu-Pro-Gly-X-Gly, or LPGXG (SEQ ID NO: 7), where X is any natural or non-natural amino acid residue, and where X optionally varies among polymeric or oligomeric repeats;
- (g) the pentapeptide Leu-Pro-Gly-Val-Gly, or LPGVG (SEQ ID NO: 8);
- (h) the hexapeptide Val-Ala-Pro-Gly-Val-Gly, or VAPGVG (SEQ ID NO: 9);
- (I) the octapeptide Gly-Val-Gly-Val-Pro-Gly-Val-Gly, or GVGVPGVG (SEQ ID NO: 10);
- (J) the nonapeptide Val-Pro-Gly-Phe-Gly-Val-Gly-Ala-Gly, or VPGFGVGAG (SEQ ID NO: 11); and
- (K) the nonapeptides Val-Pro-Gly-Val-Gly-Val-Pro-Gly-Gly, or VPGVGVPGG (SEQ ID NO: 12).
  Such structural units defined by SEQ ID NOS:1-12 may form structural repeat units, or may be used in combination to form an ELP component in accordance with the invention. In some embodiments, the ELP component is formed entirely (or almost entirely) of one or a combination of (e.g., 2, 3 or 4) structural units selected from SEQ ID NOS: 1-12. In other embodiments, at least 75%, or at least 80%, or at least 90% of the ELP component is formed from one or a combination of structural units selected from SEQ ID NOS: 1-12, and which may be present as repeating units.

In certain embodiments, the ELP component(s) contain repeat units, including tandem repeating units, of the pentapeptide Val-Pro-Gly-X-Gly (SEQ ID NO:3), where X is as defined above, and where the percentage of Val-Pro-Gly-X-Gly (SEQ ID NO:3) pentapeptide units taken with respect to the entire ELP component (which may comprise structural units other than VPGXG (SEQ ID NO:3)) is greater than about 75%, or greater than about 85%, or greater than about 95% of the ELP component. The ELP component may contain motifs having a 5 to 15-unit repeat (e.g. about 10-unit repeat) of the pentapeptide of SEQ ID NO: 3, with the guest residue X varying among at least 2 or at least 3 of the units. The guest residues may be independently selected, such as from the amino acids V, I, L, A, G, and W (and may be selected so as to retain a desired inverse phase transition property). The repeat motif itself may be repeated, for example, from about 5 to about 12 times, such as about 8 to 10 times, to create an exemplary ELP component. The ELP component as described in this paragraph may of course be constructed from any one of the structural units defined by SEQ ID NOS: 1-12, or a combination thereof.
In some embodiments, the ELP component may include a β-turn structure. Exemplary peptide sequences suitable for creating a β-turn structure are described in International Patent Application PCT/US96/05186, which is hereby incorporated by reference in its entirety. For example, the fourth residue (X) in the elastin pentapeptide sequence, VPGXG (SEQ ID NO:3), can be altered without eliminating the formation of a β-turn. Alternatively, the ELP component may lack a β-turn, or otherwise have a different conformation and/or folding character.
In certain embodiments, the ELP components include polymeric or oligomeric repeats of the pentapeptide VPGXG (SEQ ID NO: 3), where the guest residue X is any amino acid. X may be a naturally occurring or non-naturally occurring amino acid. In some embodiments, X is selected from alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, serine, threonine, tryptophan, tyrosine and valine. In some embodiments, X is a natural amino acid other than proline or cysteine.
The guest residue X (e.g., with respect to SEQ ID NO: 3, or other ELP structural unit) may be a non-classical (non-genetically encoded) amino acid. Examples of non-classical amino acids include: D-isomers of the common amino acids, 2,4-diaminobutyric acid, α-amino isobutyric acid, A-aminobutyric acid, Abu, 2-amino butyric acid, γ-Abu, ε-Ahx, 6-amino hexanoic acid, Aib, 2-amino isobutyric acid, 3-amino propionic acid, omithine, norieucine, norvaline, hydroxyproline, sarcosine, citrulline, homocitrulline, cysteic acid, t-butylglycine, t-butylalanine, phenyiglycine, cyclohexylalanine, β-alanine, fluoro-amino acids, designer amino acids such as β-methyl amino acids, Cα-methyl amino acids, Nα-methyl amino acids, and amino acid analogs in general.
Selection of X is independent in each ELP structural unit (e.g., for each structural unit defined herein having a guest residue X). For example, X may be independently selected for each structural unit as an amino acid having a positively charged side chain, an amino acid having a negatively charged side chain, or an amino acid having a neutral side chain, including in some embodiments, a hydrophobic side chain.
In still other embodiments, the ELP component(s) may include polymeric or oligomeric repeats of the pentapeptides VPGXG (SEQ ID NO:3), IPGXG (SEQ ID NO:5) or LPGXG (SEQ ID NO:7), or a combination thereof, where X is as defined above.
In each embodiment, the structural units, or in some cases polymeric or oligomeric repeats, of the ELP sequences may be separated by one or more amino acid residues that do not eliminate the overall effect of the molecule, that is, in imparting certain improvements to the therapeutic component as described. In certain embodiments, such one or more amino acids also do not eliminate or substantially affect the phase transition properties of the ELP component (relative to the deletion of such one or more amino acids).
In each repeat, X is independently selected. The structure of the resulting ELP components may be described using the notation ELPk [X_iY_j-n], where k designates a particular ELP repeat unit, the bracketed capital letters are single letter amino acid codes and their corresponding subscripts designate the relative ratio of each guest residue X in the structural units (where applicable), and n describes the total length of the ELP in number of the structural repeats. For example, ELP1 [V₅A₂G₃-10] designates an ELP component containing 10 repeating units of the pentapeptide VPGXG (SEQ ID NO:3), where X is valine, alanine, and glycine at a relative ratio of 5:2:3; ELP1 [K₁V₂F₁-4] designates an ELP component containing 4 repeating units of the pentapeptide VPGXG (SEQ ID NO:3), where X is lysine, valine, and phenylalanine at a relative ratio of 1:2:1; ELP1 [K₁V₇F₁-9] designates a polypeptide containing 9 repeating units of the pentapeptide VPGXG (SEQ ID NO:3), where X is lysine, valine, and phenylalanine at a relative ratio of 1:7:1; ELP1 [V-5] designates a polypeptide containing 5 repeating units of the pentapeptide VPGXG (SEQ ID NO:3), where X is exclusively valine; ELP1 [V-20] designates a polypeptide containing 20 repeating units of the pentapeptide VPGXG (SEQ ID NO:3), where X is exclusively valine; ELP2 [5] designates a polypeptide containing 5 repeating units of the pentapeptide AVGVP (SEQ ID NO:4); ELP3 [V-5] designates a polypeptide containing 5 repeating units of the pentapeptide IPGXG (SEQ ID NO:5), where X is exclusively valine; ELP4 [V-5] designates a polypeptide containing 5 repeating units of the pentapeptide LPGXG (SEQ ID NO:7), where X is exclusively valine. Such ELP components as described in this paragraph may be used in connection with the present invention to increase the therapeutic properties of the therapeutic component.
Further, the Tt is a function of the hydrophobicity of the guest residue. Thus, by varying the identity of the guest residue(s) and their mole fraction(s), ELPs can be synthesized that exhibit an inverse transition over a 0-100° C. range. Thus, the Tt at a given ELP length may be decreased by incorporating a larger fraction of hydrophobic guest residues in the ELP sequence. Examples of suitable hydrophobic guest residues include valine, leucine, isoleucine, phenyalanine, tryptophan and methionine. Tyrosine, which is moderately hydrophobic, may also be used. Conversely, the Tt may be increased by incorporating residues, such as those selected from the group consisting of: glutamic acid, cysteine, lysine, aspartate, alanine, asparagine, serine, threonine, glycine, arginine, and glutamine; preferably selected from alanine, serine, threonine and glutamic acid.
The ELP component in some embodiments is selected or designed to provide a Tt ranging from about 10 to about 80° C., such as from about 35 to about 60° C., or from about 38 to about 45° C. In some embodiments, the Tt is greater than about 40° C. or greater than about 42° C., or greater than about 45° C., or greater than about 50° C. The transition temperature, in some embodiments, is above the body temperature of the subject or patient (e.g., >37° C.) thereby remaining soluble in vivo, or in other embodiments, the Tt is below the body temperature (e.g., <37° C.) to provide alternative advantages, such as in vivo formation of a drug depot for sustained release of the therapeutic agent.
The Tt of the ELP component can be modified by varying ELP chain length, as the Tt generally increases with decreasing MW. For polypeptides having a molecular weight >100,000, the hydrophobicity scale developed by Urry et al. (PCT/US96/05186, which is hereby incorporated by reference in its entirety) is preferred for predicting the approximate Tt of a specific ELP sequence. However, in some embodiments, ELP component length can be kept relatively small, while maintaining a target Tt, by incorporating a larger fraction of hydrophobic guest residues (e.g., amino acid residues having hydrophobic side chains) in the ELP sequence. For polypeptides having a molecular weight <100,000, the Tt may be predicted or determined by the following quadratic function: Tt=M₀+M₁X+M₂X²where X is the MW of the fusion protein, and M₀=116.21; M₁=−1.7499; M₂=0.010349.
While the Tt of the ELP component, and therefore of the ELP component coupled to a therapeutic component, is affected by the identity and hydrophobicity of the guest residue, X, additional properties of the molecule may also be affected. Such properties include, but are not limited to solubility, bioavailability, persistence, and half-life of the molecule.
As described in PCT/US2007/077767 (published as WO 2008/030968), which is hereby incorporated by reference in its entirety, the ELP-coupled therapeutic component can retain the therapeutic component's biological activity. Additionally, ELPs themselves can exhibit long half-lives. Therefore, ELP components in accordance with the present invention substantially increase (e.g. by greater than 10%, 20%, 30%, 50%, 100%, 200%, 500% or more, in specific embodiments) the half-life of the therapeutic component when conjugated thereto. Such half-life (or in some embodiments persistance or rate of clearance) is determined in comparison to the half-life of the free (unconjugated or unfused) form of the therapeutic component. Furthermore, ELPs may target high blood content organs, when administered in vivo, and thus, can partition in the body, to provide a predetermined desired corporeal distribution among various organs or regions of the body, or a desired selectivity or targeting of a therapeutic agent. In sum, the therapeutic agents contemplated by the invention are administered or generated in vivo as active compositions having extended half-lives (e.g., circulatory half-life), among other potential benefits described herein.
The invention thus provides various agents for therapeutic (in vivo) application, where the therapeutic component is biologically active. Such therapeutic components include those listed in Table 1 (e.g., full length or functional portions or functional analogs thereof), as well as GLP-1 receptor agonists such as GLP-1 or exendin-4, insulin, or Factor VII/VIIa, and functional analogs thereof. The structure and activity of such therapeutic components are described in detail below. In some forms of the therapeutic agent, the coupling of the therapeutic component to the ELP component is effected by direct covalent bonding or indirect (through appropriate spacer groups) bonding (as described elsewhere herein). Further, the therapeutic component(s) and the ELP component(s) can be structurally arranged in any suitable manner involving such direct or indirect covalent bonding, relative to one another.

Glucagon-Like Peptide (GLP)-1 Receptor Agonists

In certain embodiments of the invention, the therapeutic agent comprises an ELP component fused or conjugated to a GLP-1 receptor agonist, such as GLP-1, exendin-4, or functional analogs thereof.
Human GLP-1 is a 37 amino acid residue peptide originating from preproglucagon which is synthesized in the L-cells in the distal ileum, in the pancreas, and in the brain. Processing of preproglucagon to give GLP-1 (7-36)amide, GLP-1 (7-37) and GLP-2 occurs mainly in the L-cells. A simple system is used to describe fragments and analogs of this peptide. For example, Gly-GLP-1 (7-37) designates a fragment of GLP-1 formally derived from GLP-1 by deleting the amino acid residues Nos. 1 to 6 and substituting the naturally occurring amino acid residue in position 8 (Ala) by Gly. Similarly, Lys³⁴(N^ε-tetradecanoyl)-GLP-1(7-37) designates GLP-1 (7-37) wherein the ε-amino group of the Lys residue in position 34 has been tetradecanoylated. Where reference in this text is made to C-terminally extended GLP-1 analogues, the amino acid residue in position 38 is Arg unless otherwise indicated, the optional amino acid residue in position 39 is also Arg unless otherwise indicated and the optional amino acid residue in position 40 is Asp unless otherwise indicated. Also, if a C-terminally extended analogue extends to position 41, 42, 43, 44 or 45, the amino acid sequence of this extension is as in the corresponding sequence in human preproglucagon unless otherwise indicated.
The parent peptide of GLP-1, proglucagon (PG), has several cleavage sites that produce various peptide products dependent on the tissue of origin including glucagon (PG[32-62]) and GLP-1[7-36]NH₂(PG[72-107]) in the pancreas, and GLP-1[7-37] (PG[78-108]) and GLP-1[7-36]NH₂(PG [78-107]) in the L cells of the intestine where GLP-1[7-36]NH₂(78-107 PG) is the major product. The GLP-1 component in accordance with the invention may be any biologically active product or deivative of proglocagon, or functional analog thereof, including: GLP-1 (1-35), GLP-1(1-36), GLP-1 (1-36)amide, GLP-1 (1-37), GLP-1 (1-38), GLP-1 (1-39), GLP-1 (1-40), GLP-1 (1-41), GLP-1 (7-35), GLP-1 (7-36), GLP-1 (7-36)amide, GLP-1 (7-37), GLP-1 (7-38), GLP-1 (7-39), GLP-1 (7-40) and GLP-1 (7-41), or a analog of the foregoing. Generally, the GLP-1 component in some embodiments may be expressed as GLP-1 (A-B), where A is an integer from 1 to 7 and B is an integer from 38 to 45, optionally with one or more amino acid substitutions as defined below.
As an overview, after processing in the intestinal L-cells, GLP-1 is released into the circulation, most notably in response to a meal. The plasma concentration of GLP-1 rises from a fasting level of approximately 15 pmol/L to a peak postprandial level of 40 pmol/L. For a given rise in plasma glucose concentration, the increase in plasma insulin is approximately threefold greater when glucose is administered orally compared with intravenously (Kreymann et al., 1987, Lancet 2(8571): 1300-4). This alimentary enhancement of insulin release, known as the incretin effect, is primarily humoral and GLP-1 is now thought to be the most potent physiological incretin in humans. GLP-1 mediates insulin production via binding to the GLP-1 receptor, known to be expressed in pancreatic β cells. In addition to the insulinotropic effect, GLP-1 suppresses glucagon secretion, delays gastric emptying (Wettergen et al., 1993, Dig Dis Sci 38: 665-73) and may enhance peripheral glucose disposal (D'Alessio et al., 1994, J. Clin Invest 93: 2293-6).
A combination of actions gives GLP-1 unique therapeutic advantages over other agents currently used to treat non-insulin-dependent diabetes mellitus (NIDDM). First, a single subcutaneous dose of GLP-1 can completely normalize post prandial glucose levels in patients with NIDDM (Gutniak et al., 1994, Diabetes Care 17: 1039-44). This effect may be mediated both by increased insulin release and by a reduction in glucagon secretion. Second, intravenous infusion of GLP-1 can delay postprandial gastric emptying in patients with NIDDM (Williams et al., 1996, J. Clin Endo Metab 81: 327-32). Third, unlike sulphonylureas, the insulinotropic action of GLP-1 is dependent on plasma glucose concentration (Holz et al., 1993, Nature 361:362-5). Thus, the loss of GLP-1-mediated insulin release at low plasma glucose concentration protects against severe hypoglycemia.
When given to healthy subjects, GLP-1 potently influences glycemic levels as well as insulin and glucagon concentrations (Orskov, 1992, Diabetologia 35:701-11), effects which are glucose dependent (Weir et al., 1989, Diabetes 38: 338-342). Moreover, it is also effective in patients with diabetes (Gutniak, M., 1992, N. Engl J Med 226: 1316-22), normalizing blood glucose levels in type 2 diabetic subjects and improving glycemic control in type 1 patients (Nauck et al., 1993, Diabetologia 36: 741-4, Creutzfeldt et al., 1996, Diabetes Care 19:580-6).
GLP-1 is, however, metabolically unstable, having a plasma half-life (t_1/2) of only 1-2 minutes in vivo. Moreover, exogenously administered GLP-1 is also rapidly degraded (Deacon et al., 1995, Diabetes 44: 1126-31). This metabolic instability has limited the therapeutic potential of native GLP-1.
GLP-1[7-36]NH₂has the following amino acid sequence: HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR (SEQ ID NO: 13), which may be employed as the GLP-1 component in accordance with the invention. Alternatively, the GLP-1 component may contain glycine (G) at the second position, giving, for example, the sequence HGEGTFTSDVSSYLEGQAAKEFIAWLVKGR (SEQ ID NO: 17). The GLP-1 component may be a biologically active fragment of GLP-1, for example, as disclosed in US 2007/0041951, which is hereby incorporated by reference in its entirety. Other fragments and modified sequences of GLP-1 are known in the art (U.S. Pat. Nos. 5,614,492; 5,545,618; European Patent Application, Publication No. EP 0658568 A1; WO 93/25579, which are hereby incorporated by reference in their entireties). Such fragments and modified sequences may be used in connection with the present invention, as well as those described below.
Certain structural and functional analogs of GLP-1 have been isolated from the venom of the Gila monster lizards (Heloderma suspectum and Heloderma horridum) and have shown clinical utility. Such molecules find use in accordance with the present invention. In particular, exendin-4 is a 39 amino acid residue peptide isolated from the venom of Heloderma suspectum and shares approximately 52% homology with human GLP-1. Exendin-4 is a potent GLP-1 receptor agonist that stimulates insulin release, thereby lowering blood glucose levels. Exendin-4 has the following amino acid sequence: HGEGTFTSDLSKQMEEEAVRLFEWLKNGGPSSGAPPPS (SEQ ID NO: 14). A synthetic version of exendin-4 known as exenatide (marketed as Byetta®) has been approved for the treatment of Type-2 Diabetes. Although exenatide is structurally analogous to native GLP-1, it has a longer half-life after injection.
While exenatide has the ability to lower blood glucose levels on its own, it can also be combined with other medications such as metformin, a thiozolidinedione, a sulfonylureas, and/or insulin to improve glucose control. Exenatide is administered by injection subcutaneously twice per day using a pre-filled pen device. Typical human responses to exenatide include improvements in the initial rapid release of endogenous insulin, an increase in β-cell growth and replication, suppression of pancreatic glucagon release, delayed gastric emptying, and reduced appetite—all of which function to lower blood glucose. Unlike sulfonylureas and meglitinides, exenatide increases insulin synthesis and secretion in the presence of glucose only, thus lessening the risk of hypoglycemia. Despite the therapeutic utility of exenatide, it has certain undesirable traits, including the requirement of twice daily injections, gastrointestional side effects, and similar to native GLP-1, a relatively short half-life (i.e. approximately 2 hr).
Various functional analogs of GLP-1 and exendin-4 are known, and which find use in accordance with the invention. These include liraglutide (Novo Nordisk, WO98/008871), R1583/taspoglutide (Roche, WO00/034331), CJC-1131 (ConjuChem, WO00/069911), ZP-10/AVE0010 (Zealand Pharma, Sanofi-Aventis, WO01/004156), and LY548806 (Eli Lilly, WO03/018516).
Liraglutide, also known as NN2211, is a GLP-1 receptor agonist analog that has been designed for once-daily injection (Harder et al., 2004, Diabetes Care 27: 1915-21). Liraglutide has been tested in patients with type-2 diabetes in a number of studies and has been shown to be effective over a variety of durations. In one study, treatment with liraglutide improved glycemic control, improved β-cell function, and reduced endogenous glucose release in patients with type-2 diabetes after one week of treatment (Degn et al., 2004, Diabetes 53: 1187-94). In a similar study, eight weeks of 0.6-mg liraglutide therapy significantly improved glycemic control without increasing weight in subjects with type 2 diabetes compared with those on placebo (Harder et al., 2004, Diabetes Care 27: 1915-21).
Thus, in certain embodiments, the GLP-1 receptor agonist in accordance with the invention is as described in WO98/008871, which is hereby incorporated by reference in its entirety. The GLP-1 receptor agonist may have at least one lipophilic substituent, in addition to one, two, or more amino acid substitutions with respect to native GLP-1. For example, the lipophilic substituent may be an acyl group selected from CH₃(CH₂)_nCO—, wherein n is an integer from 4 to 38, such as an integer from 4 to 24. The lipophilic substituent may be an acyl group of a straight-chain or branched alkyl or fatty acid (for example, as described in WO98/008871, which description is hereby incorporated by reference).
In certain embodiments, the GLP-1 component is Arg²⁶-GLP-1 (7-37), Arg³⁴-GLP-1(7-37), Lys³⁶-GLP-1 (7-37), Arg^26,34Lys³⁶-GLP-I (7-37), Arg^26,34Lys³⁶-GLP-1 (7-38), Arg^28,34Lys³⁹-GLP-1 (7-39), Arg^26,34Lys⁴⁰-GLP-1(7-40), Arg²⁶Lys³⁶-GLP-1(7-37), Arg³⁴Lys³⁶-GLP-1(7-37), Arg²⁶Lys³⁹-GLP-1(7-39), Arg³⁴Lys⁴⁰-GLP-1(7-40), Arg^26,34Lys^36,39-GLP-I (7-39), Arg^26,34Lys^36,40-GLP-1(7-40), Gly⁸Arg²⁶-GLP-1(7-37); Gly⁸Arg³⁴-GLP-1(7-37); Gly⁸Lys³⁸-GLP-1(7-37); Gly⁸Arg^26,34Lys³⁶-GLP-1(7-37), Gly⁸Arg^26,34Lys³⁹-GLP-1(7-39), Gly⁸Arg^26,34Lys⁴⁰-GLP-1(7-40), Gly⁸Arg²⁶Lys³⁶-GLP-1(7-37), Gly⁸Arg³⁴Lys³⁶-GLP-1(7-37), Gly⁸Arg²⁶Lys³⁹-GLP-1(7-39); Gly⁸Arg³⁴Lys⁴⁰-GLP-1(7-40), Gly⁸Arg^26,34Lys^36,39GLP-1(7-39) and Gly⁸Arg^26,34Lys^35,40-GLP-1(7-40), each optionally having a lipophilic substituent. For example, the GLP-1 receptor agonist may have the sequence/structure Arg³⁴Lys²⁶-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1(7-37).
Taspoglutide, also known as R1583 or BIM 51077, is a GLP-1 receptor agonist that has been shown to improve glycemic control and lower body weight in subjects with type 2 diabetes mellitus treated with metformin (Abstract No. A-1604, Jun. 7, 2008, 68th American Diabetes Association Meeting, San Francisco, Calif.).
Thus, in certain embodiments, the GLP-1 receptor agonist is as described in WO00/034331, which is hereby incorporated by reference in its entirety. In certain exemplary embodiments, the GLP-1 receptor agonist has the sequence [Aib^8,35]hGLP-1(7-36)NH₂(e.g. taspoglutide), wherein Aib is alpha-aminoisobutyric acid.
CJC-1131 is a GLP-1 analog that consists of a DPP-IV-resistant form of GLP-1 joined to a reactive chemical linker group that allows GLP-1 to form a covalent and irreversible bond with serum albumin following subcutaneous injection (Kim et al., 2003, Diabetes 52: 751-9). In a 12-week, randomized, double-blind, placebo-controlled multicenter study, CJC-1131 and metformin treatment was effective in reducing fasting blood glucose levels in type 2 diabetes patients (Ratner et al., Abstract No. 10-OR, Jun. 10-14, 2005, 65th American Diabetes Association Meeting, San Francisco, Calif.).
Thus, in certain embodiments, the GLP-1 receptor agonist is as described in WO00/069911, which is hereby incorporated by reference in its entirety. In some embodiments, the GLP-1 receptor agonist is modified with a reactive group which reacts with amino groups, hydroxyl groups or thiol groups on blood components to form a stable covalent bond. In certain embodiments, the GLP-1 receptor agonist is modified with a reactive group selected from the group consisting of succinimidyl and maleimido groups. In certain exemplary embodiments, the GLP-1 receptor agonist has the sequence/structure: D-Ala⁸Lys³⁷-(2-(2-(2-maleimidopropionamido(ethoxy)ethoxy)acetamide))-GLP-1(7-37) (e.g. CJC-1131).
AVE0010, also known as ZP-10, is a GLP-1 receptor agonist that may be employed in connection with the invention. In a recent double-blind study, patients treated with once daily dosing of AVE0010 demonstrated significant reductions in HbA1c levels (Ratner et al., Abstract No. 433-P, 68th American Diabetes Association Meeting, San Francisco, Calif.). At the conclusion of the study, the percentages of patients with HbA1c <7% ranged from 47-69% for once daily dosing compared to 32% for placebo. In addition, AVE0010 treated patients showed dose-dependent reductions in weight and post-prandial plasma glucose.
Thus, in certain embodiments, the GLP-1 receptor agonist is as described in WO01/004156, which is hereby incorporated by reference in its entirety. For example, the GLP-1 receptor agonist may have the sequence:

(SEQ ID NO: 18)

HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPSKKKKKK-NH2.

(e.g. AVE0010)

LY548806 is a GLP-1 derivative designed to be resistant to proteolysis by dipeptidase-peptidyl IV (DPP-IV) (Jackson et al., Abstract No. 562, Jun. 10-14, 2005, 65th American Diabetes Association Meeting, San Francisco, Calif.). In an animal model of hyperglycemia, LY548806 has been shown to produce a significant lowering of blood glucose levels during the hyperglycemic phase (Saha et al., 2006, J. Pharm. Exp. Ther. 316: 1159-64). Moreover, LY548806 was shown to produce a significant increase in insulin levels consistent with its known mechanism of action, namely stimulation of insulin release in the presence of hyperglycemia.
Thus, in certain embodiments, the GLP-1 receptor agonist is as described in WO03/018516, which is hereby incorporated by reference in its entirety. In some embodiments, the therapeutic agents of the present invention comprise GLP-1 analogs wherein the backbone for such analogs or fragments contains an amino acid other than alanine at position 8 (position 8 analogs). The backbone may also include L-histidine, D-histidine, or modified forms of histidine such as desamino-histidine, 2-amino-histidine, s-hydroxy-histidine, homohistidine, α-fluoromethyl-histidine, or α-methyl-histidine at position 7. In some embodiments, these position 8 analogs may contain one or more additional changes at positions 12, 16, 18, 19, 20, 22, 25, 27, 30, 33, and 37 compared to the corresponding amino acid of native GLP-1. In other embodiments, these position 8 analogs may contain one or more additional changes at positions 16, 18, 22, 25 and 33 compared to the corresponding amino acid of native GLP-1. In certain exemplary embodiments, the GLP-1 receptor agonist has the sequence: HVEGTFTSDVSSYLEEQAAKEFIAWLIKGRG-OH (SEQ ID NO: 19) (e.g. LY548806).
Thus, the present invention provides therapeutic agents comprising an elastin-like peptide (ELP) and a GLP-1 receptor agonist. For example, in certain embodiments, the GLP-1 receptor agonist is GLP-1 (SEQ ID NO:13, 17, or 59) or a functional analog thereof. In other embodiments, the GLP-1 receptor agonist is exendin-4 (SEQ ID NO:14) or a functional analog thereof. Such functional analogs of GLP-1 or exendin-4 include functional fragments truncated at the C-terminus by from 1 to 10 amino acids, including by 1, 2, 3, or up to about 5 amino acids (with respect to SEQ ID NOS: 13, 14, 17, or 59). Such functional analogs may contain from 1 to 10 amino acid insertions, deletions, and/or substitutions (collectively) with respect to the native sequence (e.g., SEQ ID NOS 13, 14, and 59), and in each case retaining the activity of the peptide. For example, the functional analog of GLP-1 or exendin-4 may have from 1 to about 3, 4, or 5 insertions, deletions and/or substitutions (collectively) with respect to SEQ ID NOS: 13, 59 and 14, and in each case retaining the activity of the peptide. Such activity may be confirmed or assayed using any available assay, including those described herein. In these or other embodiments, the GLP-1 receptor agonist component has at least about 50%, 75%, 80%, 85%, 90%, or 95% identity with the native sequence (SEQ ID NOS: 13, 59, and 14). The determination of sequence identity between two sequences (e.g., between a native sequence and a functional analog) can be accomplished using any alignment tool, including Tatusova et al., Blast 2 sequences—a new tool for comparing protein and nucleotide sequences, FEMS Miarobiol Left. 174:247-250 (1999). Such functional analogs may further comprise additional chemical modifications, such as those described in this section and/or others known in the art.
In certain embodiments, the GLP1-ELP fusion has a sequence exemplified herein as SEQ ID NOS: 54 and 56. When processed, the mature form of such fusion protein will begin with the His⁷of GLP.
In another aspect, the present invention provides methods for the treatment or prevention of type 2 diabetes, impaired glucose tolerance, type 1 diabetes, hyperglycemia, obesity, binge eating, bulimia, hypertension, syndrome X, dyslipidemia, cognitive disorders, atheroschlerosis, non-fatty liver disease, myocardial infarction, coronary heart disease and other cardiovascular disorders. The method comprises administering the therapeutic agent comprising the elastin-like peptide (ELP) and the GLP-1 receptor agonist (as described above) to a patient in need of such treatment. In these or other embodiments, the present invention provides methods for decreasing food intake, decreasing β-cell apoptosis, increasing β-cell function and β-cell mass, and/or for restoring glucose sensitivity to β-cells. Generally, the patient may be a human or non-human animal patient (e.g., dog, cat, cow, or horse). Preferably, the patient is human.
The treatment with a ELP/GLP-1 receptor agonist compound according to the present invention may also be combined with one or more pharmacologically active substances, e.g. selected from antidiabetic agents, antiobesity agents, appetite regulating agents, antihypertensive agents, agents for the treatment and/or prevention of complications resulting from or associated with diabetes and agents for the treatment and/or prevention of complications and disorders resulting from or associated with obesity. In the present context, the expression “antidiabetic agent” includes compounds for the treatment and/or prophylaxis of insulin resistance and diseases wherein insulin resistance is the pathophysiological mechanism.
The ability of a GLP-1 or exendin-4 analog, or an GLP-1 receptor agonist/ELP compound, to bind the GLP-1 receptor may be determined by standard methods, for example, by receptor-binding activity screening procedures which involve providing appropriate cells that express the GLP-1 receptor on their surface, for example, insulinoma cell lines such as RINmSF cells or INS-1 cells. In addition to measuring specific binding of tracer to membrane using radioimmunoassay methods, cAMP activity or glucose dependent insulin production can also be measured. In one method, a polynucleotide encoding the GLP-1 receptor is employed to transfect cells to thereby express the GLP-1 receptor protein. Thus, these methods may be employed for testing or confirming whether a suspected GLP-1 receptor agonist is active. An exemplary assay is described in greater detail herein.
In addition, known methods can be used to measure or predict the level of biologically activity of a GLP-1 receptor agonist or GLP-1 receptor agonist/ELP in vivo (See e.g. Siegel, et al., 1999, Regul Pept 79(2-3): 93-102). In particular, GLP-1 receptor agonists or GLP-1 receptor agonist/ELP compounds can be assessed for their ability to induce the production of insulin in vivo using a variety of known assays for measuring GLP-1 activity. For example, an ELP/GLP-1 receptor agonist compound can be introduced into a cell, such as an immortalized β-cell, and the resulting cell can be contacted with glucose. If the cell produces insulin in response to the glucose, then the modified GLP-1 is generally considered biologically active in vivo (Fehmann et al., 1992, Endoarinology 130: 159-166). An exemplary assay is described in greater detail herein.
The ability of an GLP-1 receptor agonist/ELP compound to enhance β-cell proliferation, inhibit β-cell apoptosis, and regulate islet growth may also be measured using known assays. Pancreatic β-cell proliferation may be assessed by ³H-tymidine or BrdU incorporation assays (See e.g. Buteau et al., 2003, Diabetes 52: 124-32), wherein pancreatic β-cells such as INS(832/13) cells are contacted with an ELP/GLP-1 receptor agonist compound and analyzed for increases in ³H-thymidine or BrdU incorporation. The antiapoptotic activity of an ELP/GLP-1 receptor agonist compound can be measured in cultured insulin-secreting cells and/or in animal models where diabetes occurs as a consequence of an excessive rate of beta-cell apoptosis (See e.g. Bulotta et al., 2004, Cell Biochem Biophys 40(3 suppl): 65-78).
In addition to GLP-1, other peptides of this family, such as those derived from processing of the pro-glucagon gene, such as GLP-2, GIP, and oxyntomodulin, could be conjugated or fused to the ELP component (as described herein) to enhance the therapeutic potential.

Insulin

In other embodiments, the present invention provides a therapeutic agent comprising an ELP component coupled to insulin (e.g., via fusion or conjugation). Insulin injections, e.g. of human insulin, can be used to treat diabetes. The insulin-making cells of the body are called β-cells, and they are found in the pancreas gland. These cells clump together to form the “islets of Langerhans”, named for the German medical student who described them.
The synthesis of insulin begins at the translation of the insulin gene, which resides on chromosome 11. During translation, two introns are spliced out of the mRNA product, which encodes a protein of 110 amino acids in length. This primary translation product is called preproinsulin and is inactive. It contains a signal peptide of 24 amino acids in length, which is required for the protein to cross the cell membrane.
Once the preproinsulin reaches the endoplasmic reticulum, a protease cleaves off the signal peptide to create proinsulin. Proinsulin consists of three domains: an amino-terminal B chain, a carboxyl-terminal A chain, and a connecting peptide in the middle known as the C-peptide. Insulin is composed of two chains of amino acids named chain A (21 amino acids-GIVEQCCASVCSLYQLENYCN) (SEQ ID NO: 15) and chain B (30 amino acids FVNQHLCGSHLVEALYLVCGERGFFYTPKA) (SEQ ID NO: 16) that are linked together by two disulfide bridges. There is a 3rd disulfide bridge within the A chain that links the 6th and 11th residues of the A chain together. In most species, the length and amino acid compositions of chains A and B are similar, and the positions of the three disulfide bonds are highly conserved. For this reason, pig insulin can replace deficient human insulin levels in diabetes patients. Today, porcine insulin has largely been replaced by the mass production of human proinsulin by bacteria (recombinant insulin).
Insulin molecules have a tendency to form dimers in solution, and in the presence of zinc ions, insulin dimers associate into hexamers. Whereas monomers of insulin readily diffuse through the blood and have a rapid effect, hexamers diffuse slowly and have a delayed onset of action. In the design of recombinant insulin, the structure of insulin can be modified in a way that reduces the tendency of the insulin molecule to form dimers and hexamers but that does not interrupt binding to the insulin receptor. In this way, a range of preparations are made, varying from short acting to long acting.
Within the endoplasmic reticulum, proinsulin is exposed to several specific peptidases that remove the C-peptide and generate the mature and active form of insulin. In the Golgi apparatus, insulin and free C-peptide are packaged into secretory granules, which accumulate in the cytoplasm of the β-cells. Exocytosis of the granules is triggered by the entry of glucose into the beta cells. The secretion of insulin has a broad impact on metabolism.
There are two phases of insulin release in response to a rise in glucose. The first is an immediate release of insulin. This is attributable to the release of preformed insulin, which is stored in secretory granules. After a short delay, there is a second, more prolonged release of newly synthesized insulin.
Once released, insulin is active for a only a brief time before it is degraded by enzymes. Insulinase found in the liver and kidneys breaks down insulin circulating in the plasma, and as a result, insulin has a half-life of only about 6 minutes. This short duration of action results in rapid changes in the circulating levels of insulin.
Insulin analogs have been developed with improved therapeutic properties (Owens et al., 2001, Lancet 358: 739-46; Vajo et al., 2001, Endocr Rev 22: 706-17), and such analogs may be employed in connection with the present invention. Various strategies, including elongation of the COOH-terminal end of the insulin B-chain and engineering of fatty acid-acylated insulins with substantial affinity for albumin are used to generate longer-acting insulin analogs. However, in vivo treatments with available longer-acting insulin compounds still result in a high frequency of hypo- and hyperglycemic excursions and modest reduction in HbA_1c. Accordingly, development of a truly long-acting and stable human insulin analog still remains an important task.
Functional analogs of insulin that may be employed in accordance with the invention include rapid acting analogs such as lispro, aspart and glulisine, which are absorbed rapidly (<30 minutes) after subcutaneous injection, peak at one hour, and have a relatively short duration of action (3 to 4 hours). In addition, two long acting insulin analogs have been developed: glargine and detemir, and which may be employed in connection with the invention. The long acting insulin analogs have an onset of action of approximately two hours and reach a plateau of biological action at 4 to 6 hours, and may last up to 24 hours.
Thus, in one embodiment, the insulin component may contain the A and/or B chain of lispro (also known as Humalog, Eli Lilly). Insulin lispro differs from human insulin by the substitution of proline with lysine at position 28 and the substitution of lysine with proline at position 29 of the insulin B chain. Although these modifications do not after receptor binding, they help to block the formation of insulin dimers and hexamers, allowing for larger amounts of active monomeric insulin to be available for postprandial injections.
In another embodiment, the insulin may contain an A and/or B chain of aspart (also known as Novolog, Novo Nordisk). Insulin aspart is designed with the single replacement of the amino acid proline by aspartic acid at position 28 of the human insulin B chain. This modification helps block the formation for insulin hexamers, creating a faster acting insulin.
In yet another embodiment, the insulin may contain an A and/or B chain of glulisine (also known as Apidra, Sanofi-Aventis). Insulin glulisine is a short acting analog created by substitution of asparagine at position 3 by lysine and lysine at position 29 by glutamine of human insulin B chain. Insulin glulisine has more rapid onset of action and shorter duration of action compared to regular human insulin.
In another embodiment, the insulin may contain an A and/or B chain of glargine (also known as Lantus, Sanofi-Aventis). Insulin glargine differs from human insulin in that the amino acid asparagine at position 21 of the A chain is replaced by glycine and two arginines are added to the C-terminus of the B-chain. Compared with bedtime neutral protamine Hagedom (NPH) insulin (an intermediate acting insulin), insulin glargine is associated with less noctumal hypoglycemia in patients with type 2 diabetes.
In yet another embodiment, the insulin may contain an A and/or B chain from detemir (also known as Levemir, Novo Nordisk). Insulin detemir is a soluble (at neutral pH) long-acting insulin analog, in which the amino acid threonine at B30 is removed and a 14-carbon, myristoyl fatty acid is acetylated to the epsilon-amino group of LysB29. After subcutaneous injection, detemir dissociates, thereby exposing the free fatty acid which enables reversible binding to albumin molecules. So at steady state, the concentration of free unbound insulin is greatly reduced resulting in stable plasma glucose levels.
In some embodiments, the insulin may be a single-chain insulin analog (SIA) (e.g. as described in U.S. Pat. No. 6,630,438 and WO08/019368, which are hereby incorporated by reference in their entirety). Single-chain insulin analogs encompass a group of structurally-related proteins wherein the A and B chains are covalently linked by a polypeptide linker. The polypeptide linker connects the C-terminus of the B chain to the N-terminus of the A chain. The linker may be of any length so long as the linker provides the structural conformation necessary for the SIA to have a glucose uptake and insulin receptor binding effect. In some embodiments, the linker is about 5-18 amino acids in length. In other embodiments, the linker is about 9-15 amino acids in length. In certain embodiments, the linker is about 12 amino acids long. In certain exemplary embodiments, the linker has the sequence KDDNPNLPRLVR (SEQ ID NO.: 20) or GAGSSSRRAPQT (SEQ ID NO.: 21). However, it should be understood that many variations of this sequence are possible such as in the length (both addition and deletion) and substitutions of amino acids without substantially compromising the effectiveness of the produced SIA in glucose uptake and insulin receptor binding activities. For example, several different amino acid residues may be added or removed from either end without substantially decreasing the activity of the produced SIA.
An exemplary single-chain insulin analog currently in clinical development is albulin (Duttaroy et al., 2005, Diabetes 54: 251-8). Albulin can be produced in yeast or in mammalian cells. It consists of the B and A chain of human insulin (100% identity to native human insulin) linked together by a dodecapeptide linker and fused to the NH₂terminals of the native human serum albumin. For expression and purification of albulin, Duttaroy et al. constructed a synthetic gene construct encoding a single-chain insulin containing the B- and A-chain of mature human insulin linked together by a dodecapeptide linker using four overlapping primers and PCR amplification. The resulting PCR product was ligated in-frame between the signal peptide of human serum albumin (HSA) and the NH₂terminus of mature HSA, contained within a pSAC35 vector for expression in yeast. In accordance with the present invention, the HSA component of abulin may be replaced with an ELP component as described herein.
Thus, in one aspect, the present invention provides therapeutic agents comprising an elastin-like peptide (ELP) and an insulin or functional analog thereof. For example, in certain embodiments, the insulin is a mammalian insulin, such as human insulin or porcine insulin. In accordance with the invention, the ELP component may be coupled (e.g., via recombinant fusion or chemical conjugation) to the insulin A chain, or B chain, or both. The insulin may comprise each of chains A, B, and C (SEQ ID NOS: 51 and 52), or may contain a processed form, containing only chains A and B. In some embodiments, chains A and B are connected by a short linking peptide, to create a single chain insulin. The insulin may be a functional analog of human insulin, including functional fragments truncated at the N-terminus and/or C-terminus (of either or both of chains A and B) by from 1 to 10 amino acids, including by 1, 2, 3, or about 5 amino acids. Functional analogs may contain from 1 to 10 amino acid insertions, deletions, and/or substitutions (collectively) with respect to the native sequence (e.g., SEQ ID NOS 15 and 16), and in each case retaining the activity of the peptide. For example, functional analogs may have 1, 2, 3, 4, or 5 amino acid insertions, deletions, and/or substitutions (collectively) with respect to the native sequence (which may contain chains A and B, or chains A, B, and C). Such activity may be confirmed or assayed using any available assay, including those described herein. In these or other embodiments, the insulin component has at least about 75%, 80%, 85%, 90%, 95%, or 98% identity with each of the native sequences for chains A and B (SEQ ID NOS:15 and 16). The determination of sequence identity between two sequences (e.g., between a native sequence and a functional analog) can be accomplished using any alignment tool, including Tatusova et al., Blast 2 sequences—a new tool for comparing protein and nucleotide seguences. FEMS Microbiol Left. 174:247-250 (1999). The insulin component may contain additional chemical modifications known in the art.
In another aspect, the present invention provides methods for the treatment or prevention of diabetes, including type I and II diabetes. The method comprises administering an effective amount of the therapeutic agent comprising an elastin-like peptide (ELP) component and an insulin (or functional analog thereof) component to a patient in need thereof. Generally, the patient may be a human or non-human animal (e.g., dog, cat, cow, or horse) patient. Preferably, the patient is human.
To characterize the in vitro binding properties of an insulin analog or an ELP-containing insulin analog, competition binding assays may be performed in various cell lines that express the insulin receptor (Jehle et al., 1996, Diabetologia 39: 421-432). For example, competition binding assays using CHO cells overexpressing the human insulin receptor may be employed. Insulin can also bind to the IGF-1 receptor with a lower affinity than the insulin receptor. To determine the binding affinity of an ELP-containing insulin analog, a competition binding assay can be performed using ¹²⁵I-labeled IGF-1 in L6 cells.
The activities of insulin include stimulation of peripheral glucose disposal and inhibition of hepatic glucose production. The ability of an ELP-containing insulin analog to mediate these biological activities can be assayed in vitro using known methodologies. For example, the effect of an ELP-containing analog on glucose uptake in 3T3-L1 adipocytes can be measured and compared with that of insulin. Pretreatment of the cells with a biologically active analog will generally produce a dose-dependent increase in 2-deoxyglucose uptake. The ability of an ELP-containing insulin analog to regulate glucose production may be measured in any number of cells types, for example, H4IIe hepatoma cells. In this assay, pretreatment with a biologically active analog will generally result in a dose-dependent inhibition of the amount of glucose released.

Factor VII (VIIa)

In certain embodiments, the invention provides therapeutic agents comprising an ELP component coupled (e.g., via fusion or conjugation) to a Factor VII/VIIa. Coagulation is the biological process of blood clot formation involving many different serine proteases as well as their essential cofactors and inhibitors. It is initiated by exposure of Factor VII (FVII) and Factor VIIa (FVIIa) to its membrane bound cofactor, tissue factor (TF), resulting in production of Factor Xa (FXa) and more FVIIa. The process is propagated upon production of Factor IXa (FIXa) and additional FXa that, upon binding with their respective cofactors FVIIIa and FVa, form platelet bound complexes, ultimately resulting in the formation of thrombin and a fibrin clot. Thrombin also serves to further amplify coagulation by activation of cofactors such as FV and FVII and zymogens such as Factor XI. Moreover, thrombin activates platelets leading to platelet aggregation, which is necessary for the formation of a hemostatic plug.
Factor VII circulates in the blood in a zymogen form, and is converted to its active form, Factor VIIa, by either factor IXa, factor Xa, factor XIIa, or thrombin by minor proteolysis. Factor VIIa is a two-chain, 50 kilodalton (kDa) plasma serine protease. The active form of the enzyme comprises a heavy chain (254 amino acid residues) containing a catalytic domain and a light chain (152 residues) containing 2 epidermal growth factor (EGF)-like domains. The mature factor VII/VIIa that circulates in plasma is composed of 406 amino acid residues (SEQ ID NO: 33). The light and heavy chains are held together by a disulfide bond.
As noted above, Factor VIIa is generated by proteolysis of a single peptide bond from its single chain zymogen, Factor VII, which is present at approximately 0.5 μg/ml in plasma. The conversion of zymogen Factor VII into the activated two-chain molecule occurs by cleavage of an internal peptide bond. In human Factor VII, the cleavage site is at Arg152-Ile153 (Hagen et al., 1986, PNAS USA 83: 2412-6).
“Factor VII/VIIa” as used in this application means a product consisting of either the unactivated form (factor VII) or the activated form (factor VIIa) or mixtures thereof. “Factor VII/VIIa” within the above definition includes proteins that have an amino acid sequence of native human factor VII/VIIa. It also includes proteins with a slightly modified amino acid sequence, for instance, a modified N-terminal end including N-terminal amino acid deletions or additions so long as those proteins substantially retain the activity of factor VIIa. “Factor VII” within the above definition also includes natural allelic variations that may exist and occur from one individual to another. Also, degree and location of glycosylation or other post-translation modifications may vary depending on the chosen host cells and the nature of the host cellular environment.
In the presence of calcium ions, Factor VIIa binds with high affinity to TF. TF is a 263 amino acid residue glycoprotein composed of a 219 residue extracellular domain, a single transmembrane domain, and a short cytoplasmic domain (Morrissey et al., 1987, Cell 50: 129-35). The TF extracellular domain is composed of two fibronectin type Ill domains of about 105 amino acids each. The binding of FVIIa is mediated entirely by the TF extracellular domain (Muller et al., 1994, Biochem. 33:10864-70). Residues in the area of amino acids 16-26 and 129-147 contribute to the binding of FVIIa as well as the coagulant function of the molecule. Residues Lys20, Trp45, Asp58, Tyr94, and Phe140 make a large contribution (1 kcal/mol) to the free energy (ΔG) of binding to FVIIa.
TF is expressed constitutively on cells separated from plasma by the vascular endothelium. Its expression on endothelial cells and monocytes is induced by exposure to inflammatory cytokines or bacterial lipopolysacchardes (Drake et al., 1989, J. Cell Biol. 109: 389). Upon tissue injury, the exposed extracellular domain of TF forms a high affinity, calcium dependent complex with FVII. Once bound to TF, FVII can be activated by peptide bond cleavage to yield serine protease FVIIa. The enzyme that catalyzes this step in vivo has not been elucidated, but in vitro FXa, thrombin, TF:FVIIa and FIXa can catalyze this cleavage. FVIIa has only weak activity upon its physiological substrates FX and FIX whereas the TF:FVIIa complex rapidly activates FX and FIX.
The TF:FVIIa complex constitutes the primary initiator of the extrinsic pathway of blood coagulation. The complex initiates the extrinsic pathway by activation of FX to Factor Xa (FXa), FIX to Factor IXa (FIXa), and additional FVII to FVIIa. The action of TF:FVIIa leads ultimately to the conversion of prothrombin to thrombin, which carries out many biological functions. Among the most important activities of thrombin is the conversion of fibrinogen to fibrin, which polymerizes to form a clot. The TF:FVIIa complex also participates as a secondary factor in extending the physiological effects of the contact activation system.
The initiation and subsequent regulation of coagulation is complex, since maintenance of hemostasis is crucial for survival. There is an exquisite balance between hemostasis (normal clot formation and dissolution) and thrombosis (pathogenic clot formation). Serious clinical conditions involving aberrations in coagulation include deep vein thrombosis, myocardial infarction, pulmonary embolism, stroke and disseminated intravascular coagulation (in sepsis). There are also many bleeding coagulopathies where there is insufficient clot formation. These include hemophilia A (FVIII deficiency) or hemophilia B (FIX deficiency), where procoagulant therapy is required. The challenge in this therapeutic area is to operate in the narrow window between too much and too little coagulation.
The use of exogenous FVIIa as a therapeutic agent has been shown to induce hemostasis in patients with hemophilia A and B (Hedner, 2001, Seminars Hematol. 38 (suppl. 12): 43-7; Hedner, 2004, Seminars Hematol. 41 (suppl. 1): 35-9). It also has been used to treat bleeding in patients with liver disease, anticoagulation-induced bleeding, surgery, thrombocytopenia, thrombasthenia, Bemard-Soulier syndrome, von Willebrand disease, and other bleeding disorders (See e.g. Roberts et al., 2004, Blood 104: 3858-64).
Commercial preparations of human recombinant FVIIa are sold as NovoSeven.™ NovoSeven™ is indicated for the treatment of bleeding episodes in hemophilia A or B patients and is the only recombinant FVIIa effective for bleeding episodes currently available. A circulating recombinant FVIIa half-life of 2.3 hours was reported in “Summary Basis for Approval for NovoSevenm” FDA reference number 96-0597. Moreover, the half-life of recombinant FVIIa is shorter in pediatric patients (˜1.3 hours), suggesting that higher doses of recombinant FVIIa may be required in this population (Roberts et al., 2004, Blood 104: 3858-64). Accordingly, relatively high doses and frequent administration are necessary to reach and sustain the desired therapeutic or prophylactic effect. As a consequence, adequate dose regulation is difficult to obtain and the need of frequent intravenous administrations imposes restrictions on the patient's way of living.
A molecule with a longer circulation half-life would decrease the number of necessary administrations. Given the frequent injections associated with currently available FVIIa therapy and the potential for obtaining more optimal therapeutic FVIIa levels with concomitant enhanced therapeutic effect, there is a clear need for improved FVII or FVIIa-like molecules with a longer half-life in vivo.
Recombinant human coagulation factor VIIa (rFVIIa, NovoSeven; Novo Nordisk A/S, Copenhagen, Denmark) has proven to be efficacious for the treatment of bleeding episodes in hemophilia patients with inhibitors. A small fraction of patients may be refractory to rFVIIa treatment and could potentially benefit from genetically modified FVIIa molecules with increased potencies. To this end, FVIIa analogs with increased intrinsic activity have been investigated that exhibit superior hemostatic profiles in vitro (see e.g. WO02/077218 or WO05/074975, which are hereby incorporated by reference in their entirety, and Tranholm et al., 2003, Blood 102(10): 3615-20, which is also incorporated by reference). These analogs may also be used as more efficacious hemostatic agents in other indications where efficacy of rFVIIa has been observed, including in thrombocytopenia and trauma.
Thus, in some embodiments, the Factor VIIa analog that may be used in accordance with the invention is as described in WO02/077218 or WO05/074975. For example, the FVIIa analog may have a glutamine substituted for methionine at position 298 (i.e. M298Q-FVIIa). In certain exemplary embodiments, the FVIIa analog contains two additional mutations, valine at position 158 replaced by aspartic acid and glutamic acid at position 296 replaced by valine (i.e. V158D/E296V/M298Q-FVIIa). Additionally or alternatively, the Factor VIIa analog may have an alanine residue substitution for lysine at position 337 (i.e. V158D/E296V/M298Q/K337A-FVIIa). In still other embodiments, the Factor VIIa analog has a substitution or insertion selected from Q250C; P406C; and 407C, wherein a cysteine has also been introduced in the C-terminal sequence (see, e.g. U.S. Pat. No. 7,235,638, which is hereby incorporated by reference in its entirety). The Factor VIIa analog may further comprise a substitution or insertion at one or more of positions 247, 260, 393, 396, and/or 405.
In these or other embodiments, the Factor VIIa analog comprises a substitution relative to the sequence of native Factor VIIa selected from: (a) a substitution of Lys157 with an amino acid selected from the group consisting of Gly, Val, Ser, Thr, Asp, and Glu; (b) a substitution of Lys337 with an amino acid selected from the group consisting of Ala, Gly, Val, Ser, Thr, GIn, Asp, and Glu; (c) a substitution of Asp334 with any amino acid other than Ala or Asn; and (d) a substitution of Ser336 with any amino acid other than Ala or Cys (see e.g. U.S. Pat. No. 7,176,288, which is hereby incorporated by reference in its entirety). Additionally or alternatively, the Factor VIIa analog comprises a substitution of the Leu at position 305 of Factor VII with an amino acid residue selected from the group consisting of Val, lie, Met, Phe, Trp, Pro, Gly, Ser, Thr, Cys, Tyr, Asn, Glu, Lys, Arg, His, Asp and GIn (see e.g. U.S. Pat. No. 6,905,683, which is hereby incorporated by reference in its entirety).
Thus, in one aspect, the present invention provides therapeutic agents comprising an elastin-like peptide (ELP) and a Factor VII/VIIa, or functional analog thereof. For example, in certain embodiments, the Factor VII/VIIa is human Factor VII/VIIa (e.g., SEQ ID NO: 33). The Factor VII/VIIa may be a functional analog of human Factor VII/VIIa, including functional fragments truncated at the N-terminus and/or C-terminus by from 1 to 10 amino acids, including by 1, 2, 3, or about 5 amino acids. Functional analogs may contain from 1 to 10 amino acid insertions, deletions, and/or substitutions (collectively) with respect to the native sequence (e.g., SEQ ID NO: 33), and in each case retaining the activity of the peptide. For example, such analogs may have from 1 to about 5 amino acid insertions, deletions, and/or substitutions (collectively) with respect to the native full length sequence, or with respect to one or both of the heavy and light chains. Such activity may be confirmed or assayed using any available assay, including those described herein. In these or other embodiments, the Factor VII/VIIa component has at least about 75%, 80%, 85%, 90%, 95%, or 98% identity with the native sequence (SEQ ID NO:33). The determination of sequence identity between two sequences (e.g., between a native sequence and a functional analog) can be accomplished using any alignment tool, including Tatusova et al., Blast 2 sequences —a new tool for comparing protein and nucleotide sequences, FEMS Microbiol Left. 174:247-250 (1999).
In exemplary embodiments, the FactorVII-ELP fusion has the amino acid sequence of SEQ ID NO:58. SEQ ID NO:58 further comprises a TEV protease cleavage site between the FactorVII and ELP sequences, which may be beneficial for removing the ELP sequence post expression where desired. However, in accordance with the invention, the tev sequence may be entirely removed, or replaced with another linking sequence as disclosed herein.
In another aspect, the present invention provides methods for the treatment or prevention of bleeding-related disorders. The method comprises administering an effective amount of the therapeutic agent comprising an elastin-like peptide (ELP) and a Factor VII/VIIa or functional analog thereof to a patient in need. In certain embodiments, the bleeding-related disorder is one or more of hemophilia (A or B), post-surgical bleeding, anticoagulation-induced bleeding, thrombocytopenia, Factor VII deficiency, Factor X deficiency, bleeding in patients with liver disease, thrombasthenia, Bemard-Soulier syndrome, von Willebrand disease, and intracranial hemorrhage. Generally, the patient is a human or non-human animal (e.g., dog, cat, cow, or horse) patient. Preferably, the patient is human.
To characterize the in vitro binding properties of a suspected Factor VII/VIIa analog, or an ELP-containing Factor VIIa analog, TF binding assays can be performed as described previously (See, e.g., Chaing et al., 1994, Blood 83(12): 3524-35). Briefly, recombinant human TF can be coated onto Immulon II plates in carbonate antigen buffer overnight at 4° C. BSA is also coated onto the plates for use as a control. ELP-containing Factor VIIa analogs may be added at various concentrations in TBS-T buffer. After several washes, monospecific polyclonal rabbit anti-human FVIIa sera is added and incubated for approximately an hour at room temperature. Next, goat anti-rabbit IgG conjugated to alkaline phosphatase is added, followed by the alkaline phosphatase substrate PNPP, which is used for detection. After subtraction of background, the absorbance at ˜405 nm is taken to be directly proportional to the degree of Factor VIIa binding to the immobilized TF. These values can then be compared to control plasma containing Factor VIIa.
The clotting ability of a Factor VII/VIIa analog or an ELP-containing Factor VIIa analog can be measured in human FVII deficient plasma. In this assay, the ELP-containing Factor VIIa analog diluted to varying concentrations directly into FVII deficient plasma. In a coagulometer, one part plasma± a FVIIa analog can be mixed with 2 parts Innovin™ (Dade, Miami, Fla.) prothrombin time reagent (recombinant human tissue factor with phospholipids and CaCl₂). Clot formation is detected optically and time to clotting measured. Clotting time (seconds) is compared to the mean clotting time of FVII-deficient plasma alone and plotted as the fractional clotting time versus FVIIa analog concentration.

Therapeutic Proteins

The present invention further provides therapeutic agents comprising an ELP component and at least one therapeutic protein selected from Table 1. The ELP component and therapeutic protein may be coupled by recombinant fusion or chemical conjugation as described herein. Such therapeutic proteins are listed in Table 1 by protein name and GeneSeq Accession No. The amino acid sequence of each Therapeutic Protein, which is known in the art, is hereby incorporated by reference for each Therapeutic Protein listed in Table 1. Such therapeutic proteins are further described in US patent or PCT publications that are also listed in Table 1, and such US patent and PCT publications are hereby incorporated by reference, especially with respect to the structure of such therapeutic proteins and described functional analogs.
Table 1 further describes the biological activity of each listed Therapeutic Protein, as well as an exemplary assay for determining the activity of functional analogs or agents of the invention (e.g., fusion with an ELP component). Generally, functional analogs of therapeutic proteins listed in Table 1 may include functional fragments truncated at the N-terminus and/or C-terminus by from 1 to 10 amino acids, including by 1, 2, 3, 4 or about 5 amino acids. Functional analogs may contain from 1 to 10 amino acid insertions, deletions, and/or substitutions (collectively) with respect to the base sequence (e.g., as listed in Table 1), and in each case retaining the full or partial biological activity (as listed in Table 1) of the therapeutic protein. For example, functional analogs may have 1, 2, 3, 4, or 5 amino acid insertions, deletions, and/or substitutions (collectively) with respect to the base sequence. Such activity may be confirmed or assayed using any available assay, including those described in the Table. In these or other embodiments, the therapeutic protein has at least about 75%, 80%, 85%, 90%, 95%, or 98% identity with the corresponding base sequence. The molecules may further comprise additional chemical modifications known for each in the art.
In some embodiments, the therapeutic protein (e.g., as selected from Table 1) has a size of less than about 25 kDa, or less than about 10 kDa, or less than about 5 kDa, and the corresponding therapeutic agent of the invention (e.g., comprising the ELP component) has a molecular weight of less than about 60 kDa, 55 kDa, 50 kDa, or 40 kDa.
Table 1 further lists preferred indications for each therapeutic protein, for which the corresponding therapeutic agent finds use, such as in a method for treatment or prevention related to such indication.

TABLE 1

	Exemplary Identifier	PCT/Patent Reference		Exemplary Activity Assay
	(the sequences listed in	(the patents and publications		(the publications listed in this
Therapeutic	this column are each hereby	listed in this column are each		column are each hereby incorporated
Protein X	incorporated by reference)	hereby incorporated by reference)	Biological Activity	by reference)	Preferred Indication Y

BMP-1	GeneSeq Acession	WO8800205	BMP1 belongs to the transforming	BMP-1 activity can be determined	Induction of Cartilage,
	P80618		growth factor-beta (TGFB) superfamily.	using the following assays known in	Tissue and Bone
			Bone morphogenic proteins induce	the art: Nat Genet. 2001	Growth, and Diabetes
			cartilage and bone formation, play	January; 27(1): 84-8; Eur J Biochem 1996
			important role in nephrogesis, and play	Apr. 1; 237(1): 295-302; J Biol Chem,
			an important role in the development of	Vol. 274, Issue 16, 10897-10902,
			many organs, including lung, heart,	Apr. 16, 1999; and Hogan, B. L. M.
			teeth, gut, skin, and particularly the	(1996) Genes Dev. 10, 1580-1594.
			kidney.
BMP-2	GeneSeq Accession	WO8800205	BMP-2 belongs to the transforming	BMP-2 activity can be determined	Induction of Cartilage,
	P80619		growth factor-beta (TGFB) superfamily.	using the following assays known in	Tissue and Bone
			Bone morphogenic protein induces bone	the art: Nat Genet. 2001 January;	Growth, and Diabetes
			formation.	27(1): 84-8; Eur J Biochem 1996 Apr.
				1; 237(1): 295-302; J Biol Chem, Vol.
				274, Issue 16, 10897-10902, Apr. 16,
				1999; and Hogan, B. L. M. (1996)
				Genes Dev. 10, 1580-1594.
BMP-2B	GeneSeq Accession	U.S. Pat. No. 5,631,142	BMP-2b belongs to the transforming	BMP-2b activity can be determined	Induction of Cartilage,
	W24850		growth factor-beta (TGFB) superfamily.	using the following assays known in	Tissue and Bone
			Bone morphogenic protein induces bone	the art: Nat Genet. 2001 January;	Growth, and Diabetes
			formation.	27(1): 84-8; Eur J Biochem 1996 Apr.
				1; 237(1): 295-302; I Biol Cbcre, Vol.
				274, Issue 16, 10897-10902, Apr. 16,
				1999; and Hogan, B. L. M. (1996)
				Genes Dev. 10, 1580-1594.
BMP-4	GeneSeq Accession	WO0020591	BMP-4 belongs to the transforming	BMP-4 activity can be determined	Induction of Cartilage,
	B02796		growth factor-beta (TGFB) superfamily.	using the following assays known in	Tissue and Bone
			Bone morphogenic protein induces bone	the art: Nat Genet. 2001 January;	Growth, and Diabetes
			formation.	27(1): 84-8; Eur J Biochem 1996 Apr.
				1; 237(1): 295-302; J Biol Chem, Vol.
				274, Issue 16, 10897-10902, Apr. 16,
				1999; and Hogan, B. L. M. (1996)
				Genes Dev. 10, 1580-1594.
BMP-5	GeneSeq Accession	WO0020591	BMP-5 belongs to the transforming	BMP-5 activity can be determined	Induction of Cartilage,
	B02797		growth factor-beta (TGFB) superfamily.	using the following assays known in	Tissue and Bone
			Bone morphogenic protein induces bone	the art: Nat Genet. 2001 January;	Growth, and Diabetes
			formation.	27(1): 84-8; Eur J Biochem 1996 Apr.
				1; 237(1): 295-302; J Biol Chem, Vol.
				274, Issue 16, 10897-10902, Apr. 16,
				1999; and Hogan, B. L. M. (1996)
				Genes Dev. 10, 1580-1594.
BMP-6	GeneSeq Accession	U.S. Pat. No. 5,187,076	BMP-6 belongs to the transforming	BMP-6 activity can be determined	Induction of Cartilage,
	R32904		growth factor-beta (TGFB) superfamily.	using the following assays known in	Tissue and Bone
			Bone morphogenic protein induces bone	the art: Nat Genet. 2001 January;	Growth, and Diabetes
			formation.	27(1): 84-8; Eur J Biochem 1996 Apr.
				1; 237(1): 295-302; J Biol Chem, Vol.
				274, Issue 16, 10897-10902, Apr. 16,
				1999; and Hogan, B. L. M. (1996)
				Genes Dev. 10, 1580-1594.
Osteogenic	GeneSeq Accession	WO973462	OP-1 belongs to the transforming	OP-1 activity can be determined	Induction of Cartilage,
Protein-1; OP-1;	W34783		growth factor-beta (TGFB) superfamily.	using the following assays known in	Tissue and Bone
BMP-7			Bone morphogenic protein induces bone	the art: Nat Genet. 2001 January;	Growth, and Diabetes
			formation.	27(1): 84-8; Eur J Biochem 1996 Apr.
				1; 237(1): 295-302; J Biol Chem, Vol.
				274, Issue 16, 10897-10902, Apr. 16,
				1999; and Hogan, B. L. M. (1996)
				Genes Dev. 10, 1580-1594.
Osteogenic	GeneSeq Accession	WO9406399	OP-2 belongs to the transforming	OP-2 activity can be determined	Induction of Cartilage,
Protein-2	R57973		growth factor-beta (TGFB) superfamily.	using the following assays known in	Tissue and Bone
			Bone morphogenic Protein induces bone	the art: Nat Genet. 2001 January;	Growth, and Diabetes
			formation.	27(1): 84-8; Eur J Biochem 1996 Apr.
				1; 237(1): 295-302; J Biol Chem, Vol.
				274, Issue 16, 10897-10902, Apr. 16,
				1999; and Hogan, B. L. M. (1996)
				Genes Dev. 10, 1580-1594.
GDP-1	GeneSeq Accession	WO9406449	Members of the TGF-beta family of	The effect of GDF-1 on signaling can	Developmental
	R60961		proteins initiate cell signaling by	be assayed by treating Primary	disorders, Induction of
			binding to heteromeric receptor	BAECs transferred with a construct	Cartilage, Tissue and
			complexes of type I (TbetaRI) and	called p3TP-Lux, containing a TGF-	Bone Growth, and
			type II (TbetaRII) serine/threonine	beta responsive promoter fused to a	Diabetes
			kinase receptors (reviewed by	reporter gene, and measuring
			Massague, J. et al. (1994) Trends Cell	luciferase gene expression (Wrana et
			Biol. 4: 172 178; Miyazono, K. et al.	al., 1994, Nature 370: 341-347).
			(1994) Adv. Immunol. 55: 181-220).
			Activation of this heteromeric receptor
			complex occurs when TGF-beta binds to
			TbetaRII, which then recruits and
			phosphorylates TbetaRI. Activated
			TbetaRI then propagates the signal to
			downstream targets (Chen, F. and
			Weinberg, R. A. (1995) PNA892: 1565-1569;
			Wrana, J. L. et al. (1994) Nature
			370: 341 347).
BMP-9	GeneSeq Accession	WO9533830	BMP-9 belongs to the transforming	BMP-9 activity can be determined	Induction of Cartilage,
	R86903		growth factor-beta (TGFB) superfamily.	using the following assays known in	Tissue and Bone
			Bone morphogenic protein induces bone	the art: Nat Genet. 2001 January;	Growth, and Diabetes
			formation.	27(1): 84-8; Eur J Biochem 1996 Apr.
				1; 237(1): 295-302; J Biol Chem, Vol.
				274, Issue 16, 10897-10902, Apr. 16,
				1999; and Hogan, B. L. M. (1996)
				Genes Dev. 10, 1580-1594.
BMP-10	GeneSeq Accession	WO9426893	BMP-10 belongs to the transforming	BMP-10 activity can be determined	Induction of Cartilage,
	R66202		growth factor-beta (TGFB) superfamily.	using the following assays known in	Tissue and Bone
			Bone morphogenic protein induces bone	the art: Nat Genet. 2001 January;	Growth, and Diabetes
			formation.	27(1): 84-8; Eur J Biochem 1996 Apr.
				1; 237(1): 295-302; J Biol Chem, Vol.
				274, Issue 16, 10897-10902, Apr. 16,
				1999; and Hogan, B. L. M. (1996)
				Genes Dev. 10, 1580-1594.
BMP-12	GeneSeq Accession	WO9516035	BMP-12 belongs to the transforming	BMP-12 activity can be determined	Induction of Cartilage,
	R78734		growth factor-beta (TGFB) superfamily.	using the following assays known in	Tissue and Bone
			Bone morphogenic protein induces bone	the art: Nat Genet. 2001 January;	Growth, and Diabetes
			formation.	27(1): 84-8; Eur J Biochem 1996 Apr.
				1; 237(1): 295-302; J Biol Chem, Vol.
				274, Issue 16, 10897-10902, Apr. 16,
				1999; and Hogan, B. L. M. (1996)
				Genes Dev. 10, 1580-1594.
BMP-15	GeneSeq Accession	W09636710	BMP-15 belongs to the transforming	BMP-15 activity can be determined	Induction of Cartilage,
	W11261		growth factor-beta (TGFB) superfamily.	using the following assays known in	Tissue and Bone
			Bone morphogenic protein induces bone	the art: Nat Genet. 2001 January;	Growth, and Diabetes
			formation.	27(1): 84-8; Eur J Biochem 1996 Apr.
				1; 237(1): 295-302; J Biol Chem, Vol.
				274, Issue 16, 10897-10902, Apr. 16,
				1999; and Hogan, B. L. M. (1996)
				Genes Dev. 10, 1580-1594.
BMP-17	GeneSeq Accession	WO9929718	BMP-17 belongs to the transforming	BMP-17 activity can be determined	Induction of Cartilage,
	Y17870		growth factor-beta (TGFB) superfamily.	using the following assays known in	Tissue and Bone
			Bone morphogenic protein induces bone	the art: Nat Genet. 2001 January;	Growth, and Diabetes
			formation.	27(1): 84-8; Eur J Biochem 1996 Apr.
				1; 237(1): 295-302; J Biol Chem, Vol.
				274, Issue 16, 10897-10902, Apr. 16,
				1999; and Hogan, B. L. M. (1996)
				Genes Dev. 10, 1580-1594.
BMP-18	GeneSeq Accession	WO9929718	BMP-18 belongs to the transforming	BMP-18 activity can be determined	Induction of Cartilage,
	Y17871		growth factor-beta (TGFB) superfamily.	using the following assays known in	Tissue and Bone
			Bone morphogenic protein induces bone	the art: Nat Genet. 2001 January;	Growth, and Diabetes
			formation.	27(1): 84-8; Eur J Biochem 1996 Apr.
				1; 237(1): 295-302; J Biol Chem, Vol.
				274, Issue 16, 10897-10902, Apr. 16,
				1999; and Hogan, B. L. M. (1996)
				Genes Dev. 10, 1580-1594.
Inhibin alpha	GeneSeq Accession	WO0020591	The inhibin beta A subunit joins the	Tumor suppressor activity of inhibin	Tumor suppression.
	B02806		alpha subunit to form a pituitary FSH	can be determined using assays
			secretion inhibitor. Inhibin has been	known in the art: Matzuk et al.,
			shown to regulate gonadal stromal cell	Nature 1992 Nov. 26: 360 (6402);
			proliferation negatively and to have	313-9.
			tumour-suppressor activity. In addition,
			serum levels of inhibin have been shown
			to reflect the size of granulosa-cell
			tumors and can therefore be used as a
			marker for primary as well as recurrent
			disease.
Inhibin beta	GeneSeq Accession	WO0020591	The inhibin beta A subunit joins the	Tumor suppressor activity of inhibin	Tumor suppression.
	H02808		alpha subunit to form a pituitary FSH	can be determined using assays
			secretion inhibitor. Inhibin has been	known in the art: Matzuk et al.,
			shown to regulate gonadal stromal cell	Nature 1992 Nov. 26: 360 (6402);
			proliferation negatively and to have	313-9.
			tumour-suppressor activity. In addition,
			serum levels of inhibin have been shown
			to reflect the size of granulosa-cell
			tumors and can therefore be used as a
			marker for primary as well as recurrent
			disease.
Cerebus Protein	GeneSeq Accession	WO9849296	Cerebus is believed to be involved in the	BMP activity, in the presence of the	BMP Antagonist useful
	W86032		inhibition of BMP activity	antagonist Cerebus, can be	for Osteosarcoma,
				determined using the following	abnormal bone growth.
				assays known in the art: Nat Genet.
				2001 January; 27(1): 84-8; Eur J Biochem
				1996 Apr. 1; 237(1): 295-302; J Biol
				Chem, Vol. 274, Issue 16, 10897-10902,
				Apr. 16, 1999; and Hogan, B. L. M.
				(1996) Genes Dev. 10, 1580-1594.
Soluble BMP	GeneSeq Accession	WO9614579	Soluble BMP receptor kinase protein-3	BMP activity, in the presence of the	BMP Antagonist useful
Receptor Kinase	R95227		is involved in the binding of BMPs.	soluble antagonist BMP receptor	for Osteosarcoma,
Protein-3			Soluble BMP receptor kinase protein-3	kinase protein-3, can be determined	abnormal bone growth.
			is useful as an antagonist for the	using the following assays known in
			inhibition of BMP activity.	the art: Nat Genet. 2001 January;
				27(1): 84-8; Eur J Biochem 1996 Apr.
				1; 237(1): 295-302; J Biol Chem, Vol.
				274, Issue 16, 10897-10902, Apr. 16,
				1999; and Hogan, B. L. M. (1996)
				Genes Dev. 10, 1580-1594.
BMP Processing	GeneSeq Accession	WO9741250	BMPs belong to the transforming	BMP activity, in the presence of the	Bone formation or
Enzyme Furin	W36099		growth factor-beta (TGFB) superfamily.	Furin, can be determined using the	Regeneration
			Bone morphogenic protein induces bone	following assays known in the art:	Abnormalities
			formation.	Nat Genet. 2001 January; 27(1): 84-8; Eur
				J Biochem 1996 Apr. 1; 237(1): 295-302;
				J Biol Chem, Vol. 274, Issue 16,
				10897-10902, Apr. 16, 1999; and
				Hogan, B. L. M. (1996) Genes Dev.
				10, 1580-1594.
TGF-beta 1	GeneSeq Accession	WO9216228	Members of the TGF-beta family of	The effect of TGF betas on signaling	Useful for treating
	R29657		proteins initiate cell signaling by	can be assayed by treating Primary	cancer and to promote
			binding to heteromeric receptor	BAECs transfected with a construct	wound healing.
			complexes of type I (TbetaRI) and type	called p3TP-Lux, containing a TGF-
			II (TbetaRII) serine/threonine kinase	beta responsive promoter fused to a
			receptors (reviewed by Massague, J. et	reporter gene, and measuring
			al. (1994) Trends Cell Biol. 4: 172 178;	luciferase gene expression (Wrana et
			Miyazono, K. et al. (1994) Adv.	al., 1994, Nature 370: 341-347).
			Immunol. 55: 181-220). Activation of
			this heteromeric receptor complex
			occurs when TGF-beta. binds to
			TbetaRII, which then recruits and
			phosphorylates TbetaRI. Activated
			TbetaRI then propagates the signal to
			downstream targets (Chen, F. and
			Weinberg. R. A. (1995) PNA892: 1565-1569;
			Wrana, J. L. et al. (1994) Nature
			370: 341.
TGF-beta 2	GeneSeq Accession	EP542679	Members of the TGF-beta family of	The effect of TGF betas on signaling	Useful for treating
	R39659		proteins initiate cell signaling by	can be assayed by treating Primary	cancer and to promote
			binding to heteromeric receptor	BAECs transfected with a construct	wound healing.
			complexes of type I (TbetaRI) and type	called p3TP-Lux, containing a TGF-
			II (TbetaRII) serine/threonine kinase	beta responsive promoter fused to a
			receptors (reviewed by Massague, J. et	reporter gene, and measuring
			al. (1994) Trends Cell Biol. 4: 172 178;	luciferase gene expression (Wrana et
			Miyazono, K. et al. (1994) Adv.	al., 1994, Nature 370: 341-347).
			Immunol. 55: 181-220). Activation of
			this heteromeric receptor complex
			occurs when TGF-beta. binds to
			TbetaRII, which then recruits and
			phosphorylates TbetaRI. Activated
			TbetaRI then propagates the signal to
			downstream targets (Chen, F. and
			Weinberg. R. A. (1995) PNA892: 1565-1569;
			Wrana, J. L. et al. (1994) Nature
			370: 341.
ZTGF-beta 9	GeneSeq Accession	WO0015798	Members of the TGF-beta family of	The effect of TGF betas on signaling	Useful for treating
	Y70654		proteins initiate cell signaling by	can be assayed by treating Primary	cancer and to promote
			binding to heteromeric receptor	BAECs transfected with a construct	wound healing.
			complexes of type I (TbetaRI) and type	called p3TP-Lux, containing a TGF-
			II (TbetaRII) serine/threonine kinase	beta responsive promoter fused to a
			receptors (reviewed by Massague, J. et	reporter gene, and measuring
			al. (1994) Trends Cell Biol. 4: 172 178;	luciferase gene expression (Wrana et
			Miyazono, K. et al. (1994) Adv.	al., 1994, Nature 370: 341-347).
			Immunol. 55: 181-220). Activation of
			this heteromeric receptor complex
			occurs when TGF-beta. binds to
			TbetaRII, which then recruits and
			phosphorylates TbetaRI. Activated
			TbetaRI then propagates the signal to
			downstream targets (Chen, F. and
			Weinberg. R. A. (1995) PNA892: 1565-1569;
			Wrana, J. L. et al. (1994) Nature
			370: 341.
Anti-TGF beta		GB2305921	Members of the TGF-beta family of	The effect of TGF betas on signaling	Useful for control of
family antibodies			proteins initiate cell signaling by	in the presence of an anti-TGF beta	fibrosis, immune, and
			binding to heteromeric receptor	antibody, can be assayed by treating	inflammatory disease.
			complexes of type I (TbetaRI) and type	Primary BAECs transfected with a
			II (TbetaRII) serine/threonine kinase	construct called p3TP-Lux,
			receptors (reviewed by Massague, J. et	containing a TGF-beta responsive
			al. (1994) Trends Cell Biol. 4: 172 178;	promoter fused to a reporter gene, and
			Miyazono, K. et al. (1994) Adv.	measuring luciferase gene expression
			Immunol. 55: 181-220). Activation of	(Wrana et al., 1994, Nature 370: 341-347).
			this heteromeric receptor complex
			occurs when TGF-beta. binds to
			TbetaRII, which then recruits and
			phosphorylates TbetaRI. Activated
			TbetaRI then propagates the signal to
			downstream targets (Chen, F. and
			Weinberg. R. A. (1995) PNA892: 1565-1569;
			Wrana, J. L. et al. (1994) Nature
			370: 341.
Latent TGF beta	GeneSeq Accession	WO0012551	Members of the TGF-beta family of	The effect of TGF betas on signaling	Useful for inhibiting
binding protein II	Y70552		proteins initiate cell signaling by	in the presence of a TGF beta binding	tissue or tumor growth.
			binding to heteromeric receptor	protein, can be assayed by treating
			complexes of type I (TbetaRI) and type	Primary BAECs transfected with a
			II (TbetaRII) serine/threonine kinase	construct called p3TP-Lux,
			receptors (reviewed by Massague, J. et	containing a TGF-beta responsive
			al. (1994) Trends Cell Biol. 4: 172 178;	promoter fused to a reporter gene, and
			Miyazono, K. et al. (1994) Adv.	measuring luciferase gene expression
			Immunol. 55: 181-220). Activation of	(Wrana et al., 1994, Nature 370: 341-347).
			this heteromeric receptor complex
			occurs when TGF-beta. binds to
			TbetaRII, which then recruits and
			phosphorylates TbetaRI. Activated
			TbetaRI then propagates the signal to
			downstream targets (Chen, F. and
			Weinberg. R. A. (1995) PNA892: 1565-1569;
			Wrana, J. L. et al. (1994) Nature
			370: 341.
MP52	GeneSeq Accession	WO9741250	Members of the TGF-beta family of	The effect of TGF betas on signaling	Bone formation or
	W36100		proteins initiate cell signaling by	can be assayed by treating Primary	Regeneration
			binding to heteromeric receptor	BAECs transfected with a construct	Abnormalities
			complexes of type I (TbetaRI) and type	called p3TP-Lux, containing a TGF-
			II (TbetaRII) serine/threonine kinase	beta responsive promoter fused to a
			receptors (reviewed by Massague, J. et	reporter gene, and measuring
			al. (1994) Trends Cell Biol. 4: 172 178;	luciferase gene expression (Wrana et
			Miyazono, K. et al. (1994) Adv.	al., 1994, Nature 370: 341-347).
			Immunol. 55: 181-220). Activation of
			this heteromeric receptor complex
			occurs when TGF-beta. binds to
			TbetaRII, which then recruits and
			phosphorylates TbetaRI. Activated
			TbetaRI then propagates the signal to
			downstream targets (Chen, F. and
			Weinberg. R. A. (1995) PNA892: 1565-1569;
			Wrana, J. L. et al. (1994) Nature
			370: 341.
b57 Protein	GeneSeq Accession	WO9837195	BMPs are involved in the induction of	BMP activity, in the presence of b57	BMP Antagonist useful
	W69293		bone formation. Specific antagonists are	protein, can be determined using the	for Osteosarcoma,
			useful is preventing this activity from	following assays known in the art:	abnormal bone growth.
			occurring.	Nat Genet. 2001 January; 27(1): 84-8; Eur
				J Biochem 1996 Apr. 1; 237(1): 295-302;
				J Biol Chem, Vol. 274, Issue 16,
				1089-10902, Apr. 16, 1999; and
				Hogan, B. L. M. (1996) Genes Deve.
				10, 1580-1594.
Resistin	GeneSeq Accession	WO0064920	This gcne belongs to the family defined	Ability of resistin to influence type	Type II diabetes and
	W69293		by mouse FIZZI and FIZZ3/Resistin	II diabetes can be determined using	Syndrome X.
			genes. The characteristic feature of this	assays known in the art: Pontoglio et
			family is the C-terminal stretch of 10 cys	al., J Clin Invest 1998 May 15;
			residues with identical spacing. The	101(10): 2215-22.
			mouse homolog of this protein is secreted
			by adipocytes, may be the hormone
			potantially linking obesity to type II
			diabetes.
Galectin-4	GeneSeq Accession	WO9703190	Galectins are a family of carbohydrate-	Ability of Galectin-4 polypeptides to	Lactose intolerance.
	W11841		binding proteins characterized by an	bind lactose can be determined using
			affinity for beta-galactoside containing	assays known in the art: Wada, et al.,
			glycoconjugates.	J Biol Chem 1997 Feb. 28;
				272(9): 6078-86.
APM-I; ACRP-30;	GeneSeq Accession	W00026363	ACPR30 gene is exclusively expressed in	Ability of ACRP30 polypeptides to	Obesity, Metabolic
Famoxin	Y71035		adipose tissue. ACRP30 is thought to	influence obesity and fat oxidation	disorders, Lipid
			increase fatty acid oxidation by muscle	can be determined using assays	Metabolism; Hormone
			tissue.	known in the art: Fruebis et al., Proc	Secretion.
				Nat'l Acad Sci USA 2001 Feb. 13;
				98(4): 2005-10.
ACRP-30	GeneSeq Accession	WO0063376	ACPR30 gene is exclusively expressed in	Ability of ACRP30 homologue	Obesity, Metabolic
Homologue;	B30234		adipose tissue. ACRP30 is thought to	polypeptides to influence obesity	disorders, Lipid
Complement			increase fatty acid oxidation by muscle	and fat oxidation can be determined	Metabolism; Hormone
Component Clq C			tissue.	using assays known in the art:	Secretion.
				Fruebis et al., Proc Nat'l Acad Sci
				USA
2001 Feb. 13; 98(4): 2005-10.
Calpain-10a	GeneSeq Accession	WO0023603	Calpain is believed to play a role in	Ability of Calpain-10 to influence	Diabetes mellitus;
	Y79567		insulin secretion and insulin activity, and	type II diabetes can be determined	Regulation of Insulin
			therefore may be useful in the treatment	using assays known in the art:	secretory response;
			of type II diabetes.	Pontoglio et al., J Clin Invest 1998	Insulin mediated
				May 15; 101(10): 2215-22.	glucose transport
					disorders.
Calpain-10b	GeneSeq Accession	WO0023603	Calpain is believed to play a role in	Ability of Calpain-10 to influence	Diabetes mellitus;
	Y79568		insulin secretion and insulin activity, and	type II diabetes can be determined	Regulation of Insulin
			therefore may be useful in the treatment	using assays known in the art:	secretory response;
			of type II diabetes.	Pontoglio et al., J Clin Invest 1998	Insulin mediated
				May 15; 101(10): 2215-22.	glucose transport
					disorders.
Calpain-10c	GeneSeq Accession	WO0023603	Calpain is believed to play a role in	Ability of Calpain-10 to influence	Diabetes mellitus;
	Y79569		insulin secretion and insulin activity, and	type II diabetes can be determined	Regulation of Insulin
			therefore may be useful in the treatment	using assays known in the art:	secretory response;
			of type II diabetes.	Pontoglio et al., J Clin Invest 1998	Insulin mediated
				May 15; 101(10): 2215-22.	glucose transport
					disorders
PDGF-D	GeneSeq Accession	WO0027879	Vascular Endothelial Growth Factor.	Proliferation assay using NR6R-3T3	Wound Healing;
	Y71130			cells (Rizzino 1988 Cancer Res. 48:	Atherosclermis.
				4266).
FasL	GeneSeq Accession	WO9936079	Activities associated with apoptosis and	Activity can be determined using	Apoptosis-related
	Y28594		immune system functions.	Apoptosis assays known in the art:	disorders; Autoimmune
				Walczak et al. (1996) EMBOJ 16:	disorders; Graft v-Host
				5386-5397.	disorders.
Chondro modulin-	GeneSeq Accession	W00029579	Chondromodulin proteins are cartilage	Ability of Chondromodulin-like	Antianglogenic agent;
like protein	Y71262		proteins thought to confer resistance to	protein to inhibit vascularization can	Osteoblast proliferation
			anglogeneis, and thus are useful as anti-	be determined using assays known	stimulator; prevents
			angiogenic agents that may have utility in	in the art: Hirakie et al., J Biol Chem	vascularization of
			combating cancer.	1997 Dec. 19; 272(51): 32419-26.	cartilage tissue; Useful
					to treat cancer.
Patched	GeneSeq Accession	U.S. Pat. No. 5837538	Patched is a tumour-suppressor receptor	Ability of soluble Patched to bind to	Receptor for Hedgehog
	W72969		for Sonic hedgehog (shh), which is a	and inhibit the activities of shh can	cellular proliferation
			protein that controls developmental	be determined using assays known	signaling molecule.
			patterning and growth.	in the art: Stone et al., Nature 1996	This receptor is useful
				Nov. 14; 384(6605): 129-34.	as a means of
					preventing cellular
					proliferation via the shh
					signaling pathway, thus
					useful for cancers.
Patched-2	GeneSeq Accession	WO9953058	Patched is a tumour-suppressor receptor	Ability of soluble Patched to bind to	Receptor for Hedgehog
	Y43261		for Sonic hedgehog (shh), which is a	and inhibit the activities of shh can	cellular proliferation
			protein that controls developmental	be determined using assays known	signaling molecule.
			patterning and growth.	in the art: Stone et al., Nature 1996	This receptor is useful
				Nov. 14; 384(6605): 129-34.	as a means of
					preventing cellular
					proliferation via the shh
					signaling pathway, thus
					useful for cancers.
Maspin; Protease	GeneSeq Accession	WO9405804	Maspin is a member of the serpin family	The inhibitory effects of Maspin and	Tumor suppressor which
Inhibitor 5	R50938		of serine protease inhibitors that is	other protease inhibitors can be	is down-regulated in
			thought to suppress tumor metastasis.	assayed using methods known in the	breast cancers. The
				art such as a labeled protease	maspin protein has
				substrate, for example, Universal	tumour suppressing and
				Protease Substrate (casein, resorufin-	invasion suppressing
				labeled): Roche Molecular	activity.
				Biochemicals, Cat. No. 1080733.
Endostatin	GeneSeq Accession	WO0064946	Endostatin is believed to inhibit effects of	The inhibitory effects of endostatin	Anti-angiogenic activity.
	B28399		capillary endothelial cell proliferation.	can be assayed using assays	Useful in the prevention
				disclosed by Cao et al. (1996) J.	and/or treatment of
				Biol. Chem. 271 29461-29467.	cancers.
aFGF; FGF-1	GeneSeq Accession	EP298723	Fibroblast Growth Factor	Proliferation assay using NR6R-3T3	Promotion of growth and
	P94037			cells (Rizzino 1988 Cancer Res. 48:	proliferation of cells,
				4266); Examples 23 and 39	such as epithelial cells
				disclosed herein,	and keratinocytes.
					Antagonists may be
					useful as anti-cancer
					agents.
bFGF; FGF-2	GeneSeq Accession	FR2642086	Fibroblast Growth Factor	Proliferation assay using NR6R-3T3	Promotion of growth and
	R06685			cells (Rizzino 1988 Cancer Res. 48:	proliferation of cells,
				4266); Examples 23 and 39	such as epithelial cells
				disclosed herein.	and keratinocytes.
					Antagonists may be
					useful as anti-cancer
					agents.
FGF-3; INT-2	GeneSeq Accession	WO9503831	Fibroblast Growth Factor	Proliferation assay using NR6R-3T3	Promotion of growth and
	R07824			cells (Rizzino 1988 Cancer Res. 48:	proliferation of cells,
				4266); Examples 23 and 39	such as epithelial cells
				disclosed herein.	and keratinocytes.
					Antagonists may he
					useful as anti-cancer
					agents.
FGF-4; HST-1;	GeneSeq Accession	WO9503831	Fibroblast Growth Factor	Proliferation assay using NR6R-3T3	Promotion of growth and
HBGF-4	R07825			cells (Rizzino 1988 Cancer Res. 48:	proliferation of cells,
				4266); Examples 23 and 39	such as epithelial cells
				disclosed herein.	and keratinocytes.
					Antagonists may be
					useful as anti-cancer
					agents.
FGF-5	GeneSeq Accession	WO9730155	Fibroblast Growth Factor	Proliferation assay using NR6R-3T3	Promotion of growth and
	W22600			cells (Rizzino 1988 Cancer Res. 48:	proliferation of cells,
				4266); Examples 23 and 39	such as epithelial cells
				disclosed herein.	and keratinocytes.
					Antagonists may be
					useful as anti-cancer
					agents.
FGF-6; Heparin	GeneSeq Accession	EP613946	Fibroblast Growth Factor	Proliferation assay using NR6R-3T3	Promotion of growth and
binding secreted	R58555			cells (Rizzino 1988 Cancer Res. 48:	proliferation of cells,
transforming				4266); Examples 23 and 39	such as epithelial cells
factor-2				disclosed herein.	and keratinocytes.
					Antagonists may be
					useful as anti-cancer
					agents.
FGF-8	GeneSeq Accession	WO9524928	Fibroblast Growth Factor	Proliferation assay using NR6R-3T3	Promotion of growth and
	R80783			cells (Rizzino 1988 Cancer Res. 48:	proliferation of cells,
				4266); Examples 23 and 39	such as epithelial cells
				disclosed herein.	and keratinocytes.
					Antagonists may be
					useful as anti-cancer
					agents.
FGF-9; Gila	GeneSeq Accession	WO9503831	Fibroblast Growth Factor	Proliferation assay using NR6R-3T3	Promotion of growth and
activating factor	R70822			cells (Rizzino 1988 Cancer Res. 48:	proliferation of cells,
				4266); Examples 23 and 39	such as epithelial cells
				disclosed herein.	and keratinocytes.
					Antagonists may be
					useful as anti-cancer
					agents.
FGF-12; Fibroblast	GeneSeq Accession	WO9635708	Fibroblast Growth Factor	Proliferation assay using NR6R-3T3	Promotion of growth and
growth factor	W06309			cells (Rizzino 1988 Cancer Res. 48:	proliferation of cells,
homologous				4266); Examples 23 and 39	such as epithelial cells
factor-1				disclosed herein.	and keratinocytes.
					Antagonists may be
					useful as anti-cancer
					agents.
FGF-15	GeneSeq Accession	WO9927100	Fibroblast Growth Factor	Proliferation assay using NR6R-3T3	Promotion of growth and
	Y08582			cells (Rizzino 1988 Cancer Res. 48:	proliferation of cells,
				4266); Examples 23 and 39	such as epithelial cells
				disclosed herein.	and keratinocytes.
					Antagonists may be
					useful as anti-cancer
					agents.
FGF-16	GeneSeq Accession	WO9918128	Fibroblast Growth Factor	Proliferation assay using NR6R-3T3	Promotion of growth and
	Y05474			cells (Rizzino 1988 Cancer Res. 48:	proliferation of cells,
				4266); Examples 23 and 39	such as epithelial cells
				disclosed herein.	and keratinocytes.
					Antagonists may be
					useful as anti-cancer
					agents.
FGF-18	GeneSeq Accession	WO9927100	Fibroblast Growth Factor	Proliferation assay using NR6R-3T3	Promotion of growth and
	Y08590			cells (Rizzino 1988 Cancer Res. 48:	proliferation of cells,
				4266); Examples 23 and 39	such as epithelial cells
				disclosed herein.	and keratinocytes.
					Antagonists may be
					useful as anti-cancer
					agents.
fit-3 ligand	GeneSeq Accession	EP627487	Stem Cell Progenitor	Chemokine activities can be	Promotion of immune
	R67541			determined using assays known in	cell growth and/or
				the art: Methods in Molecular	differentiation.
				Biology, 2000, vol. 138: Chemokine
				Protocols. Edited by: A. E. I. Proudfoot,
				T. N. C. Wells, and C. A. Power.
				©Humana Press Inc.,
				Totowa, NJ
VEGF-110	GeneSeq Accession	WO0013702	Promotes the growth and/or proliferation	VEGF activity can be determined	Promotion of growth and
	Y69417		of endothelial cells.	using assays known in the art, such	proliferation of cells,
				as those disclosed in International	such as vascular
				Publication No. WO0045835, for	endothelial cells.
				example.	Antagonists may be
					useful as anti-angiogenic
					agents, and may be
					applicable for cancer.
VEGB-121	GeneSeq Accession	WO0071713	Promotes the growth and/or proliferation	VEGF activity can be determined	Promotion of growth and
	B50432		of endothelial cells.	using assays known in the art, such	proliferation of cells,
				as those disclosed in International	such as vascular
				Publication No. WO0045835, for	endothelial cells.
				example.	Antagonists may be
					useful as anti-angiogenic
					agents, and may be
					applicable for cancer.
VEGF-138	GeneSeq Accession	WO9940197	Promotes the growth and/or proliferation	VEGF activity can be determined	Promotion of growth and
	Y43483		of endothelial cells.	using assays known in the art, such	proliferation of cells,
				as those disclosed in International	such as vascular
				Publication No. WO0045835, for	endothelial cells.
				example.	Antagonists may be
					useful as anti-angiogenic
					agents, and may be
					applicable for cancer.
VEGF-145	GeneSeq Accession	WO0013702	Promotes the growth and/or proliferation	VEGF activity can be determined	Promotion of growth and
	Y69413		of endothelial cells.	using assays known in the art, such	proliferation of cells,
				as those disclosed in International	such as vascular
				Publication No. WO0045835, for	endothelial cells.
				example.	Antagonists may be
					useful as anti-angiogenic
					agents, and may be
					applicable for cancer.
VEGF-162	GeneSeq Accession	W09940197	Promotes the growth and/or proliferation	VEGF activity can be determined	Promotion of growth and
	Y43484		of endothelial cells.	using assays known in the art, such	proliferation of cells,
				as those disclosed in International	such as vascular
				Publication No. WO0045835, for	endothelial cells.
				example.	Antagonists may be
					useful as anti-angiogenic
					agents, and may be
					applicable for cancer.
VEGF-165	GeneSeq Accession	WO0013702	Promotes the growth and/or proliferation	VEGF activity can be determined	Promotion of growth and
	Y69414		of endothelial cells.	using assays known in the art, such	proliferation of cells,
				as those disclosed in International	such as vascular
				Publication No. WO0045835, for	endothelial cells.
				example.	Antagonists may be
					useful as anti-angiogenic
					agents, and may be
					applicable for cancer.
VEGF-182	GeneSeq Accession	W09940197	Promotes the growth and/or proliferation	VEGF activity can be determined	Promotion of growth and
	Y43483		of endothelial cells.	using assays known in the art, such	proliferation of cells,
				as those disclosed in International	such as vascular
				Publication No. WO0045835, for	endothelial cells.
				example.	Antagonists may be
					useful as anti-angiogenic
					agents, and may be
					applicable for cancer.
VEGF-189	GeneSeq Accession	WO0013702	Promotes the growth and/or proliferation	VEGF activity can be determined	Promotion of growth and
	Y69415		of endothelial cells.	using assays known in the art, such	proliferation of cells,
				as those disclosed in International	such as vascular
				Publication No. WO0045835, for	endothelial cells.
				example.	Antagonists may be
					useful as anti-angiogenic
					agents, and may be
					applicable for cancer.
VEGF-206	GeneSeq Accession	W00013702	Promotes the growth and/or proliferation	VEGF activity can be determined	Promotion of growth and
	Y69416		of endothelial cells.	using assays known in the art, such	proliferation of cells,
				as those disclosed in International	such as vascular
				Publication No. WO0045835, for	endothelial cells.
				example.	Antagonists may be
					useful as anti-angiogenic
					agents, and may be
					applicable for cancer.
VEGF-D	GeneSeq Accession	WO9807832	Promotes the growth and/or proliferation	VEGF activity can be determined	Promotion of growth and
	W53240		of endothelial cells.	using assays known in the art, such	proliferation of cells,
				as those disclosed in International	such as vascular
				Publication No. WO0045835, for	endothelial cells.
				example.	Antagonists may be
					useful as anti-angiogenic
					agents, and may be
					applicable for cancer.
VEGF-E; VEGF-X	GeneSeq Accession	W09947677	Promotes the growth and/or proliferation	VEGF activity can be determined	Promotion of growth and
	Y33679		of endothelial cells.	using assays known in the art, such	proliferation of cells,
				as those disclosed in International	such as vascular
				Publication No. WO0045835, for	endothelial cells.
				example.	Antagonists may be
					useful as anti-angiogenic
					agents, and may be
					applicable for cancer.
VEGF Receptor;	GeneSeq Accession	WO9831794	Receptor for VEGF polypeptides	VEGF activity, in the presence of	VEGF Receptor. Fusion
KDR; flk-1	W69679			flk-1 polypeptides, can be	protein with the
				determined using assays known in	extracellular domain is
				the art, such as those disclosed in	useful as an anti-
				International Publication No.	angiogenic agent.
				WO0045835, for example.	Antagonists may be
					useful in the promotion
					of angiogenesis.
Soluble VEGF	GeneSeq Accession	U.S. Pat. No. 5,712,380	Receptor for VEGF polypeptides	VEGF activity, in the presence of	VEGF Receptor. Fusion
Receptor	W47037			VEGF Receptor polypeptides, can	protein with the
				be determined using assays known	extracellular domain is
				in the art, such as those disclosed in	useful as an anti-
				International Publication No.	angiogenic agent.
				WO0045835, for example.	Antagonists may be
					useful in the promotion
					of angiogenesis.
flt-1	GeneSeq Accession	WO0021560	Receptor for VEGF polypeptides	VEGF activity, in the presence of	VEGF Receptor. Fusion
	Y70751			flt-1 polypeptides, can be	protein with the
				determined using assays known in	extracellular domain is
				the art, such as those disclosed in	useful as an anti-
				International Publication No.	angiogenic agent.
				WO0045835, for example.	Antagonists may be
					useful in the promotion
					of angiogenesis.
VEGF R-3; flt-4	GeneSeq Accession	WO0058511	Receptor for VEGF polypeptides	VEGF activity, in the presence of	VEGF Receptor. Fusion
	B29047			flt-4 polypeptides, can be	protein with the
				determined using assays known in	extracellular domain is
				the art, such as those disclosed in	useful as an anti-
				International Publication No.	angiogenic agent.
				WO0045835, for example.	Antagonists may be
					useful in the promotion
					of angiogenesis.
Neuropilin-1	GeneSeq Accession	WO9929858	Vascular Endothelial Growth Factor	VEGF activity can be determined	Promotion of growth and
	Y06319			using assays known in the art, such	proliferation of cells,
				as those disclosed in International	such as vascular
				Publication No. WO0045835, for	endothelial cells.
				example.	Antagonists may be
					useful as anti-angiogenic
					agents, and may be
					applicable for cancer.
Neuropilin-2	GeneSeq Accession	WO9929858	Vascular Endothelial Growth Factor	VEGF activity can be determined	Promotion of growth and
	Y03618			using assays known in the art, such	proliferation of cells,
				as those disclosed in International	such as vascular
				Publication No. WO0045835, for	endothelial cells.
				example.	Antagonists may be
					useful as anti-angiogenic
					agents, and may be
					applicable for cancer.
Human fast twitch	GeneSeq Accession	W09730085	Troponins are contractile proteins that are	Ability of soluble Troponins to	Anti-angiogenesis
skeletal muscle	W22597		thought to inhibit angiogenesis. High	inhibit anglogenesis can be
troponin C			levels may contribute to the difficulty	determined using assays known in
			encountered in revascularizing the	the art:. Proc Natl Acad Sci USA
			ischemic myocardium after	1999 Mar. 16; 96(6): 2645-50.
			cardiovascular injury.
Human fast twitch	GeneSeq Accession	W09730085	Troponins are contractile proteins that are	Ability of soluble Troponins to	Anti-angiogenesis
skeletal muscle	W18054		thought to inhibit angiogenesis. High	inhibit anglogenesis can be
troponin I			levels may contribute to the difficulty	determined using assays known in
			encountered in revascularizing the	the art:. Proc Natl Acad Sci USA
			ischemic myocardium after	1999 Mar. 16; 96(6): 2645-50.
			cardiovascular injury.
Human fast twitch	GeneSeq Accession	W09730085	Troponins are contractile proteins that are	Ability of soluble Troponins to	Anti-angiogenesis
skeletal muscle	W22599		thought to inhibit angiogenesis. High	inhibit anglogenesis can be
troponin T			levels may contribute to the difficulty	determined using assays known in
			encountered in revascularizing the	the art:. Proc Natl Acad Sci USA
			ischemic myocardium after	1999 Mar. 16; 96(6): 2645-50.
			cardiovascular injury.
fragment.	GeneSeq Accession	W09719955	Troponins are contractile proteins that are	Ability of soluble Troponins to	Anti-angiogenesis
myofibrillar	W18053		thought to inhibit angiogenesis. High	inhibit anglogenesis can be
protein troponin I			levels may contribute to the difficulty	determined using assays known in
			encountered in revascularizing the	the art:. Proc Natl Acad Sci USA
			ischemic myocardium after	1999 Mar. 16; 96(6): 2645-50.
			cardiovascular injury.
myofibrillar	GeneSeq Accession	W09719955	Troponins are contractile proteins that are	Ability of soluble Troponins to	Anti-angiogenesis
protein troponin I	W18054		thought to inhibit angiogencsis. High	inhibit anglogenesis can be
			levels may contribute to the difficulty	determined using assays known in
			encountered in revascularizing the	the art:. Proc Natl Acad Sci USA
			ischemic myocardium after	1999 Mar. 16; 96(6): 2645-50.
			cardiovascular injury.
Troponin peptides	GeneSeq Accessions	WO9933874	Troponins are contractile proteins that are	Ability of soluble Troponins to	Anti-angiogenesis
	Y29581, Y29582,		thought to inhibit angiogencsis. High	inhibit anglogenesis can be
	Y29583, Y29584,		levels may contribute to the difficulty	determined using assays known in
	Y29585, and		encountered in revascularizing the	the art:. Proc Natl Acad Sci USA
	Y29586		ischemic myocardium after	1999 Mar. 16; 96(6): 2645-50.
			cardiovascular injury.
Human fast twitch	GeneSeq Accession	WO0054770	Troponins are contractile proteins that are	Ability of soluble Troponins to	Anti-angiogenesis
skeletal muscle	B00134		thought to inhibit angiogencsis. High	inhibit anglogenesis can be
Troponin subunit C			levels may contribute to the difficulty	determined using assays known in
			encountered in revascularizing the	the art:. Proc Natl Acad Sci USA
			ischemic myocardium after	1999 Mar. 16; 96(6): 2645-50.
			cardiovascular injury.
Human fast twitch	GeneSeq Accession	WO0054770	Troponins are contractile proteins that are	Ability of soluble Troponins to	Anti-angiogenesis
skeletal muscle	B00135		thought to inhibit angiogencsis. High	inhibit anglogenesis can be
Troponin subunit I			levels may contribute to the difficulty	determined using assays known in
Protein			encountered in revascularizing the	the art:. Proc Natl Acad Sci USA
			ischemic myocardium after	1999 Mar. 16; 96(6): 2645-50.
			cardiovascular injury.
Human fast twitch	GeneSeq Accession	WO0054770	Troponins are contractile proteins that are	Ability of soluble Troponins to	Anti-angiogenesis
skeletal muscle	B00136		thought to inhibit angiogencsis. High	inhibit anglogenesis can be
Troponin subunit T			levels may contribute to the difficulty	determined using assays known in
			encountered in revascularizing the	the art:. Proc Natl Acad Sci USA
			ischemic myocardium after	1999 Mar. 16; 96(6): 2645-50.
			cardiovascular injury.
Activator	GeneSeq Accession	WO9013648	PAIs are believed to play a role in cancer,	Methods that measure plasminogen	Anti-angiogenesis;
Inbibitor-1; PAI-1	R08411		and cardiovascular disease and blood-	activator inhibitor (PAI) activity are	blood-clotting disorders.
			clotting disorders.	known in the art, for example, assay
				the ability of PAI to inhibit tissue
				plasminogen activator (tPA) or
				urokinase (uPA): J Biochem
				Biophys Methods 2000 Sep. 11;
				45(2): 127-40, Breast Cancer Res
				Treat 1996; 41(2): 141-6. Methods
				that measure anti-angiogenesis
				activity are known in the art, for
				example, Proc Natl Acad Sci USA
				1999 Mar. 16; 96(6): 2645-50.
Plasminogen	GeneSeq Accession	DE3722673	PAIs are believed to play a role in cancer,	Methods that measure plasminogen	Anti-angiogenesis;
Activator	P94160		and cardiovascular disease and blood-	activator inhibitor (PAI) activity are	blood-clotting disorders.
Inhibitor-2; PAI-2			clotting disorders.	known in the art, for example, assay
				the ability of PAI to inhibit tissue
				plasminogen activator (tPA) or
				urokinase (uPA): J Biochem
				Biophys Methods 2000 Sep. 11;
				45(2): 127-40, Breast Cancer Res
				Treat 1996; 41(2): 141-6. Methods
				that measure anti-angiogenesis
				activity are known in the art, for
				example, Proc Natl Acad Sci USA
				1999 Mar. 16; 96(6): 2645-50.
Activator	GeneSeq Accession	WO9102057	PAIs are believed to play a role in cancer,	Methods that measure plasminogen	Anti-angiogenesis;
Inhibitor-2; PAI-2	R10921		and cardiovascular disease and blood-	activator inhibitor (PAI) activity are	blood-clotting disorders.
			clotting disorders.	known in the art, for example, assay
				the ability of PAI to inhibit tissue
				plasminogen activator (tPA) or
				urokinase (uPA): J Biochem
				Biophys Methods 2000 Sep. 11;
				45(2): 127-40, Breast Cancer Res
				Treat 1996; 41(2): 141-6. Methods
				that measure anti-angiogenesis
				activity are known in the art, for
				example, Proc Natl Acad Sci USA
				1999 Mar. 16; 96(6): 2645-50.
Human PAI-1	GeneSeq Accessions	WO9105048	PAIs are believed to play a role in cancer,	Methods that measure plasminogen	Anti-angiogenesis;
mutants	R11755, R11756,		and cardiovascular disease and blood-	activator inhibitor (PAI) activity are	blood-clotting disorders.
	R11757, R11758,		clotting disorders.	known in the art, for example, assay
	R11759, R11760,			the ability of PAI to inhibit tissue
	R11761, R11762			plasminogen activator (tPA) or
	and R11763			urokinase (uPA): J Biochem
				Biophys Methods 2000 Sep. 11;
				45(2): 127-40, Breast Cancer Res
				Treat 1996; 41(2): 141-6. Methods
				that measure anti-angiogenesis
				activity are known in the art, for
				example, Proc Natl Acad Sci USA
				1999 Mar. 16; 96(6): 2645-50.
CXCR3; CXC	GeneSeq Accession	WO0018431	Chemokines are a family of related small,	Chemokine activities can be	Soluble CXCR3
	Y79372		secreted proteins involved in biological	determined using assays known in	polypeptides may be
			processes ranging from hematopoiesis,	the art: Methods in Molecular	useful for inhibiting
			angiogenesis, and leukocyte trafficking.	Biology, 2000, vol. 138: Chemokine	chemokine activities and
			Members of this family are involved in a	Protocols. Edited by: A. E. I. Proudfoot,	viral infection.
			similarly diverse range of pathologies	T. N. C. Wells, and C. A. Power.
			including inflammation, allergy, tissue	©Humana Press Inc.,
			rejection, viral infection, and tumor	Totowa, NJ.
			biology. The chemokines exert their
			effects by acting on a family of seven
			transmembrane G-protein coupled
			receptors. Over 40 human chemokines
			have been described, which bind to ~17
			receptors thus far identified.
Modified Rantes	GeneSeq Accession	WO9737005	Chemokines are a family of related small,	Chemokine activities can be	Immune disorders.
	W38129		secreted proteins involved in biological	determined using assays known in
			processes ranging from hematopoiesis,	the art: Methods in Molecular
			angiogenesis, and leukocyte trafficking.	Biology, 2000, vol. 138: Chemokine
			Members of this family are involved in a	Protocols. Edited by: A. E. I. Proudfoot,
			similarly diverse range of pathologies	T. N. C. Wells, and C. A. Power.
			including inflammation, allergy, tissue	©Humana Press Inc.,
			rejection, viral infection, and tumor	Totowa, NJ.
			biology. The chemokines exert their
			effects by acting on a family of seven
			transmembrane G-protein coupled
			receptors. Over 40 human chemokines
			have been described, which bind to ~17
			receptors thus far identified.
RANTES	GeneSeq Accession	EP905240	Chemokines are a family of related small,	Chemokine activities can be	Immune disorders.
	Y05299		secreted proteins involved in biological	determined using assays known in
			processes ranging from hematopoiesis,	the art: Methods in Molecular
			angiogenesis, and leukocyte trafficking.	Biology, 2000, vol. 138: Chemokine
			Members of this family are involved in a	Protocols. Edited by: A. E. I. Proudfoot,
			similarly diverse range of pathologies	T. N. C. Wells, and C. A. Power.
			including inflammation, allergy, tissue	©Humana Press Inc.,
			rejection, viral infection, and tumor	Totowa, NJ.
			biology. The chemokines exert their
			effects by acting on a family of seven
			transmembrane G-protein coupled
			receptors. Over 40 human chemokines
			have been described, which bind to ~17
			receptors thus far identified.
MCI-la	GeneSeq Accession	WO9509232	Chemokines are a family of related small,	Chemokine activities can be	Immune disorders.
	R73914		secreted proteins involved in biological	determined using assays known in
			processes ranging from hematopoiesis,	the art: Methods in Molecular
			angiogenesis; and leukocyte trafficking.	Biology, 2000, vol. 138: Chemokine
			Members of this family are involved in a	Protocols. Edited by: A. E. I. Proudfoot,
			similarly diverse range of pathologies	T. N. C. Wells, and C. A. Power.
			including inflammation, allergy, tissue	©Humana Press Inc.,
			rejection, viral infection, and tumor	Totowa, NJ.
			biology. The chemokines exert their
			effects by acting on a family of seven
			transmembrane G-protein coupled
			receptors. Over 40 human chemokines
			have been described, which bind to ~17
			receptors thus far identified.
MCP-lb	GeneSeq Accession	WO9929728	Chemokines are a family of related small,	Chemokine activities can be	Immune disorders.
	Y26176		secreted proteins involved in biological	determined using assays known in
			processes ranging from hematopoiesis,	the art: Methods in Molecular
			angiogenesis, and leukocyte trafficking.	Biology, 2000, vol. 138: Chemokine
			Members of this family are involved in a	Protocols. Edited by: A. E. I. Proudfoot,
			similarly diverse range of pathologies	T. N. C. Wells, and C. A. Power.
			including inflammation, allergy, tissue	©Humana Press Inc.,
			rejection, viral infection, and tumor	Totowa, NJ.
			biology. The chemokines exert their
			effects by acting on a family of seven
			transmembrane G-protein coupled
			receptors. Over 40 human chemokines
			have been described, which bind to ~17
			receptors thus far identified.
MCP-I receptor	GeneSeq Accession	WO9519436	Chemokines are a family of related small,	Chemokine activities can be	Soluble MCP-1 Receptor
	R79165		secreted proteins involved in biological	determined using assays known in	polypeptides may be
			processes ranging from hematopoiesis,	the art: Methods in Molecular	useful for inhibiting
			angiogenesis, and leukocyte trafficking.	Biology, 2000, vol. 138: Chemokine	chemokine activities and
			Members of this family are involved in a	Protocols. Edited by: A. E. I. Proudfoot,	viral infection.
			similarly diverse range of pathologies	T. N. C. Wells, and C. A. Power.
			including inflammation, allergy, tissue	©Humana Press Inc.,
			rejection, viral infection, and tumor	Totowa, NJ.
			biology. The chemokines exert their
			effects by acting on a family of seven
			transmembrane G-protein coupled
			receptors. Over 40 human chemokines
			have been described, which bind to ~17
			receptors thus far identified.
MCP-3	GeneSeq Accession	W09509232	Chemokines are a family of related small,	Chemokine activities can be	Immune disorders.
	R73915		secreted proteins involved in biological	determined using assays known in
			processes ranging from hematopoiesis,	the art: Methods in Molecular
			angiogenesis, and leukocyte trafficking.	Biology, 2000, vol. 138: Chemokine
			Members of this family are involved in a	Protocols. Edited by: A. E. I. Proudfoot,
			similarly diverse range of pathologies	T. N. C. Wells, and C. A. Power.
			including inflammation, allergy, tissue	©Humana Press Inc.,
			rejection, viral infection, and tumor	Totowa, NJ.
			biology. The chemokines exert their
			effects by acting on a family of seven
			transmembrane G-protein coupled
			receptors. Over 40 human chemokines
			have been described, which bind to ~17
			receptors thus far identified.
MCP-4 receptor	GeneSeq Accession	W09809171	Chemokines are a family of related small,	Chemokine activities can be	Soluble MCP-4 Receptor
	W56689		secreted proteins involved in biological	determined using assays known in	polypeptides may be
			processes ranging from hematopoiesis,	the art: Methods in Molecular	useful for inhibiting
			angiogenesis, and leukocyte trafficking.	Biology, 2000, vol. 138: Chemokine	chemokine activities and
			Members of this family are involved in a	Protocols. Edited by: A. E. I. Proudfoot,	viral infection.
			similarly diverse range of pathologies	T. N. C. Wells, and C. A. Power.
			including inflammation, allergy, tissue	©Humana Press Inc.,
			rejection, viral infection, and tumor	Totowa, NJ.
			biology. The chemokines exert their
			effects by acting on a family of seven
			transmembrane G-protein coupled
			receptors. Over 40 human chemokines
			have been described, which bind to ~17
			receptors thus far identified.
RANTES receptor	GeneSeq Accession	U.S. Pat. No. 5,652,133	Chemokines are a family of related small,	Chemokine activities can be	Soluble RANTES
	W29588		secreted proteins involved in biological	determined using assays known in	Receptor polypeptides
			processes ranging from hematopoiesis,	the art: Methods in Molecular	may be useful for
			angiogenesis, and leukocyte trafficking.	Biology, 2000, vol. 138: Chemokine	inhibiting chemokine
			Members of this family are involved in a	Protocols. Edited by: A. E. I. Proudfoot,	activities and viral
			similarly diverse range of pathologies	T. N. C. Wells, and C. A. Power.	infection.
			including inflammation, allergy, tissue	©Humana Press Inc.,
			rejection, viral infection, and tumor	Totowa, NJ.
			biology. The chemokines exert their
			effects by acting on a family of seven
			transmembrane G-protein coupled
			receptors. Over 40 human chemokines
			have been described, which bind to ~17
			receptors thus far identified.
CCR5 variant	GeneSeq Accession	WO9854317	Chemokines are a family of related small,	Chemokine activities can be	Soluble CCR5
	W88238		secreted proteins involved in biological	determined using assays known in	polypeptides may be
			processes ranging from hematopoiesis,	the art: Methods in Molecular	useful for inhibiting
			angiogenesis, and leukocyte trafficking.	Biology, 2000, vol. 138: Chemokine	chemokine activities and
			Members of this family are involved in a	Protocols. Edited by: A. E. I. Proudfoot,	viral infection.
			similarly diverse range of pathologies	T. N. C. Wells, and C. A. Power.
			including inflammation, allergy, tissue	©Humana Press Inc.,
			rejection, viral infection, and tumor	Totowa, NJ.
			biology. The chemokines exert their
			effects by acting on a family of seven
			transmembrane G-protein coupled
			receptors. Over 40 human chemokines
			have been described, which bind to ~17
			receptors thus far identified.
CCR7	GeneSeq Accession	U.S. Pat. No. 6,153,441	Chemokines are a family of related small,	Chemokine activities can be	Soluble CCR7
	B50859		secreted proteins involved in biological	determined using assays known in	polypeptides may be
			processes ranging from hematopoiesis,	the art: Methods in Molecular	useful for inhibiting
			angiogenesis, and leukocyte trafficking.	Biology, 2000, vol. 138: Chemokine	chemokine activities and
			Members of this family are involved in a	Protocols. Edited by: A. E. I. Proudfoot,	viral infection.
			similarly diverse range of pathologies	T. N. C. Wells, and C. A. Power.
			including inflammation, allergy, tissue	©Humana Press Inc.,
			rejection, viral infection, and tumor	Totowa, NJ.
			biology. The chemokines exert their
			effects by acting on a family of seven
			transmembrane G-protein coupled
			receptors. Over 40 human chemokines
			have been described, which bind to ~17
			receptors thus far identified.
CXC3	GeneSeq Accession	WO9727299	Chemokines are a family of related small,	Chemokine activities can be	Immune disorders.
	W23345		secreted proteins involved in biological	determined using assays known in
			processes ranging from hematopoiesis,	the art: Methods in Molecular
			angiogenesis, and leukocyte trafficking.	Biology, 2000, vol. 138: Chemokine
			Members of this family are involved in a	Protocols. Edited by: A. E. I. Proudfoot,
			similarly diverse range of pathologies	T. N. C. Wells, and C. A. Power.
			including inflammation, allergy, tissue	©Humana Press Inc.,
			rejection, viral infection, and tumor	Totowa, NJ.
			biology. The chemokines exert their
			effects by acting on a family of seven
			transmembrane G-protein coupled
			receptors. Over 40 human chemokines
			have been described, which bind to ~17
			receptors thus far identified.
Eotaxin	GeneSeq Accession	WO9700960	Chemokines are a family of related small,	Chemokine activities can be	Immune disorders.
	W10099		secreted proteins involved in biological	determined using assays known in
			processes ranging from hematopoiesis,	the art: Methods in Molecular
			angiogenesis, and leukocyte trafficking.	Biology, 2000, vol. 138: Chemokine
			Members of this family are involved in a	Protocols. Edited by: A. E. I. Proudfoot,
			similarly diverse range of pathologies	T. N. C. Wells, and C. A. Power.
			including inflammation, allergy, tissue	©Humana Press Inc.,
			rejection, viral infection, and tumor	Totowa, NJ.
			biology. The chemokines exert their
			effects by acting on a family of seven
			transmembrane G-protein coupled
			receptors. Over 40 human chemokines
			have been described, which bind to ~17
			receptors thus far identified.
Neurotactin	GeneSeq Accessions	U.S. Pat. No. 6,013,257	Neurotactin may play a role in	Chemotactic leukocyte migration	Immune disorders.
	Y77537, W34307,	WO9742224	chemotactic leukocyte migration and	assays are known in the art, for
	Y53259, and,		brain inflammation processes.	example: J. Immunol. Methods 33,
	Y77539			((1980)); Nature 1997 Jun. 5;
				387(6633): 611-7.
Human CKbeta-9	GeneSeq Accession	U.S. Pat. No. 6,153,441	Chemokines are a family of related small,	Chemokine activities can be	Immune disorders.
	B50860		secreted proteins involved in biological	determined using assays known in
			processes ranging from hematopoiesis,	the art: Methods in Molecular
			angiogenesis, and leukocyte trafficking.	Biology, 2000, vol. 138: Chemokine
			Members of this family are involved in a	Protocols. Edited by: A. E. I. Proudfoot,
			similarly diverse range of pathologies	T. N. C. Wells, and C. A. Power.
			including inflammation, allergy, tissue	©Humana Press Inc.,
			rejection, viral infection, and tumor	Totowa, NJ.
			biology. The chemokines exert their
			effects by acting on a family of seven
			transmembrane G-protein coupled
			receptors. Over 40 human chemokines
			have been described, which bind to ~17
			receptors thus far identified.
Lymphotactin	GeneSeq Accession	WO0073320	Chemokines are a family of related small,	Chemokine activities can be	Immune disorders.
	B50052		secreted proteins involved in biological	determined using assays known in
			processes ranging from hematopoiesis,	the art: Methods in Molecular
			angiogenesis, and leukocyte trafficking.	Biology, 2000, vol. 138: Chemokine
			Members of this family are involved in a	Protocols. Edited by: A. E. I. Proudfoot,
			similarly diverse range of pathologies	T. N. C. Wells, and C. A. Power.
			including inflammation, allergy, tissue	©Humana Press Inc.,
			rejection, viral infection, and tumor	Totowa, NJ.
			biology. The chemokines exert their
			effects by acting on a family of seven
			transmembrane G.
MIP-3 alpha	GeneSeq Accession	WO9801557	Chemokines are a family of related small,	Chemokine activities can be	Immune disorders.
	W44398		secreted proteins involved in biological	determined using assays known in
			processes ranging from hematopoiesis,	the art: Methods in Molecular
			angiogenesis, and leukocyte trafficking.	Biology, 2000, vol. 138: Chemokine
			Members of this family are involved in a	Protocols. Edited by: A. E. I. Proudfoot,
			similarly diverse range of pathologies	T. N. C. Wells, and C. A. Power.
			including inflammation, allergy, tissue	©Humana Press Inc.,
			rejection, viral infection, and tumor	Totowa, NJ.
			biology. The chemokines exert their
			effects by acting on a family of seven
			transmembrane G.
MIP-3 beta	GeneSeq Accession	WO9801557	Chemokines are a family of related small,	Chemokine activities can be	Immune disorders.
	W44399		secreted proteins involved in biological	determined using assays known in
			processes ranging from hematopoiesis,	the art: Methods in Molecular
			angiogenesis, and leukocyte trafficking.	Biology, 2000, vol. 138: Chemokine
			Members of this family are involved in a	Protocols. Edited by: A. E. I. Proudfoot,
			similarly diverse range of pathologies	T. N. C. Wells, and C. A. Power.
			including inflammation, allergy, tissue	©Humana Press Inc.,
			rejection, viral infection, and tumor	Totowa, NJ.
			biology. The chemokines exert their
			effects by acting on a family of seven
			transmembrane G.
MIP-Gamma	GeneSeq Accession	WO9504158	Chemokines are a family of related small,	Chemokine activities can be	Immune disorders.
	R70798		secreted proteins involved in biological	determined using assays known in
			processes ranging from hematopoiesis,	the art: Methods in Molecular
			angiogenesis, and leukocyte trafficking.	Biology, 2000, vol. 138: Chemokine
			Members of this family are involved in a	Protocols. Edited by: A. E. I. Proudfoot,
			similarly diverse range of pathologies	T. N. C. Wells, and C. A. Power.
			including inflammation, allergy, tissue	©Humana Press Inc.,
			rejection, viral infection, and tumor	Totowa, NJ.
			biology. The chemokines exert their
			effects by acting on a family of seven
			transmembrane G.
Stem Cell	GeneSeq Accession	WO9104274	Chemokines are a family of related small,	Chemokine activities can be	Hematopoietic growth
Inhibitory	R11553		secreted proteins involved in biological	determined using assays known in	factors.
Factor			processes ranging from hematopoiesis,	the art: Methods in Molecular
			angiogenesis, and leukocyte trafficking.	Biology, 2000, vol. 138: Chemokine
			Members of this family are involved in a	Protocols. Edited by: A. E. I. Proudfoot,
			similarly diverse range of pathologies	T. N. C. Wells, and C. A. Power.
			including inflammation, allergy, tissue	©Humana Press Inc.,
			rejection, viral infection, and tumor	Totowa, NJ.
			biology. The chemokines exert their
			effects by acting on a family of seven
			transmembrane G.
thrombopoietin	GeneSeq Accession	WO9521920	Thrombopoietin is involved in the	Thrombopoietin (TPO) can be	Hematopoietic growth
	R79905		regulation of the growth and	assayed to determine regulation of	factors.
			differentiation of megakaryocytes and	growth and differentiation of
			preceptors thereof.	megakaryocytes. Mol Cell Biol
				2001 April; 21(8): 2659-70; Exp
				Hematol
2001 January; 29(1): 51-8 and
				within.
c-kit ligand;	GeneSeq Accession	EP992579 and	C-kit ligan is thought to stimulate the	Chemokine activities can be	Hematopoietic growth
SCF; Mast cell	Y53284, R83978	EP676470	proliferation of mast cells, and is able to	determined using assays known in	factors.
growth factor;	and R83977		augment the proliferation of both	the art: Methods in Molecular
MGF;			myeloid and lymphoid hematopoietic	Biology, 2000, vol. 138: Chemokine
Fibrosarcoma-			progenitors in bone marrow culture. C-	Protocols. Edited by: A. E. I. Proudfoot,
derived stem			kit ligand is also though to act	T. N. C. Wells, and C. A. Power.
cell factor			synergistically with other cytokines.	©Humana Press Inc.,
				Totowa, NJ.
Platelet derived	GeneSeq Accession	WO0066736	Vascular Endothelial Growth Factor	VEGF activity can be determined	Promotion of growth and
growth factor	B48653			using assays known in the art, such	proliferation of cells,
				as those disclosed in International	such as vascular
				Publication No. WO0045835, for	endothelial cells.
				example.	Antagonists may be
					useful as anti-angiogenic
					agents, and may be
					applicable for cancer.
Melanoma	GeneSeq Accession	WO9503328	Melanoma inhibiting protein has	Tumor suppressor activity of	Cancer; melanoma
inhibiting protein	R69811		melanoma-inhibiting activity and can be	melanoma inhibiting protein can be
			used to treat cancer (melanoma,	determined using assays known in
			glioblastoma, neuroblastoma, small cell	the art: Matzuk et al., Nature 1992
			lung cancer, neuroectodermal tumors) or	Nov. 26; 360(6402): 313-9.
			as an immunosuppressant (it inhibits IL-2
			or phytohaemagglutinin induced
			proliferation of peripheral blood
			lymphocytes.
Glioma-derived	GeneSeq Accession	EP399816	Vascular Endothelial Growth Factor	VEGF activity can be determined	Promotion of growth and
growth factor	R08120			using assays known in the art, such	proliferation of cells,
				as those disclosed in International	such as vascular
				Publication No. WO0045835, for	endothelial cells.
				example.	Antagonists may be
					useful as anti-angiogenic
					agents, and may be
					applicable for cancer.
Platelet derived	GeneSeq Accession	EP682110	Vascular Endothelial Growth Factor	VEGF activity can be determined	Promotion of growth and
growth factor	R84759			using assays known in the art, such	proliferation of cells,
precursor A				as those disclosed in International	such as vascular
				Publication No. WO0045835, for	endothelial cells.
				example.	Antagonists may be
					useful as anti-angiogenic
					agents, and may be
					applicable for cancer.
Platelet derived	GeneSeq Accession	EP682110	Vascular Endothelial Growth Factor	VEGF activity can be determined	Promotion of growth and
growth factor	R84760			using assays known in the art, such	proliferation of cells,
precursor B				as those disclosed in International	such as vascular
				Publication No. WO0045835, for	endothelial cells.
				example.	Antagonists may be
					useful as anti-angiogenic
					agents, and may be
					applicable for cancer.
Platelet derived	GeneSeq Accession	EP282317	Vascular Endothelial Growth Factor	VEGF activity can be determined	Promotion of growth and
growth factor Bv-	P80595 and			using assays known in the art, such	proliferation of cells,
sis	P80596			as those disclosed in International	such as vascular
				Publication No. WO0045835, for	endothelial cells.
				example.	Antagonists may be
					useful as anti-angiogenic
					agents, and may be
					applicable for cancer.
Placental Growth	GeneSeq Accessions	WO9206194	Vascular Endothelial Growth Factor	VEGF activity can be determined	Promotion of growth and
Factor	R23059 and			using assays known in the art, such	proliferation of cells,
	R23060			as those disclosed in International	such as vascular
				Publication No. WO0045835, for	endothelial cells.
				example.	Antagonists may be
					useful as anti-angiogenic
					agents, and may be
					applicable for cancer.
Placental Growth	GeneSeq Accession	DE19748734	Vascular Endothelial Growth Factor	VEGF activity can be determined	Promotion of growth and
Factor-2	Y08289			using assays known in the art, such	proliferation of cells,
				as those disclosed in International	such as vascular
				Publication No. WO0045835, for	endothelial cells.
				example.	Antagonists may be
					useful as anti-angiogenic
					agents, and may be
					applicable for cancer.
Thrombopoietin	GeneSeq Accession	WO0000612	Thrombopoietin is involved in the	Thrombopoietin (TPO) can be	Thrombocytopenia,
derivative1	Y77244		regulation of the growth and	assayed to determine regulation of	cancer.
			differentiation of megakaryocytes and	growth and differentiation of
			preceptors thereof.	megakaryocytes. Mol Cell Biol
				2001 April; 21(8): 2659-70; Exp
				Hematol
2001 January; 29(1): 51-8 and
				within.
Thrombopoietin	GeneSeq Accession	WO0000612	Thrombopoietin is involved in the	Thrombopoietin (TPO) can be	Thrombocytopenia,
derivative2	Y77255		regulation of the growth and	assayed to determine regulation of	cancer.
			differentiation of megakaryocytes and	growth and differentiation of
			preceptors thereof.	megakaryocytes. Mol Cell Biol
				2001 April; 21(8): 2659-70; Exp
				Hematol
2001 January; 29(1): 51-8 and
				within.
Thrombopoietin	GeneSeq Accession	WO0000612	Thrombopoietin is involved in the	Thrombopoietin (TPO) can be	Thrombocytopenia,
derivative3	Y77262		regulation of the growth and	assayed to determine regulation of	cancer.
			differentiation of megakaryocytes and	growth and differentiation of
			preceptors thereof.	megakaryocytes. Mol Cell Biol
				2001 April; 21(8): 2659-70; Exp
				Hematol
2001 January; 29(1): 51-8 and
				within.
Thrombopoietin	GeneSeq Accession	WO0000612	Thrombopoietin is involved in the	Thrombopoietin (TPO) can be	Thrombocytopenia,
derivative4	Y77267		regulation of the growth and	assayed to determine regulation of	cancer.
			differentiation of megakaryocytes and	growth and differentiation of
			preceptors thereof.	megakaryocytes. Mol Cell Biol
				2001 April; 21(8): 2659-70; Exp
				Hematol
2001 January; 29(1): 51-8 and
				within.
Thrombopoietin	GeneSeq Accession	WO0000612	Thrombopoietin is involved in the	Thrombopoietin (TPO) can be	Thrombocytopenia,
derivative5	Y77246		regulation of the growth and	assayed to determine regulation of	cancer.
			differentiation of megakaryocytes and	growth and differentiation of
			preceptors thereof.	megakaryocytes. Mol Cell Biol
				2001 April; 21(8): 2659-70; Exp
				Hematol
2001 January; 29(1): 51-8 and
				within.
Thrombopoietin	GeneSeq Accession	WO0000612	Thrombopoietin is involved in the	Thrombopoietin (TPO) can be	Thrombocytopenia,
derivative6	Y77253		regulation of the growth and	assayed to determine regulation of	cancer.
			differentiation of megakaryocytes and	growth and differentiation of
			preceptors thereof.	megakaryocytes. Mol Cell Biol
				2001 April; 21(8): 2659-70; Exp
				Hematol
2001 January; 29(1): 51-8 and
				within.
Thrombopoietin	GeneSeq Accession	WO0000612	Thrombopoietin is involved in the	Thrombopoietin (TPO) can be	Thrombocytopenia,
derivative7	Y77256		regulation of the growth and	assayed to determine regulation of	cancer.
			differentiation of megakaryocytes and	growth and differentiation of
			preceptors thereof.	megakaryocytes. Mol Cell Biol
				2001 April; 21(8): 2659-70; Exp
				Hematol
2001 January; 29(1): 51-8 and
				within.
Fractalkine	GeneSeq Accession	U.S. Pat. No. 6,043,086	Fractalkine is believed to play a role in	Fractalkine activity can be	Immune disorders.
	Y53255		chemotactic leukocyte migration and	determined using Chemotactic
			neurological disorders.	leukocyte migration assays known in
				the art, for example: J. Immunol.
				Methods 33, ((1980)); Nature 1997
				Jun 5; 387(6633): 611-7.
CXC3	GeneSeq Accession	WO9757599	Chemokines are a family of related small,	Chemokine activities can be	Immune disorders.
	W23345		secreted proteins involved in biological	determined using assays known in
			processes ranging from hematopoiesis,	the art: Methods in Molecular
			angiogenesis, and leukocyte trafficking.	Biology, 2000, vol. 138: Chemokine
			Members of this family are involved in a	Prototols. Edited by: A. E. I. Proudfoot,
			similarly diverse range of pathologies	T. N. C. Wells, and C. A. Power.
			including inflammation, allergy, tissue	©Humana Press Inc.,
			rejection, viral infection, and tumor	Totowa, NJ.
			biology. The chemokines exert their
			effects by acting on a family of seven
			transmembrane G-protein coupled
			receptors. Over 40 human chemokines
			have been described, which bind to ~17
			receptors thus far identified.
CCR7	GeneSeq Accession	U.S. Pat. No. 6,153,441	Chemokines are a family of related small,	Chemokine activities can be	Soluble CCR7
	B50859		secreted proteins involved in biological	determined using assays known in	polypeptides may be
			processes ranging from hematopoiesis,	the art: Methods in Molecular	useful for inhibiting
			angiogenesis, and leukocyte trafficking.	Biology, 2000, vol. 138: Chemokine	chemokine activities and
			Members of this family are involved in a	Protocols. Edited by: A. E. I. Proudfoot,	viral infection.
			similarly diverse range of pathologies	T. N. C. Wells, and C. A. Power.
			including inflammation, allergy, tissue	©Humana Press Inc.,
			rejection, viral infection, and tumor	Totowa, NJ.
			biology. The chemokines exert their
			effects by acting on a family of seven
			transmembrane G-protein coupled
			receptors. Over 40 human chemokines
			have been described, which bind to ~17
			receptors thus far identified.
Nerve Growth	GeneSeq Accession	EP414151	Nerve Growth Factor	Proliferation assay using NR6R-3T3	Neurological disorders,
Factor-beta	R11474			cells (Rizzino 1988 Cancer Res. 48:	cancer
				4266)
Nerve Growth	GeneSeq Accession	EP859056	Nerve Growth Factor	Proliferation assay using NR6R 3T3	Neurological disorders,
Factor-beta2	W69725			cells (Rizzino 1988 Cancer Res. 48:	cancer
				4266
Neurotrophin-3	GeneSeq Accession	WO9821234	Neurotrophins regulate neuronal cell	Trk tyrosine kinase activation assays	Neurological disorders,
	W8889		survival and synaptic plasticity.	known in the art can be used to assay	cancer
				for neurotrophin activity, for
				example, Proc Natl Acad Sci USA
				2001 Mar. 13; 98(6): 3555-3560.
Neurotrophin-3	GeneSeq Accession	WO9325684	Neurotrophins regulate neuronal cell	Trk tyrosine kinase activation assays	Neurological disorders,
	R47100		survival and synaptic plasticity.	known in the art can be used to assay	cancer
				for neurotrophin activity, for
				example, Proc Natl Acad Sci USA
				2001 Mar. 13; 98(6): 3555-3560.
Neurotrophin-4a	GeneSeq Accession	WO9325684	Neurotrophins regulate neuronal cell	Trk tyrosine kinase activation assays	Neurological disorders,
	R47101		survival and synaptic plasticity.	known in the art can be used to assay	cancer
				for neurotrophin activity, for
				example, Proc Natl Acad Sci USA
				2001 Mar. 13; 98(6): 3555-3560.
				13; 98(6): 3555-3560
Neurotrophin-4b	GeneSeq Accession	WO9325684	Neurotrophins regulate neuronal cell	Trk tyrosine kinase activation assays	Neurological disorders,
	R47102		survival and synaptic plasticity.	known in the art can be used to assay	cancer
			tyrosine kinases.	for neurotrophin activity, for
				example, Proc Natl Acad Sci USA
				2001 Mar. 13; 98(6): 3555-3560.
Neurotrophin-4c	GeneSeq Accession	WO9325684	Neurotrophins regulate neuronal cell	Trk tyrosine kinase activation assays	Neurological disorders,
	R47103		survival and synaptic plasticity.	known in the art can be used to assay	cancer
			tyrosine kinases.	for neurotrophin activity, for
				example, Proc Natl Acad Sci USA
				2001 Mar. 13; 98(6): 3555-3560.
Neurotrophin-4d	GeneSeq Accession	WO9325684	Neurotrophins regulate neuronal cell	Trk tyrosine kinase activation assays	Neurological disorders,
	R47102		survival and synaptic plasticity.	known in the art can be used to assay	cancer
			tyrosine kinases.	for neurotrophin activity, for
				example, Proc Natl Acad Sci USA
				2001 Mar. 13; 98(6): 3555-3560.
Platelet-Derived	GeneSeq Accession	U.S. Pat. No. 5,219,739	Vascular Endothelial Growth Factor	VEGF activity can be determined	Promotion of growth and
Growth Factor	R38918			using assays known in the art, such as	proliferation of cells,
A chain				those disclosed in International	such as vascular
				Publication No. W00045835, for	endothelial cells.
				example.	Hematopoietic and
					immune disorders.
					Antagonists may be
					useful as anti-angiogenic
					agents, and may be
					applicable for cancer
Platelet-Derived	GeneSeq Accession	U.S. Pat. No. 5,219,739	Vascular Endothelial Growth Factor	VEGF activity can be determined	Promotion of growth and
Growth Factor	R38919			using assays known in the art, such as	proliferation of cells,
B chain				those disclosed in International	such as vascular
				Publication No. W00045835, for	endothelial cells.
				example.	Hematopoietic and
					immune disorders.
					Antagonists may be
					useful as anti-angiogenic
					agents, and may be
					applicable for cancer
Stromal Derived	GeneSeq Accession	WO9948528	Stromal Growth Factor	Proliferation assay using NR6R-3T3	Hematopoietic, immune
Factor-1 alpha	Y39995			cells (Rizzino 1988 Cancer Res. 48:	disorders, cancer
				4266)
Stromal Derived	GeneSeq Accession	CA2117953	Stromal Growth Factor	Proliferation assay using NR6R-3T3	Hematopoietic, immune
Factor-1 beta	R75420			cells (Rizzino 1988 Cancer Res. 48:	disorders, cancer
				4266)
Tarc	GeneSeq Accession	WO9711969	Chemotactic for T lymphocytes. May	Chemotactic leukocyte migration	Antiinflammatory.
	W14917		play a role in T-cell development.	assays are known in the art, for	Immune disorders,
			Thought to bind CCR8 and CCR4	example: J. Immunol. Methods 33	cancer
				((1980))
Prolactin	GeneSeq Accession	WO9521625	Prolactin is involved in immune cell	Immune coil proliferation and	Reproductive system
	R78691		proliferation and apoptosis.	suppression of apoptosis by prolactin	disorders, cancer.
				can be assayed by methods well-
				known in the art, for example,
				Buckley, A R and Buckley D J, Ann NY
				Acad Sci 2000; 917: 522-33, and
				within.
Prolactin2	GeneSeq Accession	U.S. Pat. No. 5,955,346	Prolactin is involved in immune cell	Immune coil proliferation and	Reproductive system
	Y31764		proliferation and apoptosis.	suppression of apoptosis by prolactin	disorders, cancer.
				can be assayed by methods well-
				known in the art, for example,
				Buckley, A R and Buckley D J, Ann NY
				Acad Sci 2000; 917: 522-33, and
				within.
Follicle	GeneSeq Accession	EP974359	FSH stimulates secretion of interleukin-1	FSH activities can be determined	Reproductive system
stimulating	Y54160		by cells isolated from women in the	using assays known in the art; J Gend	disorders, cancer.
hormone Alpha			follicular phase	Specif Med 1999 November-December; 2(6): 30-4;
subunit				Mol Cell Endocrinol. 1997 Nov.
				15; 134(2): 109-18.
Follicle	GeneSeq Accession	EP974359	FSH stimulates secretion of interleukin-1	FSH activities can be determined	Reproductive system
stimulating	Y54161		by cells isolated from women in the	using assays known in the art; J Gend	disorders, cancer.
hormone Beta			follicular phase	Specif Med 1999 November-December; 2(6): 30-4;
subunit				Mol Cell Endocrinol. 1997 Nov.
				15; 134(2): 109-18.
Substance P	GeneSeq Accession	WO0054053	Substance P is associated with	Immuneregulation and bone marrow,	diabetes mellitus,
(tachykinin)	B23027		immunoregulation.	cell proliferation by substance P can	hypertension, cancer
				be assayed by methods well-known in
				the art, for example, Lai et al. Proc
				Natl Acad Sci USA 2001 Mar. 27;
				98(7): 3970-5; Jallat-Daloz et al.
				Allergy Asthma Proc 2001 January-February;
				22(1): 17-23; Kahler et al. Exp Lung
				Res
2001 January-February; 27(1): 25-46; and
				Adamus M A and Dabrowski Z J. J
				Cell Biochem
2001; 81(3)499-506.
Ocytocin	GeneSeq Accession	WO0053755	Oxytocin is involved in the induction of	Oxytocin and prostaglandin E(2)	inflammatory disorders
(Neurophysin I)	B24085 and		prostaglandin (E2) release as well as an	release and Ocytocin (Ca2+) increase	immunologic disorders,
	B24086		increased amount of calcium release by	can be assayed by methods well-	cancer
			smooth muscle cells.	known in the art, for example, Pavan
				et al., AM J Obset Gynecol 2000 July;
				183(1): 76-82 and Holda et al., Cell
				Calcium 1996 July; 20(1): 43 51.
Vasopressin	GeneSeq Accession	WO0053755	Vasopressinis believed to have a direct	Vasopressin activity can be	inflammatory disorders
(Neurophysin II)	B24085 and		antidiuretic action on the kidney, and it is	determined using assays known in the	immunologic disorders,
	B24086		thought to cause vasoconstriction of the	art, for example, Endocr Regul 1996	cancer
			peripheral vessels.	March; 30(1): 13-17.
IL-1	GeneSeq Accession	EP165654	Interleukins are a group of	Interleukin activity can be determined	inflammatory disorders,
	P60326		multifunctional cytokines synthesized by	using assays known in the art:	immunologic disorders,
			lymphocytes, monocytes, and	Matthews et al., in Lymphokines and	cancer
			macrophages. Known functions include	Interferens: A Practical Approach,
			stimulating proliferation of immune cells	Clemens et al., eds, IRL Press,
			(e.g., T helper cells, B cells, eosinophils,	Washington, D.C. 1987, pp. 221-225;
			and lymphocytes), chemotaxis of	and Orencole & Dinarclio (1989)
			neutrophils and T lymphocytes, and/or	Cytokine 1, 14-20.
			inhibition of interferons.
IL-1 mature	GeneSeq Accession	EP456332	Interleukins are a group of	Interleukin activity can be determined	inflammatory disorders,
	R14855		multifunctional cytokines synthesized by	using assays known in the art:	immunologic disorders,
			lymphocytes, monocytes, and	Matthews et al., in Lymphokines and	cancer
			macrophages. Known functions include	Interferens: A Practical Approach,
			stimulating proliferation of immune cells	Clemens et al., eds, IRL Press,
			(e.g., T helper cells, B cells, eosinophils,	Washington, D.C. 1987, pp. 221-225;
			and lymphocytes), chemotaxis of	and Orencole & Dinarclio (1989)
			neutrophils and T lymphocytes, and/or	Cytokine 1, 14-20.
			inhibition of interferons.
IL-1 beta	GeneSeq Accession	WO9922763	Interleukins are a group of	Interleukin activity can be determined	inflammatory disorders,
	Y08322		multifunctional cytokines synthesized by	using assays known in the art:	immunologic disorders,
			lymphocytes, monocytes, and	Matthews et al., in Lymphokines and	cancer
			macrophages. Known functions include	Interferens: A Practical Approach,
			stimulating proliferation of immune cells	Clemens et al., eds, IRL Press,
			(e.g., T helper cells, B cells, eosinophils,	Washington, D.C. 1987, pp. 221-225;
			and lymphocytes), chemotaxis of	and Orencole & Dinarclio (1989)
			neutrophils and T lymphocytes, and/or	Cytokine 1, 14-20.
			inhibition of interferons.
IL-3 variants	GeneSeq Accession	WO8806161	Interleukins are a group of	Interleukin activity can be determined	inflammatory disorders,
	P80382, P80383,		multifunctional cytokines synthesized by	using assays known in the art:	immunologic disorders,
	P80384, and		lymphocytes, monocytes, and	Matthews et al., in Lymphokines and	cancer
	P80381		macrophages. Known functions include	Interferens: A Practical Approach,
			stimulating proliferation of immune cells	Clemens et al., eds, IRL Press,
			(e.g., T helper cells, B cells, eosinophils,	Washington, D.C. 1987, pp. 221-225;
			and lymphocytes), chemotaxis of	and Kitamura et al (1989) J Cell
			neutrophils and T lymphocytes, and/or	Physiol. 140 323-334.
			inhibition of interferons.
IL-4	GeneSeq Accession	WO8702990	Interleukins are a group of	Interleukin activity can be determined	inflammatory disorders,
	P70615		multifunctional cytokines synthesized by	using assays known in the art:	immunologic disorders,
			lymphocytes, monocytes, and	Matthews et al., in Lymphokines and	cancer
			macrophages. Known functions include	Interferens: A Practical Approach,
			stimulating proliferation of immune cells	Clemens et al., eds, IRL Press,
			(e.g., T helper cells, B cells, eosinophils,	Washington, D.C. 1987, pp. 221-225;
			and lymphocytes), chemotaxis of	and Siegel & Mostowski (1990) J
			neutrophils and T lymphocytes, and/or	Immunol Methods 132, 287-295.
			inhibition of interferons.
IL-4 muteins	GeneSeq Accession	WO9747744	Interleukins are a group of	Interleukin activity can be determined	inflammatory disorders,
	W52151 W52152		multifunctional cytokines synthesized by	using assays known in the art:	immunologic disorders,
	W52153 W52154		lymphocytes, monocytes, and	Matthews et al., in Lymphokines and	cancer
	W52155 W52156		macrophages. Known functions include	Interferens: A Practical Approach,
	W52157 W52158		stimulating proliferation of immune cells	Clemens et al., eds, IRL Press,
	W52159 W52160		(e.g., T helper cells, B cells, eosinophils,	Washington, D.C. 1987, pp. 221-225;
	W52161 W52162		and lymphocytes), chemotaxis of	and Siegel & Mostowski (1990) J
	W52163 W52164		neutrophils and T lymphocytes, and/or	Immunol Methods 132, 287-295.
	and W52165		inhibition of interferons.
IL-1 alpha	GeneSeq Accession	EP324447	Interleukins are a group of	Interleukin activity can be determined	inflammatory disorders,
	P90108		multifunctional cytokines synthesized by	using assays known in the art:	immunologic disorders,
			lymphocytes, monocytes, and	Matthews et al., in Lymphokines and	cancer
			macrophages. Known functions include	Interferens: A Practical Approach,
			stimulating proliferation of immune cells	Clemens et al., eds, IRL Press,
			(e.g., T helper cells, B cells, eosinophils,	Washington, D.C. 1987, pp. 221-225;
			and lymphocytes), chemotaxis of	and Orencole & Dinarello (1989)
			neutrophils and T lymphocytes, and/or	Cytokine 1, 14-20.
			inhibition of interferons.
IL-3 variants	GeneSeq Accession	WO9307171	Interleukins are a group of	Interleukin activity can be determined	inflammatory disorders,
	R38561, R38562,		multifunctional cytokines synthesized by	using assays known in the art:	immunologic disorders,
	R38563, R38564,		lymphocytes, monocytes, and	Matthews et al., in Lymphokines and	cancer
	R38565, R38566,		macrophages. Known functions include	Interferens: A Practical Approach,
	R38567, R38568,		stimulating proliferation of immune cells	Clemens et al.; eds, IRL Press,
	R38569, R38570,		(e.g., T helper cells, B cells, eosinophils,	Washington, D.C. 1987, pp. 221-225;
	R38571, and		and lymphocytes), chemotaxis of	and Aarden et al (1987) Eur. J.
	R38572		neutrophils and T lymphocytes, and/or	Immunol 17, 1411-16.
			inhibition of interferons.
IL-6	GeneSeq Accession	WO9402512	Interleukins are a group of	Interleukin activity can be determined	inflammatory disorders,
	R45717 and		multifunctional cytokines synthesized by	using assays known in the art:	immunologic disorders,
	R45718		lymphocytes, monocytes, and	Matthews et al., in Lymphokines and	cancer
			macrophages. Known functions include	Interferens: A Practical Approach,
			stimulating proliferation of immune cells	Clemens et al., eds, IRL Press,
			(e.g., T helper cells, B cells, eosinophils,	Washington, D.C. 1987, pp. 221-225;
			and lymphocytes), chemotaxis of	and Aarden et al (1987) Eur. J.
			neutrophils and T lymphocytes, and/or	Immunol 17, 1411-16.
			inhibition of interferons.
IL-13	GeneSeq Accession	WO9404680	Interleukins are a group of	Interleukin activity can be determined	inflammatory disorders,
	R48624		multifunctional cytokines synthesized by	using assays known in the art:	immunologic disorders,
			lymphocytes, monocytes, and	Matthews et al., in Lymphokines and	cancer
			macrophages. Known functions include	Interferens: A Practical Approach,
			stimulating proliferation of immune cells	Clemens et al., eds, IRL Press,
			(e.g., T helper cells, B cells, eosinophils,	Washington, D.C. 1987, pp. 221-225;
			and lymphocytes), chemotaxis of	and Boutelier et al (1995) J.
			neutrophils and T lymphocytes, and/or	Immunol. Methods 181, 29.
			inhibition of interferons.
IL-4 mutein	GeneSeq Accession	DE4137333	Interleukins are a group of	Interleukin activity can be determined	inflammatory disorders,
	R47182		multifunctional cytokines synthesized by	using assays known in the art:	immunologic disorders,
			lymphocytes, monocytes, and	Matthews et al., in Lymphokines and	cancer
			macrophages. Known functions include	Interferens: A Practical Approach,
			stimulating proliferation of immune cells	Clemens et al., eds, IRL Press,
			(e.g., T helper cells, B cells, eosinophils,	Washington, D.C. 1987, pp. 221-225;
			and lymphocytes), chemotaxis of	and Siegel & Mostowski (1990) J
			neutrophils and T lymphocytes, and/or	Immunol Methods 132, 287-295.
			inhibition of interferons.
IL-4 mutein	GeneSeq Accession	DE4137333	Interleukins are a group of	Interleukin activity can be determined	inflammatory disorders,
Y124X	R47183		multifunctional cytokines synthesized by	using assays known in the art:	immunologic disorders,
			lymphocytes, monocytes, and	Matthews et al., in Lymphokines and	cancer
			macrophages. Known functions include	Interferens: A Practical Approach,
			stimulating proliferation of immune cells	Clemens et al., eds, IRL Press,
			(e.g., T helper cells, B cells, eosinophils,	Washington, D.C. 1987, pp. 221-225;
			and lymphocytes), chemotaxis of	and Siegel & Mostowski (1990) J
			neutrophils and T lymphocytes, and/or	Immunol Methods 132, 287-295.
			inhibition of interferons.
IL-4 mutein	GeneSeq Accession	DE4137333	Interleukins are a group of	Interleukin activity can be determined	inflammatory disorders,
Y124G	R47184		multifunctional cytokines synthesized by	using assays known in the art:	immunologic disorders,
			lymphocytes, monocytes, and	Matthews et al., in Lymphokines and	cancer
			macrophages. Known functions include	Interferens: A Practical Approach,
			stimulating proliferation of immune cells	Clemens et al., eds, IRL Press,
			(e.g., T helper cells, B cells, eosinophils,	Washington, D.C. 1987, pp. 221-225;
			and lymphocytes), chemotaxis of	and Siegel & Mostowski (1990) J
			neutrophils and T lymphocytes, and/or	Immunol Methods 132, 287-295.
			inhibition of interferons.
Human	GeneSeq Accession	WO9317698	Interleukins are a group of	Interleukin activity can be determined	inflammatory disorders,
Interleukin-10	R41664		multifunctional cytokines synthesized by	using assays known in the art:	immunologic disorders,
(precursor)			lymphocytes, monocytes, and	Matthews et al., in Lymphokines and	cancer
			macrophages. Known functions include	Interferens: A Practical Approach,
			stimulating proliferation of immune cells	Clemens et al., eds, IRL Press,
			(e.g., T helper cells, B cells, eosinophils,	Washington, D.C. 1987, pp. 221-225;
			and lymphocytes), chemotaxis of	and Thompson-Snipes et al (1991) J.
			neutrophils and T lymphocytes, and/or	Exp. Med. 173, 507-510.
			inhibition of interferons.
Human	GeneSeq Accession	WO9318783-A	Interleukins are a group of	Interleukin activity can be determined	inflammatory disorders,
Interleukin-10	R42642		multifunctional cytokines synthesized by	using assays known in the art:	immunologic disorders,
			lymphocytes, monocytes, and	Matthews et al., in Lymphokines and	cancer
			macrophages. Known functions include	Interferens: A Practical Approach,
			stimulating proliferation of immune cells	Clemens et al., eds, IRL Press,
			(e.g., T helper cells, B cells, eosinophils,	Washington, D.C. 1987, pp. 221-225;
			and lymphocytes), chemotaxis of	and Thompson-Snipes et al (1991) J.
			neutrophils and T lymphocytes, and/or	Exp. Med. 173, 507-510.
			inhibition of interferons.
Human	GeneSeq Accession	EP569042	Interleukins are a group of	Interleukin activity can be determined	inflammatory disorders,
interleukin-1	R42447		multifunctional cytokines synthesized by	using assays known in the art:	immunologic disorders,
beta precursor.			lymphocytes, monocytes, and	Matthews et al., in Lymphokines and	cancer
			macrophages. Known functions include	Interferens: A Practical Approach,
			stimulating proliferation of immune cells	Clemens et al., eds, IRL Press,
			(e.g., T helper cells, B cells, eosinophils,	Washington, D.C. 1987, pp. 221-225;
			and lymphocytes), chemotaxis of	and Orencole & Dinarello (1989)
			neutrophils and T lymphocytes, and/or	Cytokine 1, 14-20.
			inhibition of interferons.
Interleukin-	GeneSeq Accession	EP578278	Interleukins are a group of	Interleukin activity can be determined	inflammatory disorders,
1alpha	R45364		multifunctional cytokines synthesized by	using assays known in the art:	immunologic disorders,
			lymphocytes, monocytes, and	Matthews et al., in Lymphokines and	cancer
			macrophages. Known functions include	Interferens: A Practical Approach,
			stimulating proliferation of immune cells	Clemens et al., eds, IRL Press,
			(e.g., T helper cells, B cells, eosinophils,	Washington, D.C. 1987, pp. 221-225.
			and lymphocytes), chemotaxis of
			neutrophils and T lymphocytes, and/or
			inhibition of interferons.
Human	GeneSeq Accession	JP04063595	Interleukins are a group of	Interleukin activity can be determined	inflammatory disorders,
interleukin-3	R22814		multifunctional cytokines synthesized by	using assays known in the art:	immunologic disorders,
variant			lymphocytes, monocytes, and	Matthews et al., in Lymphokines and	cancer
			macrophages. Known functions include	Interferens: A Practical Approach,
			stimulating proliferation of immune cells	Clemens et al., eds, IRL Press,
			(e.g., T helper cells, B cells, eosinophils,	Washington, D.C. 1987, pp. 221-225;
			and lymphocytes), chemotaxis of	and Kitamura et al (1989) J Cell
			neutrophils and T lymphocytes, and/or	Physiol. 140 323-334.
			inhibition of interferons.
IL-1i fragments	GeneSeq Accession	EP541920	Interleukins are a group of	Interleukin activity can be determined	inflammatory disorders,
	R35484 and		multifunctional cytokines synthesized by	using assays known in the art:	immunologic disorders,
	R35485		lymphocytes, monocytes, and	Matthews et al., in Lymphokines and	cancer
			macrophages. Known functions include	Interferens: A Practical Approach,
			stimulating proliferation of immune cells	Clemens et al., eds, IRL Press,
			(e.g., T helper cells, B cells, eosinophils,	Washington, D.C. 1987, pp. 221-225;
			and lymphocytes), chemotaxis of	and Orencole & Dinarclio (1989)
			neutrophils and T lymphocytes, and/or	Cytokine 1, 14-20.
			inhibition of interferons.
IL-1 inhibitor	GeneSeq Accession	EPS541920	Interleukins are a group of	Interleukin activity can be determined	inflammatory disorders,
(IL-li)	R35486 and		multifunctional cytokines synthesized by	using assays known in the art:	immunologic disorders,
	R35484		lymphocytes, monocytes, and	Matthews et al., in Lymphokines and	cancer
			macrophages. Known functions include	Interferens: A Practical Approach,
			stimulating proliferation of immune cells	Clemens et al., eds, IRL Press,
			(e.g., T helper cells, B cells, eosinophils,	Washington, D.C. 1987, pp. 221-225;
			and lymphocytes), chemotaxis of	and Orencole & Dinarclio (1989)
			neutrophils and T lymphocytes, and/or	Cytokine 1, 14-20.
			inhibition of interferons.
ICE 22 kD subunit.	GeneSeq Accession	EP533350	Interleukins are a group of	Interleukin activity can be determined	inflammatory disorders,
	R33780		multifunctional cytokines synthesized by	using assays known in the art:	immunologic disorders,
			lymphocytes, monocytes, and	Matthews et al., in Lymphokines and	cancer
			macrophages. Known functions include	Interferens: A Practical Approach,
			stimulating proliferation of immune cells	Clemens et al., eds, IRL Press,
			(e.g., T helper cells, B cells, eosinophils,	Washington, D.C. 1987, pp. 221-225.
			and lymphocytes), chemotaxis of
			neutrophils and T lymphocytes, and/or
			inhibition of interferons.
ICE 20 kD subunit.	GeneSeq Accession	EP533350	Interleukins are a group of	Interleukin activity can be determined	inflammatory disorders,
	R33781		multifunctional cytokines synthesized by	using assays known in the art:	immunologic disorders,
			lymphocytes, monocytes, and	Matthews et al., in Lymphokines and	cancer
			macrophages. Known functions include	Interferens: A Practical Approach,
			stimulating proliferation of immune cells	Clemens et al., eds, IRL Press,
			(e.g., T helper cells, B cells, eosinophils,	Washington, D.C. 1987, pp. 221-225.
			and lymphocytes), chemotaxis of
			neutrophils and T lymphocytes, and/or
			inhibition of interferons.
ICE 10 kD	GeneSeq Accession	EP533350	Interleukins are a group of	Interleukin activity can be determined	inflammatory disorders,
subunit	R33782		multifunctional cytokines synthesized by	using assays known in the art:	immunologic disorders,
			lymphocytes, monocytes, and	Matthews et al., in Lymphokines and	cancer
			macrophages. Known functions include	Interferens: A Practical Approach,
			stimulating proliferation of immune cells	Clemens et al., eds, IRL Press,
			(e.g., T helper cells, B cells, eosinophils,	Washington, D.C. 1987, pp. 221-225.
			and lymphocytes), chemotaxis of
			neutrophils and T lymphocytes, and/or
			inhibition of interferons.
Human	GeneSeq Accession	WO9317698	Interleukins are a group of	Interleukin activity can be determined	inflammatory disorders,
Interleukin-10	R41664		multifunctional cytokines synthesized by	using assays known in the art:	immunologic disorders,
(precursor)			lymphocytes, monocytes, and	Matthews et al., inLymphokines and	cancer
			macrophages. Known functions include	Interferens: A Practical Approach,
			stimulating proliferation of immune cells	Clemens et al., eds, IRL Press,
			(e.g., T helper cells, B cells, eosinophils,	Washington, D.C. 1987, pp. 221-225;
			and lymphocytes), chemotaxis of	and Thompson-Snipes et al (1991) J.
			neutrophils and T lymphocytes, and/or	Exp. Med. 173, 507-510.
			inhibition of interferons.
Human	GeneSeq Accession	WO9318783	Interleukins are a group of	Interleukin activity can be determined	inflammatory disorders,
Interleukin-10	R42642		multifunctional cytokines synthesized by	using assays known in the art:	immunologic disorders,
			lymphocytes, monocytes, and	Matthews et al., in Lymphokines and	cancer
			macrophages. Known functions include	Interferens: A Practical Approach,
			stimulating proliferation of immune cells	Clemens et al., eds, IRL Press,
			(e.g., T helper cells, B cells, eosinophils,	Washington, D.C. 1987, pp. 221-225;
			and lymphocytes), chemotaxis of	and Thompson-Snipes et al (1991) J.
			neutrophils and T lymphocytes, and/or	Exp. Med. 173, 507-510.
			inhibition of interferons.
Human	GeneSeq Accession	EP569042	Interleukins are a group of	Interleukin activity can be determined	inflammatory disorders,
Interleukin-1	R42447		multifunctional cytokines synthesized by	using assays known in the art:	immunologic disorders,
beta precursor			lymphocytes, monocytes, and	Matthews et al., in Lymphokines and	cancer
			macrophages. Known functions include	Interferens: A Practical Approach,
			stimulating proliferation of immune cells	Clemens et al., eds, IRL Press,
			(e.g., T helper cells, B cells, eosinophils,	Washington, D.C. 1987, pp. 221-225;
			and lymphocytes), chemotaxis of	and Kitamura et al (1989) J Cell
			neutrophils and T lymphocytes, and/or	Physiol. 140 323-334.
			inhibition of interferons.
Human	GeneSeq Accession	WO9403492	Interleukins are a group of	Interleukin activity can be determined	inflammatory disorders,
interleukin-6	R49041		multifunctional cytokines synthesized by	using assays known in the art:	immunologic disorders,
			lymphocytes, monocytes, and	Matthews et al., in Lymphokines and	cancer
			macrophages. Known functions include	Interferens: A Practical Approach,
			stimulating proliferation of immune cells	Clemens et al., eds, IRL Press,
			(e.g., T helper cells, B cells, eosinophils,	Washington, D.C. 1987, pp. 221-225;
			and lymphocytes), chemotaxis of	and Aarden et al (1987) Eur. J.
			neutrophils and T lymphocytes, and/or	Immunol 17, 1411-16.
			inhibition of interferons.
Mutant Interleukin 6	GeneSeq Accession	WO9411402	Interleukins are a group of	Interleukin activity can be determined	inflammatory disorders,
S176R	R54990		multifunctional cytokines synthesized by	using assays known in the art:	immunologic disorders,
			lymphocytes, monocytes, and	Matthews et al., in Lymphokines and	cancer
			macrophages. Known functions include	Interferens: A Practical Approach,
			stimulating proliferation of immune cells	Clemens et al., eds, IRL Press,
			(e.g., T helper cells, B cells, eosinophils,	Washington, D.C. 1987, pp. 221-225;
			and lymphocytes), chemotaxis of	and Aarden et al (1987) Eur. J.
			neutrophils and T lymphocytes, and/or	Immunol 17, 1411-16.
			inhibition of interferons.
Interleukin 6	GeneSeq Accession	JP06145063	Interleukins are a group of	Interleukin activity can be determined	inflammatory disorders,
	R55256		multifunctional cytokines synthesized by	using assays known in the art:	immunologic disorders,
			lymphocytes, monocytes, and	Matthews et al., in Lymphokines and	cancer
			macrophages. Known functions include	Interferens: A Practical Approach,
			stimulating proliferation of immune cells	Clemens et al., eds, IRL Press,
			(e.g., T helper cells, B cells, eosinophils,	Washington, D.C. 1987, pp. 221-225;
			and lymphocytes), chemotaxis of	and Aarden et al (1987) Eur. J.
			neutrophils and T lymphocytes, and/or	Immunol 17, 1411-16.
			inhibition of interferons.
Interleukin 8	GeneSeq Accession	JP06100595	Interleukins are a group of	Interleukin activity can be determined	Soluble IL-8 receptor
(IL-8) receptor	R53932		multifunctional cytokines synthesized by	using assays known in the art:	polypeptides may be
			lymphocytes, monocytes, and	Matthews et al., in Lymphokines and	useful for inhibiting
			macrophages. Known functions include	Interferens: A Practical Approach,	interleukin activities.
			stimulating proliferation of immune cells	Clemens et al., eds, IRL Press,
			(e.g., T helper cells, B cells, eosinophils,	Washington, D.C. 1987, pp. 221-225;
			and lymphocytes), chemotaxis of	and Holmes et al (1991) Science 253,
			neutrophils and T lymphocytes, and/or	1278-80.
			inhibition of interferons.
Human	GeneSeq Accession	U.S. Pat. No. 5,328,988	Interleukins are a group of	Interleukin activity can be determined	inflammatory disorders,
interleukin-7	R59919		multifunctional cytokines synthesized by	using assays known in the art:	immunologic disorders,
			lymphocytes, monocytes, and	Matthews et al., in Lymphokines and	cancer
			macrophages. Known functions include	Interferens: A Practical Approach,
			stimulating proliferation of immune cells	Clemens et al., eds, IRL Press,
			(e.g., T helper cells, B cells, eosinophils,	Washington, D.C. 1987, pp. 221-225;
			and lymphocytes), chemotaxis of	and Park et al (1990) J. Exp. Med.
			neutrophils and T lymphocytes, and/or	171, 1073-79.
			inhibition of interferons.
IL-3 containing	GeneSeq Accession	WO9521254	Interleukins are a group of	Interleukin activity can be determined	inflammatory disorders,
fusion protein.	R79342 and		multifunctional cytokines synthesized by	using assays known in the art:	immunologic disorders,
	R79344		lymphocytes, monocytes, and	Matthews et al., in Lymphokines and	cancer
			macrophages. Known functions include	Interferens: A Practical Approach,
			stimulating proliferation of immune cells	Clemens et al., eds, IRL Press,
			(e.g., T helper cells, B cells, eosinophils,	Washington, D.C. 1987, pp. 221-225;
			and lymphocytes), chemotaxis of	and Kitamura et al (1989) J Cell
			neutrophils and T lymphocytes, and/or	Physiol. 140 323-334.
			inhibition of interferons.
IL-3 mutant	GeneSeq Accession	ZA9402636	Interleukins are a group of	Interleukin activity can be determined	inflammatory disorders,
proteins	R79254, R79255,		multifunctional cytokines synthesized by	using assays known in the art:	immunologic disorders,
	R79256, R79257,		lymphocytes, monocytes, and	Matthews et al., in Lymphokines and	cancer
	R79258, R79259,		macrophages. Known functions include	Interferens: A Practical Approach,
	R79260, R79261,		stimulating proliferation of immune cells	Clemens et al., eds, IRL Press,
	R79262, R79263,		(e.g., T helper cells, B cells, eosinophils,	Washington, D.C. 1987, pp. 221-225;
	R79264, R79265,		and lymphocytes), chemotaxis of	and Giri et al (1994) EMBO J. 13
	R79266, R79267,		neutrophils and T lymphocytes, and/or	2822-2830.
	R79268, R79269,		inhibition of interferons.
	R79270, R79271,
	R79272, R79273,
	R79274, R79275,
	R79276, R79277,
	R79278, R79279,
	R79280, R79281,
	R79282, 879283,
	R79284, and
	R79285
IL-12 p40	GeneSeq Accession	AU9466072	Interleukins are a group of	Interleukin activity can be determined	inflammatory disorders,
subunit.	R63018		multifunctional cytokines synthesized by	using assays known in the art:	immunologic disorders,
			lymphocytes, monocytes, and	Matthews et al., in Lymphokines and	cancer
			macrophages. Known functions include	Interferens: A Practical Approach,
			stimulating proliferation of immune cells	Clemens et al., eds, IRL Press,
			(e.g., T helper cells, B cells, eosinophils,	Washington, D.C. 1987, pp. 221-225.
			and lymphocytes), chemotaxis of
			neutrophils and T lymphocytes, and/or
			inhibition of interferons.
AGF	GeneSeq Accession	WO9429344	Interleukins are a group of	Interleukin activity can be determined	inflammatory disorders,
	R64240		multifunctional cytokines synthesized by	using assays known in the art:	immunologic disorders,
			lymphocytes, monocytes, and	Matthews et al., in Lymphokines and	cancer
			macrophages. Known functions include	Interferens: A Practical Approach,
			stimulating proliferation of immune cells	Clemens et al., eds, IRL Press,
			(e.g., T helper cells, B cells, eosinophils,	Washington, D.C. 1987, pp. 221-225.
			and lymphocytes), chemotaxis of
			neutrophils and T lymphocytes, and/or
			inhibition of interferons.
Human	GeneSeq Accession	WO9519786	Interleukins are a group of	Interleukin activity can be determined	inflammatory disorders,
interlaukin-12 40 kD	R79187		multifunctional cytokines synthesized by	using assays known in the art:	immunologic disorders,
subunit			lymphocytes, monocytes, and	Matthews et al., in Lymphokines and	cancer
			macrophages. Known functions include	Interferens: A Practical Approach,
			stimulating proliferation of immune cells	Clemens et al., eds, IRL Press,
			(e.g., T helper cells, B cells, eosinophils,	Washington, D.C. 1987, pp. 221-225;
			and lymphocytes), chemotaxis of	and Hori et al (1987), Blood 70,
			neutrophils and T lymphocytes, and/or	1069-1078.
			inhibition of interferons.
Human	GeneSeq Accession	WO9530695	Interleukins are a group of	Interleukin activity can be determined	Soluble IL-8 receptor
interleukin-15	R90843		multifunctional cytokines synthesized by	using assays known in the art:	polypeptides may be
receptor from			lymphocytes, monocytes, and	Matthews et al., in Lymphokines and	useful for inhibiting
clone P1			macrophages. Known functions include	Interferens: A Practical Approach,	interleukin activities.
			stimulating proliferation of immune cells	Clemens et al., eds, IRL Press,
			(e.g., T helper cells, B cells, eosinophils,	Washington, D.C. 1987, pp. 221-225;
			and lymphocytes), chemotaxis of	and Giri et al (1994) EMBO J. 13
			neutrophils and T lymphocytes, and/or	2822-2830.
			inhibition of interferons.
Human	GeneSeq Accession	WO9604306	Interleukins are a group of	Interleukin activity can be determined	inflammatory disorders,
interleukin-7	R92796		multifunctional cytokines synthesized by	using assays known in the art:	immunologic disorders,
			lymphocytes, monocytes, and	Matthews et al., in Lymphokines and	cancer
			macrophages. Known functions include	Interferens: A Practical Approach,
			stimulating proliferation of immune cells	Clemens et al., eds, IRL Press,
			(e.g., T helper cells, B cells, eosinophils,	Washington, D.C. 1987, pp. 221-225;
			and lymphocytes), chemotaxis of	and Park et al (1990) J. Exp. Med.
			neutrophils and T lymphocytes, and/or	171, 1073-79.
			inhibition of interferons.
interleukin-9	GeneSeq Accesion	WO9604306	Interleukins are a group of	Interleukin activity can be determined	inflammatory disorders,
	R92797		multifunctional cytokines synthesized by	using assays known in the art:	immunologic disorders,
			lymphocytes, monocytes, and	Matthews et al., in Lymphokines and	cancer
			macrophages. Known functions include	Interferens: A Practical Approach,
			stimulating proliferation of immune cells	Clemens et al., eds, IRL Press,
			(e.g., T helper cells, B cells, eosinophils,	Washington, D.C. 1987, pp. 221-225;
			and lymphocytes), chemotaxis of	and Yang et al (1989) Blood 74,
			neutrophils and T lymphocytes, and/or	1880-84.
			inhibition of interferons.
interleukin-3	GeneSeq Accession	WO9604306	Interleukins are a group of	Interleukin activity can be determined	inflammatory disorders,
	R92801		multifunctional cytokines synthesized by	using assays known in the art:	immunologic disorders,
			lymphocytes, monocytes, and	Matthews et al., in Lymphokines and	cancer
			macrophages. Known functions include	Interferens: A Practical Approach,
			stimulating proliferation of immune cells	Clemens et al., eds, IRL Press,
			(e.g., T helper cells, B cells, eosinophils,	Washington, D.C. 1987, pp. 221-225;
			and lymphocytes), chemotaxis of	and Kitamura et al (1989) J Cell
			neutrophils and T lymphocytes, and/or	Physiol. 140 323-334.
			inhibition of interferons.
Human	GeneSeq Accession	WO9604306	Interleukins are a group of	Interleukin activity can be determined	inflammatory disorders,
interleukin-5	R92802		multifunctional cytokines synthesized by	using assays known in the art:	immunologic disorders,
			lymphocytes, monocytes, and	Matthews et al., in Lymphokines and	cancer
			macrophages. Known functions include	Interferens: A Practical Approach,
			stimulating proliferation of immune cells	Clemens et al., eds, IRL Press,
			(e.g., T helper cells, B cells, eosinophils,	Washington, D.C. 1987, pp. 221-225;
			and lymphocytes), chemotaxis of	and Kitamura et al (1989) J Cell
			neutrophils and T lymphocytes, and/or	Physiol. 140 323-334.
			inhibition of interferons.
Recombinant	GeneSeq Accession	DE19617202	Interleukins are a group of	Interleukin activity can be determined	inflammatory disorders,
interleukin-16	W33373		multifunctional cytokines synthesized by	using assays known in the art:	immunologic disorders,
			lymphocytes, monocytes, and	Matthews et al., in Lymphokines and	cancer
			macrophages. Known functions include	Interferens: A Practical Approach,
			stimulating proliferation of immune cells	Clemens et al., eds, IRL Press,
			(e.g., T helper cells, B cells, eosinophils,	Washington, D.C. 1987, pp. 221-225;
			and lymphocytes), chemotaxis of	and Lim et al (1996) J. Immunol. 156,
			neutrophils and T lymphocytes, and/or	2566-70.
			inhibition of interferons.
Human IL-16	GeneSeq Accession	DE19617202	Interleukins are a group of	Interleukin activity can be determined	inflammatory disorders,
protein	W33234		multifunctional cytokines synthesized by	using assays known in the art:	immunologic disorders,
			lymphocytes, monocytes, and	Matthews et al., in Lymphokines and	cancer
			macrophages. Known functions include	Interferens: A Practical Approach,
			stimulating proliferation of immune cells	Clemens et al., eds, IRL Press,
			(e.g., T helper cells, B cells, eosinophils,	Washington, D.C. 1987, pp. 221-225;
			and lymphocytes), chemotaxis of	and Lim et al (1996) J. Immunol. 156,
			neutrophils and T lymphocytes, and/or	2566-70.
			inhibition of interferons.
Thrl 17 human	GeneSeq Accession	WO9708321	Interleukins are a group of	Interleukin activity can be determined	inflammatory disorders,
interleukin 9	W27521		multifunctional cytokines synthesized by	using assays known in the art:	immunologic disorders,
			lymphocytes, monocytes, and	Matthews et al., in Lymphokines and	cancer
			macrophages. Known functions include	Interferens: A Practical Approach,
			stimulating proliferation of immune cells	Clemens et al., eds, IRL Press,
			(e.g., T helper cells, B cells, eosinophils,	Washington, D.C. 1987, pp. 221-225.
			and lymphocytes), chemotaxis of
			neutrophils and T lymphocytes, and/or
			inhibition of interferons.
Metl 17 human	GeneSeq Accession	WO9708321	Interleukins are a group of	Interleukin activity can be determined	inflammatory disorders,
interleukin 9	W27522		multifunctional cytokines synthesized by	using assays known in the art:	immunologic disorders,
			lymphocytes, monocytes, and	Matthews et al., in Lymphokines and	cancer
			macrophages. Known functions include	Interferens: A Practical Approach,
			stimulating proliferation of immune cells	Clemens et al., eds, IRL Press,
			(e.g., T helper cells, B cells, eosinophils,	Washington, D.C. 1987, pp. 221-225;
			and lymphocytes), chemotaxis of	and Yang et al (1989) Blood 74,
			neutrophils and T lymphocytes, and/or	1880-84.
			inhibition of interferons.
Human	GeneSeq Accession	EP86-4585	Interleukins are a group of	Interleukin activity can be determined	inflammatory disorders,
intracellular IL-1	W77158		multifunctional cytokines synthesized by	using assays known in the art:	immunologic disorders,
receptor			lymphocytes, monocytes, and	Matthews et al., in Lymphokines and	cancer
antagonist.			macrophages. Known functions include	Interferens: A Practical Approach,
			stimulating proliferation of immune cells	Clemens et al., eds, IRL Press,
			(e.g., T helper cells, B cells, eosinophils,	Washington, D.C. 1987, pp. 221-225;
			and lymphocytes), chemotaxis of	and Orencole & Dinarello (1989)
			neutrophils and T lymphocytes, and/or	Cytokine 1, 14-20.
			inhibition of interferons.
Human	GeneSeq Accession	EP864585	Interleukins are a group of	Interleukin activity can be determined	inflammatory disorders,
interleukin-18	W77158		multifunctional cytokines synthesized by	using assays known in the art:	immunologic disorders,
protein (IL-18)			lymphocytes, monocytes, and	Matthews et al., in Lymphokines and	cancer
			macrophages. Known functions include	Interferens: A Practical Approach,
			stimulating proliferation of immune cells	Clemens et al., eds, IRL Press,
			(e.g., T helper cells, B cells, eosinophils,	Washington, D.C. 1987, pp. 221-225;
			and lymphocytes), chemotaxis of	and USHIO et al (1996) J. Immunol.
			neutrophils and T lymphocytes, and/or	156, 4274-79.
			inhibition of interferons.
Human	GeneSeq Accession	EP861663	Interleukins are a group of	Interleukin activity can be determined	inflammatory disorders,
interleukin-18	W77077		multifunctional cytokines synthesized by	using assays known in the art:	immunologic disorders,
			lymphocytes, monocytes, and	Matthews et al., in Lymphokines and	cancer
			macrophages. Known functions include	Interferens: A Practical Approach,
			stimulating proliferation of immune cells	Clemens et al., eds, IRL Press,
			(e.g., T helper cells, B cells, eosinophils,	Washington, D.C. 1987, pp. 221-225;
			and lymphocytes), chemotaxis of	and USHIO et al (1996) J. Immunol.
			neutrophils and T lymphocytes, and/or	156, 4274-79.
			inhibition of interferons.
Human interleukin	GeneSeq Accessions	EP861663	Interleukins are a group of	Interleukin activity can be determined	inflammatory disorders,
18 derivatives	W77083, W77084,		multifunctional cytokines synthesized by	using assays known in the art:	immunologic disorders,
	W77085, W77086,		lymphocytes, monocytes, and	Matthews et al., in Lymphokines and	cancer
	W77087, W77088,		macrophages. Known functions include	Interferons: A Practical Approach,
	and W77089		stimulating proliferation of immune cells	Clemens et al., eds, IRL Press,
			(e.g., T helper cells, B cells, eosinophils,	Washington, D.C. 1987, pp. 221-225;
			and lymphocytes), chemotaxis of	and Ushio et al (1996) J. Immunol,
			neutrophils and T lymphocytes, and/or	156, 4274-79.
			inhibition of interferons.
Interleukin-9	GeneSeq Accession	WO9827997	Interleukins are a group of	Interleukin activity can be determined	inflammatory disorders,
(IL-9) mature	W68158		multifunctional cytokines synthesized by	using assays known in the art:	immunologic disorders,
protein (Thr117			lymphocytes, monocytes, and	Matthews et al., in Lymphokines and	cancer
version).			macrophages. Known functions include	Interferons: A Practical Approach,
			stimulating proliferation of immune cells	Clemens et al., eds, IRL Press,
			(e.g., T helper cells, B cells, eosinophils,	Washington, D.C. 1987, pp. 221-225;
			and lymphocytes), chemotaxis of	and Yang et al (1989) Blood 74,
			neutrophils and T lymphocytes, and/or	1880-84.
			inhibition of interferons.
IL-9 mature	GenSeq Accession	WO9827997	Interleukins are a group of	Interleukin activity can be determined	inflammatory disorders,
protein variant	W68157		multifunctional cytokines synthesized by	using assays known in the art:	immunologic disorders,
(Met117 version)			lymphocytes, monocytes, and	Matthews et al., in Lymphokines and	cancer
			macrophages. Known functions include	Interferons: A Practical Approach,
			stimulating proliferation of immune cells	Clemens et al., eds, IRL Press,
			(e.g., T helper cells, B cells, eosinophils,	Washington, D.C. 1987, pp. 221-225;
			and lymphocytes), chemotaxis of	and Yang et al (1989) Blood 74,
			neutrophils and T lymphocytes, and/or	1880-84.
			inhibition of interferons.
Human IL-9	GeneSeq Accession	WO9824904	Interleukins are a group of	Interleukin activity can be determined	inflammatory disorders,
receptor protein	W64058		multifunctional cytokines synthesized by	using assays known in the art:	immunologic disorders,
variant #3.			lymphocytes, monocytes, and	Matthews et al., in Lymphokines and	cancer
			macrophages. Known functions include	Interferons: A Practical Approach,
			stimulating proliferation of immune cells	Clemens et al., eds, IRL Press,
			(e.g., T helper cells, B cells, eosinophils,	Washington, D.C. 1987, pp. 221-225;
			and lymphocytes), chemotaxis of	and Yang et at (1989) Blood 74,
			neutrophils and T lymphocytes, and/or	1880-84.
			inhibition of interferons.
Human IL-9	GenSeq Accession	WO9824904	Interleukins are a group of	Interleukin activity can be determined	Soluble IL-9 receptor
receptor protein	W64060		multifunctional cytokines synthesized by	using assays known in the art:	polypeptides may be
variant fragment			lymphocytes, monocytes, and	Matthews et al., in Lymphokines and	useful for inhibiting
			macrophages. Known functions include	Interferons: A Practical Approach,	interleukin activities.
			stimulating proliferation of immune cells	Clemens et al., eds, IRL Press,
			(e.g., T helper cells, B cells, eosinophils,	Washington, D.C. 1987, pp. 221-225;
			and lymphocytes), chemotaxis of	and Yang et al (1989) Blood 74,
			neutrophils and T lymphocytes, and/or	1880-84.
			inhibition of interferons.
Human IL-9	GeneSeq Accession	WO9824904	Interleukins are a group of	Interleukin activity can be determined	Soluble IL-9 receptor
receptor protein	W64061		multifunctional cytokines synthesized by	using assays known in the art:	polypeptides may be
variant #3.			lymphocytes, monocytes, and	Matthews et al., in Lymphokines and	useful for inhibiting
			macrophages. Known functions include	Interferons: A Practical Approach,	interleukin activities.
			stimulating proliferation of immune cells	Clemens et al., eds, IRL Press,
			(e.g., T helper cells, B cells, eosinophils,	Washington, D.C. 1987, pp. 221-225;
			and lymphocytes), chemotaxis of	and Yang et at (1989) Blood 74,
			neutrophils and T lymphocytes, and/or	1880-84.
			inhibition of interferons.
Human	GeneSeq Accession	WO9817689	Interleukins are a group of	Interleukin activity can be determined	inflammatory disorders,
Interleukin-12 p40	W51311		multifunctional cytokines synthesized by	using assays known in the art:	immunologic disorders,
protein			lymphocytes, monocytes, and	Matthews et al., in Lymphokines and	cancer
			macrophages. Known functions include	Interferons: A Practical Approach,
			stimulating proliferation of immune cells	Clemens et al., eds, IRL Press,
			(e.g., T helper cells, B cells, eosinophils,	Washington, D.C. 1987, pp. 221-225;
			and lymphocytes), chemotaxis of	and Hori et al (1987), Blood 70,
			neutrophils and T lymphocytes, and/or	1069-1078.
			inhibition of interferons.
Human	GeneSeq Accession	WO9817689	Interleukins are a group of	Interleukin activity can be determined	inflammatory disorders,
Interleukin-12 p35	W51312		multifunctional cytokines synthesized by	using assays known in the art:	immunologic disorders,
protein			lymphocytes, monocytes, and	Matthews et al., in Lymphokines and	cancer
			macrophages. Known functions include	Interferons: A Practical Approach,
			stimulating proliferation of immune cells	Clemens et al., eds, IRL Press,
			(e.g., T helper cells, B cells, eosinophils,	Washington, D.C. 1987, pp. 221-225;
			and lymphocytes), chemotaxis of	and Hori et al (1987), Blood 70,
			neutrophils and T lymphocytes, and/or	1069-1078.
			inhibition of interferons.
Human protein	GeneSeq Accession	DE19649233-	Interleukins are a group of	Interleukin activity can be determined	inflammatory disorders,
with IL-16 activity	W63753		multifunctional cytokines synthesized by	using assays known in the art:	immunologic disorders,
			lymphocytes, monocytes, and	Matthews et al., in Lymphokines and	cancer
			macrophages. Known functions include	Interferons: A Practical Approach,
			stimulating proliferation of immune cells	Clemens et al., eds, IRL Press,
			(e.g., T helper cells, B cells, eosinophils,	Washington, D.C. 1987, pp. 221-225;
			and lymphocytes), chemotaxis of	and Lim et al (1996) J. Immunol. 156,
			neutrophils and T lymphocytes, and/or	2566-70.
			inhibition of interferons.
Human protein	GeneSeq Accession	DE19649233-	Interleukins are a group of	Interleukin activity can be determined	inflammatory disorders,
with IL-16 activity	W59425		multifunctional cytokines synthesized by	using assays known in the art:	immunologic disorders,
			lymphocytes, monocytes, and	Matthews et al., in Lymphokines and	cancer
			macrophages. Known functions include	Interferons: A Practical Approach,
			stimulating proliferation of immune cells	Clemens et al., eds, IRL Press,
			(e.g., T helper cells, B cells, eosinophils,	Washington, D.C. 1987, pp. 221-225;
			and lymphocytes), chemotaxis of	and Lim et al (1996) J. Immunol. 156,
			neutrophils and T lymphocytes, and/or	2566-70.
			inhibition of interferons.
Human	GeneSeq Accession	U.S. Pat. No. 5,747,024	Interleukins are a group of	Interleukin activity can be determined	inflammatory disorders,
interleukin-15	W53878		multifunctional cytokines synthesized by	using assays known in the art:	immunologic disorders,
			lymphocytes, monocytes, and	Matthews et al., in Lymphokines and	cancer
			macrophages. Known functions include	Interferons: A Practical Approach,
			stimulating proliferation of immune cells	Clemens et al., eds, IRL Press,
			(e.g., T helper cells, B cells, eosinophils,	Washington, D.C. 1987, pp. 221-225;
			and lymphocytes), chemotaxis of	and Giri et al (1994) EMBO J. 13
			neutrophils and T lymphocytes, and/or	2822-2830.
			inhibition of interferons.
Human wild-type	GeneSeq Accession	WO9747744	Interleukins are a group of	Interleukin activity can be determined	inflammatory disorders,
interleukin-4 (hIL-	W52149		multifunctional cytokines synthesized by	using assays known in the art:	immunologic disorders,
4) protein			lymphocytes, monocytes, and	Matthews et al., in Lymphokines and	cancer
			macrophages. Known functions include	Interferons: A Practical Approach,
			stimulating proliferation of immune cells	Clemens et al., eds, IRL Press,
			(e.g., T helper cells, B cells, eosinophils,	Washington, D.C. 1987, pp. 221-225;
			and lymphocytes), chemotaxis of	and Siegel & Mostowski (1990) J
			neutrophils and T lymphocytes, and/or	Immunol Methods 132, 287-295.
			inhibition of interferons.
interleukin-4	GeneSeq Accessions	WO9747744	Interleukins are a group of	Interleukin activity can be determined	inflammatory disorders,
muteins	W52150, W52151,		multifunctional cytokines synthesized by	using assays known in the art:	immunologic disorders,
	W52153, W52154,		lymphocytes, monocytes, and	Matthews et al., in Lymphokines and	cancer
	W52155, W52156,		macrophages. Known functions include	Interferons: A Practical Approach,
	W52157, W52158,		stimulating proliferation of immune cells	Clemens et al., eds, IRL Press,
	W52159, W52160,		(e.g., T helper cells, B cells, eosinophils,	Washington, D.C. 1987, pp. 221-225;
	W52161, W52162,		and lymphocytes), chemotaxis of	and Siegel & Mostowski (1990) J
	W52163, W52164,		neutrophils and T lymphocytes, and/or	Immunol Methods 132, 287-295.
	W52165, W52166,		inhibition of interferons.
	and W52167
Human interleukin	GeneSeq Accession	WO9935268	Interleukins are a group of	Interleukin activity can be determined	inflammatory disorders,
1 delta	Y28408		multifunctional cytokines synthesized by	using assays known in the art:	immunologic disorders,
			lymphocytes, monocytes, and	Matthews et al., in Lymphokines and	cancer
			macrophages. Known functions include	Interferons: A Practical Approach,
			stimulating proliferation of immune cells	Clemens et al., eds, IRL Press,
			(e.g., T helper cells, B cells, eosinophils,	Washington, D.C. 1987, pp. 221-225;
			and lymphocytes), chemotaxis of	and Orencole & Dinarello (1989)
			neutrophils and T lymphocytes, and/or	Cytokine 1, 14-20.
			inhibition of interferons.
Human	GeneSeq Accession	WO9935268	Interleukins are a group of	Interleukin activity can be determined	inflammatory disorders,
interleukin-1	Y24395		multifunctional cytokines synthesized by	using assays known in the art:	immunologic disorders,
receptor antagonist			lymphocytes, monocytes, and	Matthews et al., in Lymphokines and	cancer
beta			macrophages. Known functions include	Interferons: A Practical Approach,
			stimulating proliferation of immune cells	Clemens et al., eds, IRL, Press,
			(e.g., T helper cells, B cells, eosinophils,	Washington, D.C. 1987, pp. 221-225;
			and lymphocytes), chemotaxis of	and Orencole & Dinarello (1989)
			neutrophils and T lymphocytes, and/or	Cytokine 1, 14-20.
			inhibition of interferons.
Human EDIRF II	GeneSeq Accession	WO9932632	Interleukins are a group of	Interleukin activity can be determined	inflammatory disorders,
protein sequence	Y22199		multifunctional cytokines synthesized by	using assays known in the art:	immunologic disorders,
			lymphocytes, monocytes, and	Matthews et al., in Lymphokines and	cancer
			macrophages. Known functions include	Interferons: A Practical Approach,
			stimulating proliferation of immune cells	Clemens et al., eds, IRL Press,
			(e.g., T helper cells, B cells, eosinophils,	Washington, D.C. 1987, pp. 221-225.
			and lymphocytes), chemotaxis of
			neutrophils and T lymphocytes, and/or
			inhibition of interferons.
Human EDIRF I	GeneSeq Accession	WO9932632	Interleukins are a group of	Interleukin activity can be determined	inflammatory disorders,
protein sequence	Y22197		multifunctional cytokines synthesized by	using assays known in the art:	immunologic disorders,
			lymphocytes, monocytes, and	Matthews et al., in Lymphokines and	cancer
			macrophages. Known functions include	Interferons: A Practical Approach,
			stimulating proliferation of immune cells	Clemens et al., eds, IRL Press,
			(e.g., T helper cell, B cells, eosinophils,	Washington, D.C. 1987, pp. 221-225.
			and lymphocytes), chemotaxis of
			neutrophils and T lymphocytes, and/or
			inhibition of interferons.
Human IL-1RD10	GeneSeq Accession	WO9919480	Interleukins are a group of	Interleukin activity can be determined	Soluble IL-1RD10
protein sequence	Y14131		multifunctional cytokines synthesized by	using assays known in the art:	receptor polypeptides
			lymphocytes, monocytes, and	Matthews et al., in Lymphokines and	may be useful for
			macrophages. Known functions include	Interferons: A Practical Approach,	inhibiting interleukin
			stimulating proliferation of immune cells	Clemens et al., eds, IRL Press,	activites.
			(e.g., T helper cells, B cells, eosinophils,	Washington, D.C. 1987, pp. 221-225;
			and lymphocytes), chemotaxis of	and Orencole & Dinarello (1989)
			neutrophils and T lymphocytes, and/or	Cytokine 1, 14-20.
			inhibition of interferons.
Human IL-1RD9	GeneSeq Accession	WO9919480	Interleukins are a group of	Interleukin activity can be determined	Soluble IL-1RD10
	Y14122		multifunctional cytokines synthesized by	using assays known in the art:	receptor polypeptides
			lymphocytes, monocytes, and	Matthews et al., in Lymphokines and	may be useful for
			macrophages. Known functions include	Interferons: A Practical Approach,	inhibiting interleukin
			stimulating proliferation of immune cells	Clemens et al., eds, IRL Press,	activites.
			(e.g., T helper cells, B cells, eosinophils,	Washington, D.C. 1987, pp. 221-225;
			and lymphocytes), chemotaxis of	and Orencole & Dinarello (1989)
			neutrophils and T lymphocytes, and/or	Cytokine 1, 14-20.
			inhibition of interferons.
Human DNAX	GeneSeq Accession	WO9919491	Interleukins are a group of	Interleukin activity can be determined	inflammatory disorders,
interleukin-40	Y09196		multifunctional cytokines synthesized by	using assays known in the art:	immunologic disorders,
			lymphocytes, monocytes, and	Matthews et al., in Lymphokines and	cancer
			macrophages. Known functions include	Interferons: A Practical Approach,
			stimulating proliferation of immune cells	Clemens et al., eds, IRL Press,
			(e.g., T helper cells, B cells, eosinophils,	Washington, D.C. 1987, pp. 221-225.
			and lymphocytes), chemotaxis of
			neutrophils and T lymphocytes, and/or
			inhibition of interferons.
(DIL-40)	GeneSeq Accession	WO9919491	Interleukins are a group of	Interleukin activity can be determined	inflammatory disorders,
alternative	Y09197		multifunctional cytokines synthesized by	using assays known in the art:	immunologic disorders,
sequence			lymphocytes, monocytes, and	Matthews et al., in Lymphokines and	cancer
			macrophages. Known functions include	Interferons: A Practical Approach,
			stimulating proliferation of immune cells	Clemens et al., eds, IRL Press,
			(e.g., T helper cells, B cells, eosinophils,	Washington, D.C. 1987, pp. 221-225.
			and lymphocytes), chemotaxis of
			neutrophils and T lymphocytes, and/or
			inhibition of interferons.
IL-11	GeneSeq Accession	WO9405318	Interleukins are a group of	Interleukin activity can be determined	inflammatory disorders,
	R50176		multifunctional cytokines synthesized by	using assays known in the art:	immunologic disorders,
			lymphocytes, monocytes, and	Matthews et al., in Lymphokines and	cancer
			macrophages. Known functions include	Interferons: A Practical Approach,
			stimulating proliferation of immune cells	Clemens et al., eds, IRL Press,
			(e.g., T helper cells, B cells, eosinophils,	Washington, D.C. 1987, pp. 221-225;
			and lymphocytes), chemotaxis of	and Lu et al (1994) J immunol.
			neutrophils and T lymphocytes, and/or	Methods 173, 19.
			inhibition of interferons.
Human	GeneSeq Accession	EP566410	Interleukins are a group of	Interleukin activity can be determined	inflammatory disorders,
adipogenesis	R43260		multifunctional cytokines synthesized by	using assays known in the art:	immunologic disorders,
inhibitory factor			lymphocytes, monocytes, and	Matthews et al., in Lymphokines and	cancer
			macrophages. Known functions include	Interferons: A Practical Approach,
			stimulating proliferation of immune cells	Clemens et al., eds, IRL Press,
			(e.g., T helper cells, B cells, eosinophils,	Washington, D.C. 1987, pp. 221-225.
			and lymphocytes), chemotaxis of
			neutrophils and T lymphocytes, and/or
			inhibition of interferons.
IL-11	GeneSeq Accession	JP08127539	Interleukins are a group of	Interleukin activity can be determined	inflammatory disorders,
	W02202		multifunctional cytokines synthesized by	using assays known in the art:	immunologic disorders,
			lymphocytes, monocytes, and	Matthews et al., in Lymphokines and	cancer
			macrophages. Known functions include	Interferons: A Practical Approach,
			stimulating proliferation of immune cells	Clemens et al., eds, IRL Press,
			(e.g., T helper cells, B cells, eosinophils,	Washington, D.C. 1987, pp. 221-225;
			and lymphocytes), chemotaxis of	and Lu et al (1994) J immunol.
			neutrophils and T lymphocytes, and/or	Methods 173, 19.
			inhibition of interferons.
IL-14	GeneSeq Accession	WO9416074	Interleukins are a group of	Interleukin activity can be determined	inflammatory disorders,
	R55800		multifunctional cytokines synthesized by	using assays known in the art:	immunologic disorders,
			lymphocytes, monocytes, and	Matthews et al., in Lymphokines and	cancer
			macrophages. Known functions include	Interferons: A Practical Approach,
			stimulating proliferation of immune cells	Clemens et al., eds, IRL Press,
			(e.g., T helper cells, B cells, eosinophils,	Washington, D.C. 1987, pp. 221-225;
			and lymphocytes), chemotaxis of	and Ambrus et al (1993) PNAS 90,
			neutrophils and T lymphocytes, and/or	63330-34.
			inhibition of interferons.
IL-17 receptor	GeneSeq Accession	U.S. Pat. No. 6,072,033	Interleukins are a group of	Interleukin activity can be determined	Soluble IL-17 receptor
	B03807		multifunctional cytokines synthesized by	using assays known in the art:	polypeptides may be
			lymphocytes, monocytes, and	Matthews et al., in Lymphokines and	useful for inhibiting
			macrophages. Known functions include	Interferons: A Practical Approach,	interleukin activities.
			stimulating proliferation of immune cells	Clemens et al., eds, IRL Press,
			(e.g., T helper cells, B cells, eosinophils,	Washington, D.C. 1987, pp. 221-225;
			and lymphocytes), chemotaxis of	and Yao et al (1995) J. Immunol. 155,
			neutrophils and T lymphocytes, and/or	5483-86.
			inhibition of interferons.
IL-17	GeneSeq Accession	WO9518826	Interleukins are a group of	Interleukin activity can be determined	inflammatory disorders,
	R76573		multifunctional cytokines synthesized by	using assays known in the art:	immunologic disorders,
			lymphocytes, monocytes, and	Matthews et al., in Lymphokines and	cancer
			macrophages. Known functions include	Interferons: A Practical Approach,
			stimulating proliferation of immune cells	Clemens et al., eds, IRL Press,
			(e.g., T helper cells, B cells, eosinophils,	Washington, D.C. 1987, pp. 221-225;
			and lymphocytes), chemotaxis of	and Yao et al (1995) J. Immunol. 155,
			neutrophils and T lymphocytes, and/or	5483-86.
			inhibition of interferons.
CTLA-8	GeneSeq Accession	WO9704097	Interleukins are a group of	Interleukin activity can be determined	inflammatory disorders,
	W13651		multifunctional cytokines synthesized by	using assays known in the art:	immunologic disorders,
			lymphocytes, monocytes, and	Matthews et al., in Lymphokines and	cancer
			macrophages. Known functions include	Interferons: A Practical Approach,
			stimulating proliferation of immune cells	Clemens et al., eds, IRL Press,
			(e.g., T helper cells, B cells, eosinophils,	Washington, D.C. 1987, pp. 221-225.
			and lymphocytes), chemotaxis of
			neutrophils and T lymphocytes, and/or
			inhibition of interferons.
IL-19	GeneSeq Accession	WO9808870	Interleukins are a group of	Interleukin activity can be determined	inflammatory disorders,
	W37935		multifunctional cytokines synthesized by	using assays known in the art:	immunologic disorders,
			lymphocytes, monocytes, and	Matthews et al., in Lymphokines and	cancer
			macrophages. Known functions include	Interferons: A Practical Approach,
			stimulating proliferation of immune cells	Clemens et al., eds, IRL Press,
			(e.g., T helper cells, B cells, eosinophils,	Washington, D.C. 1987, pp. 221-225;
			and lymphocytes), chemotaxis of	and Gallagher et al (2000) Genes
			neutrophils and T lymphocytes, and/or	Immun. 1, 442-50.
			inhibition of interferons.
IL-21 (TIF)	GeneSeq Accession	WO0024758	Interleukins are a group of	Interleukin activity can be determined	inflammatory disorders,
	Y92879		multifunctional cytokines synthesized by	using assays known in the art:	immunologic disorders,
			lymphocytes, monocytes, and	Matthews et al., in Lymphokines and	cancer
			macrophages. Known functions include	Interferons: A Practical Approach,
			stimulating proliferation of immune cells	Clemens et al., eds, IRL Press,
			(e.g., T helper cells, B cells, eosinophils,	Washington, D.C. 1987, pp. 221-225;
			and lymphocytes), chemotaxis of	and Parrish-Novak et al (2000)
			neutrophils and T lymphocytes, and/or	Nature 408, 57-63.
			inhibition of interferons.
IL-8 receptor	GeneSeq Accession	WO9306229	Interleukins are a group of	Interleukin activity can be determined	Soluble IL-8 receptor
	R33420		multifunctional cytokines synthesized by	using assays known in the art:	polypeptides may be
			lymphocytes, monocytes, and	Matthews et al., in Lymphokines and	useful for inhibiting
			macrophages. Known functions include	Interferons: A Practical Approach,	interleukin activities.
			stimulating proliferation of immune cells	Clemens et al., eds, IRL Press,
			(e.g., T helper cells, B cells, eosinophils,	Washington, D.C. 1987, pp. 221-225;
			and lymphocytes), chemotaxis of	and Holmes et al (1991) Science 253,
			neutrophils and T lymphocytes, and/or	1278-80.
			inhibition of interferons.
Human type II	GeneSeq Accession	U.S. Pat. No. 5,464,937	Interleukins are a group of	Interleukin activity can be determined	Soluble type II
interleukin-1	R85480		multifunctional cytokines synthesized by	using assays known in the art:	interleukin-1 receptor
receptor			lymphocytes, monocytes, and	Matthews et al., in Lymphokines and	polypeptides may be
			macrophages. Known functions include	Interferons: A Practical Approach,	useful for inhibiting
			stimulating proliferation of immune cells	Clemens et al., eds. IRL Press,	interleukin activities.
			(e.g., T helper cells, B cells, eosinophils,	Washington, D.C. 1987, pp. 221-225;
			and lymphocytes), chemotaxis of	and Orencole & Dinarello (1989)
			neutrophils and T lymphocytes, and/or	Cytokine 1, 14-20.
			inhibition of interferons.
Human	GeneSeq Accession	EP638644	Interleukins are a group of	Interleukin activity can be determined	Soluble IL-12 receptor
interleukin-12	R69632		multifunctional cytokines synthesized by	using assays known in the art:	polypeptides may be
receptor			lymphocytes, monocytes, and	Matthews et al., in Lymphokines and	useful for inhibiting
			macrophages. Known functions include	Interferons: A Practical Approach,	interleukin activities.
			stimulating proliferation of immune cells	Clemens et al., eds, IRL Press,
			(e.g., T helper cells, B cells, eosinophils,	Washington, D.C. 1987, pp. 221-225;
			and lymphocytes), chemotaxis of	and Hori et al (1987), Blood 70,
			neutrophils and T lymphocytes, and/or	1069-1078.
			inhibition of interferons.
Interleukin 8	GeneSeq Accession	U.S. Pat. No. 5,440,021	Interleukins are a group of	Interleukin activity can be determined	Soluble IL-8 receptor B
receptor B	R80758		multifunctional cytokines synthesized by	using assays known in the art:	polypeptides may be
			lymphocytes, monocytes, and	Matthews et al., in Lymphokines and	useful for inhibiting
			macrophages. Known functions include	Interferons: A Practical Approach,	interleukin activities.
			stimulating proliferation of immune cells	Clemens et al., eds, IRL Press,
			(e.g., T helper cells, B cells, eosinophils,	Washington, D.C. 1987, pp. 221-225;
			and lymphocytes), chemotaxis of	and Holmes et al (1991) Science 253,
			neutrophils and T lymphocytes, and/or	1278-80.
			inhibition of interferons.
Human IL-8	GeneSeq Accession	JP08103276	Interleukins are a group of	Interleukin activity can be determined	Soluble IL-8 receptor A
receptor protein	B09989		multifunctional cytokines synthesized by	using assays known in the art:	polypeptides may be
hIL8RA			lymphocytes, monocytes, and	Matthews et al., in Lymphokines and	useful for inhibiting
			macrophages. Known functions include	Interferons: A Practical Approach,	interleukin activities.
			stimulating proliferation of immune cells	Clemens et al., eds, IRL Press,
			(e.g., T helper cells, B cells, eosinophils,	Washington, D.C. 1987, pp. 221-225;
			and lymphocytes), chemotaxis of	and Holmes et al (1991) Science 253,
			neutrophils and T lymphocytes, and/or	1278-80.
			inhibition of interferons.
Human IL-8	GeneSeq Accession	JP08103276	Interleukins are a group of	Interleukin activity can be	Soluble IL-8 receptor
receptor protein	B09990		multifunctional cytokines synthesized	determined using asays known in the	polypeptides may be
hIL8R			by lymphocytes, monocytes, and	art: Matthews et al., in Lymphokines	useful for inhibiting
			macrophages. Known functions include	and Interferons: A Practical	interleukin activities.
			stimulating proliferation of immune	Approach, Clemens et al., eds, IRL
			cells (e.g., T helper cells, B cells,	Press, Washington, D.C. 1987, pp.
			eosinophils, and lymphocytes),	221-225; and Holmes et al (1991)
			chemotaxis of neutrophils and T	Science 253, 1278-80.
			lymphocytes, and/or inhibition of
			interferons.
Interleukin-2	GeneSeq Accession	WO9621732	Interleukins are a group of	Interleukin activity can be	Soluble IL-2 receptor
receptor associated	R97569		multifunctional cytokines synthesized	determined using assays known in	polypeptides may be
protein p43			by lymphocytes, monocytes, and	the art: Matthews et al., in	useful for inhibiting
			macrophages. Known functions include	Lymphokines and Interferons: A	interleukin activities.
			stimulating proliferation of immune	Practical Approach, Clemens et al.,
			cells (e.g., T helper cells, B cells,	eds, IRL Press, Washington, D.C.
			eosinophils, and lymphocytes),	1987, pp. 221-225; and Gillis et al
			chemotaxis of neutrophils and T	(1978) J. Immunol. 120, 2027.
			lymphocytes, and/or inhibition of
			interferons.
Human	GeneSeq Accession	WO9629408	Interleukins are a group of	Interleukin activity can be	Soluble IL-17 receptor
interleukin-17	W04185		multifunctional cytokines synthesized	determined using assays known in	polypeptides may be
receptor			by lymphocytes, monocytes, and	the art: Matthews et al., in	useful for inhibiting
			macrophages. Known functions include	Lymphokines and Interferons: A	interleukin activities.
			stimulating proliferation of immune	Practical Approach, Clemens et al.,
			cells (e.g., T helper cells, B cells,	eds, IRL Press, Washington, D.C.
			eosinophils, and lymphocytes),	1987, pp. 221-225; and Yao et al
			chemotaxis of neutrophils and T	(1995) J. Immunol. 155, 5483-86.
			lymphocytes, and/or inhibition of
			interferons.
Human	GeneSeq Accession	WO9619574	Interleukins are a group of	Interleukin activity can be	Soluble IL-11 receptor
interleukin-11	R99090		multifunctional cytokines synthesized	determined using assays known in	polypeptides may be
receptor			by lymphocytes, monocytes, and	the art: Matthews et al., in	useful for inhibiting
			macrophages. Known functions include	Lymphokines and Interferons: A	interleukin activities.
			stimulating proliferation of immune	Practical Approach, Clemens et al.,
			cells (e.g., T helper cells, B cells,	eds, IRL Press, Washington, D.C.
			eosinophils, and lymphocytes),	1987, pp. 221-225; and Lu et al
			chemotaxis of neutrophils and T	(1994) J immunol. Methods 173, 19.
			lymphocytes, and/or inhibition of
			interferons.
Human	GeneSeq Accession	WO9623067	Interleukins are a group of	Interleukin activity can be	Inflammatory disorders,
interleukin-1	W01911		multifunctional cytokines synthesized	determined using assays known in	immunologic disorders,
receptor accessory			by lymphocytes, monocytes, and	the art: Matthews et al., in	cancer
protein			macrophages. Known functions include	Lymphokines and Interferons: A
			stimulating proliferation of immune	Practical Approach, Clemens et al.,
			cells (e.g., T helper cells, B cells,	eds, IRL Press, Washington, D.C.
			eosinophils, and lymphocytes),	1987, pp. 221-225; and Orencole &
			chemotaxis of neutrophils and T	Dinarello (1989) Cytokine 1, 14-20.
			lymphocytes, and/or inhibition of
			interferons.
AGF Protein	GeneSeq Accession	U.S. Pat. No. 5,488,032	Interleukins are a group of	Interleukin activity can be	Inflammatory disorders,
	R92749		multifunctional cytokines synthesized	determined using assays known in	immunologic disorders,
			by lymphocytes, monocytes, and	the art: Matthews et al., in	cancer
			macrophages. Known functions include	Lymphokines and Interferons: A
			stimulating proliferation of immune	Practical Approach, Clemens et al.,
			cells (e.g., T helper cells, B cells,	eds, IRL Press, Washington, D.C.
			eosinophils, and lymphocytes),	1987, pp. 221-225.
			chemotaxis of neutrophils and T
			lymphocytes, and/or inhibition of
			interferons.
Human	GeneSeq Accession	W09607739	Interleukins are a group of	Interleukin activity can be	Soluble IL-type-3
interleukin-1 type-	R91064		multifunctional cytokines synthesized	determined using assays known in	receptor polypeptides
3 receptor			by lymphocytes, monocytes, and	the art: Matthews et al., in	may be useful for
			macrophages. Known functions include	Lymphokines and Interferons: A	inhibiting interleukin
			stimulating proliferation of immune	Practical Approach, Clemens et al.,	activities
			cells (e.g., T helper cells, B cells,	eds, IRL Press, Washington, D.C.
			eosinophils, and lymphocytes),	1987, pp. 221-225; and Orencole &
			chemotaxis of neutrophils and T	Dinarello (1989) Cytokine 1, 14-20.
			lymphocytes, and/or inhibition of
			interferons.
Human	GeneSeq Accession	WO9720926	Interleukins are a group of	Interleukin activity can be	Soluble IL-13 beta
interleukin-13 beta	W24972		multifunctional cytokines synthesized	determined using assays known in	receptor polypeptides
receptor			by lymphocytes, monocytes, and	the art: Matthews et al., in	may be useful for
			macrophages. Known functions include	Lymphokines and Interferons: A	inhibiting interleukin
			stimulating proliferation of immune	Practical Approach, Clemens et al.,	activities.
			cells (e.g., T helper cells, B cells,	eds, IRL Press, Washington, D.C.
			eosinophils, and lymphocytes),	1987, pp. 221-225; and Boutelier et
			chemotaxis of neutrophils and T	al (1995) J. Immunol. Methods
			lymphocytes, and/or inhibition of	181, 29.
			interferons.
Human	GeneSeq Accession	WO9720926	Interleukins are a group of	Interleukin activity can be	Soluble IL-13 alpha
interleukin-13	W24973		multifunctional cytokines synthesized	determined using assays known in	receptor polypeptides
alpha receptor			by lymphocytes, monocytes, and	the art: Matthews et al., in	may be useful for
			macrophages. Known functions include	Lymphokines and Interferons: A	inhibiting interleukin
			stimulating proliferation of immune	Practical Approach, Clemens et al.,	activities.
			cells (e.g., T helper cells, B cells,	eds, IRL Press, Washington, D.C.
			eosinophils, and lymphocytes),	1987, pp. 221-225; and Boutelier et
			chemotaxis of neutrophils and T	al (1995) J. Immunol. Methods
			lymphocytes, and/or inhibition of	181, 29.
			interferons.
Human	GeneSeq Accession	U.S. Pat. No. 5,599,905	Interleukins are a group of	Interleukin activity can be	Soluble IL-4 receptor
interleukin-4	W13499		multifunctional cytokines synthesized	determined using assays known in	polypeptides may be
receptor			by lymphocytes, monocytes, and	the art: Matthews et al., in	useful for inhibiting
			macrophages. Known functions include	Lymphokines and Interferons: A	interleukin activities.
			stimulating proliferation of immune	Practical Approach, Clemens et al.,
			cells (e.g., T helper cells, B cells,	eds, IRL Press, Washington, D.C.
			eosinophils, and lymphocytes),	1987, pp. 221-225; and Siegel &
			chemotaxis of neutrophils and T	Mostowski (1990) J Immunol
			lymphocytes, and/or inhibition of	Methods 132, 287-295.
			interferons.
Human	GeneSeq Accession	EP759466	Interleukins are a group of	Interleukin activity can be	Soluble IL-12 beta-2
interleukin-12	W12771		multifunctional cytokines synthesized	determined using assays known in	receptor polypeptides
beta-2 receptor			by lymphocytes, monocytes, and	the art: Matthews et al., in	may be useful for
			macrophages. Known functions include	Lymphokines and Interferons: A	inhibiting interleukin
			stimulating proliferation of immune	Practical Approach, Clemens et al.,	activities.
			cells (e.g., T helper cells, B cells,	eds, IRL Press, Washington, D.C.
			eosinophils, and lymphocytes),	1987, pp. 221-225; and Hori et al
			chemotaxis of neutrophils and T	(1987), Blood 70, 1069-1078.
			lymphocytes, and/or inhibition of
			interferons.
Human	GeneSeq Accession	EP759466	Interleukins are a group of	Interleukin activity can be	Soluble IL-12 beta-1
interleukin-12	W12772		multifunctional cytokines synthesized	determined using assays known in	receptor polypeptides
beta-1 receptor.			by lymphocytes, monocytes, and	the art: Matthews et al., in	may be useful for
			macrophages. Known functions include	Lymphokines and Interferons: A	inhibiting interleukin
			stimulating proliferation of immune	Practical Approach, Clemens et al.,	activities.
			cells (e.g., T helper cells, B cells,	eds, IRL Press, Washington, D.C.
			eosinophils, and lymphocytes),	1987, pp. 221-225; and Hori et at
			chemotaxis of neutrophils and T	(1987), Blood 70, 1069-1078.
			lymphocytes, and/or inhibition of
			interferons.
Human IL-9	GeneSeq Accessions	WO9824904	Interleukins are a group of	Interleukin activity can be	Soluble IL-9 receptor
receptor protein	W64055, W64056,		multifunctional cytokines synthesized	determined using assays known in	polypeptides may be
	and W64057		by lymphocytes, monocytes, and	the art: Matthews et al., in	useful for inhibiting
			macrophages. Known functions include	Lymphokines and Interferons: A	interleukin activities.
			stimulating proliferation of immune	Practical Approach, Clemens et al.,
			cells (e.g., T helper cells, B cells,	eds, IRL Press, Washington, D.C.
			eosinophils, and lymphocytes),	1987, pp. 221-225; and Yang et al
			chemotaxis of neutrophils and T	(1989), Blood 74, 1880-84..
			lymphocytes, and/or inhibition of
			interferons.
IL-10 receptor	GeneSeq Accession	U.S. Pat. No. 5,716,804	Interleukins are a group of	Interleukin activity can be	Soluble IL-10 receptor
	W41804		multifunctional cytokines synthesized	determined using assays known in	polypeptides may be
			by lymphocytes, monocytes, and	the art: Matthews et al., in	useful for inhibiting
			macrophages. Known functions include	Lymphokines and Interferons: A	interleukin activities.
			stimulating proliferation of immune	Practical Approach, Clemens et al.,
			cells (e.g., T helper cells, B cells,	eds, IRL Press, Washington, D.C.
			eosinophils, and lymphocytes),	1987, pp. 221-225; and Thompson-
			chemotaxis of neutrophils and T	Snipes et al (1991) J. Exp. Med. 173,
			lymphocytes, and/or inhibition of	507-510.
			interferons.
Human IL-6	GeneSeq Accession	JP11196867	Interleukins are a group of	Interleukin activity can be	Soluble IL-6 receptor
receptor	Y30938		multifunctional cytokines synthesized	determined using assays known in	polypeptides may be
			by lymphocytes, monocytes, and	the art: Matthews et al., in	useful for inhibiting
			macrophages. Known functions include	Lymphokines and Interferons: A	interleukin activities.
			stimulating proliferation of immune	Practical Approach, Clemens et al.,
			cells (e.g., T helper cells, B cells,	eds, IRL Press, Washington, D.C.
			eosinophils, and lymphocytes),	1987, pp. 221-225; and Aarden et al
			chemotaxis of neutrophils and T	(1987) Eur. J. Immunol 17, 1411-16.
			lymphocytes, and/or inhibition of
			interferons.
Il-17 receptor	GeneSeq Accession	U.S. Pat. No. 6,096,305	Interleukins are a group of	Interleukin activity can be	Soluble IL-17 receptor
	Y97181		multifunctional cytokines synthesized	determined using assays known in	polypeptides may be
			by lymphocytes, monocytes, and	the art: Matthews et al., in	useful for inhibiting
			macrophages. Known functions include	Lymphokines and Interferons: A	interleukin activities.
			stimulating proliferation of immune	Practical Approach, Clemens et al.,
			cells (e.g., T helper cells, B cells,	eds, IRL Press, Washington, D.C.
			eosinophils, and lymphocytes),	1987, pp. 221-225; and Yao et al
			chemotaxis of neutrophils and T	(1995) J. Immunol. 155, 5483-86.
			lymphocytes, and/or inhibition of
			interferons.
Il-17 receptor	GeneSeq Accession	U.S. Pat. No. 6,100,235	Interleukins are a group of	Interleukin activity can be	Soluble IL-17 receptor
	Y97131		multifunctional cytokines synthesized	determined using assays known in	polypeptides may be
			by lymphocytes, monocytes, and	the art: Matthews et al., in	useful for inhibiting
			macrophages. Known functions include	Lymphokines and Interferons: A	interleukin activities.
			stimulating proliferation of immune	Practical Approach, Clemens et al.,
			cells (e.g., T helper cells, B cells,	eds, IRL Press, Washington, D.C.
			eosinophils, and lymphocytes),	1987, pp. 221-225; and Yao et al
			chemotaxis of neutrophils and T	(1995) J. Immunol. 155, 5483-86.
			lymphocytes, and/or inhibition of
			interferons.
Human	GeneSeq Accession	EP509826	Interleukins are a group of	Interleukin activity can be	Soluble IL-3 receptor
interleukin-3	R25300		multifunctional cytokines synthesized	determined using assays known in	polypeptides may be
receptor			by lymphocytes, monocytes, and	the art: Matthews et al., in	useful for inhibiting
			macrophages. Known functions include	Lymphokines and Interferons: A	interleukin activities.
			stimulating proliferation of immune	Practical Approach, Clemens et al.,
			cells (e.g., T helper cells, B cells,	eds, IRL, Press, Washington, D.C.
			eosinophils, and lymphocytes),	1987, pp. 221-225; and Kitamura et
			chemotaxis of neutrophils and T	al (1989) J Cell Physiol. 140 323-334.
			lymphocytes, and/or inhibition of
			interferons.
Human GM-CSF	GeneSeq Accession	WO9102063	Interleukins are a group of	Interleukin activity can be	Soluble GM-CSF
receptor	R10919		multifunctional cytokines synthesized	determined using assays known in	receptor polypeptides
			by lymphocytes, monocytes, and	the art: Matthews et al., in	may be useful for
			macrophages. Known functions include	Lymphokines and Interferons: A	inhibiting interleukin
			stimulating proliferation of immune	Practical Approach, Clemens et al.,	activities.
			cells (e.g., T helper cells, B cells,	eds, IRL Press, Washington, D.C.
			eosinophils, and lymphocytes),	1987, pp. 221-225.
			chemotaxis of neutrophils and T
			lymphocytes, and/or inhibition of
			interferons.
Human IL-5	GeneSeq Accession	EP492214	Interleukins are a group of	Interleukin activity can be	Soluble IL-5 receptor
receptor alpha	R25064		multifunctional cytokines synthesized	determined using assays known in	alpha polypeptides may
chain			by lymphocytes, monocytes, and	the art: Matthews et al., in	be useful for inhibiting
			macrophages. Known functions include	Lymphokines and Interferons: A	interleukin activities.
			stimulating proliferation of immune	Practical Approach, Clemens et al.,
			cells (e.g., T helper cells, B cells,	eds, IRL Press, Washington, D.C.
			eosinophils, and lymphocytes),	1987, pp. 221-225; and Kitamura et
			chemotaxis of neutrophils and T	al (1989) J Cell Physiol. 140, 323-334.
			lymphocytes, and/or inhibition of
			interferons.
Il-5 receptor	GeneSeq Accession	WO9847923	Interleukins are a group of	Interleukin activity can be	Soluble IL-5 receptor
	W82842		multifunctional cytokines synthesized	determined using assays known in	polypeptides may be
			by lymphocytes, monocytes, and	the art: Matthews et al., in	useful for inhibiting
			macrophages. Known functions include	Lymphokines and Interferons: A	interleukin activities.
			stimulating proliferation of immune	Practical Approach, Clemens et al.,
			cells (e.g., T helper cells, B cells,	eds, IRL Press, Washington, D.C.
			eosinophils, and lymphocytes),	1987, pp. 221-225; and Kitamura et
			chemotaxis of neutrophils and T	al (1989) J Cell Physiol. 140, 323-334.
			lymphocytes, and/or inhibition of
			interferons.
Il-6 receptor	GeneSeq Accession	JP05091892	Interleukins are a group of	Interleukin activity can be	Soluble IL-6 receptor
	R37215		multifunctional cytokines synthesized	determined using assays known in	polypeptides may be
			by lymphocytes, monocytes, and	the art: Matthews et al., in	useful for inhibiting
			macrophages. Known functions include	Lymphokines and Interferons: A	interleukin activities.
			stimulating proliferation of immune	Practical Approach, Clemens et al.,
			cells (e.g., T helper cells, B cells,	eds, IRL Press, Washington, D.C.
			eosinophils, and lymphocytes),	1987, pp. 221-225; and Aarden et al
			chemotaxis of neutrophils and T	(1987) Eur. J. Immunol 17, 1411-16.
			lymphocytes, and/or inhibition of
			interferons.
Human B cell	GeneSeq Accession	AU8928720	Interleukins are a group of	Interleukin activity can be	Soluble B cell
stimulating factor-	P90525		multifunctional cytokines synthesized	determined using assays known in	stimulating factor-2
2 receptor			by lymphocytes, monocytes, and	the art: Matthews et al., in	receptor polypeptides
			macrophages. Known functions include	Lymphokines and Interferons: A	may be useful for
			stimulating proliferation of immune	Practical Approach, Clemens et al.,	inhibiting interleukin
			cells (e.g., T helper cells, B cells,	eds, IRL Press, Washington, D.C.	activities.
			eosinophils, and lymphocytes),	1987, pp. 221-225.
			chemotaxis of neutrophils and T
			lymphocytes, and/or inhibition of
			interferons.
IL-7 receptor clone	GeneSeq Accession	EP403114	Interleukins are a group of	Interleukin activity can be	Soluble IL-7 receptor
	R08330		multifunctional cytokines synthesized	determined using assays known in	polypeptides may be
			by lymphocytes, monocytes, and	the art: Matthews et al., in	useful for inhibiting
			macrophages. Known functions include	Lymphokines and Interferons: A	interleukin activities.
			stimulating proliferation of immune	Practical Approach, Clemens et al.,
			cells (e.g., T helper cells, B cells,	eds, IRL Press, Washington, D.C.
			eosinophils, and lymphocytes),	1987, pp. 221-225; and Park et al
			chemotaxis of neutrophils and T	(1990) J. Exp. Med. 171, 1073-79.
			lymphocytes, and/or inhibition of
			interferons.
EPO receptor;	GeneSeq Accession	WO9008822	EPO Receptor is involved in the	EPO Receptor activity can be	Inflammatory disorders,
EPOR	R06512		proliferation and differentiation of	determined using assays known in	immunologic disorders,
			erythroblasts.	the art, such as, J Biol Chem 2001	cancer, erythroblast
				Mar. 23; 276(12: 8995-9002; JAK2	proliferation and
				protein tyrosine kinase activity:	differentiation
				Blood 1994 Sep. 1; 84(5): 1501-7 and
				Mol Cell Biol. 1994
				October; 14(10: 6506-14.
IL-15 receptor	GeneSeq Accession	WO9530695	Interleukins are a group of	Interleukin activity can be	Soluble IL-15 receptor
	R90843		multifunctional cytokines synthesized	determined using assays known in	polypeptides may be
			by lymphocytes, monocytes, and	the art: Matthews et al., in	useful for inhibiting
			macrophages. Known functions include	Lymphokines and Interferons: A	interleukin activities.
			stimulating proliferation of immune	Practical Approach, Clemens et al.,
			cells (e.g., T helper cells, B cells,	eds, IRL Press, Washington, D.C.
			eosinophils, and lymphocytes),	1987, pp. 221-225; and Giri et al
			chemotaxis of neutrophils and T	(1994) EMBO J. 13 2822-2830.
			lymphocytes, and/or inhibition of
			interferons.
CD137; 4-1BB	GeneSeq Accession	WO9507984	Activities associated with apoptosis,	Apoptosis activity, NF-kB	Soluble 4-1BB receptor
Receptor Protein	R70977		NF-kB activation, and co-stimulation of	activation, and B and T cell co-	polypeptides may be
			immune cells such as T and B cells.	stimulation can be determined using	useful for inhibiting
				assays known in the art: Moore et	apoptosis, NF-kB
				al., 1999, Science, 285(5425): 260-3;	activation, and/or co-
				Song H Y et al., 1997 Proc Natl Acad	stimulation of immune
				Sci USA 94(18): 9792-6; Epsevik	cells such as B and T
				and Nissen-Meyer, 1986, J.	cells.
				Immunol. Methods.
BCMA	GeneSeq Accession	WO0068378	Activities associated with apoptosis,	Apoptosis activity, NF-kB	Soluble BCMA receptor
	Y71979		NF-kB activation, and co-stimulation of	activation, and B and T cell co-	polypeptides may be
			immune cells such as T and B cells.	stimulation can be determined using	useful for inhibiting
				assays known in the art: Moore et	apoptosis, NF-kB
				al., 1999, Science, 285(5425): 260-3;	activation, and/or co-
				Song H Y et al., 1997 Proc Natl Acad	stimulation of immune
				Sci USA 94(18): 9792-6; Epsevik	cells such as B and T
				and Nissen-Meyer, 1986, J.	cells.
				Immunol. Methods.
CD27	GeneSeq Accession	WO9201049	Activities associated with apoptosis,	Apoptosis activity, NF-kB	Soluble CD27
	R20814		NF-kB activation, and co-stimulation of	activation, and B and T cell co-	polypeptides may be
			immune cells such as T and B cells.	stimulation can be determined using	useful for inhibiting
				assays known in the art: Moore et	apoptosis, NF-kB
				al., 1999, Science, 285(5425): 260-3;	activation, and/or co-
				Song H Y et al., 1997 Proc Natl Acad	stimulation of immune
				Sci USA 94(18): 9792-6; Epsevik	cells such as B and T
				and Nissen-Meyer, 1986, J.	cells.
				Immunol. Methods.
CD30	GeneSeq Accession	DE4200043	Activities associated with apoptosis,	Apoptosis activity, NF-kB	Soluble CD30
	R35478		NF-kB activation, and co-stimulation of	activation, and B and T cell co-	polypeptides may be
			immune cells such as T and B cells.	stimulation can be determined using	useful for inhibiting
				assays known in the art: Moore et	apoptosis, NF-kB
				al., 1999, Science, 285(5425): 260-3;	activation, and/or co-
				Song H Y et al., 1997 Proc Natl Acad	stimulation of immune
				Sci USA 94(18): 9792-6; Epsevik	cells such as B and T
				and Nissen-Meyer, 1986, J.	cells.
				Immunol. Methods.
CD40	GeneSeq Accession	WO9945944	Activities associated with apoptosis,	Apoptosis activity, NF-kB	Soluble CD40
	Y33499		NF-kB activation, and co-stimulation of	activation, and B and T cell	polypeptides may be
			immune cells such as T and B cells.	co-stimulation can be determined	useful for inhibiting
				using assays known in the art:	apoptosis, NF-kB
				Moore et al., 1999, Science	activation, and/or co-
				285(5425): 260-3; Song H Y et al.,	stimulation of immune
				1997 Proc Natl Acad Sci USA	cells such as B and T
				94(18): 9792-6; Epsevik and	cells.
				Nissen-Meyer, 1986, J. Immunol.
				Methods.
EDAR	Genbank Accession		Activities associated with apoptosis,	Apoptosis activity, NF-kB activation,	Immune Disorders,
	AAD50077		NF-kB activation, and co-stimulation of	and B and T cell co-stimulation can	Lymphomas, X-linked
			immune cells such as T and B cells.	be determined using assays known in	hypohidrotic ectodermal
				the art: Moore et al., 1999, Science,	dysplasia
				285(5425): 260-3; Song H Y et al.,
				1997 Proc Natl Acad Sci USA
				94(18): 9792-6; Epsevik and Nissen-
				Meyer, 1986, J. Immunol. Methods.
OX40; ACT-4	GeneSeq Accession	WO9512673	Activities associated with apoptosis,	Apoptosis activity, NF-kB activation,	Immune Disorders,
	R74737		NF-kB activation, and co-stimulation of	and B and T cell co-stimulation can	Lymphomas, T cell
			immune cells such as T and B cells.	be determined using assays known in	disorders
				the art: Moore et al., 1999, Science,
				285(5425): 260-3; Song H Y et al.,
				1997 Proc Natl Acad Sci USA
				94(18): 9792-6; Epsevik and Nissen-
				Meyer, 1986, J. Immunol. Methods.
TACI	GeneSeq Accession	WO9839361	Activities associated with apoptosis,	Apoptosis activity, NF-kB activation,	Soluble TACI receptor
	W75783		NF-kB activation, and co-stimulation of	and B and T cell co-stimulation can	polypeptides may be
			immune cells such as T and B cells.	be determined using assays known in	useful for inhibiting
				the art: Moore et al., 1999, Science,	apoptosis, NF-kB
				285(5425): 260-3; Song H Y et al.,	activation, and/or co-
				1997 Proc Natl Acad Sci USA	stimulation of immune
				94(18): 9792-6; Epsevik and Nissen-	cells such as B and T
				Meyer, 1986, J. Immunol. Methods.	cells.
TNF-R	GeneSeq Accession	AU9058976	Activities associates with apoptosis,	Apoptosis activity, NF-kB	Soluble TNF-R receptor
	R10986		NF-kB activation, and co-stimulation of	activation, and B and T cell co-	polypeptides may be
			immune cells such as T and B cells.	stimulation can be determined using	useful for inhibiting
				assays known in the art: Moore et al.,	apoptosis, NF-kB
				1999, Science, 285(5425): 260-3;	activation, and/or co-
				Song H Y et al., 1997 Proc Natl Acad	stimulation of immune
				Sci USA 94(18): 9792-6; Epsevik	cells such as B and T
				and Nissen-Meyer, 1986, J. Immunol.	cells.
				Methods.
TNF-RII; TNF	GeneSeq Accession	EP418014	Activities associated with apoptosis,	Apoptosis activity, NF-kB activation,	Soluble TNFR-II
p75 receptor;	R11141		NF-kB activation, and co-stimulation of	and B and T cell co-stimulation can	receptor polypeptides
Death Receptor			immune cells such as T and B cells.	be determined using assays known in	may be useful for
				the art: Moore et al., 1999, Science,	inhibiting apoptosis,
				285(5425): 260-3; Song H Y et al.,	NF-kB activation,
				1997 Proc Natl Acad Sci USA	and/or co-stimulation of
				94(18)9792-6; Epsevik and Nissen-	immune cells such as B
				Meyer, 1986, J. Immunol. Methods.	and T cells.
hAPO-4; TROY	GeneSeq Accession	WO9911791	Activities associated with apoptosis,	Apoptosis activity, NF-kB activation,	Immune Disorders,
	W93581		NF-kB activation, and co-stimulation of	and B and T cell co-stimulation can	Cancers
			immune cells such as T and B cells.	be determined using assays known in
				the art: Moore et al., 1999, Science,
				285(5425): 260-3; Song H Y et al.,
				1997 Proc Natl Acad Sci USA
				94(18): 9792-6; Epsevik and Nissen-
				Meyer, 1986, J. Immunol. Methods.
TNF-alpha	GeneSeq Accession	EP205038	Activities associated with apoptosis,	Apoptosis activity, NF-kB activation,	Inflammatory disorders,
precursor	P60074		NF-kB activation, and co-stimulation of	and B and T cell co-stimulation can	immunologic disorders,
			immune cells such as T and B cells.	be determined using assays known in	cancer
				the art: Moore et al., 1999, Science,
				285(5425): 260-3; Song H Y et al.,
				1997 Proc Natl Acad Sci USA
				94(18): 9792-6; Epsevik and Nissen-
				Meyer, 1986, J. Immunol. Methods.
Human TNF-	GeneSeq Accession	EP619372	Activities associated with apoptosis,	Apoptosis activity, NF-kB activation,	Inflammatory disorders,
alpha	R62463		NF-kB activation, and co-stimulation of	and B and T cell co-stimulation can	immunologic disorders,
			immune cells such as T and B cells	be determined using assays known in	cancer
				the art: Moore et al., 1999, Science,
				285(5425): 260-3; Song H Y et al.,
				1997 Proc Natl Acad Sci USA
				94(18): 9792-6; Epsevik and Nissen-
				Meyer, 1986, J. Immunol. Methods.
Human TNF-	GeneSeq Accession	EP563714	Activities associated with apoptosis,	Apoptosis activity, NF-kB activation,	Inflammatory disorders,
alpha	R42679		NF-kB activation, and co-stimulation of	and B and T cell co-stimulation can	immunologic disorders,
			immune cells such as T and B cells.	be determined using assays known in	cancer
				the art: Moore et al., 1999, Science,
				285(5425): 260-3; Song H Y et al.,
				1997 Proc Natl Acad Sci USA
				94(18): 9792-6; Epsevik and Nissen-
				Meyer, 1986, J. Immunol. Methods.
Human TNF-	GeneSeq Accession	WO0064479	Activities associated with apoptosis,	Apoptosis activity, NF-kB activation,	Inflammatory disorders,
beta (LT-alpha)	B37799		NF-kB activation, and co-stimulation of	and B and T cell co-stimulation can	immunologic disorders,
			immune cells such as T and B cells.	be determined using assays known in	cancer
				the art: Moore et al., 1999, Science,
				285(5425): 260-3; Song H Y et al.,
				1997 Proc Natl Acad Sci USA
				94(18): 9792-6; Epsevik and Nissen-
				Meyer, 1986, J. Immunol. Methods.
LT-alpha	GeneSeq Accession	EP250000	Activities associated with apoptosis,	Apoptosis activity, NF-kB activation,	Inflammatory disorders,
	P70107		NF-kB activation, and co-stimulation of	and B and T cell co-stimulation can	immunologic disorders,
			immune cells such as T and B cells.	be determined using assays known in	cancer
				the art: Moore et al., 1999, Science,
				285(5425): 260-3; Song H Y et al.,
				1997 Proc Natl Acad Sci USA
				94(18): 9792-6; Epsevik and Nissen-
				Meyer, 1986, J. Immunol. Methods.
LT-beta	GeneSeq Accession	WO9413808	Activities associated with apoptosis,	Apoptosis activity, NF-kB activation,	Inflammatory disorders,
	R56869		NF-kB activation, and co-stimulation of	and B and T cell co-stimulation can	immunologic disorders,
			immune cells such as T and B cells.	be determined using assays known in	cancer
				the art: Moore et al., 1999, Science,
				285(5425): 260-3; Song H Y et al.,
				1997 Proc Natl Acad Sci USA
				94(18)9792-6; Epsevik and Nissen-
				Meyer, 1986, J. Immunol. Methods.
OPGL	GeneSeq Accession	WO9846751	Activities associated with apoptosis,	Apoptosis activity, NF-kB activation,	Inflammatory disorders,
	W83195		NF-kB activation, and co-stimulation of	and B and T cell co-stimulation can	immunologic disorders,
			immune cells such as T and B cells.	be determined using assays known in	cancer, loss of bone
				the art: Moore et al., 1999, Science,	mass
				285(5425): 260-3; Song H Y et al.,
				1997 Proc Natl Acad Sci USA
				94(18)9792-6; Epsevik and Nissen-
				Meyer, 1986, J. Immunol. Methods.
FasL	GeneSeq Accession	WO9903999	Activities associated with apoptosis,	Apoptosis activity, NF-kB activation,	Inflammatory disorders,
	W98071		NF-kB activation, and co-stimulation of	and B and T cell co-stimulation can	immunologic disorders,
			immune cells such as T and B cells.	be determined using assays known in	cancer
				the art: Moore, et al., 1999, Science,
				285(5425): 260-3; Song H Y et al.,
				1997 Proc Natl Acad Sci USA
				94(18)9792-6; Epsevik and Nissen-
				Meyer, 1986, J. Immunol. Methods.
FasL	GeneSeq Accession	WO9903998	Activities associated with apoptosis,	Apoptosis activity, NF-kB activation,	Inflammatory disorders,
	W95041		NF-kB activation, and co-stimulation of	and B and T cell co-stimulation can	imunologic disorders,
			immune cells such as T and B cells.	be determined using assays known in	cancer
				the art: Moore et al., 1999, Science,
				285(5425): 260-3; Song H Y et al.,
				1997 Proc Natl Acad Sci USA
				94(18): 9792-6; Epsevik and Nissen-
				Meyer, 1986, J. Immunol. Methods.
CD27L	GeneSeq Accession	WO9405691	Activities associated with apoptosis,	Apoptosis activity, NF-kB activation,	Inflammatory disorders,
	R50121		NF-kB activation, and co-stimulation of	and B and T cell co-stimulation can	immunologic disorders,
			immune cells such as T and B cells.	be determined using assays known in	cancer
				the art: Moore et al., 1999, Science,
				285(5425): 260-3; Song H Y et al.,
				1997 Proc Natl Acad Sci USA
				94(18): 9792-6; Epsevik and Nissen-
				Meyer, 1986, J. Immunol. Methods.
CD30 ligand	GeneSeq Accession	WO9324135	Activities associated with apoptosis,	Apoptosis activity, NF-kB activation,	Inflammatory disorders,
	R45007		NF-kB activation, and co-stimulation of	and B and T cell co-stimulation can	immunologic disorders,
			immune cells such as T and B cells.	be determined using assays known in	cancer
				the art: Moore et al., 1999, Science,
				285(5425): 260-3; Song H Y et al.,
				1997 Proc Natl Acad Sci USA
				94(18): 9792-6; Epsevik and Nissen-
				Meyer, 1986, J. Immunol. Methods.
CD40L	GeneSeq Accession	WO9529935	Activities associated with apoptosis,	Apoptosis activity, NF-kB activation,	Inflammatory disorders,
	R85486		NF-kB activation, and co-stimulation of	and B and T cell co-stimulation can	immunologic disorders,
			immune cells such as T and B cells.	be determined using assays known in	cancer
				the art: Moore, et al., 1999, Science,
				285(5425): 260-3; Song H Y et al.,
				1997 Proc Natl Acad Sci USA
				94(18): 9792-6; Epsevik and Nissen-
				Meyer, 1986, J. Immunol. Methods.
4-1BB ligand	GeneSeq Accession	U.S. Pat. No. 5,674,704	Activities associated with apoptosis,	Apoptosis activity, NF-kB activation,	Inflammatory disorders,
	W26657		NF-kB activation, and co-stimulation of	and B and T cell co-stimulation can	immunologic disorders,
			immune cells such as T and B cells.	be determined using assays known in	cancer
				the art: Moore et al., 1999, Science,
				285(5425): 260-3; Song H Y et al.,
				1997 Proc Natl Acad Sci USA
				94(18): 9792-6; Epsevik and Nissen-
				Meyer, 1986, J. Immunol. Methods.
FAS Ligand	GeneSeq Accession	WO0058465	Activities associated with apoptosis,	Apoptosis activity, NF-kB activation,	Soluble DcR3
Inhibitory	B19335		NF-kB activation, and co-stimulation of	and B and T cell co-stimulation can	polypeptides may be
Protein (DcR3)			immune cells such as T and B cells.	be determined using assays known in	useful for inhibiting
				the art: Moore et al., 1999, Science,	apoptosis, NF-kB
				285(5425): 260-3; Song H Y et al.,	activation, and/or co-
				1997 Proc Natl Acad Sci USA	stimulation of immune
				94(18): 9792-6; Epsevik and Nissen-	cells such as B and T
				Meyer, 1986, J. Immunol. Methods	cells.
OX40L	GeneSeq Accession	WO9521915	Activities associated with apoptosis,	Apoptosis activity, NF-kB activation,	Inflammatory disorders,
	R79903		NF-kB activation, and co-stimulation of	and B and T cell co-stimulation can	immunologic disorders,
			immune cells such as T and B cells.	be determined using assays known in	cancer
				the art: Moore et al., 1999, Science,
				285(5425): 260-3; Song H Y et al.,
				1997 Proc Natl Acad Sci USA
				94(18): 9792-6; Epsevik and Nissen-
				Meyer, 1986, J. Immunol. Methods.
Protease	GeneSeq Accessions	WO9106561	Peptides that inhibit the function/binding	HIV protease activities are known in	HIV, inflammatory
inhibitor	R12435, R12436,		of HIV	the art: HIV protease assays:	disorders, immunologic
peptides	R12437, R12438,			EP0387231. One can modify the	disorders, cancer, viral
	R12439, R12440,			assay to look for inhibition using any	infections
	and R1244			of the disclosed protease inhibitor
				polypeptides.
Retroviral protease	GeneSeq Accessions	EP387231	Peptides that inhibit the function/binding	HIV protease activities are known in	HIV, inflammatory
inhibitors	R06660, R06661,		of HIV	the art: HIV protease assays:	disorders, immunologic
	R06662, R06663,			EP0387231. One can modify the	disorders, cancer, viral
	R06664, R06665,			assay to look for inhibition using any	infections
	R06666, R06667,			of the disclosed protease inhibitor
	R06668, R06669,			polypeptides.
	R06670, R06671,
	R06672, R06673,
	R06674, R06675,
	and R06676
HIV protease	GeneSeq Accessions	WO9301828	Peptides that inhibit the function/binding of	HIV protease activities are known in the	HIV, inflammatory
inhibiting	R59293, R59294,		HIV	art: HIV protease assays: EP0387231.	disorders, immunologic
peptides	R59295, R59296,			One can modify, the assay to look for	disorders, cancer, viral
	R59297, R59298,			inhibition using any of the disclosed	infections
	R59299, R592300,			protease inhibitor polypeptides.
	R59301, R59302,
	R59301, R59302,
	R59303, R59304,
	R59305, R59306,
	R59307, R59308,
	R59309, R59310,
	R59311, R59312,
	R59313, R59314,
	R59315, R59316,
	R59317 R59318,
	R59319, R59320,
	R59321, R59322,
	R59323, R59324,
	R59325, R59326,
	R59327, R59328,
	R59329, R59330,
	R59331, R59332,
	R59333, R59334,
	R59335, R59336,
	R59337, R59338,
	R59339, R59340,
	R59341, R59342,
	R59343, R59344,
	R59345, R59346,
	R59347, R59348,
	R59349, and
	R59350
HIV-1 protease	GeneSeq Accessions	DE4412174	Peptides that inhibit the function/binding of	HIV protease activities are known in the	HIV, inflammatory
hinibitors	R86326, R86327,		HIV	art: HIV protease assays: EP0387231.	disorders, immunologic
	R86328, R86329,			One can modify the assay to look for	disorders, cancer, viral
	R86330, R86331,			inhibition using any of the disclosed	infections
	R86332, R86333,			protease inhibitor polypeptides.
	R86334, R86335,
	R86336, R86337,
	R86338, R86339,
	R86340, R86341,
	R86342, R86343,
	R86344, R86345,
	R86346, R86347,
	R86348, R86349,
	R86350, R86351,
	R86352, R86353,
	R86354, R86355,
	R86356, R86357,
	R86358, R86359,
	R86360, R86361,
	R86362, R86363,
	R86364, R86365,
	R86366, R86367,
	R86368, R86369,
	R86370, and
	R86371
HIV Inhibitor	GeneSeq Accession	WO9959615	Peptides that inhibit the function/binding	HIV protease activities are known in	HIV, inflammatory
Peptide	Y89687		of HIV	the art: HIV protease assays:	disorders, immunologic
				EP0387231. One can modify the	disorders, cancer, viral
				assay to look for inhibition using any	infections
				of the disclosed protease inhibitor
				polypeptides.
HIV Inhibitor	GenSeq Accession	WO9948513	Peptides that inhibit the function/binding	HIV Protease activities are known in	HIV, inflammatory
Peptide	Y31955		of HIV	the art; HIV protease assays:	disorders, immunologic
				EP0387231. One can modify the	disorders, cancer, viral
				assay to look for inhibition using any	infections.
				of the disclosed protease inhibitor
				polypeptides.
HIV Inhibitor	www.sciencexpress.org;		Peptides that inhibit the function/binding	HIV protease activities are known in	HIV, inflammatory
Peptide	Published online		of HIV	the art: HIV protease assays:	disorders, immunologic
	12 Jan. 2001;			EP0387231: One can modify the	disorders, cancer, viral
	10.1126/science.1057453			assay to look for inhibition using any	infections
				of the disclosed protease inhibitor
				polypeptides.
Human monocyte	GeneSeq Accession	WO9509232	Chemokines are a family of small,	Chemokine activities can be	Immune disorders,
chemoattractant	R73915		secreted proteins involved in biological	determined using assays known in	particularly useful for
factor hMCP-3			processes ranging from hematopoiesis,	the art: Methods in Molecular	treating bacterial and/or
			angiogenesis, and leukocyte trafficking.	Biology, 2000, vol. 138: Chemokine	viral menigitis
			Members of this family are involved in a	Protocols, Edited by: A. E. I. Proudfoot,
			similarly diverse range of pathologies	T. N. C. Wells, and C. A. Power.
			including inflammation, allergy, tissue	©Humana Press Inc.,
			rejection, viral infection, and tumor	Totowa, NJ
			biology. The chemokines exert their
			effects by acting on a family of seven
			transmembrane G-protein-coupled
			receptors. Over 40 human chemokines
			have been described, which bind to −17
			receptors thus far identified.
Human monocyte	GeneSeq Accession	WO9509232	Chemokines are a family of related	Chemokine activities can be	Immune disorders,
chemoattractant	R73914		small, secreted proteins involved in	determined using assays known in	particularly useful for
factor hMCP-1			biological processes ranging from	the art: Methods in Molecular	treating bacterial and/or
			hematopoiesis, angiogenesis, and	Biology, 2000, vol. 138: Chemokine	viral menigitis
			leukocyte trafficking. Members of this	Protocols. Edited by: A. E. I. Proudfoot,
			family are involved in a similarly	T. N. C. Wells, and C. A. Power.
			diverse range of pathologies including	©Humana Press Inc.,
			inflammation, allergy, tissue rejection,	Totowa, NJ
			viral infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to −17 receptors thus far
			identified.
Human gro-beta	GeneSeq Accessions	WO9429341	Chemokines are a family of small,	Chemokine activities can be	immune disorders,
chemokine	R66699 and		secreted proteins involved in biological	determined using assays known in	inflammatory disorders,
	W17671		processes ranging from hematopoiesis,	the art: Methods in Molecular	blood-related disorders,
			angiogenesis, and leukocyte trafficking.	Biology, 2000, vol. 138: Chemokine	stem cell
			Members of this family are involved in a	Protocols. Edited by: A. E. I. Proudfoot,	transplantation, cancer
			similarly diverse range of pathologies	T. N. C. Wells, and C. A. Power.
			including inflammation, allergy, tissue	©Humana Press Inc.,
			rejection, viral infection, and tumor	Totowa, NJ.
			biology. The chemokines exert their
			effects by acting on a family of seven
			transmembrane G-protein-coupled
			receptors. Over 40 human chemokines
			have been described, which bind to −17
			receptors thus far identified.
Human gro-	GeneSeq Accessions	WO9429341	Chemokines are a family of related	Chemokine activities can be	Immune disorders,
gamma chemokine	R66700 and		small, secreted proteins involved in	determined using assays known in	inflammatory disorders,
	W17672		biological processes ranging from	the art: Methods in Molecular	blood-related disorders,
			hematopoiesis, angiogenesis, and	Biology, 2000, vol. 138: Chemokine	stem cell
			leukocyte trafficking. Members of this	Protocols. Edited by: A. E. I. Proudfoot,	transplantation, cancer
			family are involved in a similarly	T. N. C. Wells, and C. A. Power.
			diverse range of pathologies including	©Humana Press Inc.,
			inflammation, allergy, tissue rejection,	Totowa, NJ
			viral infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to −17 receptors thus far
			identified
Human gro-alpha	GeneSeq Accessions	WO9429341	Chemokines are a family of related	Chemokine activities can be	Immune disorders,
chemokine	R66698 and		small, secreted proteins involved in	determined using assays known in	inflammatory disorders,
	W18024		biological processes ranging from	the art: Methods in Molecular	blood-related disorders,
			hematopoiesis, angiogenesis, and	Biology, 2000, vol. 138: Chemokine	stem cell
			leukocyte trafficking. Members of this	Protocols. Edited by: A. E. I. Proudfoot,	transplantation, cancer
			family are involved in a similarly	T. N. C. Wells, and C. A. Power.
			diverse range of pathologies including	©Humana Press Inc.,
			inflammation, allergy, tissue rejection,	Totowa, NJ
			viral infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to −17 receptors thus far
			identified
Human eosinophil-	GeneSeq Accession	WO9632481	Chemokines are a family of related	Chemokine activities can be	Immune disorders,
expressed	W05186		small, secreted proteins involved in	determined using assays known in	particularly treatment of
chemokine (EEC)			biological processes ranging from	the art: Methods in Molecular	eosinophilia,
			hematopoiesis, angiogenesis, and	Biology, 2000, vol. 138: Chemokine	inflammation, allergies,
			leukocyte trafficking. Members of this	Protocols. Edited by: A. E. I. Proudfoot,	asthma, leukaemia and
			family are involved in a similarly	T. N. C. Wells, and C. A. Power.	lymphoma
			diverse range of pathologies including	©Humana Press Inc.,
			inflammation, allergy, tissue rejection,	Totowa, NJ
			viral infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to −17 receptors thus far
			identified
Chemokine-like	GeneSeq Accessions	WO9613587	Chemokines are a family of related	Chemokine activities can be	Cancer and blood-
protein PF4-414	R92318 and		small, secreted proteins involved in	determined using assays known in	related disorders,
Full-Length and	R99809		biological processes ranging from	the art: Methods in Molecular	particularly
Mature			hematopoiesis, angiogenesis, and	Biology, 2000, vol. 138: Chemokine	myelosuppression
			leukocyte trafficking. Members of this	Protocols. Edited by: A. E. I. Proudfoot,
			family are involved in a similarly	T. N. C. Wells, and C. A. Power.
			diverse range of pathologies including	©Humana Press Inc.,
			inflammation, allergy, tissue rejection,	Totowa, NJ
			viral infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to −17 receptors thus far
			identified
Chemokine-like	GeneSeq Accession	WO9613587	Chemokines are a family of related	Chemokine activities can be	Cancer and blood-
protein IL-8M3	R99812		small, secreted proteins involved in	determined using assays known in	related disorders,
			biological processes ranging from	the art: Methods in Molecular	particularly
			hematopoiesis, angiogenesis, and	Biology, 2000, vol. 138: Chemokine	myelosuppression
			leukocyte trafficking. Members of this	Protocols. Edited by: A. E. I. Proudfoot,
			family are involved in a similarly	T. N. C. Wells, and C. A. Power.
			diverse range of pathologies including	©Humana Press Inc.,
			inflammation, allergy, tissue rejection,	Totowa, NJ; and Holmes et al (1991)
			viral infection, and tumor biology. The	Science 253, 1278-80.
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to −17 receptors thus far
			identified
Human	GeneSeq Accession	WO9613587	Chemokines are a family of related	Chemokine activities can be	Cancer and blood-
interleukin-8	R99814		small, secreted proteins involved in	determined using assays known in	related disorders,
(IL-8)			biological processes ranging from	the art: Methods in Molecular	particularly
			hematopoiesis, angiogenesis, and	Biology, 2000, vol. 138: Chemokine	myelosuppression
			leukocyte trafficking. Members of this	Protocols. Edited by: A. E. I. Proudfoot,
			family are involved in a similarly	T. N. C. Wells, and C. A. Power.
			diverse range of pathologies including	©Humana Press Inc.,
			inflammation, allergy, tissue rejection,	Totowa, NJ; and Holmes et al (1991)
			viral infection, and tumor biology. The	Science 253, 1278-80.
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to −17 receptors thus far
			identified
Chemokine-like	GeneSeq Accessions	WO9613587	Chemokines are a family of related	Chemokine activities can be	Cancer and blood-
protein IL-8M1	R99815 and		small, secreted proteins involved in	determined using assays known in	related disorders,
Full-Length and	R99803		biological processes ranging from	the art: Methods in Molecular	particularly
Mature			hematopoiesis, angiogenesis, and	Biology, 2000, vol. 138: Chemokine	myelosuppression
			leukocyte trafficking. Members of this	Protocols. Edited by: A. E. I. Proudfoot,
			family are involved in a similarly	T. N. C. Wells, and C. A. Power.
			diverse range of pathologies including	©Humana Press Inc.,
			inflammation, allergy, tissue rejection,	Totowa, NJ; and Holmes et al (1991)
			viral infection, and tumor biology. The	Science 253, 1278-80.
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to −17 receptors thus far
			identified
Chemokine-like	GeneSeq Accessions	WO9613587	Chemokines are a family of related	Chemokine activities can be	Cancer and blood-
protein IL-8M8	R99816 and		small, secreted proteins involved in	determined using assasys known in	related disorders,
Full-Length and	R99805		biological processes ranging from	the art: Methods in Molecular	particularly
Mature			hematopoiesis, angiogenesis, and	Biology, 2000, vol. 138: Chemokine	myelosuppression.
			leukocyte trafficking. Members of this	Protocols. Edited by: A. E. I. Proudfoot;
			family are involved in a similarly	T. N. C. Wells, and C. A. Power.
			diverse range of pathologies including	©Humana Press Inc.,
			inflammation, allergy, tissue rejection,	Totowa, NJ; and Holmes et al (1991)
			viral infection, and tumor biology. The	Science 253, 1278-80.
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identified.
Chemokine-like	GeneSeq Accessions	WO9613587	Chemokines are a family of related	Chemokine activities can be	Cancer and blood-
protein IL-8M8	R99817 and		small, secreted proteins involved in	determined using assasys known in	related disorders,
Full-Length and	R99806		biological processes ranging from	the art: Methods in Molecular	particularly
Mature			hematopoiesis, angiogenesis, and	Biology, 2000, vol. 138: Chemokine	myelosuppression.
			leukocyte trafficking. Members of this	Protocols. Edited by: A. E. I. Proudfoot;
			family are involved in a similarly	T. N. C. Wells, and C. A. Power.
			diverse range of pathologies including	©Humana Press Inc.,
			inflammation, allergy, tissue rejection,	Totowa, NJ; and Holmes et al (1991)
			viral infection, and tumor biology. The	Science 253, 1278-80.
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identified.
Chemokine-like	GeneSeq Accessions	WO9613587	Chemokines are a family of related	Chemokine activities can be	Cancer and blood-
protein IL-8M8	R99818 and		small, secreted proteins involved in	determined using assasys known in	related disorders,
Full-Length and	R99804		biological processes ranging from	the art: Methods in Molecular	particularly
Mature			hematopoiesis, angiogenesis, and	Biology, 2000, vol. 138: Chemokine	myelosuppression.
			leukocyte trafficking. Members of this	Protocols. Edited by: A. E. I. Proudfoot;
			family are involved in a similarly	T. N. C. Wells, and C. A. Power.
			diverse range of pathologies including	©Humana Press Inc.,
			inflammation, allergy, tissue rejection,	Totowa, NJ; and Holmes et al (1991)
			viral infection, and tumor biology. The	Science 253, 1278-80.
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identified.
Chemokine-like	GeneSeq Accessions	WO9613587	Chemokines are a family of related	Chemokine activities can be	Cancer and blood-
protein IL-8M8	R99819 and		small, secreted proteins involved in	determined using assasys known in	related disorders,
Full-Length and	R99807		biological processes ranging from	the art: Methods in Molecular	particularly
Mature			hematopoiesis, angiogenesis, and	Biology, 2000, vol. 138: Chemokine	myelosuppression.
			leukocyte trafficking. Members of this	Protocols. Edited by: A. E. I. Proudfoot;
			family are involved in a similarly	T. N. C. Wells, and C. A. Power.
			diverse range of pathologies including	©Humana Press Inc.,
			inflammation, allergy, tissue rejection,	Totowa, NJ
			viral infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identified.
Chemokine-like	GeneSeq Accessions	WO9613587	Chemokines are a family of related	Chemokine activities can be	Cancer and blood-
protein IL-8M8	R99822 and		small, secreted proteins involved in	determined using assasys known in	related disorders,
Full-Length and	R9807		biological processes ranging from	the art: Methods in Molecular	particularly
Mature			hematopoiesis, angiogenesis, and	Biology, 2000, vol. 138: Chemokine	myelosuppression.
			leukocyte trafficking. Members of this	Protocols. Edited by: A. E. I. Proudfoot;
			family are involved in a similarly	T. N. C. Wells, and C. A. Power.
			diverse range of pathologies including	©Humana Press Inc.,
			inflammation, allergy, tissue rejection,	Totowa, NJ
			viral infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identified.
Human foetal	GeneSeq Accession	WO9622374	Chemokines are a family of related	Chemokine activities can be	Immune disorders
spleen expressed	R98499		small, secreted proteins involved in	determined using assasys known in
chemokine, FSEC			biological processes ranging from	the art: Methods in Molecular
			hematopoiesis, angiogenesis, and	Biology, 2000, vol. 138: Chemokine
			leukocyte trafficking. Members of this	Protocols. Edited by: A. E. I. Proudfoot;
			family are involved in a similarly	T. N. C. Wells, and C. A. Power.
			diverse range of pathologies including	©Humana Press Inc.,
			inflammation, allergy, tissue rejection,	Totowa, NJ
			viral infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identified.
Liver expressed	GeneSeq Accession	WO9616979	Chemokines are a family of related	Chemokine activities can be	Inflammation of the
chemokine-	R95689		small, secreted proteins involved in	determined using assasys known in	liver
1(LVEC-1)			biological processes ranging from	the art: Methods in Molecular
			hematopoiesis, angiogenesis, and	Biology, 2000, vol. 138: Chemokine
			leukocyte trafficking. Members of this	Protocols. Edited by: A. E. I. Proudfoot;
			family are involved in a similarly	T. N. C. Wells, and C. A. Power.
			diverse range of pathologies including	©Humana Press Inc.,
			inflammation, allergy, tissue rejection,	Totowa, NJ
			viral infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identified.
Liver expressed	GeneSeq Accession	WO9616979	Chemokines are a family of related	Chemokine activities can be	Inflammation of the
chemokine-	R95690		small, secreted proteins involved in	determined using assasys known in	liver
2(LVEC-2)			biological processes ranging from	the art: Methods in Molecular
			hematopoiesis, angiogenesis, and	Biology, 2000, vol. 138: Chemokine
			leukocyte trafficking. Members of this	Protocols. Edited by: A. E. I. Proudfoot;
			family are involved in a similarly	T. N. C. Wells, and C. A. Power.
			diverse range of pathologies including	©Humana Press Inc.,
			inflammation, allergy, tissue rejection,	Totowa, NJ
			viral infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identified.
Pituitary expressed	GeneSeq Accession	WO9616979	Chemokines are a family of related	Chemokine activities can be	Inflammation,
chemokine	R95691		small, secreted proteins involved in	determined using assasys known in	particularly of the liver
(PGEC)			biological processes ranging from	the art: Methods in Molecular
			hematopoiesis, angiogenesis, and	Biology, 2000, vol. 138: Chemokine
			leukocyte trafficking. Members of this	Protocols. Edited by: A. E. I. Proudfoot;
			family are involved in a similarly	T. N. C. Wells, and C. A. Power.
			diverse range of pathologies including	©Humana Press Inc.,
			inflammation, allergy, tissue rejection,	Totowa, NJ
			viral infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines liave been described,
			which bind to ~17 receptors thus far
			identified.
Adenoid-expressed	GeneSeq Accession	WO9617868	Chemokines are a family of related	Chemokine activities can be	Inflammation,
chemokine	R97664		small, secreted proteins involved in	determined using assasys known in	angiogenesis,
(ADEC)			biological processes ranging from	the art: Methods in Molecular	tumorigenesis,
			hematopoiesis, angiogenesis, and	Biology, 2000, vol. 138: Chemokine	musculoskeletal
			leukocyte trafficking. Members of this	Protocols. Edited by: A. E. I. Proudfoot;	disorders
			family are involved in a similarly	T. N. C. Wells, and C. A. Power.
			diverse range of pathologies including	©Humana Press Inc.,
			inflammation, allergy, tissue rejection,	Totowa, NJ
			viral infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identified.
Human	GeneSeq Accession		Chemokines are a family of related	Chemokine activities can be	Immune disorders, cell
chemokineCC-2	W38170		small, secreted proteins involved in	determined using assays known in	migration, proliferation,
			biological processes ranging from	the art: Methods in Molecular	and differentiation,
			hematopoiesis, angiogenesis, and	Biology, 2000, vol. 138; Chemokine	disorders
			leukocyte trafficking. Members of this	protocols. Edited by: A. E. I. Proudfoot,
			family are involved in a similarly	T. N. C. Wells, and C. A. Power.
			diverse range of pathologies including	©Humana Press Inc.
			inflammation, allergy, tissue rejection,	Totowa, NJ
			viral infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane
			G-protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identified.
Human	GeneSeq Accession	WO9741230	Chemokines are a family of related	Chemokine activities can be	Immune disorders, cell
chemokine	W38171		small, secreted proteins involved in	determined using assays known in the	migration, proliferation,
HCC-1			biological processes ranging from	art: Methods in molecular Biology	and differentiation
			hematopiesis, anglogenesis and	2000, vol. 138: Chemokine	disorders
			leukocyte trafficking. Members of this	Protocols. Edited by A. E. I. Proudfoot,
			family are involved in a similarly	T. N. C. Wells and C. A. Power
			diverse range of pathologies including	©Humana Press Inc., Totowa,
			inflammation, allergy, tissue rejection,	NJ
			viral infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane
			G-protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identified.
Human	GeneSeq Accession	WO9741230	Chemokines are a family of related	Chemokine activities can be	Immune disorders, cell
chemokine CC-3	W38172		small, secreted proteins involved in	determined using assays known in the	migration, proliferation
			biological processes ranging from	art: Methods in molecular Biology,	and differentiation
			hemotopoiesis, anglogenesis, and	2000, vol. 138: Chemokine	disorders
			leukocyte trafficking. Members of this	Protocols, Edited by A. E. I. Proudfoot,
			family are involved in a similarly	T. N. C. Wells, and C. A. Power
			diverse range of pathologies including	©Humana Press Inc., Totowa,
			inflammation, allergy, tissue rejection,	NJ
			viral infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identified.
Novel	GeneSeq Accession	WO9739126	Chemokines are a family of related	Chemokine activities can be	Immune disorders,
betachemokine	W27271		small, secreted proteins involved in	determined using assays known in the	vascular disorders,
designated PTEC			biological processes ranging from	art: Methods in molecular Biology,	cancer
			hemotopoiesis, anglogenesis, and	2000, vol. 138: Chemokine
			leukocyte trafficking. Members of this	Protocols, Edited by A. E. I. Proudfoot,
			family are involved in a similarly	T. N. C. Wells, and C. A. Power
			diverse range of pathologies including	©Humana Press Inc., Totowa,
			inflammation, allergy, tissue rejection,	NJ
			viral infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identified.
Human CX3C	GeneSeq Accession	WO9727299	Chemokines are a family of related	Chemokine activities can be	Immune disorders,
111 amino acid	W23344		small, secreted proteins involved in	determined using assays known in the	inflammatory diseases,
chemokine			biological processes ranging from	art: Methods in molecular Biology,	abnormal proliferation,
			hemotopoiesis, anglogenesis, and	2000, vol. 138: Chemokine	regeneration,
			leukocyte trafficking. Members of this	Protocols, Edited by A. E. I. Proudfoot,	degeneration, and
			family are involved in a similarly	T. N. C. Wells, and C. A. Power	atrophy
			diverse range of pathologies including	©Humana Press Inc., Totowa,
			inflammation, allergy, tissue rejection,	NJ
			viral infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identified.
Human CCF18	GeneSeq Accession	WO9721812	Chemokines are a family of related	Chemokine activities can be	Abnormal physiology
chemokine	W25942		small, secreted proteins involved in	determined using assays known in the	and development
			biological processes ranging from	art: Methods in molecular Biology,	disorders, can also be
			hemotopoiesis, anglogenesis, and	2000, vol. 138: Chemokine	used as an anti-viral
			leukocyte trafficking. Members of this	Protocols, Edited by A. E. I. Proudfoot,	agent
			family are involved in a similarly	T. N. C. Wells, and C. A. Power
			diverse range of pathologies including	©Humana Press Inc., Totowa,
			inflammation, allergy, tissue rejection,	NJ
			viral infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identified.
Human beta-	GeneSeq Accession	WO9725427	Chemokines are a family of related	Chemokine activities can be	Chemotaxis,
chemokine	W26655		small, secreted proteins involved in	determined using assays known in the	blood-related disorders,
H1305 (MCP-2)			biological processes ranging from	art: Methods in molecular Biology,	viral infection, HIV,
			hemotopoiesis, anglogenesis, and	2000, vol. 138: Chemokine	wound healing, cancer
			leukocyte trafficking. Members of this	Protocols, Edited by A. E. I. Proudfoot,
			family are involved in a similarly	T. N. C. Wells, and C. A. Power
			diverse range of pathologies including	©Humana Press Inc., Totowa,
			inflammation, allergy, tissue rejection,	NJ
			viral infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identified.
Human	GeneSeq Accession	WO9712914	Chemokines are a family of related	Chemokine activities can be	Inflammatory and
eosinocyte CC	W14990		small, secreted proteins involved in	determined using assays known in the	immune disorders
type chemokine			biological processes ranging from	art: Methods in molecular Biology,
eotaxin			hemotopoiesis, anglogenesis, and	2000, vol. 138: Chemokine
			leukocyte trafficking. Members of this	Protocols, Edited by A. E. I. Proudfoot,
			family are involved in a similarly	T. N. C. Wells, and C. A. Power
			diverse range of pathologies including	©Humana Press Inc., Totowa,
			inflammation, allergy, tissue rejection,	NJ
			viral infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identified.
Human thymus	GeneSeq Accession	WO9711969	Chemokines are a family of related	Chemokine activities can be	Inflammatory and
and activation	W14018		small, secreted proteins involved in	determined using assays known in the	immune disorders
regulated			biological processes ranging from	art: Methods in molecular Biology,
cytokine			hemotopoiesis, anglogenesis, and	2000, vol. 138: Chemokine
(TARC)			leukocyte trafficking. Members of this	Protocols, Edited by A. E. I. Proudfoot,
			family are involved in a similarly	T. N. C. Wells, and C. A. Power
			diverse range of pathologies including	©Humana Press Inc., Totowa,
			inflammation, allergy, tissue rejection,	NJ
			viral infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identified.
Human	GeneSeq Accession	WO9712041	Chemokines are a family of related	Chemokine activities can be	Cancer, would healing,
chemokine beta-	W16315		small, secreted proteins involved in	determined using assays known in the	immune disorders
8 short forms			biological processes ranging from	art: Methods in molecular Biology,
			hemotopoiesis, anglogenesis, and	2000, vol. 138: Chemokine
			leukocyte trafficking. Members of this	Protocols, Edited by A. E. I. Proudfoot,
			family are involved in a similarly	T. N. C. Wells, and C. A. Power
			diverse range of pathologies including	©Humana Press Inc., Totowa,
			inflammation, allergy, tissue rejection,	NJ
			viral infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identified.
Microphage	GeneSeq Accession	WO9640923	Chemokines are a family of related	Chemokine activities can be	Inflammatory
derived	W20058		small, secreted proteins involved in	determined using assays known in	diseases, wound
chemokine, MDC			biological processes ranging from	the art: Methods in Molecular	healin,
			hermaatopoiesis, angiogenesis, and	Biology, 2000, vol. 138: Chemokine	angiogenesis
			leukocyte trafficking. Members of this	Protocols. Edited by: A. E. I. Proudfoot,
			family are involved in a similarly	T. N. C. Wells, and C. A. Power.
			diverse range of pathologies including	©Humana Press Inc.,
			inflammation, allergy, tissue rejection,	Totowa, NJ
			viral infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identified.
Human chemokine	GeneSeq Accession	WO9844117	Chemokines are a family of related	Chemokine activities can be	Inflammatory and
ZSIG-35	W30565		small, secreted proteins involved in	determined using assays known in	immune diseases
			biological processes ranging from	the art: Methods in Molecular
			hematopoiesis, angiogenesis, and	Biology, 2000, vol. 138: Chemokine
			leukocyte trafficking. Members of this	Protocols. Edited by: A. E. I. Proudfoot,
			family are involved in a similarly	T. N. C. Wells, and C. A. Power.
			diverse range of pathologies including	©Humana Press Inc.,
			inflammation, allergy, tissue rejection,	Totowa, NJ
			viral infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identified.
Primate CC	GeneSeq Accesssion	WO98328658	Chemokines are a family of related	Chemokine activities can be	Immune and
chemokine	W69990		small, secreted proteins involved in	determined using assays known in	inflammatory
“ILINCK”			biological processes ranging from	the art: Methods in Molecular	disorders,
			hematopoiesis, angiogenesis, and	Biology, 2000, vol. 138: Chemokine	abnormal
			leukocyte trafficking.	Protocols. Edited by: A. E. I. Prodfoot,	proliferation,
				T. N. C. Wells, and C. A. Power.	regeneration,
				©Humana Press Inc.,	generation and
				Totowa, NJ	atrophy disorders
Primate CXC	GeneSeq Accession	WO9832858	Chemokines are a family of related	Chemokine activities can be	Immune and
chemokine	W69989		small, secreted proteins involved in	determined using assays known in	inflammatory
“IBICK”			biological processes ranging from	the art: Methods in Molecular	disorders,
			hematopoiesis, angiogenesis, and	Biology, 2000, vol. 138: Chemokine	abnormal
			leukocyte trafficking. Members of this	Protocols. Editd by: A. E. I. Proudfoot,	proliferation,
			family are involved in a similarly	T. N. C. Wells, and C. A. Power.	regeneration,
			diverse range of pathologies including	©Humana Press Inc.,	generation and
			inflammation, allergy, tissue rejection,	Totowa, NJ	atrophy disorders
			viral infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identified.
Human CC-type	GeneSeq Accession	WO9831809	Chemokines are a family of related	Chemokine activities can be	Immune,
chemokine protein	W69163		small, secreted proteins involved in	determined using assays known in	inflammatory, and
designated SLC			biological processes ranging from	the art: Methods in Molecular	infectious
(secondary			hematopoiesis, angiogenesis, and	Biology, 2000, vol. 138: Chemokine	disorders, cancer
lymphoid			leukocyte trafficking. Members of this	Protocols. Edited by: A. E. I. Proudfoot,
chemokine)			family are involved in a similarly	T. N. C. Wells, and C. A. Power.
			diverse range of pathologies including	©Humana Press Inc.,
			inflammation, allergy, tissue rejection,	Totowa, NJ
			viral infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identified.
Human CC	GeneSeq Accession	WO9826071	Chemokines are a family of related	Chemokine activities can be	Cancer and
chemokine ELC	W62542		small, secreted proteins involved in	determined using assays known in	infectious
protein			biological processes ranging from	the art: Methods in Molecular	diseases,
			hematopoiesis, angiogenesis, and	Biology, 2000, vol. 138: Chemokine	particularly
			leukocyte trafficking. Members of this	Protocols. Edited by: A. E. I. Proudfoot,	herpes virus
			family are involved in a similarly	T. N. C. Wells, and C. A. Power.
			diverse range of pathologies including	©Humana Press Inc.,
			inflammation, allergy, tissue rejection,	Totowa, NJ
			viral infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identified.
Human DVic-1	GeneSeq Accession	Wo9823750	Chemokines are a family of related	Chemokine activities can be	Abnormal
C-C chemokine	W60649		small, secreted proteins involved in	determined using assays known in	proliferation,
			biological processes ranging from	the art: Methods in Molecular	regeneration,
			hematopoiesis, angiogenesis, and	Biology, 2000, vol. 138: Chemokine	degeneration, and
			leukocyte trafficking. Members of this	Protocols. Edited by: A. E. I. Proudfoot,	atrophy disorders,
			family are involved in a similarly	T. N. C. Wells, and C. A. Power.	including cancer
			diverse range of pathologies including	©Humana Press Inc.,
			inflammation, allergy, tissue rejection,	Totowa, NJ
			viral infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identified.
Human C-C	GeneSeq Accession	WO9823750	Chemokines are a family of related	Chemokine activities can be	Immune
chemokine	W60650		small, secreted proteins involved in	determined using assays known in	disorders, cell
DGWCC			biological processes ranging from	the art: Methods in Molecular	proliferation
			hematophoiesis, angiogenesis, and	Biology, 2000, vol. 138: Chemokine	disorders, cancer
			leukocyte trafficking. Members of this	Protocols. Edited by: A. E. I. Proudfoot,
			family are involved in a similarly	T. N. C. Wells, and C. A. Power.
			diverse range of pathologies including	©Humana Press Inc.,
			inflammation, allergy, tissue rejection,	Totowa, NJ
			viral infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identifed.
Human STCP-1	GeneSeq Accession	WO9824907	Chemokines are a family of related	Chemokine activities can be	Immune
	W62783		small, secreted proteins involved in	determined using assays known in	disorders,
			biological processes ranging from	the art: Methods in Molecular	particularly T cell
			hematopoiesis, angiogenesis, and	Biology, 2000, vol. 138: Chemokine	related disorders,
			leukocyte trafficking. Members of this	Protocols. Edited by: A. E. I. Proudfoot,	viral infection,
			family are involved in a similarly	T. N. C. Wells, and C. A. Power.	and inflammation,
			diverse range of pathologies including	©Humana Press Inc.,	especially joint
			inflammation, allergy, tissue rejection,	Totowa, NJ
			viral infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identified.
Exodua protein	GeneSeq Accession	WO9821330	Chamokines are a family of related	Chemokine activities can be	Immune and
	W61279		small, secreted proteins involved in	determined using assays known in	inflammatory
			biological processes ranging from	the art: Methods in Molecular	disorders,
			hematopoiesis, angiogenesis, and	Biology, 2000, vol. 138: Chemokine	angiogenesis,
			leukocyte trafficking. Members of this	Protocols. Edited by: A. E. I. Proudfoot,	cancer, and
			family are involved in a similarly	T. N. C. Wells, and C. A. Power.	proliferation
			diverse range of pathologies including	©Humana Press Inc.,	disorders,
			inflammation, allergy, tissue rejection,	Totowa, NJ	particularly
			viral infection, and tumor biology. The		myeloproliferative
			chemokines exert their effects by acting		diseases
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identified.
Human	GeneSeq Acession	WO9814581	Chemokines are a family of related	Chemokine activities can be	Cancer and degenerative
Chr19Kine	W50887		small, secreted proteins involved in	determined using assays known in	disorders
protein			biological processes ranging from	the art: Methods in Molecular
			hematopoiesis, angiogenesis, and	Biology, 2000, vol. 138:
			leukocyte trafficking. Members of this	Chemokine Protocols, Edited by:
			family are involved in a similarly	A. E. I. Proudfoot, T. N. C. Wells, and
			diverse range of pathologies including	C. A. Power. ©Humana Press Inc.,
			inflammation, allergy, tissue rejection,	Totowa, NJ
			viral infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identified.
Human T cell	GeneSeq Accession	U.S. Pat. No. 5,780,268	Chemokines area family of related	Chemokine activities can be	Immune, inflammatory,
mixed	W58703		small, secreted proteins involved in	determined using assays known in the	and infectious disorders,
lymphocyte			biological processes ranging from	art: Mehtods of Molecular Biology,	cancer
reaction			hematopoiesis, angiogenesis, and	2000, vol. 138: Chemokine
expressed			leukocyte trafficking. Members of this	Protocols. Edited by: A. E. I. Proudfoot,
chemokine			family are involved in a similarly	T. N. C. Wells, and C. A. Power
(TMEC)			diverse range of pathologies including	©Humana Press Inc., Totowa,
			inflammation, allergy, tissue rejection,	NJ
			viral infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identified.
Human 6CKine	GeneSeq Accession	W09814581	Chemokines area family of related	Chemokine activities can be	Cancer and degenerative
protein	W50885		small, secreted proteins involved in	determined using assays known in the	disorders
			biological processes ranging from	art: Mehtods of Molecular Biology,
			hematopoiesis, angiogenesis, and	2000, vol. 138: Chemokine
			leukocyte trafficking. Members of this	Protocols. Edited by: A. E. I. Proudfoot,
			family are involved in a similarly	T. N. C. Wells, and C. A. Power
			diverse range of pathologies including	©Humana Press Inc., Totowa,
			inflammation, allergy, tissue rejection,	NJ
			viral infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identified.
human liver and	GeneSeq Accession	WO9817800	Chemokines area family of related	Chemokine activities can be	Immune, inflammatory,
activation	W57475		small, secreted proteins involved in	determined using assays known in the	and infectious disorders,
regulated			biological processes ranging from	art: Mehtods of Molecular Biology,	cancer
chemokine			hematopoiesis, angiogenesis, and	2000, vol. 138: Chemokine
(LARC)			leukocyte trafficking. Members of this	Protocols. Edited by: A. E. I. Proudfoot,
			family are involved in a similarly	T. N. C. Wells, and C. A. Power
			diverse range of pathologies including	©Humana Press Inc., Totowa,
			inflammation, allergy, tissue rejection,	NJ
			viral infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identified.
RANTES	GeneSeq Accession	WO9744462	Chemokines area family of related	Chemokine activities can be	Infectious diseases,
peptide	W29538		small, secreted proteins involved in	determined using assays known in the	particularly HIV
			biological processes ranging from	art: Mehtods of Molecular Biology,
			hematopoiesis, angiogenesis, and	2000, vol. 138: Chemokine
			leukocyte trafficking. Members of this	Protocols. Edited by: A. E. I. Proudfoot,
			family are involved in a similarly	T. N. C. Wells, and C. A. Power
			diverse range of pathologies including	©Humana Press Inc., Totowa,
			inflammation, allergy, tissue rejection,	NJ
			viral infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identified.
RANTES 8-68	GeneSeq Accession	WO9744462	Chemokines area family of related	Chemokine activities can be	Infectious diseases,
	W29529		small, secreted proteins involved in	determined using assays known in the	particularly HIV
			biological processes ranging from	art: Mehtods of Molecular Biology,
			hematopoiesis, angiogenesis, and	2000, vol. 138: Chemokine
			leukocyte trafficking. Members of this	Protocols. Edited by: A. E. I. Proudfoot,
			family are involved in a similarly	T. N. C. Wells, and C. A. Power
			diverse range of pathologies including	©Humana Press Inc., Totowa,
			inflammation, allergy, tissue rejection,	NJ
			viral infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identified.
RANTES 9-68	GeneSeq Accession	WO9744462	Chemokines area family of related	Chemokine activities can be	Infectious diseases,
	W29528		small, secreted proteins involved in	determined using assays known in the	particularly HIV
			biological processes ranging from	art: Mehtods of Molecular Biology,
			hematopoiesis, angiogenesis, and	2000, vol. 138: Chemokine
			leukocyte trafficking. Members of this	Protocols. Edited by: A. E. I. Proudfoot,
			family are involved in a similarly	T. N. C. Wells, and C. A. Power
			diverse range of pathologies including	©Humana Press Inc., Totowa,
			inflammation, allergy, tissue rejection,	NJ
			viral infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identified.
Human	GeneSeq Accession	WO9811226	Chemokines area family of related	Chemokine activities can be	Abnormal proliferation,
chemokine	W59433		small, secreted proteins involved in	determined using assays known in the	regeneration,
protein 331D5			biological processes ranging from	art: Mehtods of Molecular Biology,	degeneration or atrophy,
			hematopoiesis, angiogenesis, and	2000, vol. 138: Chemokine	including cancer
			leukocyte trafficking. Members of this	Protocols. Edited by: A. E. I. Proudfoot,
			family are involved in a similarly	T. N. C. Wells, and C. A. Power
			diverse range of pathologies including	©Humana Press Inc., Totowa,
			inflammation, allergy, tissue rejection,	NJ
			viral infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identified.
Human	GeneSeq Accession	WO9811226	Chemokines area family of related	Chemokine activities can be	Abnormal proliferation,
chemokine	W59430		small, secreted proteins involved in	determined using assays known in the	regeneration,
protein 61164			biological processes ranging from	art: Mehtods of Molecular Biology,	degeneration or atrophy,
			hematopoiesis, angiogenesis, and	2000, vol. 138: Chemokine	including cancer
			leukocyte trafficking. Members of this	Protocols. Edited by: A. E. I. Proudfoot,
			family are involved in a similarly	T. N. C. Wells, and C. A. Power
			diverse range of pathologies including	©Humana Press Inc., Totowa,
			inflammation, allergy, tissue rejection,	NJ
			viral infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identified.
Chemokine	GeneSeq Accession	WO9809171	Chemokines area family of related	Chemokine activities can be	Immune, Inflammatory,
MCP-4	W56690		small, secreted proteins involved in	determined using assays known in the	and infectious diseases
			biological processes ranging from	art: Mehtods of Molecular Biology,
			hematopoiesis, angiogenesis, and	2000, vol. 138: Chemokine
			leukocyte trafficking. Members of this	Protocols. Edited by: A. E. I. Proudfoot,
			family are involved in a similarly	T. N. C. Wells, and C. A. Power
			diverse range of pathologies including	©Humana Press Inc., Totowa,
			inflammation, allergy, tissue rejection,	NJ
			viral infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identified.
Human stromal	GeneSeq Accession	FR2751658	Chemokines are a family of related	Chemokine activities can be	HIV infections
cell-derived	W50766		small, secreted proteins involved in	determined using assays known in
chemokine, SDF-1			biological processes ranging from	the art: Methods in Molecular
			hematopoiesis, angiogenesis, and	Biology, 2000, vol. 138: Chemokine
			leukocyte trafficking. Members of this	Protocols. Edited by: A. E. I. Proudfoot,
			family are involved in a similarly	T. N. C. Wells, and C. A. Power.
			diverse range of pathologies including	©Humana Press Inc.,
			inflammation, allergy, tissue rejection,	Totowa, NJ
			viral infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identified.
Thymus expressed	GeneSeq Accession	WO9801557	Chemokines are a family of related	Chemokine activities can be	Immune and
chemokine	W44397		small, secreted proteins involved in	determined using assays known in the	inflammatory disorders
(TECK)			biological processes ranging from	art: Methods in Molecular Biology,
			hematopoiesis, angiogenesis, and	2000, vol. 138: Chemokine Protocols.
			leukocyte trafficking. Members of this	Edited by: A. E. I. Proudfoot, T. N. C. Wells,
			family are involved in a similarly	and C. A. Power. ©Humana
			diverse range of pathologies including	Press Inc., Totowa, NJ
			inflammation, allergy, tissue rejection,
			viral infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identified.
Human chemokine	GeneSeq Accession	WO9801557	Chemokines are a family of related	Chemokine activities can be	Immune and
MIP-3alpha	W44398		small, secreted proteins involved in	determined using assays known in the	inflammatory disorders
			biological processes ranging from	art: Methods in Molecular Biology,
			hematopoiesis, angiogenesis, and	2000, vol. 138: Chemokine Protocols.
			leukocyte trafficking. Members of this	Edited by: A. E. I. Proudfoot, T. N. C. Wells,
			family are involved in a similarly	and C. A. Power. ©Humana
			diverse range of pathologies including	Press Inc., Totowa, NJ
			inflammation, allergy, tissue rejection,
			viral infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identified.
Human chemokine	GeneSeq Accession	WO9801557	Chemokines are a family of related	Chemokine activities can be	Immune and
MIP-3beta	W44399		small, secreted proteins involved in	determined using assays known in the	inflammatory disorders
			biological processes ranging from	art: Methods in Molecular Biology,
			hematopoiesis, angiogenesis, and	2000, vol. 138: Chemokine Protocols.
			leukocyte trafficking. Members of this	Edited by: A. E. I. Proudfoot, T. N. C. Wells,
			family are involved in a similarly	and C. A. Power. ©Humana
			diverse range of pathologies including	Press Inc., Totowa, NJ
			inflammation, allergy, tissue rejection,
			viral infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identified.
Human monocyte	GeneSeq Accession	WO9802459	Chemokines are a family of related	Chemokine activities can be	Immune disorders,
chemotactic	W42072		small, secreted proteins involved in	determined using assays known in the	respiratory disorders,
proprotein (MCPP)			biological processes ranging from	art: Methods in Molecular Biology,	cancer
sequence			hematopoiesis, angiogenesis, and	2000, vol. 138: Chemokine Protocols.
			leukocyte trafficking. Members of this	Edited by: A. E. I. Proudfoot, T. N. C. Wells,
			family are involved in a similarly	and C. A. Power. ©Humana
			diverse range of pathologies including	Press Inc., Totowa, NJ
			inflammation, allergy, tissue rejection,
			viral infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identified.
Macrophage-	GeneSeq Accessions	U.S. Pat. No. 5,688,927/	Chemokines are a family of related	Chemokine activities can be	Immune, and
derived chemokine	W40811 and	U.S. Pat. No. 5,932,703	small, secreted proteins involved in	determined using assays known in the	inflammatory disorders,
(MDC)	Y24414		biological processes ranging from	art: Methods in Molecular Biology,	cancer
			hematopoiesis, angiogenesis, and	2000, vol. 138: Chemokine Protocols.
			leukocyte trafficking. Members of this	Edited by: A. E. I. Proudfoot, T. N. C. Wells,
			family are involved in a similarly	and C. A. Power. ©Humana
			diverse range of pathologies including	Press Inc., Totowa, NJ
			inflammation, allergy, tissue rejection,
			viral infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identified.
Macrophage	GeneSeq Accession	U.S. Pat. No. 5,932,703	Chemokines are a family of related	Chemokine activities can be	Immune and
derived chemokine	Y24416		small, secreted proteins involved in	determined using assays known in the	inflammatory disorders
analogue MDC-			biological processes ranging from	art: Methods in Molecular Biology,
eyfy			hematopoiesis, angiogenesis, and	2000, vol. 138: Chemokine Protocols.
			leukocyte trafficking. Members of this	Edited by: A. E. I. Proudfoot, T. N. C. Wells,
			family are involved in a similarly	and C. A. Power. ©Humana
			diverse range of pathologies including	Press Inc., Totowa, NJ
			inflammation, allergy, tissue rejection,
			viral infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identified.
Macrophage	GeneSeq Accession	U.S. Pat. No. 5,932,703	Chemokines are a family of related	Chemokine activities can be	Immune and
derived chemokine	Y24413		small, secreted proteins involved in	determined using assays known in the	inflammatory disorders
analogue MDC			biological processes ranging from	art: Methods in Molecular Biology,
(n + 1)			hematopoiesis, angiogenesis, and	2000, vol. 138: Chemokine Protocols.
			leukocyte trafficking. Members of this	Edited by: A. E. I. Proudfoot, T. N. C. Wells,
			family are involved in a similarly	and C. A. Power. ©Humana
			diverse range of pathologies including	Press Inc., Totowa, NJ
			inflammation, allergy, tissue rejection,
			viral infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identified.
Macrophage	GeneSeq Accession	U.S. Pat. No. 5,932,703	Chemokines are a family of related	Chemokine activities can be	Immune and
derived chemokine	Y24415		small, secreted proteins involved in	determined using assays known in the	inflammatory disorders
analogue MDC-yl			biological processes ranging from	art: Methods in Molecular Biology,
			hematopoiesis, angiogenesis, and	2000, vol. 138: Chemokine Protocols.
			leukocyte trafficking. Members of this	Edited by: A. E. I. Proudfoot, T. N. C. Wells,
			family are involved in a similarly	and C. A. Power. ©Humana
			diverse range of pathologies including	Press Inc., Totowa, NJ
			inflammation, allergy, tissue rejection,
			viral infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identified.
Human type CC	GeneSeq Accession	JP11243960	Chemokines are a family of related	Chemokine activities can be	Allergic diseases and
chemokine eotaxin	Y43178		small, secreted proteins involved in	determined using assays known in the	HIV infection
3 protein sequence			biological processes ranging from	art: Methods in Molecular Biology,
			hematopoiesis, angiogenesis, and	2000, vol. 138: Chemokine Protocols.
			leukocyte trafficking. Members of this	Edited by: A. E. I. Proudfoot, T. N. C. Wells,
			family are involved in a similarly	and C. A. Power. ©Humana
			diverse range of pathologies including	Press Inc., Totowa, NJ
			inflammation, allergy, tissue rejection,
			viral infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identified.
Human MCP-3	GeneSeq Acession	WO9946392	Chemokines are a family of related	Chemokine activities can be	Cancer and immune
and human Muc-1	Y29893		small, secreted proteins involved in	determined using assays known in	disorders, particularly
core epitope			biological processes ranging from	the art: Methods in Molecular	HIV infection
(VNT) fusion			hematopoiesis, angiogenesis, and	Biology, 2000, vol. 138: Chemokine
protein			leukocyte trafficking. Members of this	Protocols. Edited by: A. E. I. Proudfoot,
			family are involved in a similarily	T. N. C. Wells, and C. A. Power.
			diverse range of pathologies including	©Humana Press Inc.,
			inflammation, allergy, tissue rejection,	Totowa, NJ
			viral infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identified.
Human IP-10 and	GeneSeq Accession	WO9946392	Chemokines are a family of related	Chemokine activities can be	Cancer and immune
human Muc-1 core	Y29894		small, secreted proteins involved in	determined using assays known in the	disorders, particularly
epitope (VNT)			biological processes ranging from	art: Methods in Molecular Biology,	HIV infection
fusion protein			hematopoiesis, angiogenesis, and	2000, vol. 138: Chemokine Protocols.
			leukocyte trafficking. Members of this	Edited by: A. E. I. Proudfoot, T. N. C. Wells,
			family are involved in a similarily	and C. A. Power. ©Humana
			diverse range of pathologies including	Press Inc., Totowa, NJ
			inflammation, allergy, tissue rejection,
			viral infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identified.
Human IP-10 and	GeneSeq Accession	W09946392	Chemokines are a family of related	Chemokine activities can be	Cancer and immune
HIV-1 gp 120	Y29897		small, secreted proteins involved in	determined using assays known in the	disorders, particularly
hypervariable			biological processes ranging from	art: Methods in Molecular Biology,	HIV infection
region fusion			hematopoiesis, angiogenesis, and	2000, vol. 138: Chemokine Protocols.
protein			leukocyte trafficking. Members of this	Edited by: A. E. I. Proudfoot, T. N. C. Wells,
			family are involved in a similarily	and C. A. Power. ©Humana
			diverse range of pathologies including	Press Inc., Totowa, NJ
			inflammation, allergy, tissue rejection,
			viral infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identified.
Human mammary	GeneSeq Accessions	WO9936540	Chemokines are a family of related	Chemokine activities can be	Breast disease,
associated	Y29092 and		small, secreted proteins involved in	determined using assays known in the	including cancer
chemokine	Y29093		biological processes ranging from	art: Methods in Molecular Biology,
(MACK) protein			hematopoiesis, angiogenesis, and	2000, vol. 138: Chemokine Protocols.
Full-Length and			leukocyte trafficking. Members of this	Edited by: A. E. I. Proudfoot, T. N. C. Wells,
Mature			family are involved in a similarily	and C. A. Power. ©Humana
			diverse range of pathologies including	Press Inc., Totowa, NJ
			inflammation, allergy, tissue rejection,
			viral infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identified.
Tim-1 protein	GeneSeq Accession	WO9933990	Chemokines are a family of related	Chemokine activities can be	Inflammation due to
	Y28290		small, secreted proteins involved in	determined using assays known in the	stimuli such as heart
			biological processes ranging from	art: Methods in Molecular Biology,	attacks and stroke,
			hematopoiesis, angiogenesis, and	2000, vol. 138: Chemokine Protocols.	infection, physical
			leukocyte trafficking. Members of this	Edited by: A. E. I. Proudfoot, T. N. C. Wells,	trauma, UV or ionizing
			family are involved in a similarily	and C. A. Power. ©Humana	radiation, burns,
			diverse range of pathologies including	Press Inc., Totowa, NJ	frostbite or corrosive
			inflammation, allergy, tissue rejection,		chemicals
			viral infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identified.
Human Lkn-1	GeneSeq Accessions	WO9928473 and	Chemokines are a family of related	Chemokine activities can be	HIV infection and
Full-Length and	Y17280, Y17274,	WO9928472	small, secreted proteins involved in	determined using assays known in the	cancer, particularly
Mature protein	Y17281, and		biological processes ranging from	art: Methods in Molecular Biology,	leukemia
	Y17275		hematopoiesis, angiogenesis, and	2000, vol. 138: Chemokine Protocols.
			leukocyte trafficking. Members of this	Edited by: A. E. I. Proudfoot, T. N. C. Wells,
			family are involved in a similarily	and C. A. Power. ©Humana
			diverse range of pathologies including	Press Inc., Totowa, NJ
			inflammation, allergy, tissue rejection,
			viral infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identified.
N-terminal	GeneSeq Accession	WO9920759	Chemokines are a family of related	Chemokine activities can be	Inhibit or stimulate
modified	Y05818		small, secreted proteins involved in	determined using assays known in the	angiogenesis, inhibit the
chemokine met-			biological processes ranging from	art: Methods in Molecular Biology,	binding of HIV
hSDF-1 alpha			hematopoiesis, angiogenesis, and	2000, vol. 138: Chemokine Protocols.
			leukocyte trafficking. Members of this	Edited by: A. E. I. Proudfoot, T. N. C. Wells,
			family are involved in a similarily	and C. A. Power. ©Humana
			diverse range of pathologies including	Press Inc., Totowa, NJ
			inflammation, allergy, tissue rejection,
			viral infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identified.
N-terminal	GeneSeq Accession	WO9920759	Chemokines are a family of related	Chemokine activities can be	Inhibit or stimulate
modified	Y05819		small, secreted proteins involved in	determined using assays known in the	angiogenesis, inhibit the
chemokine met-			biological processes ranging from	art: Methods in Molecular Biology,	binding of HIV,
hSDF-1 beta			hematopoiesis, angiogenesis, and	2000, vol. 138: Chemokine Protocols.	antiinflammatory;
			leukocyte trafficking. Members of this	Edited by: A. E. I. Proudfoot, T. N. C. Wells,	immunosuppressant
			family are involved in a similarily	and C. A. Power. ©Humana
			diverse range of pathologies including	Press Inc., Totowa, NJ
			inflammation, allergy, tissue rejection,
			viral infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identified.
N-terminal	GeneSeq Accession	WO9920759	Chemokines are a family of related	Chemokine activities can be	Inhibit or stimulate
modified	Y05820		small, secreted proteins involved in	determined using assays known in the	angiogenesis, inhibit the
chemokine			biological processes ranging from	art: Methods in Molecular Biology,	binding of HIV,
GroHEK/hSDF-			hematopoiesis, angiogenesis, and	2000, vol. 138: Chemokine Protocols.	antiinflammatory;
1alpha			leukocyte trafficking. Members of this	Edited by: A. E. I. Proudfoot, T. N. C. Wells,	immunosuppressant
			family are involved in a similarily	and C. A. Power. ©Humana
			diverse range of pathologies including	Press Inc., Totowa, NJ
			inflammation, allergy, tissue rejection,
			viral infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identified.
N-terminal	GeneSeq Accession	WO9920759	Chemokines are a family of related	Chemokine activities can be	Inhibit or stimulate
modified	Y05821		small, secreted proteins involved in	determined using assays known in the	angiogenesis, inhibit the
chemokine			biological processes ranging from	art: Methods in Molecular Biology,	binding of HIV,
GroHEK/hSDF-			hematopoiesis, angiogenesis, and	2000, vol. 138: Chemokine Protocols.	antiinflammatory;
1beta.			leukocyte trafficking. Members of this	Edited by: A. E. I. Proudfoot, T. N. C. Wells,	immunosuppressant
			family are involved in a similarily	and C. A. Power. ©Humana
			diverse range of pathologies including	Press Inc., Totowa, NJ
			inflammation, allergy, tissue rejection,
			viral infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identified.
Chemokine	GeneSeq Accession	WO9912968	Chemokines are a family of related	Chemokine activities can be	Increase or enhance an
Eotaxin	Y14230		small, secreted proteins involved in	determined using assays known in	inflammatory response,
			biological processes ranging from	the art: Methods in Molecular	an immune response
			hematopoiesis, agiogenesis, and	Bilogy, 2000, vol. 138: Chemokine	orhaematopoietic cell-
			leukocye trafficking. Members of this	Protocols. Edited by: A. E. I. Proudfoot,	associated activity; treat
			family are involved in a similarly	T. N. C. Wells, and C. A. Power.	a vascular indication;
			diverse range of pathologies including	©Humana Press Inc.,	Cancer; enhance wound
			inflammation, allergy, tissue rejection,	Totowa, NJ	healing, to prevent or
			viralk infection, and tumor biology. The		treat asthma, organ
			chemokines exert their effects by acting		transplant rejction,
			on a family of seven transmembrane G-		rheumatoid arthritis or
			protein-coupled receptors. Over 40		allergy
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identified.
Chemokine	GeneSeq Accession	WO9912968	Chemokines are a family of related	Chemokine activities can be	Immune disorders,
hMCP1a	Y14225		small, secreted proteins involved in	determined using assays known in	Vascular disorders,
			biological processes ranging from	the art: Methods in Molecular	Wound healing, cancer,
			hematopoiesis, agiogenesis, and	Bilogy, 2000, vol. 138: Chemokine	prevent organ transplant
			leukocye trafficking. Members of this	Protocols. Edited by: A. E. I. Proudfoot,	rejection, Increase or
			family are involved in a similarly	T. N. C. Wells, and C. A. Power.	enhance an
			diverse range of pathologies including	©Humana Press Inc.,	inflammatory response,
			inflammation, allergy, tissue rejection,	Totowa, NJ
			viralk infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identified.
Chemokine	GeneSeq Accession	WO9912968	Chemokines are a family of related	Chemokine activities can be	Immune disorders,
hMCP1b	Y14226		small, secreted proteins involved in	determined using assays known in	Vascular disorders,
			biological processes ranging from	the art: Methods in Molecular	Wound healing, cancer,
			hematopoiesis, agiogenesis, and	Bilogy, 2000, vol. 138: Chemokine	prevent organ transplant
			leukocye trafficking: Members of this	Protocols. Edited by: A. E. I. Proudfoot,	rejection, Increase or
			family are involved in a similarly	T. N. C. Wells, and C. A. Power.	enhance an
			diverse range of pathologies including	©Humana Press Inc.,	inflammatory response,
			inflammation, allergy, tissue rejection,	Totowa, NJ
			viralk infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identified.
Chemokine	GeneSeq Accession	WO9912968	Chemokines are a family of related	Chemokine activities can be	Immune disorders,
hSDF1b	Y14228		small, secreted proteins involved in	determined using assays known in	Vascular disorders,
			biological processes ranging from	the art: Methods in Molecular	Wound healing, cancer,
			hematopoiesis, agiogenesis, and	Bilogy, 2000, vol. 138: Chemokine	prevent organ transplant
			leukocye trafficking. Members of this	Protocols. Edited by: A. E. I. Proudfoot,	rejection, Increase or
			family are involved in a similarly	T. N. C. Wells, and C. A. Power.	enhance an
			diverse range of pathologies including	©Humana Press Inc.,	inflammatory response,
			inflammation, allergy, tissue rejection,	Totowa, NJ
			viralk infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identified.
Chemokine	GeneSeq Accession	WO9912968	Chemokines are a family of related	Chemokine activities can be	Immune disorders,
hIL-8	Y14229		small, secreted proteins involved in	determined using assays known in	Vascular disorders,
			biological processes ranging from	the art: Methods in Molecular	Wound healing, cancer,
			hematopoiesis, agiogenesis, and	Bilogy, 2000, vol. 138: Chemokine	prevent organ transplant
			leukocye trafficking. Members of this	Protocols. Edited by: A. E. I. Proudfoot,	rejection, Increase or
			family are involved in a similarly	T. N. C. Wells, and C. A. Power.	enhance an
			diverse range of pathologies including	©Humana Press Inc.,	inflammatory response,
			inflammation, allergy, tissue rejection,	Totowa, NJ; and Holmes et al (1991)
			viralk infection, and tumor biology. The	Science 253, 1278-80.
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identified.
Chemokine	GeneSeq Accession	WO9912968	Chemokines are a family of related	Chemokine activities can be	Immune disorders,
hMCP1	Y14222		small, secreted proteins involved in	determined using assays known in	Vascular disorders,
			biological processes ranging from	the art: Methods in Molecular	Wound healing, cancer,
			hematopoiesis, agiogenesis, and	Bilogy, 2000, vol. 138: Chemokine	prevent organ transplant
			leukocye trafficking. Members of this	Protocols. Edited by: A. E. I. Proudfoot,	rejection, Increase or
			family are involved in a similarly	T. N. C. Wells, and C. A. Power.	enhance an
			diverse range of pathologies including	©Humana Press Inc.,	inflammatory response,
			inflammation, allergy, tissue rejection,	Totowa, NJ
			viralk infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identified.
Chemokine	GeneSeq Accession	WO9912968	Chemokines are a family of related	Chemokine activities can be	Immune disorders,
hMCP2	Y14223		small, secreted proteins involved in	determined using assays known in	Vascular disorders,
			biological processes ranging from	the art: Methods in Molecular	Wound healing, cancer,
			hematopoiesis, agiogenesis, and	Bilogy, 2000, vol. 138: Chemokine	prevent organ transplant
			leukocye trafficking. Members of this	Protocols. Edited by: A. E. I. Proudfoot,	rejection, Increase or
			family are involved in a similarly	T. N. C. Wells, and C. A. Power.	enhance an
			diverse range of pathologies including	©Humana Press Inc.,	inflammatory response,
			inflammation, allergy, tissue rejection,	Totowa, NJ
			viralk infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identified.
Chemokine	GeneSeq Accession	WO9912968	Chemokines are a family of related	Chemokine activities can be	Immune disorders,
hMCP3	Y14224		small, secreted proteins involved in	determined using assays known in	Vascular disorders,
			biological processes ranging from	the art: Methods in Molecular	Wound healing, cancer,
			hematopoiesis, agiogenesis, and	Bilogy, 2000, vol. 138: Chemokine	prevent organ transplant
			leukocye trafficking. Members of this	Protocols. Edited by: A. E. I. Proudfoot,	rejection, Increase or
			family are involved in a similarly	T. N. C. Wells, and C. A. Power.	enhance an
			diverse range of pathologies including	©Humana Press Inc.,	inflammatory response,
			inflammation, allergy, tissue rejection,	Totowa, NJ
			viralk infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identified.
C-C chemokine,	GeneSeq Accession	EP905240	Chemokines are a family of related	Chemokine activities can be	Inflammatory, Immune
MCP2	Y05300		small, secreted proteins involved in	determined using assays known in	and infectious diseases;
			biological processes ranging from	the art: Methods in Molecular	pulmonary diseases and
			hematopoiesis, agiogenesis, and	Bilogy, 2000, vol. 138: Chemokine	skin disorders; tumours,
			leukocye trafficking. Members of this	Protocols. Edited by: A. E. I. Proudfoot,	and angiogenesis-and
			family are involved in a similarly	T. N. C. Wells, and C. A. Power.	haematopoiesis-related
			diverse range of pathologies including	©Humana Press Inc.,	diseases
			inflammation, allergy, tissue rejection,	Totowa, NJ
			viralk infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identified.
Wild type	GeneSeq Accession	EP906954	Chemokines are a family of related	Chemokine activities can be	Inflammatory, Immume
monocyte	Y07233		small, secreted proteins involved in	determined using assays known in	and infectious diseases;
chemotactic			biological processes ranging from	the art: Methods in Molecular	pulmonary diseases and
protein 2			hematopoiesis, agiogenesis, and	Bilogy, 2000, vol. 138: Chemokine	skin disorders; tumours,
			leukocye trafficking. Members of this	Protocols. Edited by: A. E. I. Proudfoot,	and angiogenesis-and
			family are involved in a similarly	T. N. C. Wells, and C. A. Power.	haematopoiesis-related
			diverse range of pathologies including	©Humana Press Inc.,	diseases
			inflammation, allergy, tissue rejection,	Totowa, NJ
			viralk infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identified.
Truncated	GeneSeq Accession	EP906954	Chemokines area family of related small,	Chemokines activities can be	Inflammatory, immune
monocyte	Y07234		secreted proteins involved in biological	determined using assays known in the	and infectious diseases;
chemotactic			processes ranging from hematopoiesis,	art: Methods in Molecular Biology,	pulmonry diseases and
protein 2 (6-76)			angiogenesis, and leukocyte trafficking.	2000, vol. 138: Chemokine	skin disorders; tumours,
			Members of this family are involved in a	Protocols. Edited by: A. E. I. Proudfoot,	and angiogenesis-and
			similarly diverse range of pathologies	T. N. C. Wells, and C. A. Power,	haematopoiesis-related
			including inflammation, allergy, tissue	Humana Press Inc., Totowa,	diseases
			rejection, viral infection, and tumor	NJ
			biology. The chemokines exert their
			effects by acting on a fmaily of seven
			transmembrane G-protein-coupled
			receptors. Over 40 human chemokines
			have been described, which bind to ~17
			receptors thus far identified.
Truncated	GeneSeq Accessions	EP905241;	Chemokines area family of related small,	Chemokines activities can be	Inflammatory, immune
RANTES	Y07236 and	EP906954	secreted proteins involved in biological	determined using assays known in the	and infectious diseases;
protein (3-68)	Y07232		processes ranging from hematopoiesis,	art: Methods in Molecular Biology,	pulmonry diseases and
			angiogenesis, and leukocyte trafficking.	2000, vol. 138: Chemokine	skin disorders; tumours,
			Members of this family are involved in a	Protocols. Edited by: A. E. I. Proudfoot,	and angiogenesis-and
			similarly diverse range of pathologies	T. N. C. Wells, and C. A. Power,	haematopoiesis-related
			including inflammation, allergy, tissue	Humana Press Inc., Totowa,	diseases
			rejection, viral infection, and tumor	NJ
			biology. The chemokines exert their
			effects by acting on a fmaily of seven
			transmembrane G-protein-coupled
			receptors. Over 40 human chemokines
			have been described, which bind to ~17
			receptors thus far identified.
Wild type	GeneSeq Accession	EP905241	Chemokines area family of related small,	Chemokines activities can be	Inflammatory, immune
monocyte	Y07237		secreted proteins involved in biological	determined using assays known in the	and infectious diseases;
chemotactic			processes ranging from hematopoiesis,	art: Methods in Molecular Biology,	pulmonry diseases and
protein 2			angiogenesis, and leukocyte trafficking.	2000, vol. 138: Chemokine	skin disorders; tumours,
			Members of this family are involved in a	Protocols. Edited by: A. E. I. Proudfoot,	and angiogenesis-and
			similarly diverse range of pathologies	T. N. C. Wells, and C. A. Power,	haematopoiesis-related
			including inflammation, allergy, tissue	Humana Press Inc., Totowa,	diseases
			rejection, viral infection, and tumor	NJ
			biology. The chemokines exert their
			effects by acting on a fmaily of seven
			transmembrane G-protein-coupled
			receptors. Over 40 human chemokines
			have been described, which bind to ~17
			receptors thus far identified.
Truncated	GeneSeq Accession	EP905241	Chemokines area family of related small,	Chemokines activities can be	Inflammatory, immune
monocyte	Y07238		secreted proteins involved in biological	determined using assays known in the	and infectious diseases;
chemotactic			processes ranging from hematopoiesis,	art: Methods in Molecular Biology,	pulmonry diseases and
protein 2 (6-76)			angiogenesis, and leukocyte trafficking.	2000, vol. 138: Chemokine	skin disorders; tumours,
			Members of this family are involved in a	Protocols. Edited by: A. E. I. Proudfoot,	and angiogenesis-and
			similarly diverse range of pathologies	T. N. C. Wells, and C. A. Power,	haematopoiesis-related
			including inflammation, allergy, tissue	Humana Press Inc., Totowa,	diseases
			rejection, viral infection, and tumor	NJ
			biology. The chemokines exert their
			effects by acting on a fmaily of seven
			transmembrane G-protein-coupled
			receptors. Over 40 human chemokines
			have been described, which bind to ~17
			receptors thus far identified.
A partial	GeneSeq Accession	EP897980	Chemokines area family of related small,	Chemokines activities can be	Soluble CXCR4B
CXCR4B	W97363		secreted proteins involved in biological	determined using assays known in the	receptor polypeptides
protein			processes ranging from hematopoiesis,	art: Methods in Molecular Biology,	may be useful for
			angiogenesis, and leukocyte trafficking.	2000, vol. 138: Chemokine	inhibiting chemokine
			Members of this family are involved in a	Protocols. Edited by: A. E. I. Proudfoot,	activities and viral
			similarly diverse range of pathologies	T. N. C. Wells, and C. A. Power,	infection.
			including inflammation, allergy, tissue	Humana Press Inc., Totowa,
			rejection, viral infection, and tumor	NJ
			biology. The chemokines exert their
			effects by acting on a family of seven
			transmembrane G-protein-coupled
			receptors. Over 40 human chemokines
			have been described, which bind to ~17
			receptors thus far identified.
Interferon	GeneSeq Accession	U.S. Pat. No. 5,871,723	Chemokines area family of related small,	Chemokines activities can be	Angiogenesis, Cancer,
gamma-	W96709		secreted proteins involved in biological	determined using assays known in the	Inflammatory and
inducible			processes ranging from hematopoiesis,	art: Methods in Molecular Biology,	Immune disorders,
protein (IP-10)			angiogenesis, and leukocyte trafficking.	2000, vol. 138: Chemokine	Cardio-Vascular
			Members of this family are involved in a	Protocols. Edited by: A. E. I. Proudfoot,	discorders, Musco-
			similarly diverse range of pathologies	T. N. C. Wells, and C. A. Power,	skeletal disorders
			including inflammation, allergy, tissue	Humana Press Inc., Totowa,
			rejection, viral infection, and tumor	NJ
			biology. The chemokines exert their
			effects by acting on a fmaily of seven
			transmembrane G-protein-coupled
			receptors. Over 40 human chemokines
			have been described, which bind to ~17
			receptors thus far identified.
A monokine	GeneSeq Accession	U.S. Pat. No. 5,871,723	Chemokines area family of related small,	Chemokines activities can be	Angiogenesis, Cancer,
induced by	W96710		secreted proteins involved in biological	determined using assays known in the	Inflammatory and
gamma-			processes ranging from hematopoiesis,	art: Methods in Molecular Biology,	Immune disorders,
interferon			angiogenesis, and leukocyte trafficking.	2000, vol. 138: Chemokine	Cardio-Vascular
(MIG)			Members of this family are involved in a	Protocols. Edited by: A. E. I. Prougfoot;	discorders, Musco-
			similarly diverse range of pathologies	T. N. C. Wells, and C. A. Power,	skeletal disorders
			including inflammation, allergy, tissue	Humana Press Inc., Totowa,
			rejection, viral infection, and tumor	NJ
			biology. The chemokines exert their
			effects by acting on a fmaily of seven
			transmembrane G-protein-coupled
			receptors. Over 40 human chemokines
			have been described, which bind to ~17
			receptors thus far identified.
Interleukin-8	GeneSeq Accession	U.S. Pat. No. 5,871,723	Chemokines area family of related small,	Chemokines activities can be	Angiogenesis, Cancer,
(IL-8) protein.	W96711		secreted proteins involved in biological	determined using assays known in the	Inflammatory and
			processes ranging from hematopoiesis,	art: Methods in Molecular Biology,	Immune disorders,
			angiogenesis, and leukocyte trafficking.	2000, vol. 138: Chemokine	Cardio-Vascular
			Members of this family are involved in a	Protocols. Edited by: A. E. I. Proudfoot,	discorders, Musco-
			similarly diverse range of pathologies	T. N. C. Wells, and C. A. Power,	skeletal disorders
			including inflammation, allergy, tissue	Humana Press Inc., Totowa,
			rejection, viral infection, and tumor	NJ; and Holmes et al (1991) Science
			biology. The chemokines exert their	253, 1278-80.
			effects by acting on a fmaily of seven
			transmembrane G-protein-coupled
			receptors. Over 40 human chemokines
			have been described, which bind to ~17
			receptors thus far identified.
Epithelial	GeneSeq Accession	U.S. Pat. No. 5,871,723	Chemokines area family of related small,	Chemokines activities can be	Angiogenesis, Cancer,
neutrophil	W96712		secreted proteins involved in biological	determined using assays known in the	Inflammatory and
activating			processes ranging from hematopoiesis,	art: Methods in Molecular Biology,	Immune disorders,
protein-78			angiogenesis, and leukocyte trafficking.	2000, vol. 138: Chemokine	Cardio-Vascular
(ENA-78)			Members of this family are involved in a	Protocols. Edited by: A. E. I. Proudfoot,	discorders, Musco-
			similarly diverse range of pathologies	T. N. C. Wells, and C. A. Power,	skeletal disorders
			including inflammation, allergy, tissue	Humana Press Inc., Totowa,
			rejection, viral infection, and tumor	NJ
			biology. The chemokines exert their
			effects by acting on a fmaily of seven
			transmembrane G-protein-coupled
			receptors. Over 40 human chemokines
			have been described, which bind to ~17
			receptors thus far identified.
Growth related	GeneSeq Accession	U.S. Pat. No. 5,871,723	Chemokines area family of related small,	Chemokines activities can be	Angiogenesis, Cancer,
oncogene-alpha	W96713		secreted proteins involved in biological	determined using assays known in the	Inflammatory and
(GRO-alpha).			processes ranging from hematopoiesis,	art: Methods in Molecular Biology,	Immune disorders,
			angiogenesis, and leukocyte trafficking.	2000, vol. 138: Chemokine	Cardio-Vascular
			Members of this family are involved in a	Protocols. Edited by: A. E. I. Proudfoot,	discorders, Musco-
			similarly diverse range of pathologies	T. N. C. Wells, and C. A. Power,	skeletal disorders
			including inflammation, allergy, tissue	Humana Press Inc., Totowa,
			rejection, viral infection, and tumor	NJ
			biology. The chemokines exert their
			effects by acting on a fmaily of seven
			transmembrane G-protein-coupled
			receptors. Over 40 human chemokines
			have been described, which bind to ~17
			receptors thus far identified.
Growth related	GeneSeq Accession	U.S. Pat. No. 5,871,723	Chemokines are a family of related	Chemokine activities can be	Angiogenesis, Cancer,
oncogene-beta	W96714		small, secreted proteins involved in	determined using assays known in	Inflammatory and
(GRO-beta).			biological processes ranging from	the art: Methods in Molecular	Immune disorders,
			hematopoiesis, angiogenesis, and	Biology, 2000, vol. 138: Chemokine	Cardio-Vascular
			leukocyte trafficking. Members of this	Protocols. Edited by: A. E. I. Proudfoot,	disorders, Musco-
			family are involved in a similarly	T. N. C. Wells, and C. A. Power,	skeletal disorders
			diverse range of pathologies including	©Humana Press Inc.,
			inflammation, allergy, tissue rejection,	Totowa, NJ
			viral infection and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identified
Growth related	GeneSeq Accession	U.S. Pat. No. 5,871,723	Chemokines are a family of related	Chemokine activities can be	Angiogenesis, Cancer,
oncogene-gamma	W96715		small, secreted proteins involved in	determined using assays known in	Inflammatory and
(GRO-gamma)			biological processes ranging from	the art: Methods in Molecular	Immune disorders,
			hematopoiesis, angiogenesis, and	Biology, 2000, vol. 138: Chemokine	Cardio-Vascular
			leukocyte trafficking. Members of this	Protocols. Edited by: A. E. I. Proudfoot,	disorders, Musco-
			family are involved in a similarly	T. N. C. Wells, and C. A. Power,	skeletal disorders
			diverse range of pathologies including	©Humana Press Inc.,
			inflammation, allergy, tissue rejection,	Totowa, NJ
			viral infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identified.
A platelet basic	GeneSeq Accession	U.S. Pat. No. 5,871,723	Chemokines are a family of related	Chemokine activities can be	Angiogenesis, Cancer,
protein (PBP)	W96716		small, secreted proteins involved in	determined using assays known in	Inflammatory and
			biological processes ranging from	the art: Methods in Molecular	Immune disorders,
			hematopoiesis, angiogenesis, and	Biology, 2000, vol. 138: Chemokine	Cardio-Vascular
			leukocyte trafficking. Members of this	Protocols. Edited by: A. E. I. Proudfoot,	disorders, Musco-
			family are involved in a similarly	T. N. C. Wells, and C. A. Power,	skeletal disorders
			diverse range of pathologies including	©Humana Press Inc.,
			inflammation, allergy, tissue rejection,	Totowa, NJ
			viral infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identified.
Connective tissue	GeneSeqAccession	U.S. Pat. No. 5,871,723	Chemokines are a family of related	Chemokine activities can be	Angiogenesis, Cancer,
activating protein-	S96717		small, secreted proteins involved in	determined using assays known in	Inflammatory and
III (CTAP-III)			biological processes ranging from	the art: Methods in Molecular	Immune disorders,
			hematopoiesis, angiogenesis, and	Biology, 2000, vol. 138: Chemokine	Cardio-Vascular
			leukocyte trafficking. Members of this	Protocols. Edited by: A. E. I. Proudfoot,	disorders, Musco-
			family are involved in a similarly	T. N. C. Wells, and C. A. Power,	skeletal disorders
			diverse range of pathologies including	©Humana Press Inc.,
			inflammation, allergy, tissue rejection,	Totowa, NJ
			viral infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identified.
Beta-	GeneSeq Accession	U.S. Pat. No. 5,871,723	Chemokines are a family of related	Chemokine activities can be	Angiogenesis, Cancer,
thromboglobulin	W96718		small, secreted proteins involved in	determined using assays known in	Inflammatory and
protein (beta-TG)			biological processes ranging from	the art: Methods in Molecular	Immune disorders,
			hematopoiesis, angiogenesis, and	Biology, 2000, vol. 138: Chemokine	Cardio-Vascular
			leukocyte trafficking. Members of this	Protocols. Edited by: A. E. I. Proudfoot,	disorders, Musco-
			family are involved in a similarly	T. N. C. Wells, and C. A. Power,	skeletal disorders
			diverse range of pathologies including	©Humana Press Inc.,
			inflammation, allergy, tissue rejection,	Totowa, NJ
			viral infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identified.
Neutrophil	GeneSeq Accession	U.S. Pat. No. 5,871,723	Chemokines are a family of related	Chemokine activities can be	Angiogenesis, Cancer,
activating peptide-	W96719		small, secreted proteins involved in	determined using assays known in	Inflammatory and
2 (NAP-2)			biological processes ranging from	the art: Methods in Molecular	Immune disorders,
			hematopoiesis, angiogenesis, and	Biology, 2000, vol. 138: Chemokine	Cardio-Vascular
			leukocyte trafficking. Members of this	Protocols. Edited by: A. E. I. Proudfoot,	disorders, Musco-
			family are involved in a similarly	T. N. C. Wells, and C. A. Power,	skeletal disorders
			diverse range of pathologies including	©Humana Press Inc.,
			inflammation, allergy, tissue rejection,	Totowa, NJ
			viral infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identified.
Granulocyte	GeneSeq Accession	U.S. Pat. No. 5,871,723	Chemokines are a family of related	Chemokine activities can be	Angiogenesis, Cancer,
chemotactic	W96720		small, secreted proteins involved in	determined using assays known in	Inflammatory and
protein-2 (GCP-2)			biological processes ranging from	the art: Methods in Molecular	Immune disorders,
			hematopoiesis, angiogenesis, and	Biology, 2000, vol. 138: Chemokine	Cardio-Vascular
			leukocyte trafficking. Members of this	Protocols. Edited by: A. E. I. Proudfoot,	disorders, Musco-
			family are involved in a similarly	T. N. C. Wells, and C. A. Power,	skeletal disorders
			diverse range of pathologies including	©Humana Press Inc.,
			inflammation, allergy, tissue rejection,	Totowa, NJ
			viral infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identified.
Human chemokine	GeneSeq Accession	EP887409	Chemokines are a family of related	Chemokine activities can be	Immune disorders, viral,
MIG-beta protein	W90124		small, secreted proteins involved in	determined using assays known in	parasitic, fungal or
			biological processes ranging from	the art: Methods in Molecular	bacterial infections,
			hematopoiesis, angiogenesis, and	Biology, 2000, vol. 138: Chemokine	Cancer; autoimmune
			leukocyte trafficking. Members of this	Protocols. Edited by: A. E. I. Proudfoot,	diseases or transplant
			family are involved in a similarly	T. N. C. Wells, and C. A. Power,	rejection
			diverse range of pathologies including	©Humana Press Inc.,
			inflammation, allergy, tissue rejection,	Totowa, NJ
			viral infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identified.
Human ZCHEMO-8	GeneSeq Accession	WO9854326	Chemokines are a family of related	Chemokine activities can be	Immune disorders,
	W82716		small, secreted proteins involved in	determined using assays known in	cancer, myelopoietic
			biological processes ranging from	the art: Methods in Molecular	disorders, autoimmune
			hematopoiesis, angiogenesis, and	Biology, 2000, vol. 138: Chemokine	disorders and
			leukocyte trafficking. Members of this	Protocols. Edited by: A. E. I. Proudfoot,	immunodeficiencies,
			family are involved in a similarly	T. N. C. Wells, and C. A. Power,	Inflammatory and
			diverse range of pathologies including	©Humana Press Inc.,	infectious diseases,
			inflammation, allergy, tissue rejection,	Totowa, NJ	Vascular disorders,
			viral infection, and tumor biology. The		wound healing
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identified.
Human Act-2	GeneSeq Accession	WO9854326	Chemokines are a family of related	Chemokine activities can be	Immune disorders,
protein	W82717		small, secreted proteins involved in	determined using assays known in	cancer, myelopoietic
			biological processes ranging from	the art: Methods in Molecular	disorders, autoimmune
			hematopoiesis, angiogenesis, and	Biology, 2000, vol. 138: Chemokine	disorders and
			leukocyte trafficking. Members of this	Protocols. Edited by: A. E. I. Proudfoot,	immunodeficiencies,
			family are involved in a similarly	T. N. C. Wells, and C. A. Power,	Inflammatory and
			diverse range of pathologies including	©Humana Press Inc.,	infectious diseases,
			inflammation, allergy, tissue rejection,	Totowa, NJ	Vascular disorders,
			viral infection, and tumor biology. The		wound healing
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identified.
Human SISD	GeneSeq Acession	WO9854326	Chemokines are a family of related	Chemokine activities can be	Immune disorders,
protein	W82720		small, secreted proteins involved in	determined using assays known in	cancer, myelopoietic
			biological processes ranging from	the art: Methods in Molecular	disorders, autoimmune
			hematopoiesis, angiogenesis, and	Biology, 2000, vol. 138:	disorders and
			leukocyte trafficking. Members of this	Chemokine Protocols, Edited by:	immunodeficiencies,
			family are involved in a similarly	A. E. I. Proudfoot, T. N. C. Wells, and	Inflammatory and
			diverse range of pathologies including	C. A. Power. ©Humana Press Inc.,	infectious diseases,
			inflammation, allergy, tissue rejection,	Totowa, NJ	Vascular disorders,
			viral infection, and tumor biology. The		wound healing
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identified.
Human M110	GeneSeq Accession	WO9854326	Chemokines area family of related	Chemokine activities can be	Immune disorders,
protein	W82721		small, secreted proteins involved in	determined using assays known in the	cancer, myelopoietic
			biological processes ranging from	art: Mehtods of Molecular Biology,	disorders, autoimmune
			hematopoiesis, angiogenesis, and	2000, vol. 138: Chemokine	disorders and
			leukocyte trafficking. Members of this	Protocols. Edited by: A. E. I. Proudfoot,	immunodeficiencies,
			family are involved in a similarly	T. N. C. Wells, and C. A. Power	Inflammatory and
			diverse range of pathologies including	©Humana Press Inc., Totowa,	infectious diseases,
			inflammation, allergy, tissue rejection,	NJ	Vascular disorders,
			viral infection, and tumor biology. The		wound healing
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identified.
Human M11A	GeneSeq Accession	WO9854326	Chemokines area family of related	Chemokine activities can be	Immune disorders,
protein	W82722		small, secreted proteins involved in	determined using assays known in the	cancer, myelopoietic
			biological processes ranging from	art: Mehtods of Molecular Biology,	disorders, autoimmune
			hematopoiesis, angiogenesis, and	2000, vol. 138: Chemokine	disorders and
			leukocyte trafficking. Members of this	Protocols. Edited by: A. E. I. Proudfoot,	immunodeficiencies,
			family are involved in a similarly	T. N. C. Wells, and C. A. Power	Inflammatory and
			diverse range of pathologies including	©Humana Press Inc., Totowa,	infectious diseases,
			inflammation, allergy, tissue rejection,	NJ	Vascular disorders,
			viral infection, and tumor biology. The		wound healing
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identified.
Human CCC3	GeneSeq Accession	WO9854326	Chemokines area family of related	Chemokine activities can be	Immune disorders,
protein	W82723		small, secreted proteins involved in	determined using assays known in the	cancer, myelopoietic
			biological processes ranging from	art: Mehtods of Molecular Biology,	disorders, autoimmune
			hematopoiesis, angiogenesis, and	2000, vol. 138: Chemokine	disorders and
			leukocyte trafficking. Members of this	Protocols. Edited by: A. E. I. Proudfoot,	immunodeficiencies,
			family are involved in a similarly	T. N. C. Wells, and C. A. Power	Inflammatory and
			diverse range of pathologies including	©Humana Press Inc., Totowa,	infectious diseases,
			inflammation, allergy, tissue rejection,	NJ	Vascular disorders,
			viral infection, and tumor biology. The		wound healing
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identified.
A human L105	GeneSeq Accession	WO9856818	Chemokines area family of related	Chemokine activities can be	Cancer, wound healing
chemokine	W87588		small, secreted proteins involved in	determined using assays known in the
designated			biological processes ranging from	art: Mehtods of Molecular Biology,
huL105_3.			hematopoiesis, angiogenesis, and	2000, vol. 138: Chemokine
			leukocyte trafficking. Members of this	Protocols. Edited by: A. E. I. Proudfoot,
			family are involved in a similarly	T. N. C. Wells, and C. A. Power
			diverse range of pathologies including	©Humana Press Inc., Totowa,
			inflammation, allergy, tissue rejection,	NJ
			viral infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identified.
A human L105	GeneSeq Accession	WO9856818	Chemokines area family of related	Chemokine activities can be	Cancer, wound healing
chemokine	W87589		small, secreted proteins involved in	determined using assays known in the
designated			biological processes ranging from	art: Mehtods of Molecular Biology,
huL105_7.			hematopoiesis, angiogenesis, and	2000, vol. 138: Chemokine
			leukocyte trafficking. Members of this	Protocols. Edited by: A. E. I. Proudfoot,
			family are involved in a similarly	T. N. C. Wells, and C. A. Power
			diverse range of pathologies including	©Humana Press Inc., Totowa,
			inflammation, allergy, tissue rejection,	NJ
			viral infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identified.
Human mature	GeneSeq Accession	WO9848828	Chemokines area family of related	Chemokine activities can be	Infectious diseases,
gro-alpha	W81498		small, secreted proteins involved in	determined using assays known in the	sepsis
polypeptide			biological processes ranging from	art: Mehtods of Molecular Biology,
used to treat			hematopoiesis, angiogenesis, and	2000, vol. 138: Chemokine
sepsis			leukocyte trafficking. Members of this	Protocols. Edited by: A. E. I. Proudfoot,
			family are involved in a similarly	T. N. C. Wells, and C. A. Power
			diverse range of pathologies including	©Humana Press Inc., Totowa,
			inflammation, allergy, tissue rejection,	NJ
			viral infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identified.
Human mature	GeneSeq Accession	WO9848828	Chemokines area family of related	Chemokine activities can be	Infectious diseases,
gro-gamma	W81500		small, secreted proteins involved in	determined using assays known in the	sepsis
polypeptide			biological processes ranging from	art: Mehtods of Molecular Biology,
used to treat			hematopoiesis, angiogenesis, and	2000, vol. 138: Chemokine
sepsis			leukocyte trafficking. Members of this	Protocols. Edited by: A. E. I. Proudfoot,
			family are involved in a similarly	T. N. C. Wells, and C. A. Power
			diverse range of pathologies including	©Humana Press Inc., Totowa,
			inflammation, allergy, tissue rejection,	NJ
			viral infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identified.
Human thymus	GeneSeq Accessions	WO0053635	Chemokines area family of related	Chemokine activities can be	Inflammatory disorders,
expressed	B19607 and		small, secreted proteins involved in	determined using assays known in the	cancer, Immune and
chemokine	B19608		biological processes ranging from	art: Mehtods of Molecular Biology,	vascular disorders
TECK and			hematopoiesis, angiogenesis, and	2000, vol. 138: Chemokine
TECK variant			leukocyte trafficking. Members of this	Protocols. Edited by: A. E. I. Proudfoot,
			family are involved in a similarly	T. N. C. Wells, and C. A. Power
			diverse range of pathologies including	©Humana Press Inc., Totowa,
			inflammation, allergy, tissue rejection,	NJ
			viral infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identified.
Human	GeneSeq Accession	WO0042071	Chemokines area family of related	Chemokine activities can be	Autoimmune disorders,
chemokine	B15791		small, secreted proteins involved in	determined using assays known in the	Immune, Vascular and
SDF1alpha			biological processes ranging from	art: Mehtods of Molecular Biology,	Inflammatory disorders
			hematopoiesis, angiogenesis, and	2000, vol. 138: Chemokine
			leukocyte trafficking. Members of this	Protocols. Edited by: A. E. I. Proudfoot,
			family are involved in a similarly	T. N. C. Wells, and C. A. Power
			diverse range of pathologies including	©Humana Press Inc., Totowa,
			inflammation, allergy, tissue rejection,	NJ
			viral infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identified.
Human chemokine	GeneSeq Accession	WO0042071	Chemokines are a family of related	Chemokine activities can be	Autoimmune disorders,
GROalpha	B15793		small, secreted proteins involved in	determined using assasys known in	Immune, Vascular and
			biological processes ranging from	the art: Methods in Molecular	Inflammatory diorders
			hematopoiesis, angiogenesis, and	Biology, 2000, vol. 138: Chemokine
			leukocyte trafficking. Members of this	Protocols. Edited by: A. E. I. Proudfoot;
			family are involved in a similarly	T. N. C. Wells, and C. A. Power.
			diverse range of pathologies including	©Humana Press Inc.,
			inflammation, allergy, tissue rejection,	Totowa, NJ
			viral infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identified.
Human chemokine	GeneSeq Accession	WO0042071	Chemokines are a family of related	Chemokine activities can be	Autoimmune disorders,
eotaxin	B15794		small, secreted proteins involved in	determined using assasys known in	Immune, Vascular and
			biological processes ranging from	the art: Methods in Molecular	Inflammatory disorders
			hematopoiesis, angiogenesis, and	Biology, 2000, vol. 138: Chemokine
			leukocyte trafficking. Members of this	Protocols. Edited by: A. E. I. Proudfoot;
			family are involved in a similarly	T. N. C. Wells, and C. A. Power.
			diverse range of pathologies including	©Humana Press Inc.,
			inflammation, allergy, tissue rejection,	Totowa, NJ
			viral infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identified.
Human chemokine	GeneSeq Accession	WO0042071	Chemokines are a family of related	Chemokine activities can be	Autoimmune disorders,
MIG	B15803		small, secreted proteins involved in	determined using assasys known in	Immune, Vascular and
			biological processes ranging from	the art: Methods in Molecular	Inflammatory disorders
			hematopoiesis, angiogenesis, and	Biology, 2000, vol. 138: Chemokine
			leukocyte trafficking. Members of this	Protocols. Edited by: A. E. I. Proudfoot;
			family are involved in a similarly	T. N. C. Wells, and C. A. Power.
			diverse range of pathologies including	©Humana Press Inc.,
			inflammation, allergy, tissue rejection,	Totowa, NJ
			viral infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identified.
Human chemokine	GeneSeq Accession	WO0042071	Chemokines are a family of related	Chemokine activities can be	Autoimmune disorders,
PF4	B15804		small, secreted proteins involved in	determined using assasys known in	Immune, Vascular and
			biological processes ranging from	the art: Methods in Molecular	Inflammatory disorders
			hematopoiesis, angiogenesis, and	Biology, 2000, vol. 138: Chemokine
			leukocyte trafficking. Members of this	Protocols. Edited by: A. E. I. Proudfoot;
			family are involved in a similarly	T. N. C. Wells, and C. A. Power.
			diverse range of pathologies including	©Humana Press Inc.,
			inflammation, allergy, tissue rejection,	Totowa, NJ
			viral infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identified.
Human chemokine	GeneSeq Accession	WO0042071	Chemokines are a family of related	Chemokine activities can be	Autoimmune disorders,
I-309	B15805		small, secreted proteins involved in	determined using assasys known in	Immune, Vascular and
			biological processes ranging from	the art: Methods in Molecular	Inflammatory disorders
			hematopoiesis, angiogenesis, and	Biology, 2000, vol. 138: Chemokine
			leukocyte trafficking. Members of this	Protocols. Edited by: A. E. I. Proudfoot;
			family are involved in a similarly	T. N. C. Wells, and C. A. Power.
			diverse range of pathologies including	©Humana Press Inc.,
			inflammation, allergy, tissue rejection,	Totowa, NJ
			viral infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identified.
Human chemokine	GeneSeq Accession	WO0042071	Chemokines are a family of related	Chemokine activities can be	Autoimmune disorders,
HCC-1	B15806		small, secreted proteins involved in	determined using assasys known in	Immune, Vascular and
			biological processes ranging from	the art: Methods in Molecular	Inflammatory disorders
			hematopoiesis, angiogenesis, and	Biology, 2000, vol. 138: Chemokine
			leukocyte trafficking. Members of this	Protocols. Edited by: A. E. I. Proudfoot;
			family are involved in a similarly	T. N. C. Wells, and C. A. Power.
			diverse range of pathologies including	©Humana Press Inc.,
			inflammation, allergy, tissue rejection,	Totowa, NJ
			viral infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identified.
Human chemokine	GeneSeq Accession	WO0042071	Chemokines are a family of related	Chemokine activities can be	Autoimmune disorders,
C10	B15807		small, secreted proteins involved in	determined using assasys known in	Immune, Vascular and
			biological processes ranging from	the art: Methods in Molecular	Inflammatory disorders
			hematopoiesis, angiogenesis, and	Biology, 2000, vol. 138: Chemokine
			leukocyte trafficking. Members of this	Protocols. Edited by: A. E. I. Proudfoot;
			family are involved in a similarly	T. N. C. Wells, and C. A. Power.
			diverse range of pathologies including	©Humana Press Inc.,
			inflammation, allergy, tissue rejection,	Totowa, NJ
			viral infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identified.
Human chemokine	GeneSeq Accession	WO0042071	Chemokines are a family of related	Chemokine activities can be	Autoimmune disorders,
CCR-2	B15808		small, secreted proteins involved in	determined using assasys known in	Immune, Vascular and
			biological processes ranging from	the art: Methods in Molecular	Inflammatory disorders
			hematopoiesis, angiogenesis, and	Biology, 2000, vol. 138: Chemokine
			leukocyte trafficking. Members of this	Protocols. Edited by: A. E. I. Proudfoot;
			family are involved in a similarly	T. N. C. Wells, and C. A. Power.
			diverse range of pathologies including	©Humana Press Inc.,
			inflammation, allergy, tissue rejection,	Totowa, NJ
			viral infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identified.
Human chemokine	GeneSeq Accession	WO0042071	Chemokines are a family of related	Chemokine activities can be	Autoimmune disorders,
ENA-78	B15809		small, secreted proteins involved in	determined using assasys known in	Immune, Vascular and
			biological processes ranging from	the art: Methods in Molecular	Inflammatory disorders
			hematopoiesis, angiogenesis, and	Biology, 2000, vol. 138: Chemokine
			leukocyte trafficking. Members of this	Protocols. Edited by: A. E. I. Proudfoot;
			family are involved in a similarly	T. N. C. Wells, and C. A. Power.
			diverse range of pathologies including	©Humana Press Inc.,
			inflammation, allergy, tissue rejection,	Totowa, NJ
			viral infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identified.
Human chemokine	GeneSeq Accession	WO0042071	Chemokines are a family of related	Chemokine activities can be	Autoimmune disorders,
GRObeta	B15810		small, secreted proteins involved in	determined using assasys known in	Immune, Vascular and
			biological processes ranging from	the art: Methods in Molecular	Inflammatory disorders
			hematopoiesis, angiogenesis, and	Biology, 2000, vol. 138: Chemokine
			leukocyte trafficking. Members of this	Protocols. Edited by: A. E. I. Proudfoot;
			family are involved in a similarly	T. N. C. Wells, and C. A. Power.
			diverse range of pathologies including	©Humana Press Inc.,
			inflammation, allergy, tissue rejection,	Totowa, NJ
			viral infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identified.
Human chemokine	GeneSeq Accession	WO0042071	Chemokines are a family of related	Chemokine activities can be	Autoimmune disorders,
IP-10	B15811		small, secreted proteins involved in	determined using assays known in	Immune, Vascular and
			biological processes ranging from	the art: Methods in Molecular	Inflammatory disorders
			hematopoiesis, angiogenesis, and	Biology, 2000, vol. 138: Chemokine
			leukocyte trafficking. Members of this	Protocols. Edited by: A. E. I. Proudfoot,
			family are involved in a similarly	T. N. C. Wells, and C. A. Power.
			diverse range of pathologies including	©Humana Press Inc.,
			inflammation, allergy, tissue rejection,	Totowa, NJ
			viral infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identified.
Human chemokine	GeneSeq Accession	WO0042071	Chemokines are a family of related	Chemokine activities can be	Autoimmune disorders,
SDF1beta	B15812		small, secreted proteins involved in	determined using assays known in	Immune, Vascular and
			biological processes ranging from	the art: Methods in Molecular	Inflammatory disorders
			hematopoiesis, angiogenesis, and	Biology, 2000, vol. 138: Chemokine
			leukocyte trafficking. Members of this	Protocols. Edited by: A. E. I. Proudfoot,
			family are involved in a similarly	T. N. C. Wells, and C. A. Power.
			diverse range of pathologies including	©Humana Press Inc.,
			inflammation, allergy, tissue rejection,	Totowa, NJ
			viral infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identified.
Human chemokine	GeneSeq Accession	WO0042071	Chemokines are a family of related	Chemokine activities can be	Autoimmune disorders,
GRO alpha	B15813		small, secreted proteins involved in	determined using assays known in	Immune, Vascular and
			biological processes ranging from	the art: Methods in Molecular	Inflammatory disorders
			hematopoiesis, angiogenesis, and	Biology, 2000, vol. 138: Chemokine
			leukocyte trafficking. Members of this	Protocols. Edited by: A. E. I. Proudfoot,
			family are involved in a similarly	T. N. C. Wells, and C. A. Power.
			diverse range of pathologies including	©Humana Press Inc.,
			inflammation, allergy, tissue rejection,	Totowa, NJ
			viral infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identified.
Human chemokine	GeneSeq Accession	WO0042071	Chemokines are a family of related	Chemokine activities can be	Autoimmune disorders,
MIP1beta	B15831		small, secreted proteins involved in	determined using assays known in	Immune, Vascular and
			biological processes ranging from	the art: Methods in Molecular	Inflammatory disorders
			hematopoiesis, angiogenesis, and	Biology, 2000, vol. 138: Chemokine
			leukocyte trafficking. Members of this	Protocols. Edited by: A. E. I. Proudfoot,
			family are involved in a similarly	T. N. C. Wells, and C. A. Power.
			diverse range of pathologies including	©Humana Press Inc.,
			inflammation, allergy, tissue rejection,	Totowa, NJ
			viral infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identified.
A human C-C	GeneSeq Accession	U.S. Pat. No. 6,096,300	Chemokines are a family of related	Chemokine activities can be	Cancer
chemokine	B07939		small, secreted proteins involved in	determined using assays known in
designated exodus			biological processes ranging from	the art: Methods in Molecular
			hematopoiesis, angiogenesis, and	Biology, 2000, vol. 138: Chemokine
			leukocyte trafficking. Members of this	Protocols. Edited by: A. E. I. Proudfoot,
			family are involved in a similarly	T. N. C. Wells, and C. A. Power.
			diverse range of pathologies including	©Humana Press Inc.,
			inflammation, allergy, tissue rejection,	Totowa, NJ
			viral infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identified.
Human chemokine	GeneSeq Accession	U.S. Pat. No. 6,084,071	Chemokines are a family of related	Chemokine activities can be	Chemotaxis, Gene
L105_7	Y96922		small, secreted proteins involved in	determined using assays known in	Therapy, Wound
			biological processes ranging from	the art: Methods in Molecular	healing
			hematopoiesis, angiogenesis, and	Biology, 2000, vol. 138: Chemokine
			leukocyte trafficking. Members of this	Protocols. Edited by: A. E. I. Proudfoot,
			family are involved in a similarly	T. N. C. Wells, and C. A. Power.
			diverse range of pathologies including	©Humana Press Inc.,
			inflammation, allergy, tissue rejection,	Totowa, NJ
			viral infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identified.
Human chemokine	GeneSeq Accession	U.S. Pat. No. 6,084,071	Chemokines are a family of related	Chemokine activities can be	Chemotaxis, Gene
L105_3	Y96923		small, secreted proteins involved in	determined using assays known in	Therapy, Wound
			biological processes ranging from	the art: Methods in Molecular	healing
			hematopoiesis, angiogenesis, and	Biology, 2000, vol. 138: Chemokine
			leukocyte trafficking. Members of this	Protocols. Edited by: A. E. I. Proudfoot,
			family are involved in a similarly	T. N. C. Wells, and C. A. Power.
			diverse range of pathologies including	©Humana Press Inc.,
			inflammation, allergy, tissue rejection,	Totowa, NJ
			viral infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identified.
Human secondary	GeneSeq Accession	WO0038706	Chemokines are a family of related	Chemokine activities can be	Cancer, Vascular and
lymphoid	B01434		small, secreted proteins involved in	determined using assays known in	Immune disorders
chemokine (SLC)			biological processes ranging from	the art: Methods in Molecular
			hematopoiesis, angiogenesis, and	Biology, 2000, vol. 138: Chemokine
			leukocyte trafficking. Members of this	Protocols. Edited by: A. E. I. Proudfoot,
			family are involved in a similarly	T. N. C. Wells, and C. A. Power.
			diverse range of pathologies including	©Humana Press Inc.,
			inflammation, allergy, tissue rejection,	Totowa, NJ
			viral infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identified.
Human non-ELR	GeneSeq Accession	WO0029439	Chemokines are a family of related	Chemokine activities can be	Immune and
CXC chemokine	Y96310		small, secreted proteins involved in	determined using assays known in	Inflammatory disorders,
H174			biological processes ranging from	the art: Methods in Molecular	Cancer, Haemostatic
			hematopoiesis, angiogenesis, and	Biology, 2000, vol. 138: Chemokine	and thrombolytic
			leukocyte trafficking. Members of this	Protocols. Edited by: A. E. I. Proudfoot,	activity
			family are involved in a similarly	T. N. C. Wells, and C. A. Power.
			diverse range of pathologies including	©Humana Press Inc.,
			inflammation, allergy, tissue rejection,	Totowa, NJ
			viral infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identified.
Human non-ELR	GeneSeq Accession	WO0029439	Chemokines are a family of related	Chemokine activities can be	Immune and
CXC chemokine	Y96311		small, secreted proteins involved in	determined using assays known in	Inflammatory disorders,
IP10			biological processes ranging from	the art: Methods in Molecular	Cancer, haemostatic and
			hematopoiesis, angiogenesis, and	Biology, 2000, vol. 138: Chemokine	thrombolytic activity
			leukocyte trafficking. Members of this	Protocols. Edited by: A. E. I. Proudfoot,
			family are involved in a similarly	T. N. C. Wells, and C. A. Power.
			diverse range of pathologies including	©Humana Press Inc.,
			inflammation, allergy, tissue rejection,	Totowa, NJ
			viral infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ~17 receptors thus far
			identified.
Human non-ELR	GeneSeq Accession	WO0029439	Chemokines are a family of related	Chemokine activities can be	Immune and
CXC chemokine	Y96313		small, secreted proteins involved in	determined using assays known in	Inflammatory disorders,
Mig			biological processes ranging from	the art: Methods in Molecular	Cancer, haemostatic and
			hematopoiesis, angiogenesis, and	Biology, 2000, vol. 138: Chemokine	thrombolytic activity
			leukocyte trafficking. Members of this	Protocols. Edited by: A. E. I. Proudfoot,
			family are involved in a similarly	T. N. C. Wells, and C. A. Power.
			diverse range of pathologies including	©Humana Press Inc.,
			inflammation, allergy, tissue rejection,	Totowa, NJ
			viral infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ^~17 receptors thus far
			identified.
Human chemokine	GeneSeq Accession	WO0028035	Chemokines are a family of related	Chemokine activities can be	Cancer, wound healing,
Ckbeta-7	Y96280		small, secreted proteins involved in	determined using assays known in	inflammatory and
			biological processes ranging from	the art: Methods in Molecular	immunoregulatory
			hematopoiesis, angiogenesis, and	Biology, 2000, vol. 138: Chemokine	disorders
			leukocyte trafficking. Members of this	Protocols. Edited by: A. E. I. Proudfoot,
			family are involved in a similarly	T. N. C. Wells, and C. A. Power.
			diverse range of pathologies including	©Humana Press Inc.,
			inflammation, allergy, tissue rejection,	Totowa, NJ
			viral infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ^~17 receptors thus far
			identified.
Human chemokine	GeneSeq Accession	WO0028035	Chemokines are a family of related	Chemokine activities can be	Cancer, wound healing,
MIP-1alpha	Y96281		small, secreted proteins involved in	determined using assays known in	inflammatory and
			biological processes ranging from	the art: Methods in Molecular	immunoregulatory
			hematopoiesis, angiogenesis, and	Biology, 2000, vol. 138: Chemokine	disorders
			leukocyte trafficking. Members of this	Protocols. Edited by: A. E. I. Proudfoot,
			family are involved in a similarly	T. N. C. Wells, and C. A. Power.
			diverse range of pathologies including	©Humana Press Inc.,
			inflammation, allergy, tissue rejection,	Totowa, NJ
			viral infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ^~17 receptors thus far
			identified.
Human mature	GenSeq Accession	WO0028035	Chemokines are a family of related	Chemokine activities can be	Cancer, wound healing,
chemokine	Y96282		small, secreted proteins involved in	determined using assays known in	inflammatory and
Ckbeta-7			biological processes ranging from	the art: Methods in Molecular	immunoregulatory
(optionally			hematopoiesis, angiogenesis, and	Biology, 2000, vol. 138: Chemokine	disorders
truncated)			leukocyte trafficking. Members of this	Protocols. Edited by: A. E. I. Proudfoot,
			family are involved in a similarly	T. N. C. Wells, and C. A. Power.
			diverse range of pathologies including	©Humana Press Inc.,
			inflammation, allergy, tissue rejection,	Totowa, NJ
			viral infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ^~17 receptors thus far
			identified.
Human chemokine	GeneSeq Accession	WO0018431	Chemokines are a family of related	Chemokine activities can be	Soluble CXCR3
receptor CXCR3	Y79372		small, secreted proteins involved in	determined using assays known in	polypeptides may be
			biological processes ranging from	the art: Methods in Molecular	useful for inhibiting
			hematopoiesis, angiogenesis, and	Biology, 2000, vol. 138: Chemokine	chemokine activities
			leukocyte trafficking. Members of this	Protocols. Edited by: A. E. I. Proudfoot,	and viral infection.
			family are involved in a similarly	T. N. C. Wells, and C. A. Power.
			diverse range of pathologies including	©Humana Press Inc.,
			inflammation, allergy, tissue rejection,	Totowa, NJ
			viral infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ^~17 receptors thus far
			identified.
Human neurotactin	GeneSeq Accession	U.S. Pat. No. 6,043,086	Chemokines are a family of related	Chemokine activities can be	Neurological disorders,
chemokine like	Y53259		small, secreted proteins involved in	determined using assays known in	Immune and respiratory
domain			biological processes ranging from	the art: Methods in Molecular	disorders
			hematopoiesis, angiogenesis, and	Biology, 2000, vol. 138: Chemokine
			leukocyte trafficking. Members of this	Protocols. Edited by: A. E. I. Proudfoot,
			family are involved in a similarly	T. N. C. Wells, and C. A. Power.
			diverse range of pathologies including	©Humana Press Inc.,
			inflammation, allergy, tissue rejection,	Totowa, NJ
			viral infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ^~17 receptors thus far
			identified.
Human CC type	GeneSeq Accession	JP11302298	Chemokines are a family of related	Chemokine activities can be	Cancer and infectious
chemokine	Y57771		small, secreted proteins involved in	determined using assays known in	diseases
interleukin C			biological processes ranging from	the art: Methods in Molecular
			hematopoiesis, angiogenesis, and	Biology, 2000, vol. 138: Chemokine
			leukocyte trafficking. Members of this	Protocols. Edited by: A. E. I. Proudfoot,
			family are involved in a similarly	T. N. C. Wells, and C. A. Power.
			diverse range of pathologies including	©Humana Press Inc.,
			inflammation, allergy, tissue rejection,	Totowa, NJ
			viral infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ^~17 receptors thus far
			identified
Human CKbeta-9	GeneSeq Accession	U.S. Pat. No. 6,153,441	Chemokines are a family of related	Chemokine activities can be	Cancer, Auto-immune
	B50860		small, secreted proteins involved in	determined using assays known in	and inflammatory
			biological processes ranging from	the art: Methods in Molecular	disorders,
			hematopoiesis, angiogenesis, and	Biology, 2000, vol. 138: Chemokine	Cardiovascular
			leukocyte trafficking. Members of this	Protocols. Edited by: A. E. I. Proudfoot,	disorders
			family are involved in a similarly	T. N. C. Wells, and C. A. Power.
			diverse range of pathologies including	©Humana Press Inc.,
			inflammation, allergy, tissue rejection,	Totowa, NJ
			viral infection, and tumor biology. The
			chemokines exert their effects by acting
			on a family of seven transmembrane G-
			protein-coupled receptors. Over 40
			human chemokines have been described,
			which bind to ^~17 receptors thus far
			identified
Preproapolipoprotein	GeneSeq Accession	WO9637608	Apoa-1 participates in the reverse	Lipid binding activity can be	Useful for
“paris” variant	W08602		transport of cholesterol from tissues to	determined using assays known in	cardiovascular
			the liver for excretion by promoting	the art, such as, for example, the	disorders, cholesterol
			cholesterol efflux from tissues and by	Cholesterol Efflux Assays of	disorders, and
			acting as a cofactor for the lecithin	Takahaski et al., P.N.A.S., Vol. 96,	Hyperlipidaemia
			cholesterol acyltransferase (lcat).	Issue 20, 11358-11363, Sep.
				28, 1999.
Preproapolipoprotein		5,721,114	Apoa-1 participates in the reverse	Lipid binding activity can be	Useful for
“milano” variant			transport of cholesterol from tissues to	determined using assays known in	cardiovascular
			the liver for excretion by promoting	the art, such as, for example, the	disorders, cholesterol
			cholesterol efflux from tissues and by	Cholesterol Efflux Assays of	disorders, and
			acting as a cofactor for the lecithin	Takahaski et al., P.N.A.S., Vol. 96,	Hyperlipidaemia
			cholesterol acyltransferase (lcat).	Issue 20, 11358-11363, Sep.
				28, 1999.
Glycodelin-A;	GeneSeq Accession	WO9628169	Naturally produced female contraceptive	Glycodelin-A activity can be	Naturally derived
Progesterone-	W00289		that is removed rapidly from the body	determined using the hemizona	contraceptive useful for
associated			following 2-3 days production. Uses	assay as described in Oehninger, S.,	the prevention of
endometrial			include contraception	Coddington, C. C., Hodgen, G. D.,	pregnancy.
protein				and Seppala, M (1995) Fertil. Steril.
				63, 377-383.
NOGO-A	Genbank Accession		NOGO polypeptides are potent	Inhibition of Neurite outgrowth.	NOGO-A polypeptide
	CAB99248		inhibitors of neurite growth.	Antagonists to NOGO polypeptides	antagonists are useful
				may promote the outgrowth of	for the promotion of
				neurites, thus inducing regeneration	neural growth, which
				of neurons.	could be useful in the
					treatment of neural
					disorders and
					dysfunction due to
					degenerative diseases or
					trauma; useful in the
					treatment of neoplastic
					diseases of the CNS;
					induce regeneration of
					neurons or to promote
					the structural plasticity
					of the CNS.
NOGO-B	Genbank Accession		NOGO polypeptides are potent	Inhibition of Neurite outgrowth.	NOGO-B polypeptide
	CAB99249		inhibitors of neurite growth.	Antagonists to NOGO polypeptides	antagonists are useful
				may promote the outgrowth of	for the promotion of
				neurites, thus inducing regeneration	neural growth, which
				of neurons.	could be useful in the
					treatment of neural
					disorders and
					dysfunction due to
					degenerative diseases or
					trauma; useful in the
					treatment of neoplastic
					diseases of the CNS;
					induce regeneration of
					neurons or to promote
					the structural plasticity
					of the CNS.
NOGO-C	Genbank Accession		NOGO polypeptides are potent	Inhibition of Neurite outgrowth.	NOGO-C polypeptide
	CAB99250		inhibitors of neurite growth.	Antagonists to NOGO polypeptides	antagonists are useful
				may promote the outgrowth of	for the promotion of
				neurites, thus inducing regeneration	neural growth, which
				of neurons.	could be useful in the
					treatment of neural
					disorders and
					dysfunction due to
					degenerative diseases or
					trauma; useful in the
					treatment of neoplastic
					diseases of the CNS;
					induce regeneration of
					neurons or to promote
					the structural plasticity
					of the CNS.
NOGO-66	Genbank Accession		NOGO polypeptides are potent	Inhibition of Neurite outgrowth by	NOGO-66 receptor
Receptor	AAG53612		inhibitors of neurite growth, and are	mediating the biological effects of	polypeptides are useful
			thought to mediate their effects through	NOGO polypeptides. Soluble	for the promotion of
			the NOGO-66 Receptor.	NOGO-66 receptor polypeptides	neural growth, which
				may promote the outgrowth of	could be useful in the
				neurites, thus inducing regeneration	treatment of neural
				of neurons.	disorders and
					dysfunction due to
					degenerative diseases or
					trauma; useful in the
					treatment of neoplastic
					diseases of the CNS;
					induce regeneration of
					neurons or to promote
					the structural plasticity
					of the CNS.
Antibodies specific		U.S. Pat. No. 5,416,197	These antibodies are useful for the	Collapsin activity, which is thought	Useful for the
for collapsin			promotion of neurite outgrowth	to inhibit the outgrowth of neurites,	promotion of neural
				can be assayed in the presence of	growth, which could be
				antibodies specific for collapsing	useful in the treatment
				using assays known in the art, such	of neural disorders and
				as, for example, the collapse assay	dysfunction due to
				disclosed by Luo et al., Cell 1993	degenerative diseases or
				Oct. 22; 75(2): 217-27	trauma.
Humanized Anti-		WO9845331	These agents have anti-inflammatory	VEGF activity can be determined	Promotion of growth
VEGF Antibodies,			and anti-cancer applications	using assays known in the art, such	and proliferation of
and fragments				as those disclosed in International	cells, such as vascular
thereof				Publication No. WO0045835, for	endothelial cells.
				example.	Antagonists may be
					useful as anti-
					angiogenic agents, and
					may be applicable for
					cancer
Humanized Anti-		WO0029584	These agents have anti-inflammatory	VEGF activity can be determined	Promotion of growth
VEGF Antibodies,			and anti-cancer applications	using assays known in the art, such	and proliferation of
and fragments				as those disclosed in International	cells, such as vascular
thereof				Publication No. WO0045835, for	endothelial cells.
				example.	Antagonists may be
					useful as anti-
					angiogenic agents, and
					may be applicable for
					cancer
Membrane bound	GeneSeq. Accession	WO9963088	Cancer, Immune Disorders	These proteins can be used for	Activities can be
proteins	Y66631-Y66765			linking bioactive molecules to cells	determined using assay
				and for modulating biological	known in the art,
				activities of cells, using the	suchas, for example, the
				polypeptides for specific targeting.	assays disclosed in
				The polypeptide targeting can be	International
				used to kill the target cells, e.g. for	Publication No.
				the treatment of cancers. These	WO0121658.
				proteins are useful for the treatment
				of immune system disorders.
Secreted and	GenSeq Accession	WO0053756	Cancer, Immune Disorders	These proteins can be used for	Activities can be
Transmembrane	B44241-B44334			linking bioactive molecules to cells	determined using assay
polypeptides				and for modulating biological	known in the art,
				activities of cells, using the	suchas, for example, the
				polypeptides for specific targeting.	assays disclosed in
				The polypeptide targeting can be	International
				used to kill the target cells, e.g. for	Publication No.
				the treatment of cancers. These	WO0121658
				proteins are useful for the treatment
				of immune system disorders.
Secreted and	GeneSeq Accession	WO9946281	Cancer, Immune Disorders	These proteins can be used for	Activities can be
Transmembrane	Y41685-Y41774			linking bioactive molecules to cells	determined using assay
polypeptides				and for modulating biological	known in the art,
				activities of cells, using the	suchas, for example, the
				polypeptides for specific targeting.	assays disclosed in
				The polypeptide targeting can be	International
				used to kill the target cells, e.g. for	Publication No.
				the treatment of cancers. These	WO0121658
				proteins are useful for the treatment
				of immune system disorders.

Conjugation and Coupling

The present invention provides therapeutic agents comprising an ELP component and a therapeutic component, such as therapeutic proteins listed in Table 1, as well as a GLP-1 receptor agonists, insulin, Factor VII/VIIa, and functional analogs as described. Such agents may be prepared by recombinant technology and/or chemical coupling (e.g., conjugation).
A recombinantly-produced ELP fusion protein, in accordance with certain embodiments of the invention, includes the ELP component and the therapeutic component associated with one another by genetic fusion. For example, the fusion protein may be generated by translation of a polynucleotide encoding the therapeutic component cloned in-frame with the ELP component (or vice versa). Such an ELP fusion protein may contain one or more copies of the therapeutic component attached to the N-terminus and/or the C-terminus of the ELP component. In some embodiments, the therapeutic proteinacious component is attached to both the N- and C-terminus of the ELP component and the fusion protein may contain one or more equivalents of the therapeutic component on either or both ends of the ELP component.
In certain embodiments, the ELP component and the therapeutic components can be fused using a linker peptide of various lengths to provide greater physical separation and allow more spatial mobility between the fused portions, and thus maximize the accessibility of the therapeutic component, for instance, for binding to its cognate receptor. The linker peptide may consist of amino acids that are flexible or more rigid. For example, a flexible linker may include amino acids having relatively small side chains, and which may be hydrophilic. Without limitation, the flexible linker may contain a stretch of glycine and/or serine residues. More rigid linkers may contain, for example, more sterically hindering amino acid side chains, such as (without limitation) tyrosine or histidine. The linker may be less than about 50, 40, 30, 20, 10, or 5 amino acid residues. The linker can be covalently linked to and between an ELP component and a therapeutic component, for example, via recombinant fusion.
The linker or peptide spacer may be protease-cleavable or non-cleavable. By way of example, cleavable peptide spacers include, without limitation, a peptide sequence recognized by proteases (in vitro or in vivo) of varying type, such as Tev, thrombin, factor Xa, plasmin (blood proteases), metalloproteases, cathepsins (e.g., GFLG, etc.), and proteases found in other corporeal compartments. In some embodiments employing cleavable linkers, the fusion protein (“the therapeutic agent”) may be inactive, less active, or less potent as a fusion, which is then activated upon cleavage of the spacer in vivo. Alternatively, where the therapeutic agent is sufficiently active as a fusion, a non-cleavable spacer may be employed. The non-cleavable spacer may be of any suitable type, including, for example, non-cleavable spacer moieties having the formula [(Gly)n-Ser]m (SEQ ID NO.: 22) where n is from 1 to 4, inclusive, and m is from 1 to 4, inclusive. Alternatively, a short ELP sequence different than the backbone ELP could be employed instead of a linker or spacer, while accomplishing the necessary effect.
In still other embodiments, the therapeutic agent is a recombinant fusion having a therapeutic component flanked on each terminus by an ELP component. At least one of said ELP components may be attached via a cleavable spacer, such that the therapeutic component is inactive, but activated in vivo by proteolytic removal of a single ELP component. The resulting single ELP fusion being active, and having an enhanced half-life (or other property described herein) in vivo.
In other embodiments, the present invention provides chemical conjugates of the ELP component and the therapeutic component. The conjugates can be made by chemically coupling an ELP component to a therapeutic component by any number of methods well known in the art (See e.g. Nilsson et al., 2005, Ann Rev Biophys Bio Structure 34: 91-118). In some embodiments, the chemical conjugate can be formed by covalently linking the therapeutic component to the ELP component, directly or through a short or long linker moiety, through one or more functional groups on the therapeutic proteinacious component, e. g., amine, carboxyl, phenyl, thiol or hydroxyl groups, to form a covalent conjugate. Various conventional linkers can be used, e. g., diisocyanates, diisothiocyanates, carbodiimides, bis (hydroxysuccinimide) esters, maleimide-hydroxysuccinimide esters, glutaraldehyde and the like.
Non-peptide chemical spacers can additionally be of any suitable type, including for example, by functional linkers described in Bioconjugate Techniques, Greg T. Hermanson, published by Academic Press, Inc., 1995, and those specified in the Cross-Linking Reagents Technical Handbook, available from Pierce Biotechnology, Inc. (Rockford, Ill.), the disclosures of which are hereby incorporated by reference, in their respective entireties. Illustrative chemical spacers include homobifunctional linkers that can attach to amine groups of Lys, as well as heterobifunctional linkers that can attach to Cys at one terminus, and to Lys at the other terminus.
In certain embodiments, relatively small ELP components (e.g., ELP components of less than about 30 kDa, 25 kDa, 20 kDa, 15 kDa, or 10 kDa), that do not transition at room temperature (or human body temperature, e.g., Tt >37° C.), are chemically coupled or crosslinked. For example, two relatively small ELP components, having the same or different properties, may be chemically coupled. Such coupling, in some embodiments, may take place in vivo, by the addition of a single cysteine residue at or around the C-terminus of the ELP. Such ELP components may each be fused to one or more therapeutic components, so as to increase activity or avidity at the target.

Polynucleotides, Vectors, and Host Cells

In another aspect, the invention provides polynucleotides comprising a nucleotide sequence encoding the therapeutic agent of the invention. Such polynucleotides further comprise, in addition to sequences encoding the ELP and therapeutic components, one or more expression control elements. For example, the polynucleotide, may comprise one or more promoters or transcriptional enhancers, ribosomal binding sites, transcription termination signals, and polyadenylation signals, as expression control elements. The polynucleotide may be inserted within any suitable vector, which may be contained within any suitable host cell for expression.
A vector comprising the polynucleotide can be introduced into a cell for expression of the therapeutic agent. The vector can remain episomal or become chromosomally integrated, as long as the insert encoding the therapeutic agent can be transcribed. Vectors can be constructed by standard recombinant DNA technology. Vectors can be plasmids, phages, cosmids, phagemids, viruses, or any other types known in the art, which are used for replication and expression in prokaryotic or eukaryotic cells. It will be appreciated by one of skill in the art that a wide variety of components known in the art (such as expression control elements) may be included in such vectors, including a wide variety of transcription signals, such as promoters and other sequences that regulate the binding of RNA polymerase onto the promoter. Any promoter known to be effective in the cells in which the vector will be expressed can be used to initiate expression of the therapeutic agent. Suitable promoters may be inducible or constitutive. Examples of suitable promoters include the SV40 early promoter region, the promoter contained in the 3′ long terminal repeat of Rous sarcoma virus, the HSV-1 (herpes simplex virus-1) thymidine kinase promoter, the regulatory sequences of the metallothionein gene, etc., as well as the following animal transcriptional control regions, which exhibit tissue specificity and have been utilized in transgenic animals: elastase I gene control region which is active in pancreatic acinar cells; insulin gene control region which is active in pancreatic beta cells, immunoglobulin gene control region which is active in lymphoid cells, mouse mammary tumor virus control region which is active in testicular, breast, lymphoid and mast cells, albumin gene control region which is active in liver, alpha-fetoprotein gene control region which is active in liver, alpha 1-antitrypsin gene control region which is active in the liver, beta-globin gene control region which is active in erythroid cells, myelin basic protein gene control region which is active in oligodendrocyte cells in the brain, myosin light chain-2 gene control region which is active in skeletal muscle, and gonadotropin releasing hormone gene control region which is active in the hypothalamus.

Pharmaceutical Compositions

The present invention further provides pharmaceutical compositions comprising the therapeutic agents of the invention (as described above) together with a pharmaceutically acceptable carrier or excipient. Such pharmaceutical compositions may be employed in the methods of treatment as described above, for each of the therapeutic proteins, e.g., the therapeutic proteins listed in Table 1, GLP-1 receptor agonists, insulin, and Factor VII/VIIa embodiments.
The therapeutic agents of the invention may overcome certain deficiencies of peptide agents when administered (e.g., parenterally), including in some embodiments, the limitation that such peptides may be easily metabolized by plasma proteases or cleared from circulation by kidney filtration. Traditionally, the oral route of administration of peptide agents may also be problematic, because in addition to proteolysis in the stomach, the high acidity of the stomach destroys such peptide agents before they reach their intended target tissue. Peptides and peptide fragments produced by the action of gastric and pancreatic enzymes are cleaved by exo and endopeptidases in the intestinal brush border membrane to yield di- and tripeptides, and even if proteolysis by pancreatic enzymes is avoided, polypeptides are subject to degradation by brush border peptidases. Any of the peptide agents that survive passage through the stomach are further subjected to metabolism in the intestinal mucosa where a penetration barrier prevents entry into the cells. In certain embodiments, the therapeutic agents of the invention may overcome such deficiencies, and provide compositional forms having enhanced efficacy, bioavailability, therapeutic half-life, persistence, degradation assistance, etc. The therapeutic agents of the invention thus include oral and parenteral dose forms, as well as various other dose forms, by which peptide agents can be utilized in a highly effective manner. For example, in some embodiments, such agents may achieve high mucosal absorption, and the concomitant ability to use lower doses to elicit an optimum therapeutic effect.
The therapeutic agents of the present invention may be administered in smaller doses and/or less frequently than unfused or unconjugated counterparts. While one of skill in the art can determine the desirable dose in each case, a suitable dose of the therapeutic agent for achievement of therapeutic benefit, may, for example, be in a range of about 1 microgram (μg) to about 100 milligrams (mg) per kilogram body weight of the recipient per day, preferably in a range of about 10 μg to about 50 mg per kilogram body weight per day and most preferably in a range of about 10 μg to about 50 mg per kilogram body weight per day. The desired dose may be presented as one dose or two or more sub-doses administered at appropriate intervals throughout the day. These sub-doses can be administered in unit dosage forms, for example, containing from about 10 μg to about 1000 mg, preferably from about 50 μg to about 500 mg, and most preferably from about 50 μg to about 250 mg of active ingredient per unit dosage form. Alternatively, if the condition of the recipient so requires, the doses may be administered as a continuous infusion.
The mode of administration and dosage forms will of course affect the therapeutic amount of the peptide active therapeutic agent that is desirable and efficacious for a given treatment application. For example, orally administered dosages can be at least twice, e.g., 2-10 times, the dosage levels used in parenteral administration methods.
The therapeutic agents of the invention may be administered per se as well as in various forms including pharmaceutically acceptable esters, salts, and other physiologically functional derivatives thereof. The present invention also contemplates pharmaceutical formulations, both for veterinary and for human medical use, which include therapeutic agents of the invention. In such pharmaceutical and medicament formulations, the therapeutic agents can be used together with one or more pharmaceutically acceptable carrier(s) therefore and optionally any other therapeutic ingredients. The carrier(s) must be pharmaceutically acceptable in the sense of being compatible with the other ingredients of the formulation and not unduly deleterious to the recipient thereof. The therapeutic agents are provided in an amount effective to achieve the desired pharmacological effect, as described above, and in a quantity appropriate to achieve the desired daily dose.
The formulations of the therapeutic agent include those suitable for parenteral as well as non-parenteral administration, and specific administration modalities include oral, rectal, buccal, topical, nasal, ophthalmic, subcutaneous, intramuscular, intravenous, transdermal, intrathecal, intra-articular, intra-arterial, sub-arachnoid, bronchial, lymphatic, vaginal, and intra-uterine administration. Formulations suitable for oral and parenteral administration are preferred.
When the therapeutic agent is used in a formulation including a liquid solution, the formulation advantageously can be administered orally or parenterally. When the therapeutic agent is employed in a liquid suspension formulation or as a powder in a biocompatible carrier formulation, the formulation may be advantageously administered orally, rectally, or bronchially.
When the therapeutic agent is used directly in the form of a powdered solid, the active agent can be advantageously administered orally. Alternatively, it may be administered bronchially, via nebulization of the powder in a carrier gas, to form a gaseous dispersion of the powder which is inspired by the patient from a breathing circuit comprising a suitable nebulizer device.
The formulations comprising the therapeutic agent of the present invention may conveniently be presented in unit dosage forms and may be prepared by any of the methods well known in the art of pharmacy. Such methods generally include the step of bringing the therapeutic agents into association with a carrier which constitutes one or more accessory ingredients. Typically, the formulations are prepared by uniformly and intimately bringing the therapeutic agent into association with a liquid carrier, a finely divided solid carrier, or both, and then, if necessary, shaping the product into dosage forms of the desired formulation.
Formulations suitable for oral administration may be presented as discrete units such as capsules, cachets, tablets, or lozenges, each containing a predetermined amount of the active ingredient as a powder or granules; or a suspension in an aqueous liquor or a non-aqueous liquid, such as a syrup, an elixir, an emulsion, or a draught.
A tablet may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine, with the therapeutic agent being in a free-flowing form such as a powder or granules which optionally is mixed with a binder, disintegrant, lubricant, inert diluent, surface active agent, or discharging agent. Molded tablets comprised of a mixture of the powdered peptide active therapeutic agent-ELP construct(s) with a suitable carrier may be made by molding in a suitable machine.
A syrup may be made by adding the peptide active therapeutic agent-ELP construct(s) to a concentrated aqueous solution of a sugar, for example sucrose, to which may also be added any accessory ingredient(s). Such accessory ingredient(s) may include flavorings, suitable preservative, agents to retard crystallization of the sugar, and agents to increase the solubility of any other ingredient, such as a polyhydroxy alcohol, for example glycerol or sorbitol.
Formulations suitable for parenteral administration conveniently comprise a sterile aqueous preparation of the therapeutic agent, which preferably is isotonic with the blood of the recipient (e.g., physiological saline solution). Such formulations may include suspending agents and thickening agents or other microparticulate systems which are designed to target the peptide active therapeutic agent to blood components or one or more organs. The formulations may be presented in unit-dose or multi-dose form.
Nasal spray formulations comprise purified aqueous solutions of the therapeutic agent with preservative agents and isotonic agents. Such formulations are preferably adjusted to a pH and isotonic state compatible with the nasal mucus membranes.
Formulations for rectal administration may be presented as a suppository with a suitable carrier such as cocoa butter, hydrogenated fats, or hydrogenated fatty carboxylic acid.
Topical formulations comprise the therapeutic agent dissolved or suspended in one or more media, such as mineral oil, petroleum, polyhydroxy alcohols, or other bases used for topical pharmaceutical formulations.
In addition to the aforementioned ingredients, the formulations of this invention may further include one or more accessory ingredient(s) selected from diluents, buffers, flavoring agents, disintegrants, surface active agents, thickeners, lubricants, preservatives (including antioxidants), and the like.
The features and advantages of the present invention are more fully shown with respect to the following non-limiting examples.

EXAMPLES

Example 1: Construction of Various ELP Component Constructs

Cloning steps were conducted in Escherichia coli strain XL1-Blue (rec A1, endA1, gyrA96, thi-1, hsdR17 (r_k ⁻, m_k+), supE44, relA1, lac[F′, proAB, lαcl^qZΔM15, Tn10 (Tet^r)] (Stratagene La Jolla, Calif.). pUC19 (NEB, Beverly, Mass.) was used as the cloning vector for the ELP construction (Meyer and Chilkoti, Nat. Biotechnol., 17(11):1112-5, 1999). Modified forms of pET15b and pET24d vectors (Novagen) were used to express ELP and ELP-fusion proteins in BL21 Star (DE3) strain (F⁻, ompT, hsdS_B(r_B ⁻ m_B ⁻), gal, dcm, rne131, (DE3)) (Invitrogen Carlsbed, Calif.) or BLR(DE3) (F⁻, ompT, hsdS_B(r_B ⁻ m_B ⁻), gal, dcm, Δ(srl-recA) 306::Tn10(TcR)(DE3)) (Novagen Madison, Wis.). Synthetic DNA oligos were purchased from Integrated DNA Technologies, Coralville, Iowa. All vector constructs were made using standard molecular biology protocols (e.g., Current Protocols in Molecular Biology, ed. Ausubel, et al., 1995).
Construction of ELP1 [V₅A₂G₃] Gene Series
The ELP1 [V₅A₂G₃] series designate polypeptides containing multiple repeating units of the pentapeptide VPGXG (SEQ ID NO: 3), where X is valine, alanine, and glycine at a relative ratio of 5:2:3.
The ELP1 [V₅A₂G₃] series monomer, ELP1 [V₅A₂G₃-10], was created by annealing four 5′ phosphorylated, PAGE purified synthetic oligos to form double stranded DNA with EcoRI and HindIII compatible ends (Meyer and Chilkoti, Nat. Biotechnol., 17(11):1112-5, 1999). The oligos were annealed in a 1 μM mixture of the four oligos in 50 μl IX ligase buffer (Invitrogen) to 95° C. in a heating block than the block was allowed to cool slowly to room temperature. The ELP1 [V₅A₂G₃-10]/EcoRI-HindIII DNA segment was ligated into a pUC19 vector digested with EcoRI and HindIII and CIAP dephosphorylated (Invitrogen) to form pUC19-ELP1 [V₅A₂G₃-10]. Building of the ELP1 [V₅A₂G₃] series library began by inserting ELP1 [V₅A₂G₃-10] PflMI/BglI fragment from pUC19-ELP1 [V₅A₂G₃-10] into pUC19-ELP1 [V₅A₂G₃-10] linearized with PflMI and dephosphorylated with CIAP to create pUC19-ELP1 [V₅A₂G₃-20]. pUC19-ELP1 [V₅A₂G₃-20] was then built up to pUC19-ELP1 [V₅A₂G₃-30] and pUC19-ELP1 [V₅A₂G₃-40] by ligating ELP1 [V₅A₂G₃-10] or ELP1 [V₅A₂G₃-20] PflMI/BglI fragments respectively into PflMI digested pUC 19-ELP1 [V₅A₂G₃-20]. This procedure was used to expand the ELP1 [V₅A₂G₃] series to create pUC19-ELP1 [V₅A₂G₃-60], pUC19-ELP1 [V₅A₂G₃-90] and pUC19-ELP1 [V₅A₂G₃-180] genes.
Construction of ELP1 [K₁V₂F₁] Gene Series
The ELP1 [K₁V₂F₁] series designate polypeptides containing multiple repeating units of the pentapeptide VPGXG (SEQ ID NO: 3), where X is lysine, valine, and phenylalanine at a relative ratio of 1:2:1.
The ELP1 [K₁V₂F₁] series monomer, ELP1 [K₁V₂F₁-4], was created by annealing two 5′ phosphorylated, PAGE purified synthetic oligos to form double stranded DNA with EcoRI and HindIII compatible ends (Meyer and Chilkoti, 1999). The oligos were annealed in a 1 μM mixture of the four oligos in 50 μl 1× ligase buffer (Invitrogen) to 95° C. in a heating block then the block was allowed to cool slowly to room temperature. The ELP1 [K₁V₂F₁-4]/EcoRI-HindIII DNA segment was ligated into a pUC19 vector digested with EcoRI and HindIII and CIAP dephosphorylated (Invitrogen) to form pUC19-ELP1 [K₁V₂F₁-4]. Building of the ELP1 [K₁V₂F₁] series library began by inserting ELP1 [K₁V₂F₁-4] PflMI/Bgl1 fragment from pUC19-ELP1 [K₁V₂F₁-4] into pUC19-ELP1 [K₁V₂F₁-4] linearized with PflM1 and dephosphorylated with CIAP to create pUC19-ELP1 [K₁V₂F₁-8]. Using the same procedure the ELP1 [K₁V₂F₁] series was doubled at each ligation to form pUC19-ELP1 [K₁V₂F₁-16], pUC19-ELP1 [K₁V₂F₁-32], pUC19-ELP1 [K₁V₂F₁-64] and pUC19-ELP1 [K₁V₂F₁-128].
Construction of ELP1 [K₁V₇F₁] Gene Series
The ELP1 [K₁V₇F₁] series designate polypeptides containing multiple repeating units of the pentapeptide VPGXG (SEQ ID NO: 3), where X is lysine, valine, and phenylalanine at a relative ratio of 1:7:1.
The ELP1 [K₁V₇F₁] series monomer, ELP1 [K₁V₇F₁-9], was created by annealing four 5′ phosphorylated, PAGE purified synthetic oligos to form double stranded DNA with PflMI and HindIII compatible ends. The ELP1 [K₁V₇F₁-9] DNA segment was than ligated into PflM1/HindIII dephosphorylated PUC19-ELP1 [V₅A₂G₃-180] vector thereby substituting ELP1 [V₅A₂G₃-180] for ELP1 [K₁V₇F₁-9] to create the pUC19-ELP1 [K₁V₇F₁-9] monomer. The ELP1 [K₁V₇F₁] series was expanded in the same manner as the ELP1 [K₁V₂F₁] series to create pUC19-ELP1 [K₁V₇F₁-18], PUC19-ELP1 [K₁V₇F₁-36], pUC19-ELP1 [K₁V₇F₁-72] and pUC19-ELP1 [K₁V₇F₁-144].

Construction of ELP1 M Gene Series

The ELP1 [V] series designate polypeptides containing multiple repeating units of the pentapeptide VPGXG (SEQ ID NO: 3), where X is exclusively valine.
The ELP1 [V] series monomer, ELP1 [V-5], was created by annealing two 5′ phosphorylated, PAGE purified synthetic oligos to form double stranded DNA with EcoRI and HindIII compatible ends. The ELP1 [V-5] DNA segment was than ligated into EcoRI/HindIII dephosphorylated pUC19 vector to create the pUC19-ELP1 [V-5] monomer. The ELP1 [V] series was created in the same manner as the ELP1 [V₅A₂G₃] series, ultimately expanding pUC19-ELP1 [V-5] to pUC19-ELP1 [V-60] and pUC19-ELP1 [V-120].

Construction of ELP2 Gene Series

The ELP2 series designate polypeptides containing multiple repeating units of the pentapeptide AVGVP.
The ELP2 series monomer, ELP2 [5], was created by annealing two 5′ phosphorylated, PAGE purified synthetic oligos to form double stranded DNA with EcoRI and HindIII compatible ends. The ELP2 [5] DNA segment was than ligated into EcoRI/HindIII dephosphorylated pUC19 vector to create the pUC19-ELP2[5] monomer. The ELP2 series was expanded in the same manner as the ELP1 [K₁V₂F₁] series to create pUC19-ELP2[10], pUC19-ELP2 [30], pUC 19-ELP2 [60] and pUC 19-ELP2 [120].

Construction of ELP3 M Gene Series

The ELP3 [V] series designate polypeptides containing multiple repeating units of the pentapeptide IPGXG (SEQ ID NO: 5), where X is exclusively valine.
The ELP3 [V] series monomer, ELP3 [V-5], was created by annealing two 5′ phosphorylated, PAGE purified synthetic oligos to form double stranded DNA with PfLM1 amino terminal and GGC carboxyl terminal compatible ends due to the lack of a convenient carboxyl terminal restriction site but still enable seamless addition of the monomer. The ELP3 [V-5] DNA segment was then ligated into PflM1/BglI dephosphorylated pUC19-ELP4[V-5], thereby substituting ELP4 [V-5] for ELP3 [V-5] to create the pUC19-ELP3 [V-5] monomer. The ELP3 [V] series was expanded by ligating the annealed ELP3 oligos into pUC19-ELP3[V-5] digested with PflMI. Each ligation expands the ELP3 [V] series by 5 to create ELP3 [V-10], ELP3 [V-15], etc.

Construction of the ELP4 M Gene Series

The ELP4 [V] series designate polypeptides containing multiple repeating units of the pentapeptide LPGXG (SEQ ID NO: 7), where X is exclusively valine.
The ELP4 [V] series monomer, ELP4 [V-5], was created by annealing two 5′ phosphorylated, PAGE purified synthetic oligos to form double stranded DNA with EcoRI and HindIII compatible ends. The ELP4 [V-5] DNA segment was than ligated into EcoRI/HindIII dephosphorylated pUC19 vector to create the pUC19-ELP4[V-5] monomer. The ELP4 [V] series was expanded in the same manner as the ELP1 [K₁V₂F₁] series to create pUC19-ELP4[V-10], pUC19-ELP4[V-30], pUC19-ELP4[V-60] and pUC19-ELP4[V-120].
The ELP genes were also inserted into other vectors such as pET15b-SD0, pET15b-SD3, pET15b-SD5, pET15b-SD6, and pET24d-SD21. The pET vector series are available from Novagen, San Diego, Calif.
The pET15b-SD0 vector was formed by modifying the pET15b vector using SD0 double-stranded DNA segment containing the multicloning restriction site (SacI-NdeI-NcoI-XhoI-SnaBI-BamHI). The SD0 double-stranded DNA segment had XbaI and BamHI compatible ends and was ligated into XbaI/BamHI linearized and 5-dephosphorylated pET15b to form the pet15b-SD0 vector.
The pET15b-SD3 vector was formed by modifying the pET15b-SD0 vector using SD3 double-stranded DNA segment containing a SfiI restriction site upstream of a hinge region-thrombin cleavage site followed by the multicloning site (NdeI-NcoI-XhoI-SnaBI-BamHI). The SD3 double-stranded DNA segment had SacI and NdeI compatible ends and was ligated into SacI/NdeI linearized and 5-dephosphorylated pET15b-SD0 to form the pET15b-SD3 vector.
The pET15b-SD5 vector was formed by modifying the pET15b-SD3 vector using the SD5 double-stranded DNA segment containing a SfiI restriction site upstream of a thrombin cleavage site followed by a hinge and the multicloning site (NdeI-NcoI-XhoI-SnaBI-BamHI). The SD5 double-stranded DNA segment had SfiI and NdeI compatible ends and was ligated into SfiI/NdeI linearized and 5-dephosphorylated pET15b-SD3 to form the pET15b-SD5 vector.
The pET15b-SD6 vector was formed by modifying the pET15b-SD3 vector using the SD6 double-stranded DNA segment containing a SfiI restriction site upstream of a linker region-TEV cleavage site followed by the multicloning site (NdeI-NcoI-XhoI-SnaBI-BamHÏ). The SD6 double-stranded DNA segment had SfiI and NheI compatible ends and was ligated into SfiI/NdeI linearized and 5-dephosphorylated pET15b-SD3 to form the pET15b-SD6 vector.
The pET24d-SD21 vector was formed by modifying the pET24d vector using the SD21 double-stranded DNA segment with NcoI and NheI compatible ends. The SD21 double-stranded DNA segment was ligated into NcoI/NheI linearized and 5′ dephosphorylated pET24d to create the pET24d-SD21 vector, which contained a new multi-cloning site NcoI-SfiI-NheI-BamHI-EcoRI-SacI-San-HindIII-NotI-XhoI with two stop codons directly after the SfiI site for insertion and expression of ELP with the minimum number of extra amino acids.
The pUC19-ELP1 [V₅A₂G₃-60], pUC19-ELP1 [V₅A₂G₃-90], and pUC19-ELP1 [V₅A₂G₃-180] plasmids produced in XL1-Blue were digested with PflMI and BglI, and the ELP-containing fragments were ligated into the SfiI site of the pET15b-SD3 expression vector as described hereinabove to create pET15b-SD3-ELP1 [V₅A₂G₃-60], pET15b-SD5-ELP1 [V₅A₂G₃-90] and pET15b-SD5-ELP1 [V₅A₂G₃-180], respectively.
The pUC19-ELP1 [V₅A₂G₃-90], pUC19-ELP1 [V₅A₂G₃-180], pUC19-ELP1 [V-60] and pUC19-ELP1 [V-120] plasmids produced in XL1-Blue were digested with PflMI and BglI, and the ELP-containing fragments were ligated into the SfiI site of the pET15b-SD5 expression vector as described hereinabove to create pET15b-SD5-ELP1 [V₅A₂G₃-90], pET15b-SD5-ELP1 [V₅A₂G₃-180], pET15b-SD5-ELP1 [V-60] and pET15b-SD5-ELP1 [V-120], respectively.
The pUC19-ELP1 [V₅A₂G₃-90] plasmid produced in XL1-Blue was digested with PflMI and BglI, and the ELP-containing fragment was ligated into the SfiI site of the pET15b-SD6 expression vector as described hereinabove to create pET15b-SD6-ELP1 [V₅A₂G₃-90].
The pUC19-ELP1 [K₁V₂F₁-64], and pUC19-ELP1 [K₁V₂F₁-128] plasmids produced in XL1-Blue were digested with PflMI and BglI, and the ELP-containing fragments were ligated into the SfiI site of the pET24d-SD21 expression vector as described hereinabove to create pET24d-SD21-ELP1 [K₁V₂F₁-64] and pET24d-SD21-ELP1 [K₁V₂F₁-128], respectively.
The pUC19-ELP1 [K₁V₇F₁-72] and pUC19-ELP1 [K₁V₇F₁-144] plasmids produced in XL1-Blue were digested with PflMI and BglI, and the ELP-containing fragments were ligated into the SfiI site of the pET24d-SD21 expression vector as described hereinabove to create pET24d-SD21-ELP1 [K₁V₇F₁-72], pET24d-SD21-ELP1 [K₁V₇F₁-144], respectively.
The pUC19-ELP2[60] and pUC19-ELP2[120] plasmids produced in XL1-Blue were digested with NcoI and HindIII, and the ELP-containing fragments were ligated into the NcoI and HindIII sites of the pET24d-SD21 expression vector as described hereinabove to create pET24d-SD21-ELP2[60], pET24d-SD21-ELP2[120], respectively.
The pUC19-ELP4[V-60] and pUC19-ELP4[V-120] plasmids produced in XL1-Blue were digested with NcoI and HindIII, and the ELP-containing fragments were ligated into the NcoI and HindIII sites of the pET24d-SD21 expression vector as described hereinabove to create pET24d-SD21-ELP4[V-60], pET24d-SD21-ELP4[V-120], respectively.

Example 2: Isolation and Purification of Fusion Proteins Containing Insulin a Peptide (Insa)

ELP-InsA fusion proteins included the following:
Insulin A peptide and ELP1 [V-60] polypeptide with an enterokinase protease cleavage site therebetween.
Insulin A peptide and ELP1 [V₅A₂G₃-90] polypeptide with an enterokinase protease cleavage site therebetween.
Insulin A peptide and ELP1 [V-120] polypeptide with an enterokinase protease cleavage site therebetween.
Insulin A peptide and ELP1 [V₅A₂G₃-180] polypeptide with an enterokinase protease cleavage site therebetween.
A single colony of E. coli strain BLR (DE3) (Novagen) containing the respective ELP-InsA fusion protein was inoculated into 5 ml CircleGrow (Q-BIOgene, San Diego, Calif.) supplemented with 100 μg/ml ampicillin (Sigma) and grown at 37° C. with shaking at 250 rpm for 5 hours. The 5 ml culture was then inoculated into a 500 ml culture and allowed to grow at 25° C. for 16 hours before inducing with 1 mM IPTG for 4 hours at 25° C. The culture was harvested and suspended in 40 ml 20 mM Tris-HCl pH 7.4, 50 mM NaCl, 1 mM DTT and 1 Complete EDTA free Protease inhibitor pellet (Roche, Indianapolis, Ind.). Cells were lysed by ultrasonic disruption on ice for 3 minutes, which consisted of 10 seconds bursts at 35% power separated by 30 second cooling down intervals. Cell debris was removed by centrifugation at 20,000 g, 4° C. for 30 minutes.
Inverse phase transition was induced by adding NaCl to the cell lysate at room temperature to achieve a final concentration of 1.0 M therein, followed by centrifugation at 20,000 g for 15 minutes at room temperature. The resulting pellet contained the respective ELP-InsA fusion protein and non-specifically NaCl precipitated proteins.
The pellet was re-suspended in 40 ml ice-cold ml 20 mM Tris-HCl pH 7.4, 50 mM NaCl, 1 mM DTT and re-centrifuged at 20,000 g, 4° C. for 15 minutes to remove the non-specifically NaCl precipitated proteins. The inverse transition cycle was repeated two additional times to increase the purity of the respective ELP-InsA fusion protein and reduce the final volume to 0.5 ml.

Example 3: Half-Life of ELP1

The pharmacokinetics of ELP1 were determined by intravenously administering [¹⁴C]ELP1 to nude mice (Balb/c nu/nu) bearing a leg/flank FaDu xenograft and collecting blood samples at various time intervals after administration. The blood pharmacokinetics exhibited a characteristic distribution and elimination response for large macromolecules, which was well described by a bi-exponential process.
The plasma concentration time-course curve was fit to the analytical solution of a two-compartment model to approximate both an elimination and distribution response. Certain pharmakinetic parameters are shown in Table 1 below. The distribution volume of the ELP (1.338 μl) was nearly identical to the hypothetical plasma volume of 1.363 μl (Barbee, R. W., et al., Am. J. Physio. 263(3) (1992) R728-R733), indicating that the ELP did not rapidly distribute or bind to specific organs and tissues directly after administration. The AUC is a measure of the cumulative exposure to ELP in the central compartment or the blood plasma. The body clearance is defined as the rate of ELP elimination in the body relative to its plasma concentration and is the summation of clearance through all organs including the kidney, liver and others.

TABLE 1

Pharmacokinetic parameters calculated for [¹⁴C]ELP1

k₁	k₂	k_e	V_d	AUC	Cl_B
(hr⁻¹)	(hr⁻¹)	(hr⁻¹)	(μL)	(mg ELP hr/ml)	(μL/hr)

ELP1-150	3.54	1.99	0.24	1,338	7.1	317

The mass transfer rate constants are from a standard two-compartment model (k₁; from central to peripheral compartment; k₂, from peripheral to central compartment; and k_e, elimination from central compartment). The distribution volume (V_d), central compartment concentration time-course area under the curve (AUC) and body clearance (Cl_B) are displayed. Data are shown as the mean values (n=5, except V_dand initial plasma concentration (C_O) was calculated from a similar cohort with n=3).

Example 4: Biodistribution of ELPs in Nude Mice

¹⁴C Labeled ELP1-150 and/or ¹⁴C Labeled ELP2-160
¹⁴C labeled ELP1-150 and/or ¹⁴C labeled ELP2-160 were administered to nude mice with a FaDu tumor (mean+/−SD, n=6). The tumor was heated post administration of the ELP in a water bath at 41.5° C. The distribution was highest to the organs with the highest blood content: liver, kidneys, spleen, and lungs.
¹⁴C Labeled ELP2-[V₁A₈G₇-160]
¹⁴C labeled ELP2-[V₁A₈G₇-160] (T_t>60° C.) was administered to nude mice for a plasma concentration of 15 μM. ELP concentrations were determined following 1 hour of heating (41° C.) of an implanted FaDu tumor, located in the right hind leg of the nude mouse. Data are shown as the mean, plus the 95% confidence interval. N=6.
ELP concentration was measured 1.5 hours following systemic administration of ¹⁴C labeled ELP2-[V₁A₈G₇-160]. The highest distribution is seen in organs with the highest blood content: liver, kidneys, spleen, and lungs.

Example 5: Exendin-4 ELP Fusion

The DNA sequence for Exendin-4 (Ex-4) (SEQ ID NO: 14) was reverse translated from the amino acid sequence using codons optimized for E. coli expression. The DNA sequence encoding Exendin-4 was constructed by annealing together synthetic oligonucleotides with overhanging 5′ and 3′ ends compatible with the restriction sites NdeI and XhoI in the plasmid pET24d-ELP1-90 (FIG. 1 ). This plasmid was digested with the restriction enzymes NdeI and XhoI and the annealed DNA sequence was ligated into the cut vector. Insertion was confirmed by restriction digest and DNA sequencing. The resulting plasmid was designated as pET24d-Ex-4 ELP1-90 (FIG. 2A), and the sequence of the resulting Exendin-4-ELP fusion shown in FIG. 2B. Primers for construction of the fusion are also indicated.
pET24d-Ex-4 ELP1-90 was used to transform the E. coli strain BRL (Invitrogen) and selected transformants were grown in media 3 (1.2% Tryptone Peptone, 2.4% yeast extract, 5 g/L casamino acids, 2% glycerol, 2.313 g Potassium phosphate dibasic/L, 12.541 g Potassium phosphate monobasic/L) in shake flasks. Production proceeded by autoinduction by inoculating 1 OD cells into 1L of media 3 and allowing growth to proceed for 17 hr at 37° C. without addition of inducer. The product was recovered by collection of the cell pellet, sonicated to disrupt the cells and recovered by thermal and/or salt induced transition modulated by the ELP moiety (Improved Non-chromatographic Purification of a Recombinant Protein by Cationic Elastin-like Polypeptides, Dong Woo Lim, Kimberly Trabbic-Carison, J. Andrew MacKay, and Ashutosh Chilkoti. Biomacromolecules 2007, 8, 1417-1424).
This example is with the ELP designated 1-90. This is based on the VPGXG (SEQ ID NO: 3) motif where X is a V, G or A in the ratio 5:3:2 in a 10 unit repeat, repeated 8× with a final (C-terminal) 10-unit repeat where X is a V, G, A and W in the ratio 4:3:2:1.
[(VPGXG)10]₉where the X residue in the ten sequential iterations of the repeat unit (numerical subscript) can be described as [(V_{1, 4, 5, 6, 10}G_{2, 7, 9}A_{3, 8})₈(V_{1, 4, 5, 6}G_{2, 7, 9}A_{3, 8}W₁₀)].
The ELP may be any combination of VPGXG (SEQ ID NO: 3) units where X is any of the 20 natural amino, acids, except proline, in any combination of repeat units of any length. In addition, the amino acid may be an unnatural amino acid for which the host strain has been engineered to accept an engineered tRNA for incorporation at specific codon (Wang L, Brock A, Herberich B, Schultz PG. Expanding the genetic code of Escherichia coli. [2001] Science 292, 498-500).
This construct was produced in the cytosol with an N-terminal methionine, which is normally removed by methionine aminopeptidase. Complete and accurate processing of the methionine, however, cannot be assumed; this enzyme may also remove the N-terminal histidine of the Exendin-4 moiety. This could result in a mixture of, unprocessed, processed and incorrectly processed products. Consequently, further constructs were developed to generate products with correctly processed N-termini.
Primers were designed to add a Tev protease (Tobacco Etch Virus cysteine protease) cleavage site between the N-terminal methionine and the histidine at the N-terminus of Exendin-4. This allows for removal of the methionine and the Tev recognition sequence to give the mature N-terminus of Exendin-4 (histidine). This can be done post-production or the Tev protease can be co-expressed to cleave the recognition sequence during production, for instance, as an intein (Ge, X., Yang, D. S. C., Trabbic-Carison, K., Kim, B., Chilkoti, A. and Filipe, C. D. M. Self-Cleavable Stimulus Responsive Taos for Protein Purification without Chromatography. J. Am. Chem. Soc. 127, 11228-11229, 2005). The Tev Exendin-4 sequence is shown in FIG. 3A. FIG. 3B shows additional sequences added, labeled as “Linker Tev,” provide a better target for the Tev protease.
An alternative route to obtaining a correctly processed N-terminus for Ex-4 is to use a leader or signal sequence that directs the product to the periplasm and which is cleaved by a signal peptidase in the process. In this instance, a signal sequence, DsbA, that directs the transcript to the signal recognition particle for direct secretion of the polypeptide into the periplasm is given. (See FIG. 4A). The plasmid pET24d-DsbA-Ex-4 ELP1-90 is shown in FIG. 4B.
While this example illustrates the preparation of therapeutic agents with Exendin-4 sequences, such sequences can be replaced with GLP-1, insulin, Factor VII/VIIa, or other therapeutic protein listed in Table 1, generated in exactly or a similar manner as detailed for Exendin-4.

Example 6: GLP1-ELP Fusion Protein

The ELP plasmid constructs were used to prepare two GLP1-ELP fusion proteins, GLP1(A8G,7-37)ELP1-90 and GLP1(A8G,7-37)ELP1-120. The plasmid constructs, fusion-encoding nucleotide sequence, as well as the amino acid sequence of the resulting fusion proteins are shown in FIGS. 5 and 6 .
Both constructs contain an N-terminal Tev protease site to allow processing to the mature form where His⁷of GLP1 is at the N-terminus. The processed fusion proteins have calculated molecular weights of about 39,536 and about 50,828, respectively.

Example 7: FVII ELP Fusion Protein

The coagulation factor VII (FVII) gene was modified by PCR from a cDNA clone (Oragene) to add restriction sites at the 5′ and 3′ ends for cloning into the ELP-containing vector. At the 5′ end an NheI site was added and at the 3′ end a NotI site was added. The DNA and amino acid sequences of the Factor VII gene are shown in the accompanying Sequence Listing as SEQ ID NOS: 34 and 33, respectively. The DNA sequences of the 5′ and 3′ primers used to PCR amplify the factor VII (FVII) gene were:

	P13:
	(SEQ ID NO.: 49)
	CTAGCTAGCATGGTCTCCCAGGCCCTC

	P14:
	(SEQ ID NO.: 50)
	TATTCTTGCGGCCGCGGGAAATGGGGCTCGCAG

The resulting PCR fragment was digested with the restriction enzymes NheI and NotI and ligated into the plasmid pcDNA3.1+ ELP1-90 previously digested with the restriction enzymes NheI and NotI (FIG. 7A).
The resulting plasmid, pcDNA3.1+ FVII-ELP1-90, was transiently transfected into HEK293 cells and culture media harvested. The ELP fusion was purified by phase transition (FIGS. 9 and 10 ).
The nucleotide and amino acid sequences of the FactorVII-ELP fusion is shown in FIG. 7B. As shown, the FactorVII-ELP fusion protein contains a Tev protease linker between the FactorVII component and the ELP component. This linker is optional.

Example 8: Insulin ELP Fusion Protein

The cDNA for the human insulin gene is modified at the 5′ and 3′ ends for insertion in to pET24d-ELP1-90. The 5′ primer adds an N-terminal methionine for bacterial expression and an NdeI restriction enzyme site. The 3′ primer adds an XhoI restriction enzyme site. The PCR product and the plasmid are both digested with the restriction enzymes NdeI and XhoI and ligated together. The sequence of the insulin (Chains B, C, and A fused to ELP1 is shown in FIG. 8A.
Correct insertion is determined by restriction digest and DNA sequencing. The resulting plasmid, designated pET24d Insulin-ELP1-90, is shown in FIG. 8B.
The native insulin form is generated after recovery from E. coli by treatment with trypsin and carboxypeptidase B to remove the C-peptide chain.
For correct processing of the N-terminus of the B-chain similar modifications to those made for the Exendin-4 fusion (protease cleavage site, signal sequence) can be implemented (see Example 4). Alternatively, the first two residues can be Met-Arg, which can also be removed by trypsin digestion in production of the final material (R. M. Belagaje, S. G. Reams, S. C. Ly and W. F. Prouty, Increased production of low molecular weight recombinant proteins in Escherichia coli. Protein Sci. 6, 1953-1962, 1997).
Additional constructs would place the insulin cDNA at the 3′ end of the ELP for a C-terminal fusion, add linkers between the Insulin and ELP sequences, and/or use modified forms of insulin which have no C-peptide (single chain insulins as described) removing the need for additional processing.

Example 9: Synthesis of the ELP Gene for Conjugation

A gene encoding a 50 amino acid sequence was constructed from chemically-synthesized oligonucleotides using standard molecular biology protocols. The 50 amino acid sequence contained 10 repeats of the pentapeptide VPGXG (SEQ ID NO: 3), where the guest residues (V, G, and A in a 5:3:2 molar ratio) were selected to provide a Tt of 40° C. The gene was oligomerized end-to-end by standard molecular biology techniques, to produce an oligomeric ELP gene. Additionally a single 50 amino acid sequence was constructed containing the 10 repeat pentapeptide VPGXG (SEQ ID NO: 3) polypeptide where the guest residues were V, G, A and C in a 4:3:2:1 molar ratio. This sequence could be added at any cycle of the oligomerization process to introduce a single cysteine residue into the final construct at a chosen point along the length of the construct.
The example given here is with the ELP designated 1-90. This is based on the VPGXG (SEQ ID NO: 3) motif where X is a V, G or A in the ratio 5:3:2 in a 10-unit repeat, repeated 8× with a final (C-terminal) 10-unit repeat where X is a V, G, A and C in the ratio 4:3:2:1, i.e., [(VPGXG)10]9 (SEQ ID NO.: 3).
Alternatively, the residue could be one of either arginine, lysine, aspartic acid or glutamic acid. The purpose of these amino acids is to provide a reactive side chain for the chemical conjugation of, for example, insulin. In this particular case the use of an ELP would be to extend the circulating half-life of the therapeutic protein (e.g., insulin) to provide prolonged basal glucose control. Conjugated to an ELP that transitions at body temperature, the insulin would form a precipitated depot at the site of injection in a similar manner to Lantus® (Sanofi Aventis) but without the requirement for formulation in acidic (pH 4.0) conditions with m-cresol for a more tolerable injection.

Example 10: Potency and Half-Life of Factor VII-ELP

FIG. 11 shows the activation of Factor X by FactorVIIa-ELP1-90, and by Factor VIIa as a comparison. Factor VII-ELP was produced in HEK cells. Factor VIIa was derived from human plasma. As shown, FactorVIIa-ELP retains full activity.
When administered to rats by i.v., Factor VII-ELP demonstrated a half-life of about 690 minutes. In contrast, Factor VII demonstrated a half-life of 45-60 minutes. Half-life in this example was measured by sandwich ELISA for FactorVII. FIG. 12 .
Also in contrast, the reported half-life for NovoSeven™ is 45 minutes, the reported half-life for FactorVIIa-albumin fusion is 263 minutes, and the reported half-life for Factor VIIa-PEG is 300 minutes in mice and 600 minutes in dog.

Example 11: GLP-1 (or Exendin-4) In Vitro Bioassay

Activation of the GLP-1 receptor (GLP1R) results in production of cAMP secondary messenger within the cell. Therefore, GLP-1 or Exendin-4 analogs and corresponding therapeutic agents may be tested by their ability to activate GLP1R on the cell surface and produce cAMP.
For this bioassay CHO cells transfected with cDNA coding for GLP1R are used. These cells respond to stimulation by GLP-1 and produce high levels of cAMP. Log phase growing cells are plated and increasing concentrations of test compounds (e.g., therapeutic agent of the invention, or GLP-1 or exendin-4 functional analog) are added to the cells. After an appropriate incubation period (usually 15-60 min) in physiological buffer at 37° C. the cAMP produced is measured using a CatchPoint cAMP assay kit from Molecular Devices (Sunnyvale, Calif.). The EC₅₀of each test compound as compared to GLP-1 peptide or Exendin-4 peptide (or as compared to an unfused or unconjugated counterpart of a therapeutic agent of the invention) is indicative of the changes in activity due to a specific modifications introduced into the peptide, or due to particular chemical or recombinant coupling to an ELP component.
As shown in FIG. 13 , both GLP1-ELP (PB0868) and Exendin-4-ELP (PB 0859) maintain high activity in vitro, shown in comparison to Exendin alone. It is of note that the specific activity of Albugon® and Liraglutide® run 50-100 fold less than the exendin peptide.

Example 12: GLP-1 (or Exendin-4) In Vivo Bioassay

The activity of GLP-1 or Exendin analogues or corresponding therapeutic agents may be tested in animals. For this assay, normal or diabetic animals may be used. Diabetic animals with blood glucose concentration 300-500 mg/dl are injected with different doses of GLP-1 or Exendin analogues or corresponding therapeutic agent, and changes in blood glucose monitored with a glucometer. The drop in glucose at different times points post administration is compared to that resulting with standard amounts of GLP-1 or Exendin-4 peptide, or compared to an unfused or unconjugated counterpart of a therapeutic agent of the invention. Alternatively, the blood glucose excursion in normal or diabetic animals during specific time period after administration of exogenous glucose is compared to GLP-1 or Exendin-4 (or to unfused or unconjugated counterparts of therapeutic agents). In this way the activity of the analogues and fusion proteins can be compared to the natural peptides.
FIG. 14 shows the pharmacokinetics of GLP1-ELP1-120 in rats administered both by i.v. and subcutaneously. Three rats were used for each time point. The dose was ˜10 mg/kg. The T_1/2when administered by i.v. was about 12.9 hours. The T_1/2when administered subcutaneously was about 8.6 hours.
FIG. 15 shows the pharmacokinetics of GLP1-ELP1-120 in rabbits administered both by i.v. and subcutaneously. Three rabbits were used for each time point. The dose was ˜1 mg/kg. The T_1/2when administered by i.v. was about 20 hours. The T_1/2when administered subcutaneously was about 24 hours.
FIG. 16 shows the sustained glycemic control in diabetic mice with GLP1-ELP1-90.
All reference cited herein are hereby incorporated by reference in their entireties. While the invention has been has been described herein in reference to specific aspects, features and illustrative embodiments of the invention, it will be appreciated that the utility of the invention is not thus limited, but rather extends to and encompasses numerous other variations, modifications and alternative embodiments, as will suggest themselves to those of ordinary skill in the field of the present invention, based on the disclosure herein

Claims

What is claimed is:

1. A therapeutic agent comprising an elastin-like peptide (ELP) component and a therapeutic component, the therapeutic component having an extended circulatory half-life and/or a lower therapeutically effective dose when compared to the therapeutic component alone.

2. The therapeutic agent of claim 1, wherein the therapeutic component is a therapeutic protein listed in Table 1 or a functional portion or functional analog thereof.

3. The therapeutic agent of claim 2, wherein an ELP component is covalently bonded to the therapeutic protein at an N- and/or C-terminus thereof.

4. The therapeutic agent of any one of claims 1-3, wherein a therapeutic component is covalently bonded to the ELP component at the N-terminus of the ELP component, and a second therapeutic component is covalently bonded to the ELP component at the C-terminus of the ELP component.

5. The therapeutic agent of any one of claims 1-4, wherein a therapeutic component is covalently bonded to the ELP component at an N- and/or C-terminus thereof.

6. The therapeutic agent of any one of claims 1-5, wherein a first ELP component is covalently bonded to the therapeutic component at the N-terminus of the therapeutic component, and a second ELP component is covalently bonded to the therapeutic component at the C-terminus of the therapeutic component.

7. The therapeutic agent of any one of claims 1-6, further comprising a spacer moiety between the ELP component and the therapeutic component.

8. The therapeutic agent of claim 7, wherein the spacer moiety comprises one or more of a protease-resistant moiety, a non-peptide chemical moiety, and a protease cleavage site.

9. The therapeutic agent of claim 8, wherein the protease cleavage site is a thrombin cleavage site, a factor Xa cleavage site, a metalloprotease cleavage site, an enterokinase cleavage site, a Tev cleavage site, and a cathepsin cleavage site.

10. The therapeutic agent of claim 9, wherein the spacer moiety comprises a non-cleavable moiety having the formula [(Gly)_n-Ser]_m(SEQ ID NO: 22) where n is from 1 to 4, inclusive, and m is from 1 to 4, inclusive.

11. The therapeutic agent of any one of claims 1-10, wherein the ELP comprises at least one repeating unit selected from SEQ ID NOS: 1-12.

12. The therapeutic agent of claim 11, wherein said repeating unit is VPGXG (SEQ ID NO: 3).

13. The therapeutic agent of claim 12, wherein X is any natural or non-natural amino acid residue, and wherein X varies among at least two units.

14. The therapeutic agent of claim 13, wherein each X is independently selected from alanine, arginine, asparagine, aspartic acid, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, serine, threonine, tryptophan, tyrosine and valine residues.

15. The therapeutic agent of any one of claims 1-14, wherein the therapeutic agent has a molecular weight of less than about 50 kDa.

16. The therapeutic agent of any one of claims 1-15, wherein the ELP component has a Tt greater than 37° C.

17. The therapeutic agent of any one of claims 1-16, wherein the therapeutic agent is a genetically encoded fusion protein.

18. A polynucleotide comprising a nucleotide sequence encoding the therapeutic agent of claim 17.

19. The polynucleotide of claim 18, further comprising an expression control element operably linked to said nucleotide sequence.

20. The polynucleotide of claim 19, wherein said expression control element comprises a promoter.

21. A vector comprising the polynucleotide of any one of claims 18-20.

22. An isolated host cell containing the vector of claim 21 or the polynucleotide of any one of claims 18-20.

23. A pharmaceutical composition comprising the therapeutic agent of any one of claims 1-18, and a pharmaceutically acceptable carrier and/or excipient.

24. A method of treating or preventing a disease, disorder, or condition in a subject, comprising administering an effective amount of the therapeutic agent of any one of claims 1-17 or the pharmaceutical composition of claim 23 to a subject in need thereof.

25. The method of claim 24, wherein the subject has an indication listed in Table 1.

26. A therapeutic agent comprising an elastin-like peptide (ELP) component and a glucagon-like peptide (GLP)-1 receptor agonist.

27. The therapeutic agent of claim 26, wherein the GLP-1 receptor agonist is GLP-1 or functional analog thereof.

28. The therapeutic agent of claim 26, wherein the GLP-1 receptor agonist is an exendin-4 or functional analog thereof.

29. The therapeutic agent of any one of claims 26-28, wherein the ELP component is covalently bonded to the GLP-1 receptor agonist at an N- and/or C-terminus thereof.

30. The therapeutic agent of any one of claims 26-29, wherein a first GLP-1 receptor agonist is covalently bonded to the ELP component at the N-terminus of the ELP component, and a second GLP-1 receptor agonist is covalently bonded to the ELP component at the C-terminus of the ELP component.

31. The therapeutic agent of any one of claims 26-30, wherein the GLP-1 receptor agonist is covalently bonded to the ELP component at an N- and/or C-terminus thereof.

32. The therapeutic agent of any one of claims 26-31, wherein a first ELP component is covalently bonded to the GLP-1 receptor agonist at the N-terminus of the GLP-1 receptor agonist, and a second ELP component is covalently bonded to the GLP-1 receptor agonist at the C-terminus of the GLP-1 receptor agonist.

33. The therapeutic agent of any one of claims 26-32, further comprising a spacer moiety between the ELP component and GLP-receptor agonist.

34. The therapeutic agent of claim 33, wherein the spacer moiety comprises one or more of a protease-resistant moiety, a non-peptide chemical moiety, and a protease cleavage site.

35. The therapeutic agent of claim 34, wherein the protease cleavage site is a thrombin cleavage site, a factor Xa cleavage site, a metalloprotease cleavage site, an enterokinase cleavage site, a Tev cleavage site, and a cathepsin cleavage site.

36. The therapeutic agent of claim 34, wherein the spacer moiety comprises a non-cleavable moiety having the formula [(Gly)_n-Ser]_m(SEQ ID NO.: 22) where n is from 1 to 4, inclusive, and m is from 1 to 4, inclusive.

37. The therapeutic agent of any one of claims 26-36, wherein the ELP comprises at least one repeating unit selected from SEQ ID NOS: 1-12.

38. The therapeutic agent of claim 37, wherein said repeating unit is VPGXG (SEQ ID NO: 3).

39. The therapeutic agent of claim 38, wherein X is any natural or non-natural amino acid residue, and wherein X varies among at least two units.

40. The therapeutic agent of claim 38, wherein each X is independently selected from alanine, arginine, asparagine, aspartic acid, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, serine, threonine, tryptophan, tyrosine and valine residues.

41. The therapeutic agent of any one of claims 26-40, wherein the therapeutic agent has a molecular weight of less than about 50 kDa.

42. The therapeutic agent of any one of claims 26-40, wherein the ELP component has a Tt greater than 37° C.

43. The therapeutic agent of any one of claims 26-42, wherein the therapeutic agent is a genetically encoded fusion protein.

44. A polynucleotide comprising a nucleotide sequence encoding the therapeutic agent of claim 43.

45. The polynucleotide of claim 44, further comprising an expression control element operably linked to said nucleotide sequence.

46. The polynucleotide of claim 45, wherein said expression control element comprises a promoter.

47. A vector comprising the polynucleotide of any one of claims 44-46.

48. An isolated host cell containing the vector of claim 47 or the polynucleotide of any one of claims 44-46.

49. A pharmaceutical composition comprising the therapeutic agent of any one of claims 26-43, and a pharmaceutically acceptable carrier and/or excipient.

50. A method of treating or preventing a biological condition, disorder, or disease in a subject, comprising administering an effective amount of the therapeutic agent of any one of claims 26-43 or the pharmaceutical composition of claim 49 to a subject in need thereof.

51. The method of claim 50, wherein the subject has diabetes.

52. A therapeutic agent comprising an elastin-like peptide (ELP) component and an insulin or functional analog thereof.

53. The therapeutic agent of claim 52, wherein the ELP component is covalently bonded to the insulin or functional analog at an N- and/or C-terminus thereof.

54. The therapeutic agent of claim 52 or 53, wherein a first insulin or functional analog is covalently bonded to the ELP component at the N-terminus of the ELP component, and a second insulin or functional analog is covalently bonded to the ELP component at the C-terminus of the ELP component.

55. The therapeutic agent of claim 52, wherein the insulin or functional analog is covalently bonded to the ELP component at an N- and/or C-terminus thereof.

56. The therapeutic agent of claim 52 or 53, wherein a first ELP component is covalently bonded to the insulin or functional analog at an N-terminus thereof, and a second ELP component is covalently bonded to the insulin or functional analog at a C-terminus thereof.

57. The therapeutic agent of any one of claims 52-56, further comprising a spacer moiety between the ELP component and the insulin or functional analog.

58. The therapeutic agent of claim 57, wherein the spacer moiety comprises one or more of a protease-resistant moiety, a non-peptide chemical moiety, and a protease cleavage site.

59. The therapeutic agent of claim 58, wherein the protease cleavage site is a thrombin cleavage site, a factor Xa cleavage site, a metalloprotease cleavage site, an enterokinase cleavage site, a Tev cleavage site, or a cathepsin cleavage site.

60. The therapeutic agent of claim 58, wherein the spacer moiety comprises a non-cleavable moiety having the formula [(Gly)_n-Ser]_m(SEQ ID NO: 22) where n is from 1 to 4, inclusive, and m is from 1 to 4, inclusive.

61. The therapeutic agent of any one of claims 52-60, wherein the ELP component comprises at least one repeating unit selected from SEQ ID NOS: 1-12.

62. The therapeutic agent of claim 61, wherein said repeating unit is VGPXG (SEQ ID NO: 3).

63. The therapeutic agent of claim 61, wherein the repeating unit is Ile-Pro-Gly-X-Gly (SEQ ID NO: 5) or Leu-Pro-Gly-X-Gly (SEQ ID NO: 7), wherein X is any natural or non-natural amino acid residue, and wherein X varies among at least two units.

64. The therapeutic agent of claim 62 or 63, wherein each X is independently selected from alanine, arginine, asparagine, aspartic acid, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, serine, threonine, tryptophan, tyrosine and valine residues.

65. The therapeutic agent of any one of claims 52-64, wherein the therapeutic agent has a molecular weight of less than about 50 kDa.

66. The therapeutic agent of any one of claims 52-65, wherein the ELP component has a Tt greater than 37° C.

67. The therapeutic agent of any one of claims 52-66, wherein the therapeutic agent is a genetically encoded fusion protein.

68. A polynucleotide comprising a nucleotide sequence encoding the therapeutic agent of claim 67.

69. The polynucleotide of claim 68, further comprising an expression control element operably linked to said nucleotide sequence.

70. The polynucleotide of claim 69, wherein said expression control element comprises a promoter.

71. A vector comprising the polynucleotide of any one of claims 68-70.

72. An isolated host cell containing the vector of claim 71 or the polynucleotide of any one of claims 68-70.

73. A pharmaceutical composition comprising the therapeutic agent of any one of claims 52-67, and a pharmaceutically acceptable carrier and/or excipient.

74. A method of preventing or treating a biological condition, disorder, or disease in a subject, comprising administering an effective amount of the therapeutic agent of any one of claims 52-67 or the pharmaceutical composition of claim 73 to a subject in need thereof.

75. The method of claim 74, wherein the subject has diabetes.

76. A therapeutic agent comprising an elastin-like peptide (ELP) component and a Factor VII/VIIa or functional analog thereof.

77. The therapeutic agent of claim 76, wherein the ELP component is covalently bonded to the Factor VII/VIIa or functional analog at an N- and/or C-terminus of the Factor VII/VIIa.

78. The therapeutic agent of claim 76 or 77, wherein a first Factor VII/VIIa or functional analog is covalently bonded to the ELP at the N-terminus of the ELP component, and a second Factor VII/VIIa or functional analog is covalently bonded to the ELP component at the C-terminus of the ELP component.

79. The therapeutic agent of claim 76, wherein the Factor VII/VIIa or functional analog is covalently bonded to the ELP component at an N- and/or C-terminus of the ELP component.

80. The therapeutic agent of claim 76 or 77, wherein a first ELP component is covalently bonded to the Factor VII/VIIa or functional analog at an N-terminus thereof, and a second ELP component is covalently bonded to the Factor VII/VIIa or functional analog at a C-terminus thereof.

81. The therapeutic agent of any one of claims 76-80, further comprising a spacer moiety between the ELP component and factor VII/VIIa or functional analog.

82. The therapeutic agent of claim 81, wherein the spacer moiety comprises one or more of a protease-resistant moiety, a non-peptide chemical moiety, and a protease cleavage site.

83. The therapeutic agent of claim 82, wherein the protease cleavage site is a thrombin cleavage site, a factor Xa cleavage site, a metalloprotease cleavage site, an enterokinase cleavage site, a Tev cleavage site, and a cathepsin cleavage site.

84. The therapeutic agent of claim 82, wherein the spacer moiety comprises a non-cleavable moiety having the formula [(Gly)_n-Ser]_m(SEQ ID NO: 22) where n is from 1 to 4, inclusive, and m is from 1 to 4, inclusive.

85. The therapeutic agent of any one of claims 76-84, wherein the ELP component comprises at least one repeating unit selected from SEQ ID NOS: 1-12.

86. The therapeutic agent of claim 85, wherein said repeating unit is VPGXG (SEQ ID NO: 3).

87. The therapeutic agent of claim 86, wherein X is any natural or non-natural amino acid residue, and wherein X varies among at least two units.

88. The therapeutic agent of claim 86, wherein each X is independently selected from alanine, arginine, asparagine, aspartic acid, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, serine, threonine, tryptophan, tyrosine and valine residues.

89. The therapeutic agent of any one of claims 76-88, wherein the therapeutic agent has a molecular weight of less than about 70 kDa.

90. The therapeutic agent of any one of claims 76-89, wherein the ELP component has a Tt greater than 37° C.

91. The therapeutic agent of any one of claims 76-90, wherein the therapeutic agent is a genetically encoded fusion protein.

92. A polynucleotide comprising a nucleotide sequence encoding the therapeutic agent of claim 91.

93. The polynucleotide of claim 92, further comprising an expression control element operably linked to said nucleotide sequence.

94. The polynucleotide of claim 93, wherein said expression control element comprises a promoter.

95. A vector comprising the polynucleotide of any one of claims 92-94.

96. An isolated host cell containing the vector of claim 95 or the polynucleotide of any one of claims 92-95.

97. A pharmaceutical composition comprising the therapeutic agent of any one of claims 76-91, and a pharmaceutically acceptable carrier and/or excipient.

98. A method of preventing or treating a subject for a biological condition, disorder, or disease, comprising administering an effective amount of the therapeutic agent of any one of claims 76-91 or the pharmaceutical composition of claim 97 to a subject in need thereof.

99. The method of claim 98, wherein the subject has a hemorrhage.

100. The method of claim 98 or 99, wherein the subject has hemophilia.